(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/189047 A3

(51) International Patent Classification:

C07K 14/705 (2006.01)	*A61K 45/00* (2006.01)
C12N 15/62 (2006.01)	*A61P 31/00* (2006.01)
A61K 39/39 (2006.01)	*A61P 33/02* (2006.01)
A61K 9/127 (2006.01)	*A61P 35/00* (2006.01)
A61K 31/7084 (2006.01)	*A61P 31/12* (2006.01)
A61K 39/00 (2006.01)	*A61K 39/215* (2006.01)
A61K 47/69 (2017.01)	*A61P 31/14* (2006.01)

(21) International Application Number:
PCT/US2021/023485

(22) International Filing Date:
22 March 2021 (22.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/US2020/024023 20 March 2020 (20.03.2020) US
63/001,088 27 March 2020 (27.03.2020) US
63/003,171 31 March 2020 (31.03.2020) US
63/006,585 07 April 2020 (07.04.2020) US
63/017,514 29 April 2020 (29.04.2020) US
63/142,418 27 January 2021 (27.01.2021) US

(71) Applicant: **CODIAK BIOSCIENCES, INC.** [US/US]; 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US).

(72) Inventors: **SATHYANARAYANAN, Sriram**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **SOOS, Tim**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **XU, Ke**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **NOYES, Aaron**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **DOOLEY, Kevin P.**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **ZHANG, Eric**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **MCCOY, Christine**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **FINN, Jonathan**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US).

(74) Agent: **KIM, Ji Eun** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
04 November 2021 (04.11.2021)

(54) Title: EXTRACELLULAR VESICLES FOR THERAPY

(57) Abstract: The present disclosure relates to extracellular vesicles comprising one or more antigens from a coronavirus (e.g., SARS-CoV-1 or SARS-CoV-2) and optionally an adjuvant. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and/or prevent diseases or disorders, *e.g.*, infectious diseases.

WO 2021/189047 A3

EXTRACELLULAR VESICLES FOR THERAPY

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This PCT application claims the priority benefit of International Application No. PCT/US2020/024023, filed on March 20, 2020; U.S. Provisional Application Nos. 63/001,088, filed on March 27, 2020; 63/003,171, filed on March 31, 2020; 63/006,585, filed on April 7, 2020; 63/017,514, filed on April 29, 2020; and 63/142,418, filed on January 27, 2021; each of which is herein incorporated by reference in its entirety.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY VIA EFS-WEB

[0002] The content of the electronically submitted sequence listing (Name: 4000_097PC06_Seqlisting_ST25.txt, Size: 352,293 bytes; and Date of Creation: March 22, 2021) submitted in this application is incorporated herein by reference in its entirety.

FIELD OF DISCLOSURE

[0003] The present disclosure relates to modified extracellular vesicles, *e.g.*, exosomes (*e.g.*, comprises one or more payloads, *e.g.*, an antigen and adjuvant/immune modulator) that is useful as a vaccine that can be used to treat and/or prevent a range of medical disorders, including, but not limited to, infectious diseases. The present disclosure also relates to methods of producing such EVs and uses thereof.

BACKGROUND OF DISCLOSURE

[0004] EVs are important mediators of intercellular communication. They are also important biomarkers in the diagnosis and prognosis of many diseases, such as cancer. As drug delivery vehicles, EVs offer many advantages over traditional drug delivery methods (*e.g.*, peptide immunization, DNA vaccines) as a new treatment modality in many therapeutic areas. However, despite its advantages, many EVs have had limited clinical efficacy. For example, dendritic-cell derived exosomes (DEX) were investigated in a Phase II clinical trial as maintenance immunotherapy after first line chemotherapy in patients with inoperable non-small cell lung cancer

(NSCLC). However, the trial was terminated because the primary endpoint (at least 50% of patients with progression-free survival (PFS) at 4 months after chemotherapy cessation) was not reached. Besse, B., *et al.*, *Oncoimmunology* 5(4):e1071008 (2015).

[0005] Accordingly, new and more effective engineered-EVs are necessary to better enable therapeutic use and other applications of EV-based technologies.

SUMMARY OF DISCLOSURE

[0006] Provided herein is an isolated extracellular vesicle (EV) comprising at least one antigen derived from a coronavirus. In some aspects, the coronavirus is a severe acute respiratory syndrome (SARS) coronavirus. In some aspects, the antigen is a universal SARS coronavirus antigen.

[0007] In some aspects, an EV disclosed herein comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more antigens, wherein the first antigen is derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus. In some aspects, wherein the second antigen is derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus. In some aspects, the second antigen is not derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus. In certain aspects, the first and second antigens are the same. In some aspects, the first and second antigens are different.

[0008] In some aspects, an antigen derived from COVID-19 virus that can be expressed in an EV disclosed herein is derived from a spike (S) protein. In some aspects, the antigen comprises a receptor-binding domain (RBD) of the S protein. In certain aspects, the antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the S protein.

[0009] In some aspects, an antigen derived from COVID-19 virus expressed in an EV of the present disclosure is derived from an envelope (E) protein. In certain aspects, the antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the E protein.

[0010] In some aspects, an antigen derived from COVID-19 virus that can be expressed in an EV of the present disclosure is derived from a membrane (M) protein. In certain aspects, the antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the M protein.

[0011] In some aspects, an EV comprises a second antigen, wherein the second antigen is derived from a spike (S) protein of a COVID-19 virus. In some aspects, the second antigen comprises a receptor-binding domain (RBD) of the S protein. In certain aspects, the second antigen

comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the S protein.

[0012] In some aspects, an EV comprises a second antigen, wherein the second antigen is derived from an envelope (E) protein of a COVID-19 virus. In certain aspects, the second antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the E protein.

[0013] In some aspects, an EV comprises a second antigen, wherein the second antigen derived from COVID-19 virus is derived from a membrane (M) protein. In certain aspects, the second antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the M protein.

[0014] In some aspects, an EV of the present disclosure comprises a first antigen and a second antigen, wherein the first antigen comprises a receptor-binding domain (RBD) of the S protein and the second antigen comprises a T-antigen.

[0015] In some aspects, an EV of the present disclosure further comprises at least one adjuvant.

[0016] In some aspects, an EV disclosed herein induces a cellular immune response, a humoral immune response, or both cellular and humoral immune responses. In certain aspects, the induction of the cellular immune response, the humoral immune response, or both cellular and humor immune responses is increased by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more, compared to (i) a corresponding EV that does not comprise the adjuvant or the antigen or (ii) the adjuvant or the antigen without the EV.

[0017] In some aspects, an EV disclosed herein induces a CD4+ T cell response, a CD8+ T cell response, or both CD4+ and CD8+ T cell responses. In some aspects, an EV disclosed herein induces a CD8+ T cell response. In some aspects, an EV expands a tissue resident memory T-cell response.

[0018] In some aspects, an EV of the present disclosure further comprises a first scaffold moiety. In certain aspects, the first antigen is linked to the first scaffold moiety. In some aspects, the second antigen is linked to the first scaffold moiety. In some aspects, an EV comprising a first scaffold moiety disclosed herein further comprises a second scaffold moiety. In certain aspects, the first antigen is linked to the first scaffold moiety, and the second antigen is linked to the second

scaffold moiety. In some aspects, the first scaffold moiety and the second scaffold moiety are the same. In some aspects, the first scaffold moiety and the second scaffold moiety are different.

[0019] In some aspects, the first scaffold moiety is a Scaffold X. In some aspects, the first scaffold moiety is a Scaffold Y. In some aspects, the second scaffold moiety is a Scaffold Y. In some aspects, the second scaffold moiety is a Scaffold X.

[0020] In some aspects, a Scaffold X that can be expressed in an EV disclosed herein is capable of: (i) anchoring the first antigen on the luminal surface of the EV; (ii) anchoring the first antigen on the exterior surface of the EV; (iii) anchoring the second antigen on the luminal surface of the EV; (iv) anchoring the second antigen on the exterior surface of the EV; or (v) combinations thereof. In some aspects, the Scaffold X is selected from the group consisting of prostaglandin F2 receptor negative regulator (the PTGFRN protein); basigin (the BSG protein); immunoglobulin superfamily member 2 (the IGSF2 protein); immunoglobulin superfamily member 3 (the IGSF3 protein); immunoglobulin superfamily member 8 (the IGSF8 protein); integrin beta-1 (the ITGB1 protein); integrin alpha-4 (the ITGA4 protein); 4F2 cell-surface antigen heavy chain (the SLC3A2 protein); a class of ATP transporter proteins (the ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B4 proteins), and any combination thereof.

[0021] In some aspects, a Scaffold Y that can be expressed in an EV disclosed herein is capable of: (i) anchoring the first antigen on the luminal surface of the EV; (ii) anchoring the second antigen on the luminal surface of the EV; or (iii) both. In certain aspects, the Scaffold Y is selected from the group consisting of myristoylated alanine rich Protein Kinase C substrate (the MARCKS protein); myristoylated alanine rich Protein Kinase C substrate like 1 (the MARCKSL1 protein); brain acid soluble protein 1 (the BASP1 protein), and any combination thereof.

[0022] In some aspects, the first antigen is linked to a first scaffold moiety on the luminal surface of the EV, and the second antigen is linked to a second scaffold moiety on the luminal surface of the EV. In certain aspects, a) each of the first scaffold moiety and the second scaffold moiety is Scaffold Y; b) the first scaffold moiety is Scaffold Y, and the second scaffold moiety is Scaffold X; c) the first scaffold moiety is Scaffold X, and the second scaffold moiety is Scaffold Y; or d) each of the first scaffold moiety and the second scaffold moiety is Scaffold X.

[0023] In some aspects, the first antigen is linked to a first scaffold moiety on the luminal surface of the EV, and the second antigen is in the lumen of the EV. In some aspects, the first antigen is in the lumen of the EV, and the second antigen is linked to a first scaffold moiety on the luminal surface of the EV. In some aspects, the first antigen is linked to a first scaffold moiety on

the luminal surface of the EV and the second antigen is linked to a second scaffold moiety on the exterior surface of the EV. In some aspects, the first scaffold moiety is Scaffold Y, and the second scaffold moiety is Scaffold X; or b) each of the first scaffold moiety and the second scaffold moiety is Scaffold X.

[0024] In some aspects, the first antigen is linked to a first scaffold moiety on the exterior surface of the EV, and the second antigen is linked to a second scaffold moiety on the luminal surface of the EV. In certain aspects, a) first scaffold moiety is Scaffold X, and the second scaffold moiety is Scaffold Y; or b) each of the first scaffold moiety and the second scaffold moiety is Scaffold X.

[0025] In some aspects, the first antigen is in the lumen of the EV and the second antigen is in the lumen of the EV.

[0026] In some aspects, the antigen is linked to a first scaffold moiety on the exterior surface of the EV and the adjuvant is linked to a second scaffold moiety on the exterior surface of the EV. In some of such aspects, the first scaffold and the second scaffold moiety are Scaffold X.

[0027] In some aspects, the first antigen is linked to a first scaffold moiety on the exterior surface of the EV and the second antigen is in the lumen of the EV. In some of such aspects, the first scaffold moiety is Scaffold X.

[0028] In some aspects, the first antigen is in the lumen of the EV and the second antigen is linked to a first scaffold moiety on the exterior surface of the EV. In some of such aspects, the first scaffold moiety is Scaffold X.

[0029] In some aspects, the first antigen is linked to a first scaffold moiety on the surface of the EV and the second antigen is linked to the first scaffold moiety on the luminal surface of the EV. In some aspects, the first antigen is linked to a first scaffold moiety on the luminal surface of the EV and the second antigen is linked to the first scaffold moiety on the exterior surface of the EV. In some of such aspects, the first scaffold moiety is Scaffold X.

[0030] In some aspects, an EV disclosed herein comprises a second antigen, wherein (i) the second antigen is linked to the first scaffold moiety by a linker, an affinity ligand, or both, (ii) the second antigen is linked to the second scaffold moiety by a linker, an affinity ligand, or both, (iii) the second antigen is linked to the first scaffold moiety by a linker, an affinity ligand, or both, (iv) the second antigen is linked to the second scaffold moiety by a linker, an affinity ligand, or both, or (v) combinations thereof. In certain aspects, the linker and/or the affinity ligand is a polypeptide. In certain aspects, the linker is a non-polypeptide moiety.

[0031] In some aspects, the first scaffold moiety or the second scaffold moiety of an EV disclosed herein is PTGFRN protein, In some aspects, the first scaffold moiety or the second scaffold moiety comprises an amino acid sequence as set forth in SEQ ID NO: 33. In some aspects, the first scaffold moiety or the second scaffold moiety comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% identical to SEQ ID NO: 1.

[0032] In some aspects, the first scaffold moiety or the second scaffold moiety of an EV disclosed herein is BASP1 protein. In some aspects, the first scaffold moiety or the second scaffold moiety comprises a peptide of (G)(π)(X)(Φ/π)(π)(+)(+), wherein each parenthetical position represents an amino acid, and wherein π is any amino acid selected from the group consisting of Pro, Gly, Ala, and Ser, X is any amino acid, Φ is any amino acid selected from the group consisting of Val, Ile, Leu, Phe, Trp, Tyr, and Met, and (+) is any amino acid selected from the group consisting of Lys, Arg, and His; and wherein position five is not (+) and position six is neither (+) nor (Asp or Glu). In some aspects, the first scaffold moiety or the second scaffold moiety comprises an amino acid sequence set forth in any one of SEQ ID NOs: 50-155. In some aspects, the first scaffold moiety or the second scaffold moiety comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% identical to SEQ ID NO: 3.

[0033] Also provided herein is an isolated extracellular vesicle comprising (i) a first antigen derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus and (ii) a second antigen derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus, wherein: (a) the first antigen is linked to a first Scaffold Y on the luminal surface, and the second antigen is linked to a second Scaffold Y on the luminal surface of the EV; (b) the first antigen is linked to a Scaffold Y on the luminal surface, and the second antigen is in the lumen of the EV; (c) the first antigen is in the lumen of the EV, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV; (d) the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the exterior surface of the EV; (e) the first antigen is in the lumen of the EV, and the second antigen is linked to a Scaffold X on the exterior surface of the EV; (f) the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the luminal surface of the EV; (g) the first antigen is in the lumen of the EV, and the second antigen is linked to a Scaffold X on the luminal surface of the EV; (h) the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked

to the Scaffold X on the exterior surface of the EV; (i) the first antigen is linked to a first Scaffold X on the exterior surface of the EV, and the second antigen is linked to a second Scaffold X on the exterior surface of the EV; (j) the first antigen is linked to a Scaffold X on the exterior surface of the EV, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV; (k) the first antigen is linked to a Scaffold X on the exterior surface of the EV, and the second antigen is in the lumen of the EV; (l) the first antigen is linked to a Scaffold X on the exterior surface of the EV, and the second antigen is linked to the Scaffold X on the luminal surface of the EV; (m) the first antigen is linked to a first Scaffold X on the luminal surface of the EV, and the second antigen is linked to a second Scaffold X on the luminal surface of the EV; (n) the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV; (o) the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is in the lumen of the EV; (p) the first antigen is linked to a first Scaffold X on the exterior surface of the EV, and the second antigen is linked to a second Scaffold X on the luminal surface of the EV; (q) the first antigen is linked to a first Scaffold X on the luminal surface of the EV, and the second antigen is linked to a second Scaffold X on the exterior surface of the EV; (r) the first antigen is in the lumen of the EV, and the second antigen is in the lumen of the EV; (s) the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked directly to the luminal surface of the EV; (t) the first antigen is linked directly to the luminal surface of the EV, and the second antigen is in the lumen of the EV; (u) the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV; (v) the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the luminal surface of the EV; (w) the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked directly to the exterior surface of the EV; (x) the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the exterior surface of the EV; (y) the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked directly to the luminal surface of the EV; (z) the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked directly to the exterior surface of the EV; (aa) the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked directly to the luminal surface of the EV; (bb) the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked directly to the exterior surface of the EV; (cc) the first antigen is in the lumen of the EV, and the second antigen

is linked directly to the luminal surface of the EV; or (dd) the first antigen is in the lumen of the EV, and the second antigen is linked directly to the exterior of the EV.

[0034] In some aspects, an EV disclosed herein further comprises an immune modulator. In certain aspects, the immune modulator is linked directly to the luminal surface or exterior surface of the EV. In some aspects, the immune modulator is linked to a Scaffold X on the exterior surface of the EV or on the luminal surface of the EV. In some aspects, the immune modulator is linked to a Scaffold Y on the luminal surface of the EV.

[0035] In some aspects, an EV disclosed herein comprises an adjuvant, wherein the adjuvant is linked directly to the luminal surface or exterior surface of the EV. In certain aspects, the adjuvant is linked to a Scaffold X on the exterior surface of the EV or in the lumen of the EV. In some aspects, the adjuvant is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, the adjuvant is in the lumen of the EV.

[0036] In some aspects, the adjuvant is a Stimulator of Interferon Genes (STING) agonist, a toll-like receptor (TLR) agonist, an inflammatory mediator, RIG-I agonists, alpha-gal-cer (NKT agonist), heat shock proteins (*e.g.*, HSP65 and HSP70), C-type lectin agonists (*e.g.*, beta glucan (Dectin 1), chitin, and curdlan), or any combination thereof.

[0037] In some aspects, the adjuvant is a STING agonist. In some aspects, the STING agonist comprises a cyclic dinucleotide STING agonist or a non-cyclic dinucleotide STING agonist.

[0038] In some aspects, the adjuvant is a TLR agonist. In some aspects, the TLR agonist comprises a TLR2 agonist (*e.g.*, lipoteichoic acid, atypical LPS, MALP-2 and MALP-404, OspA, porin, LcrV, lipomannan, GPI anchor, lysophosphatidylserine, lipophosphoglycan (LPG), glycophosphatidylinositol (GPI), zymosan, hsp60, gH/gL glycoprotein, hemagglutinin), a TLR3 agonist (*e.g.*, double-stranded RNA, *e.g.*, poly(I:C)), a TLR4 agonist (*e.g.*, lipopolysaccharides (LPS), lipoteichoic acid, β-defensin 2, fibronectin EDA, HMGB1, snapin, tenascin C), a TLR5 agonist (*e.g.*, flagellin), a TLR6 agonist, a TLR7/8 agonist (*e.g.*, single-stranded RNA, CpG-A, Poly G10, Poly G3, Resiquimod), a TLR9 agonist (*e.g.*, unmethylated CpG DNA), or any combination thereof.

[0039] In some aspects, an EV disclosed herein is an exosome.

[0040] In some aspects, an EV of the present disclosure further comprises a targeting moiety. In some aspects, the targeting moiety specifically binds to a marker for a dendritic cell. In certain aspects, the marker is present only on the dendritic cell. In some aspects, the dendritic cell

comprises a plasmacytoid dendritic cell (pDC), a myeloid/conventional dendritic cell 1 (cDC1), a myeloid/conventional dendritic cell 2 (cDC2), inflammatory monocyte derived dendritic cells, Langerhans cells, dermal dendritic cells, lysozyme-expressing dendritic cells (LysoDCs), Kupffer cells, or any combination thereof. In some aspects, the dendritic cell is cDC1. In some aspects, the marker comprises a C-type lectin domain family 9 member A (Clec9a) protein, a dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), CD207, CD40, Clec6, dendritic cell immunoreceptor (DCIR), DEC-205, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), MARCO, Clec12a, Clec10a, DC-asialoglycoprotein receptor (DC-ASGPR), DC immunoreceptor 2 (DCIR2), Dectin-1, macrophage mannose receptor (MMR), BDCA-1 (CD303, Clec4c), Dectin-2, Bst-2 (CD317), Langerin, CD206, CD11b, CD11c, CD123, CD304, XCR1, AXL, Siglec 6, CD209, SIRPA, CX3CR1, GPR182, CD14, CD16, CD32, CD34, CD38, CD10, or any combination thereof. In certain aspects, the marker is Clec9a protein.

[0041] In some aspects, the targeting moiety specifically binds to a marker for a T cell. In certain aspects, the marker comprises a CD3 molecule.

[0042] In some aspects, the targeting moiety is linked directly to the exterior surface of the EV. In certain aspects, the targeting moiety is linked to a Scaffold X on the exterior surface of the EV. In some aspects, the targeting moiety is linked directly to the exterior surface of the EV by a linker, an affinity ligand, or both. In some aspects, the targeting moiety is linked to the Scaffold X by a linker. In certain aspects, the linker and/or the affinity ligand is a polypeptide.

[0043] Provided herein is a pharmaceutical composition comprising an EV described herein and a pharmaceutically acceptable carrier.

[0044] Provided herein is a cell that produces an EV of the present disclosure. Present disclosure further provides a cell comprising one or more vectors, wherein the vectors comprises a nucleic acid sequence encoding: (i) an antigen (*e.g.*, those described herein), (ii) adjuvant (*e.g.*, those described herein), (iii) immune modulator, (iv) targeting moiety (*e.g.*, those described herein), or (v) combinations thereof.

[0045] Provided herein is a kit comprising an EV described herein and instructions for use. Also provided herein is an EV-drug conjugate comprising any of the EVs described herein.

[0046] Provided herein is a method of making EVs comprising culturing a cell disclosed herein under a suitable condition and obtaining the EVs.

[0047] Provided herein is a method of inducing an immune response in a subject in need thereof comprising administering any of the EVs disclosed herein to the subject.

[0048] Provided herein is a method of preventing or treating a disease in a subject in need thereof, comprising administering any of the EVs disclosed herein to the subject, wherein the disease is associated with the antigen. In certain aspects, the disease is an infection.

[0049] In some aspects, an EV disclosed herein is administered parenterally, orally, intravenously, intramuscularly, intranasally, subcutaneously, or intraperitoneally.

[0050] In some aspects, methods disclosed herein (*e.g.*, inducing an immune response or preventing or treating a disease) comprises administering an additional therapeutic agent to the subject.

[0051] In some aspects, the present disclosure is directed to a method of vaccinating a subject in need thereof, comprising (i) administering a priming dose which comprises an extracellular vesicle comprising an adjuvant and an antigen to the subject and (ii) administering a boosting dose which comprises an extracellular vesicle comprising the antigen to the subject.

[0052] In some aspects, the antigen is derived from a coronavirus.

[0053] In some aspects, the priming dose is administered subcutaneously. In some aspects, the boost dose is administered intranasally.

[0054] In some aspects, the adjuvant is a STING agonist. In some aspects, the antigen is linked to a scaffold moiety. In some aspects, the scaffold moiety is Scaffold X.

[0055] In some aspects, the EV in the boosting dose does not contain any adjuvant.

[0056] In some aspects, the antigen, adjuvant, immune modulator, and/or targeting moiety is linked to a surface of the EV by an anchoring moiety, affinity agent, chemical conjugation, cell penetrating peptide (CPP), split intein, SpyTag/SpyCatcher, ALFA-tag, Streptavidin/Avitag, Sortase, SNAP-tag, ProA/Fc-binding peptide, or any combinations thereof.

[0057] Present disclosure further provides a method of preparing an extracellular vesicle (EV) for a vaccine, comprising loading an antigen to an EV that has been isolated from a producer cell. Also disclosed herein is a method of manufacturing a vaccine for a disease or disorder, comprising loading an antigen to an extracellular vesicle (EV) that has been isolated from a producer cell.

[0058] In some aspects, the EV further comprises an adjuvant. In certain aspects, the EV comprises the adjuvant prior to the loading of the antigen to the EV.

[0059] In some aspects, the method of preparing an EV for a vaccine and/or the method of manufacturing a vaccine for a disease or disorder further comprises loading the adjuvant. In certain

aspects, the adjuvant is loaded before or after the loading of the antigen. In certain aspects, the adjuvant is loaded together with the antigen.

[0060] In some aspects, the antigen of an EV useful for the method of preparing an EV for a vaccine and/or the method of manufacturing a vaccine for a disease or disorder described herein is linked to the exterior surface and/or the luminal surface of the EV by an anchoring moiety, affinity agent, chemical conjugation, cell penetrating peptide (CPP), split intein, SpyTag/SpyCatcher, ALFA-tag, Streptavidin/Avitag, Sortase, SNAP-tag, ProA/Fc-binding peptide, or any combinations thereof.

[0061] In some aspects, the antigen is derived from and/or comprises a virus, a bacterium, a parasite, a fungus, a protozoa, a tumor, an allergen, a self-antigen, or any combination thereof. In certain aspects, the antigen is derived from a virus causing a pandemic. In certain aspects, the antigen is derived from a coronavirus, an influenza virus, an Ebola virus, a Chikungunya virus (CHIKV), a Crimean-Congo hemorrhagic fever (CCGF) virus, a Hendra virus, a Lassa virus, a Marburg virus, a monkeypox virus, a Nipah virus, a Hendra virus, a Rift Valley fever (RVF) virus, a Variola virus, a yellow fever virus, a Zika virus, a measles virus, a human immunodeficiency virus (HIV), a hepatitis C virus (HCV), a dengue fever virus (DENV), a parvovirus (*e.g.*, B19 virus), a norvovirus, a respiratory syncytial virus (RSV), a lentivirus, an adenovirus, a flavivirus, a filovirus, a rhinovirus, a human papillomavirus (HPV), or any combination thereof. In some aspects, the antigen is derived from *Vibrio cholera*, *Yersinia pestis* bacteria, *Mycobacterium tuberculosis* (MTB), *streptococcus* bacteria (*e.g.*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*), *staphylococcal* bacteria (*e.g.*, *Staphylococcus aureus*), *shigella* bacteria, *Escherichia coli*, *salmonella, chlamydia* bacteria (*e.g.*, *chlamydia trachomatis*), *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Haemophilus influenza*, *Clostridia difficile*, *Plasmodium*, *Leishmania*, *Schistosoma, Trypanosoma*, *Brucella*, *Cryptosporidium*, *Entamoeba*, *Neisseria meningitis*, *Bacillus subtilis*, *Haemophilius influenzae*, *Neisseria gonorrhoeae*, *Borrelia burgdorferi*, *corynebacterium diphteriae*, *moraxella catarrhalis*, *campylobacter jejuni*, *clostridium tetanus*, *clostridium perfringens*, *treponema pallidum* or any combination thereof.

[0062] In some aspects, the loading of the antigen to the EV occurs at least about 1 day, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 2 years, at least

about 3 years, at least about 4 years, at least about 5 years, at least 6 years, at least 7 years, at least 8 years, at least 9 years, at least 10 years, at least 15 years, at least 20 years, at least 25 years or more after isolating the EV from the producer cell.

[0063] In some aspects, the time required for manufacturing the vaccine ("manufacturing time) is reduced compared to a reference manufacturing time (*e.g.*, manufacturing time of a method wherein the loading of the antigen occurs by introducing the antigen into the producer cell, or manufacturing time of a method for producing a vaccine that does not comprise an EV, such as a traditional peptide vaccine). In certain aspects, the manufacturing time is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% or more, compared to the reference manufacturing time. In some aspects, the manufacturing time is less than about 12 months, less than about 11 months, less than about 10 months, less than about 9 months, less than about 8 months, less than about 7 months, less than about 6 months, less than about 5 months, less than about 4 months, less than about 3 months, less than about 2 months, or less than about 1 month. In some aspects, the manufacturing time is less than about 6 months.

[0064] In some aspects, an EV useful for the method of preparing an EV for a vaccine and/or the method of manufacturing a vaccine for a disease or disorder described herein further comprises a targeting moiety. In some aspects, the targeting moiety prior to the loading of the antigen to the EV.

[0065] In some aspects, the method of preparing an EV for a vaccine and/or the method of manufacturing a vaccine for a disease or disorder further comprises loading the targeting moiety. In certain aspects, the targeting moiety are loaded before or after the loading of the antigen. In certain aspects, the targeting moiety is loaded together with the antigen.

[0066] In some aspects, after the loading of the antigen, the EV is capable of inducing a T-cell immune response, a B-cell immune response, or both T-cell and B-cell immune responses.

[0067] Also provided herein is an EV prepared by any of the methods described herein. Provided herein is a kit comprising such an EV, and instructions for use.

[0068] Also provided herein is a vaccine comprising any of the EVs described herein, wherein the antigen is capable of eliciting an immune response in a subject that receives an administration of the vaccine. In certain aspects, the vaccine is regionalized or individualized.

[0069] Provided herein is a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject any of the EVs or vaccines described herein. In certain aspects, the disease or disorder comprises an infectious disease.

BRIEF DESCRIPTION OF FIGURES

[0070] **FIG. 1** shows an exemplary EV comprising one or more antigens, one or more adjuvants, one or more molecules for targeting moiety, or any combination thereof.

[0071] **FIG. 2** shows an exemplary EV comprising one or more SARS-CoV2 antigens (*e.g.*, spike proteins, which are linked to a Scaffold X on the exterior surface; and T cell epitopes, which are linked to a Scaffold X on the luminal surface) and one or more adjuvants (*e.g.*, STING agonist loaded into the lumen).

[0072] **FIG. 3** provides an illustration of the down (closed) and up (open) conformation of the coronavirus spike protein. As shown, in the up conformation, the receptor-binding domain (RBD) of the spike protein is exposed to the surface.

[0073] **FIG. 4** provides an illustration of exemplary ways in which a coronavirus spike antigen can be expressed in an EV disclosed herein. As described herein, in some aspects, the full-length trimeric spike protein can be directly linked to the surface (*e.g.*, exterior surface) of an EV (*see* diagram "I"). In some aspects, a monomeric subunit of the full-length trimeric spike protein can be directly linked to the surface (*e.g.*, exterior surface) of the EV (*see* diagram "II"). In some aspects, a monomeric subunit of the full-length trimeric spike protein can be expressed on the surface (*e.g.*, exterior surface) of the EV linked to a Scaffold X (*see* diagram "III"). In some aspects, a receptor-binding domain of a spike protein (*i.e.*, subunit) can be expressed on the surface (*e.g.*, exterior surface) of the EV linked to a Scaffold X (*see* diagram "IV").

[0074] **FIG. 5** provides an illustration of how different subunits of a coronavirus spike protein can be expressed separately on the surface (*e.g.*, exterior surface) of an EV linked to a scaffold moiety (*e.g.*, Scaffold X).

[0075] **FIG. 6** provides an illustration of exemplary methods in which a spike protein antigen and a T-antigen can be expressed together in an EV. As shown, in the 1st step, the spike protein antigen can be linked to a Scaffold X and then expressed on the surface of the EV. Then, the EV can be further modified to express the T-antigen on the luminal surface of the EV. On the left of the illustration, the T-antigen is linked to the C-terminus of Scaffold X, allowing other payloads

(*e.g.*, adjuvants and/or immune modulators) to be linked to Scaffold Y. On the right, the T-antigen is linked to a Scaffold Y.

[0076] **FIG. 7** provides an illustration of exemplary scaffold X fusion proteins comprising an affinity ligand described in the present disclosure. As shown, the affinity ligand can be synthesized as a fusion to a coronavirus spike protein antigen (*e.g.*, a monomeric subunit of the full-length trimeric spike protein (*see* diagram "I") or the RBD of the spike protein (*see* diagram "II"). Then, the affinity ligand can be used to link or conjugate the coronavirus spike protein antigen to a moiety on EVs, e.g., a Scaffold X moiety.

[0077] **FIG. 8** provides a table describing the administration schedule and experimental design of an exemplary "prime-pull" administration strategy described herein. The different treatment groups were as follows: (1) 1st dose: PBS subcutaneously; 2nd dose: PBS intranasally; (2) 1st dose: PrX-OVA-STING subcutaneously; 2nd dose: PrX-OVA-STING intranasally; (3) 1st dose: PrX-OVA-STING subcutaneously; 2nd dose: PrX-OVA intranasally; (4) 1st dose: PrX-OVA-STING intranasally; 2nd dose: PrX OVA subcutaneously; (5) 1st dose: PrX-OVA-STING intranasally; 2nd dose: PrX-OVA-STING intranasally; (6) 1st dose: PrX-OVA-STING subcutaneously; 2nd dose: PrX-OVA-STING subcutaneously; (7) 1st dose: PrX-OVA-STING intradermally; 2nd dose: PrX-OVA intranasally; (8) 1st dose: PrX-OVA-STING intradermally; 2nd dose: PrX-OVA-STING intradermally; and (9) 1st dose: recombinant OVA + soluble STING agonist subcutaneously; 2nd dose: recombinant OVA + soluble STING agonist intranasally.

[0078] **FIGs. 9A** and **9B** provide the number of OVA-specific CD8+ effector memory T cells in the lungs of animals treated with EVs using the "prime-pull" administration strategy (as described in FIG. 8). The OVA-specific CD8+ effector memory T cells were quantified using flow cytometry (CD44^{hi} and CD62L^{lo}). The results are shown as both percentage of total cells in the lung (FIG. 9A) and total number of OVA-specific CD8+ effector memory T cells (FIG. 9B).

[0079] **FIGs. 10A, 10B,** and **10C** provide the number of total OVA-specific T cells (as measured using IFN-γ ELISPOT) in the lungs of animals treated with EVs using the "prime-pull" administration strategy (as described in FIG. 8). FIG. 10A provides the number of OVA-specific CD4+ T cells. FIG. 10B provides the number of OVA-specific CD8+ T cells. FIG. 10C provides comparison of non-specific T cell inflammatory activation in the lungs of animals from the different groups (as described in FIG. 8).

[0080] **FIGs. 11A** and **11B** provide the total number T cells in the lungs of animals treated with EVs using the "prime-pull" administration strategy (as described in FIG. 8). In FIG. 11A, the

number of T cells was quantified using flow cytometry by gating on cells with the following phenotypic expression: Ly6G-, IA/IE-. CD24-, CD11c-, and CD11b-. In FIG. 11B, the number of T cells in the lung was quantified using IFN-γ ELISPOT by stimulating the lung cells with PMA/ionomycin, which activates T cells in an antigen-independent manner.

[0081] **FIGs. 12A** and **12B** provide the number of OVA-specific CD4+ and CD8+ T cells, respectively, in the spleen of animals treated with EVs using the "prime-pull" administration strategy (as described in FIG. 8). In FIGs. 12A and 12B, the number of antigen-specific T cells was quantified using IFN-γ ELISPOT.

[0082] **FIGs. 13A** and **13B** provide the number of OVA-specific CD8+ effector memory T cells in the spleen of animals treated with EVs using the "prime-pull" administration strategy (as described in FIG. 8). The OVA-specific CD8+ effector memory T cells were quantified using flow cytometry ($CD44^{hi}$ and $CD62L^{lo}$). The results are shown as both percentage of total cells in the lung (FIG. 13A) and total number of OVA-specific CD8+ effector memory T cells (FIG. 13B).

[0083] **FIGs. 14A, 14B, 14C,** and **14D** provide comparison of anti-RBD antibody responses in animals vaccinated with EVs comprising the RBD region of coronavirus spike protein. Animals from each of the groups received two doses of the EV construct: priming dose at day 0 and a boosting dose at day 14. FIG. 14A shows the different treatment groups and the route of administration for each of the doses (either subcutaneous (SQ) or intranasal (IN)). For all the EVs tested, the RBD was fused to the N-terminus of PTGFRN (full-length or truncated) and associated with the exterior surface of the EV. The different EVs included: (i) "exoRBD (s)" = RBD fused to truncated PTGFRN; (ii) "STING exoRBD (s)" = RBD fused to truncated PTGFRN + STING agonist in the lumen of the EV; (iii) "STING" = soluble STING agonist (*i.e.*, not associated with an EV); (iv) "exoRBD (l)" = RBD fused to full-length PTGFRN; (v) "STING exoRBD (l)" = RBD fused to full-length PTGFRN + STING agonist in the lumen of the EV; or (vi) "PTGFRN" = comprising PTGFRN alone (*i.e.*, not fused to RBD) + STING agonist in the lumen of the EV. FIG. 14B show the amount of anti-RBD antibodies detected in the sera of animals from the different treatment groups at day 28 post initial vaccination. A commercially available anti-RBD antibody was used as a positive control ("Ab") and a well containing RBD only was used as a negative control ("RBD"). FIGs. 14C and 14D show the neutralization data. FIG. 14C provides the results for groups 1-5. FIG. 14D provides the results for groups 6-10. Each of the curves for the different groups shown in FIGs. 14C and 14D represent an individual animal.

[0084] **FIGs. 15A, 15B, 15C,** and **15D** provide the effect of different B cell co-stimulators on anti-RBD antibody responses in animals vaccinated with EVs comprising the RBD of coronavirus spike protein. Animals from each of the groups were vaccinated subcutaneously twice: priming dose at day 0 and a boosting dose at day 14 with different vaccine compositions described in FIG 15A. The different vaccination regimens included: (i) "exoRBD + STING" = RBD fused to PTGFRN co-loaded with STING in the lumen; (ii) "exoRBD + STING / PrX-Itgb1 + STING" = RBD fused to PTGFRN co-loaded with STING in the lumen and co-administered with PTGFRN exosomes with a T helper peptide epitope to Itgb1 attached to the surface and co-loaded with STING in the lumen; (iii) " exoRBD + STING / PrX-OVA + STING" = RBD fused to PTGFRN co-loaded with STING in the lumen and co-administered with exosomes expressing OVA (Ovalbumin) fused to PTGFRN co-loaded with STING ; (iv) " exoRBD + STING / Anti-CD40 agonist (IP)" = RBD fused to PTGFRN co-loaded with STING in the lumen and soluble anti-CD40 agonist antibody administered intraperitoneally; (v) "PrX Spike + STING" = coronavirus spike protein attached to the surface of PTGFRN exosomes and co-loaded with STING in the lumen; (vi) "rRBD + STING" = recombinant RBD protein + soluble STING; (vii) "rSpike + STING" = recombinant Spike protein + STING; or (viii) PBS alone. FIG. 15B shows the amount of anti-RBD antibodies detected in the sera of animals from the different groups after subcutaneous dosing at day 35 post initial vaccination. FIGs. 15C and 15D show the neutralization data after subcutaneous administration. FIG. 15C provides the results for groups 1-5. FIG. 15D provides the results for groups 6-10. FIGs. Each of the curves for the different groups shown in FIGs. 15C and 15D represent an individual animal.

[0085] **FIGs. 16A, 16B, 16C, 16D, 16E, 16F,** and **16G** show the effect of alum and CpG adjuvants on the ability of EVs described herein to induce antigen-specific antibodies *in vivo*. FIG. 16A provides a table showing the administration schedule and experimental design. FIGs. 16B, 16C, and 16D provide comparison of anti-OVA IgG levels in the sera of animals from the different treatment groups at days 14, 28, and 42 post initial treatment, respectively. FIGs. 16E, 16F, and 16G provide comparison of anti-OVA IgM levels in the sera of animals from the different treatment groups at days 14, 28, and 42 post initial treatment, respectively

[0086] **FIGs. 17A, 17B, 17C, 17D, 17E,** and **17F** show the use of plug-and-play system described herein to modify EVs to comprise a coronavirus antigen. FIG. 17A provides a schematic illustrating the interaction between ALFA-tagged RBD protein and ALFA nanobody (NbALFA) fused to Scaffold X (*e.g.*, PTGFRN) on the exterior surface of the EV ("Exo-ALFA-RBD"). FIG.

17B shows the purification of RBD-ALFAtag-His protein by immobilized metal affinity chromatography. FIG. 17C shows SDS-PAGE demonstrating the purity and molecular weight of the purified RBD-ALFAtag-His protein. FIGs. 17D and 17E show the loading of RBD-ALFAtag protein onto NbALFA EVs as measured by SDS-PAGE and Western blot, respectively. FIG. 17F provides a quantitative comparison of the results shown in FIGs. 17D and 17E.

[0087] **FIGs. 18A** and **18B** provide comparison of anti-RBD antibody levels in animals vaccinated with recombinant RBD protein or with RBD protein presented on the exterior surface of an EV. The RBD protein was either fused directly to the N-terminus of PTGFRN (FIG. 18A) or conjugated using the ALFA plug-and-play system described herein (FIG. 18B). In FIG. 18A, the animals were vaccinated with one of the following: (i) "exoRBD" = RBD fused directly to PTGFRN; (ii) "rRBD + STING" = recombinant RBD protein + soluble STING agonist; (iii) "rRBD + Exo" = recombinant RBD protein + EV alone (*i.e.*, RBD not associated with the EV); and (iv) PBS alone. In FIG. 18B, the animals were vaccinated with one of the following: (i) "NbALFA Exo + RBD-ALFAtag" = RBD conjugated to PTGFRN using the ALFA plug-and-play system; (ii) "rRBD" = recombinant RBD protein alone; (iii) "rRBD" = recombinant RBD protein + soluble STING agonist; (iv) "Exo + rRBD" = recombinant RBD protein + EV alone (*i.e.*, RBD not associated with the EV); and (v) PBS alone. The amount of RBD administered is given over each bar.

[0088] **FIGs. 19A, 19B,** and **19C** provide schematic of the different ways in which the RBD and T cell epitopes of coronavirus can be displayed in the EVs described herein. In FIG. 19A, the RBD protein is fused to the N-terminus of the full-length PTGFRN (*see* diagrams I, II, and III) or a PTGFRN fragment (*see* diagrams IV and V). The T cell epitopes of coronavirus is displayed on the luminal surface of the EV as either concatemer protein antigen (*see* diagram I) or concatemer peptide antigens (*see* diagrams II-V). In FIG. 19B, the RBD protein is fused to the N-terminus of the full-length PTGFRN, and a single peptide comprising a single pan SARS T cell epitope (*e.g.*, derived from the spike (S) protein, nucleocapsid (N) protein, or membrane (M) protein) is displayed on the luminal surface fused to the C-terminus of the PTGFRN. In FIG. 19C, the RBD protein is fused to the N-terminus of the full-length PTGFRN, and the S2 (left image) and ORF3a (right image) proteins of coronavirus are displayed on the luminal surface (*e.g.*, fused to BASP-1 moiety or the C-terminus of PTGFRN).

[0089] **FIGs. 20A** and **20B** show the expression of the T cell epitopes included in the EVs described in FIG. 19A (*i.e.*, diagrams I, II, III, IV, and V) as measured by Western blot and HiBiT assay.

[0090] **FIGs. 21A** and **21B** show that the EVs described herein can express multiple copies of coronavirus antigen. FIG. 21A provides schematic of RBD protein fused to the N-terminus of full-length PTGFRN (diagram I) or whole spike protein fused to the N-terminus of a PTGFRN fragment (diagrams II and III) on the exterior surface of the EV. In diagrams I and III, HiBiT was conjugated to the C-terminus of PTGFRN. FIG. 21B shows the expression level of the constructs in the EVs as measured using HiBiT Assay.

[0091] **FIGs. 22A, 22B,** and **22C** show that EVs described herein can be modified to comprise T cell epitopes of coronavirus either on the exterior or on the luminal surface of the EVs. FIG. 22A (1-4) provides a schematic of RBD protein fused to the N-terminus of full-length PTGFRN (1) and the exterior surface expression of a concatemer consisting of 8 T cell epitope peptides (8-mer) fused to the N-terminus of full-length PTGFRN (2) or the luminal expression of the 8-mer concatemer by fusion to the C terminus of full-length PTGFRN (3); or by fusion to BASP-1 (4). FIG 22A (5-10) provides a schematic of the 8-mer concatemer described in (2-4) above expressed as two 4-mer concatemer peptides (Group 1 and 2) each fused to the N-terminus of full-length PTGFRN for surface expression (5 and 8) or expressed in the lumen by fusion to the C terminus of full-length PTGFRN (6 and 9); or by fusion to BASP-1 (5 and 10). For each, FLAG tag and HiBiT was conjugated to either the C-terminus of PTGFRN (1,2 and 5) or the c terminus of the 8-mer (3 and 4) or 4-mers (6,7,9 and 10). FIG. 22B and C shows the expression level of the constructs in the EVs as measured using HiBiT Assay and a western blot for the HiBit tag respectively.

[0092] **FIGs. 23A, 23B, 23C,** and **23D** show the anti-tumor effects of EVs described herein in an E.G7-OVA tumor model. FIG. 23A provides the administration schedule and experimental design. FIG. 23B provides the tumor volume in the animals from the different treatment groups at various time points post treatment. FIG. 23C provides the survival rate of the animals from the different treatment groups. FIG. 23D provides the tumor growth rate in the animals.

[0093] **FIG. 24** shows a schematic illustrating the overall process involved in preparing the EV-based vaccines of the present disclosure.

[0094] **FIGs. 25A**, **25B, 25C**, and **25D** show exosomes that have been modified to comprise an acceptor domains fused to the N-terminus of a PTGFRN protein. The acceptor domains

included: (1) SpyCatcher (diamond), (2) CfaC (square), and (3) ALFANb (triangle). FIG. 25A shows the cell growth of stable HEK293 cells lines engineered to overexpress each acceptor domain fused to PTGFRN during exosome production. FIG. 25B shows the viability of the stable cell pool over the same time period as shown in FIG. 25A. FIG. 25C shows the successful purification of exosomes comprising the acceptor domain-PTGFRN fusion protein using iodixanol density gradient ultracentrifugation. FIG. 25D provides SDS-PAGE analysis showing the transgene expression of each acceptor domain compared to un-engineered exosomes (WT).

[0095] **FIG. 26** provides a workflow for assessing the loading of NanoLuc fused to a donor domain onto exosomes expressing the cognate acceptor domain fused to PTGFRN. Unbound NanoLuc is removed by ultracentrifugation (UC) and the resulting exosomes are analyzed by a variety of assays.

[0096] **FIG. 27A** provides a workflow for labeling exosomes overexpressing ALFA nanobody (ALFANb) with NanoLuc fused to the ALFAtag. **FIG. 27B** provides SDS-PAGE analysis post-loading and UC cleanup showing association of NanoLuc-ALFAtag with ALFANb expressing exosomes.

[0097] **FIG. 28A** provides standard curves of NanoLuc fused to ALFA tag or poly-histidine tags. **FIG. 28B** provides a quantitative analysis of the loading of (i) NanoLuc fused to ALFA tag or (ii) NanoLuc fused to poly-histidine tag on the modified exosomes. The quantitative value was determined using the standard curves from FIG. 28A. The fold-change over the background histidine-tag expression is noted.

[0098] **FIG. 29A** provides a workflow for assessing the stability of the ALFA-NanoLuc interaction over time. **FIG. 29B** provides a quantitative analysis of the stability of the ALFA-NanoLuc expression compared to NanoLuc fused to a poly-histidine tag.

[0099] **FIG. 30A** provides a workflow for labeling exosomes overexpressing CfaC with NanoLuc fused to the CfaN. **FIG. 30B** provides SDS-PAGE analysis post-loading and UC cleanup showing association of NanoLuc-CfaN with CfaC expressing exosomes.

[0100] **FIG. 31A** provides standard curves of NanoLuc fused to CfaN or a polyhistidine tag. **FIG. 31B** provides a quantitative analysis of the loading of (i) NanoLuc fused to CfaN or (ii) NanoLuc fused to a poly-histidine tag on the modified exosomes. The quantitative value was determined using the standard curves from FIG. 31A. The fold-change over the background histidine-tag expression is noted.

[0101] **FIG. 32A** provides the workflow for labeling exosomes overexpressing SpyCatcher with NanoLuc fused to the SpyTag. **FIG. 32B** provides SDS-PAGE analysis post-loading and UC cleanup showing association of NanoLuc-SpyTag with SpyCatcher expressing exosomes.

[0102] **FIG. 33A** provides standard curves of NanoLuc fused to SpyTag or a poly-histidine tag. **FIG. 33B** provides a quantitative analysis of the loading of (i) NanoLuc fused to SpyTag or (ii) NanoLuc fused to poly-histidine tag on the modified exosomes. The quantitative value was determined using the standard curves from FIG. 33A. The fold-change over the background histidine-tag expression is noted.

[0103] **FIG. 34** provides a comparison of the loading of NanoLuc fused to one of the following donor domains in the modified exosomes: (i) ALFAtag, (ii) CfaN, and (iii) SpyTag.

[0104] **FIG. 35** shows a schematic illustrating surface conjugation of a moiety of interest to a scaffold protein associated with an exosome membrane.

[0105] **FIG. 36** shows a table listing mechanistic characteristics of small molecules and oligonucleotides conjugated to exosomes. pAB-pNP: p-Aminobenzyl alcholog p-Nitrophenyl carbonate; DBCO: dibenzylcyclooctyne.

[0106] **FIG. 37** shows a table listing lipid-linker-reactive groups as intermediates. The reactive group on the linker and its respective functional group on the moiety of interest is listed.

[0107] **FIGs. 38A, 38B, 38C,** and **38D** show examples of MCC-950, a small molecule, conjugation. FIG. 38A shows MCC-950-Val-Cit-Maleimide conjugation. FIG. 38B shows MCC-950-Val-Cit-Methacrylate conjugation. FIG. 38C shows MCC-950-Val-Cit-Pyridinyl Disulfide conjugation. FIG. 38D shows a schematic illustrating the conjugation site of a sulfhydryl group on an exosome bound scaffold protein.

[0108] **FIGs. 39A** and **39B** show examples of oligonucleotide/protein conjugation. FIG. 39A shows an oligo-maleimide conjugation and a schematic illustrating its conjugation site of a sulfhydryl group on an exosome bound scaffold protein. FIG. 39B shows an oligo-NHS ester conjugation and a schematic illustrating its conjugation site on a primary amine group on an exosome bound scaffold protein.

[0109] **FIG. 40** shows a table listing the function group on the scaffold protein of exosomes, activation thereof, and functional group on the protein/peptide to be conjugated, and the degradability of the linkage. Due to the same functional groups, options for protein to protein / peptide conjugation is limited to click chemistry. DBCO: dibenzylcyclooctyne.

[0110] **FIG. 41** shows an example of protein/peptide conjugation (Schiff base enabled).

[0111] **FIG. 42** shows an example of protein/peptide conjugation (click chemistry).

[0112] **FIGs. 43A** and **43B** provide schematic of EVs comprising the ALFA plug and play system described herein. As shown in FIG. 43A, ALFA nanobody (NbALFA) is fused to Scaffold X (*e.g.*, PTGFRN) on the exterior surface of the EV ("NbALFA EV"). The crystal structure shows the stable, non-covalent interaction of the NbALFA with the ALFAtag. FIG. 43B shows the loading of moieties of interest (MOI) onto the exterior surface of the NbALFA EVs. As further described herein, the moieties of interest are fused to an ALFAtag and then, mixed with the NbALFA EVs, resulting in the stable association of the ALFAtagged moieties of interest to the exterior surface of the NbALFA EVs. The EVs can be loaded with the same moiety of interest (see top drawing) or a mixture of different moiety of interest (see bottom drawing).

[0113] **FIG. 44** provides SDS-PAGE (top) and Western blot (bottom) results demonstrating that NbALFA EVs can be simultaneously loaded with multiple moieties of interest. Wild-type EVs or NbALFA EVs were mixed with 10 μg of NLuc-ALFAtag or molar equivalent of mouse IL-12 fused to ALFAtag ("mIL12-ALFAtag").

DETAILED DESCRIPTION OF DISCLOSURE

[0114] The present disclosure is directed to an engineered EV that delivers one or more antigens, *e.g.*, derived from a coronavirus, e.g., SARS-CoV-1 virus and/or SARS-CoV-2 virus. The EV platform allows luminal expression of one or more antigens and surface expression of one or more antigens designed to create a modular vaccination system. Various adjuvants can be incorporated into the EVs to enhance the immune response against a broad array of antigens. The engineered EVs can comprise one or more payloads and can improve at least one property (*e.g.*, such as those disclosed herein) of the EV, and uses thereof. In some aspects, the one or more payloads comprise an antigen, an adjuvant, and/or an immune modulator. In certain aspects, the EV comprises one or more additional moieties (*e.g.*, targeting moiety). In some aspects, the one or more payloads (*e.g.*, antigen, adjuvant, and/or the immune modulator) and/or the one or more additional moieties (*e.g.*, targeting moiety) can be attached (or linked) to one or more scaffold moieties on the surface of EVs or on the luminal surface of EVs. Non-limiting examples of the various aspects are shown in the present disclosure.

I. Definitions

[0115] In order that the present description can be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

[0116] It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, "a nucleotide sequence," is understood to represent one or more nucleotide sequences. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.

[0117] Furthermore, "and/or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and/or" as used in a phrase such as "A and/or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and/or" as used in a phrase such as "A, B, and/or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0118] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of" and/or "consisting essentially of" are also provided.

[0119] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.

[0120] Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleotide sequences are written left to right in 5' to 3' orientation. Amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0121] The term "**about**" is used herein to mean approximately, roughly, around, or in the regions of. When the term "about" is used in conjunction with a numerical range, it modifies that

range by extending the boundaries above and below the numerical values set forth. In general, the term "about" can modify a numerical value above and below the stated value by a variance of, *e.g.*, 10 percent, up or down (higher or lower).

[0122] As used herein, the term "**extracellular vesicle**" or "**EV**" refers to a cell-derived vesicle comprising a membrane that encloses an internal space. Extracellular vesicles comprise all membrane-bound vesicles (*e.g.*, exosomes, nanovesicles) that have a smaller diameter than the cell from which they are derived. In some aspects, extracellular vesicles range in diameter from 20 nm to 1000 nm, and can comprise various macromolecular payload either within the internal space (*i.e.*, lumen), displayed on the external surface of the extracellular vesicle, and/or spanning the membrane. In some aspects, the payload can comprise nucleic acids, proteins, carbohydrates, lipids, small molecules, and/or combinations thereof. In certain aspects, an extracellular vehicle comprises a scaffold moiety. By way of example and without limitation, extracellular vesicles include apoptotic bodies, fragments of cells, vesicles derived from cells by direct or indirect manipulation (*e.g.*, by serial extrusion or treatment with alkaline solutions), vesiculated organelles, and vesicles produced by living cells (*e.g.*, by direct plasma membrane budding or fusion of the late endosome with the plasma membrane). Extracellular vesicles can be derived from a living or dead organism, explanted tissues or organs, prokaryotic or eukaryotic cells, and/or cultured cells. In some aspects, the extracellular vesicles are produced by cells that express one or more transgene products.

[0123] As used herein, the term "**exosome**" refers to an extracellular vesicle with a diameter between 20-300 nm (*e.g.*, between 40-200 nm). Exosomes comprise a membrane that encloses an internal space (*i.e.*, lumen), and, in some aspects, can be generated from a cell (*e.g.*, producer cell) by direct plasma membrane budding or by fusion of the late endosome or multi-vesicular body with the plasma membrane. In certain aspects, an exosome comprises a scaffold moiety. As described *infra*, exosome can be derived from a producer cell, and isolated from the producer cell based on its size, density, biochemical parameters, or a combination thereof. In some aspects, the EVs of the present disclosure are produced by cells that express one or more transgene products. Unless indicated otherwise, the terms "extracellular vesicle" and "exosomes" can be used interchangeably.

[0124] As used herein, the term "**nanovesicle**" refers to an extracellular vesicle with a diameter between 20-250 nm (*e.g.*, between 30-150 nm) and is generated from a cell (*e.g.*, producer cell) by direct or indirect manipulation such that the nanovesicle would not be produced by the cell

without the manipulation. Appropriate manipulations of the cell to produce the nanovesicles include but are not limited to serial extrusion, treatment with alkaline solutions, sonication, or combinations thereof. In some aspects, production of nanovesicles can result in the destruction of the producer cell. In some aspects, population of nanovesicles described herein are substantially free of vesicles that are derived from cells by way of direct budding from the plasma membrane or fusion of the late endosome with the plasma membrane. In certain aspects, a nanovesicle comprises a scaffold moiety. Nanovesicles, once derived from a producer cell, can be isolated from the producer cell based on its size, density, biochemical parameters, or a combination thereof.

[0125] As used herein, the term "**associated with**," when used in the context of an EV of the present disclosure, refers to a physical interaction with the EV. For instance, when a moiety of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety) is associated with an EV, the moiety of interest is linked to the exterior surface of the EV, linked to the luminal surface of the EV, and/or in the lumen of the EV. As described herein, the moiety of interest can be directly linked to the exterior and/or luminal surface of the EV. In some aspects, the moiety of interest is linked to the exterior and/or luminal surface via one or more scaffold/anchoring moieties, such as those described herein. Accordingly, when a moiety of interest is not associated with an EV, in some aspects, the moiety of interest is in a soluble form.

[0126] As used herein the term "**surface-engineered EVs**" (*e.g.*, Scaffold X-engineered EVs) refers to an EV with the membrane or the surface of the EV modified in its composition so that the surface of the engineered EV is different from that of the EV prior to the modification or of the naturally occurring EV. The engineering can be on the surface of the EV or in the membrane of the EV so that the surface of the EV is changed. For example, the membrane is modified in its composition of a protein, a lipid, a small molecule, a carbohydrate, *etc.* The composition can be changed by a chemical, a physical, or a biological method or by being produced from a cell previously or concurrently modified by a chemical, a physical, or a biological method. Specifically, the composition can be changed by a genetic engineering or by being produced from a cell previously modified by genetic engineering. In some aspects, a surface-engineered EV comprises an exogenous protein (*i.e.*, a protein that the EV does not naturally express) or a fragment or variant thereof that can be exposed to the surface of the EV or can be an anchoring point (attachment) for a moiety exposed on the surface of the EV. In other aspects, a surface-engineered EV comprises a higher expression (*e.g.*, higher number) of a natural exosome protein (*e.g.*, Scaffold X) or a

fragment or variant thereof that can be exposed to the surface of the EV or can be an anchoring point (attachment) for a moiety exposed on the surface of the EV.

[0127] As used herein the term "**lumen-engineered EVs**" (*e.g.*, Scaffold Y-engineered EVs) refers to an EV with the membrane or the lumen of the EV modified in its composition so that the lumen of the engineered EV is different from that of the EV prior to the modification or of the naturally occurring EV. The engineering can be directly in the lumen or in the membrane of the EV so that the lumen of the EV is changed. For example, the membrane is modified in its composition of a protein, a lipid, a small molecule, a carbohydrate, *etc*. so that the lumen of the EV is modified. The composition can be changed by a chemical, a physical, or a biological method or by being produced from a cell previously modified by a chemical, a physical, or a biological method. Specifically, the composition can be changed by a genetic engineering or by being produced from a cell previously modified by genetic engineering. In some aspects, a lumen-engineered exosome comprises an exogenous protein (*i.e.*, a protein that the EV does not naturally express) or a fragment or variant thereof that can be exposed in the lumen of the EV or can be an anchoring point (attachment) for a moiety exposed on the inner layer of the EV. In other aspects, a lumen-engineered EV comprises a higher expression of a natural exosome protein (*e.g.*, Scaffold X or Scaffold Y) or a fragment or variant thereof that can be exposed to the lumen of the exosome or can be an anchoring point (attachment) for a moiety exposed in the lumen of the exosome.

[0128] The term "**modified**," when used in the context of EVs described herein, refers to an alteration or engineering of an EV and/or its producer cell, such that the modified EV is different from a naturally-occurring EV. In some aspects, a modified EV described herein comprises a membrane that differs in composition of a protein, a lipid, a small molecular, a carbohydrate, *etc.* compared to the membrane of a naturally-occurring EV (*e.g.*, membrane comprises higher density or number of natural exosome proteins and/or membrane comprises proteins that are not naturally found in exosomes (*e.g.*, antigen, adjuvant, and/or immune modulator). In certain aspects, such modifications to the membrane changes the exterior surface of the EV (*e.g.*, surface-engineered EVs described herein). In certain aspects, such modifications to the membrane changes the lumen of the EV (*e.g.*, lumen-engineered EVs described herein).

[0129] As used herein, the term "**scaffold moiety**" refers to a molecule that can be used to anchor a payload or any other compound of interest (*e.g.*, antigen, adjuvant, and/or immune modulator) to the EV either on the luminal surface or on the exterior surface of the EV. In certain aspects, a scaffold moiety comprises a synthetic molecule. In some aspects, a scaffold moiety

comprises a non-polypeptide moiety. In other aspects, a scaffold moiety comprises a lipid, carbohydrate, or protein that naturally exists in the EV. In some aspects, a scaffold moiety comprises a lipid, carbohydrate, or protein that does not naturally exist in the EV. In certain aspects, a scaffold moiety is Scaffold X. In some aspects, a scaffold moiety is Scaffold Y. In further aspects, a scaffold moiety comprises both Scaffold X and Scaffold Y. Non-limiting examples of other scaffold moieties that can be used with the present disclosure include: aminopeptidase N (CD13); Neprilysin, AKA membrane metalloendopeptidase (MME); ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1); Neuropilin-1 (NRP1); CD9, CD63, CD81, PDGFR, GPI anchor proteins, lactadherin, LAMP2, and LAMP2B.

[0130] As used herein, the term "**Scaffold X**" refers to exosome proteins that have recently been identified on the surface of exosomes. *See, e.g.*, U.S. Pat. No. 10,195,290, which is incorporated herein by reference in its entirety. Non-limiting examples of Scaffold X proteins include: prostaglandin F2 receptor negative regulator ("the PTGFRN protein"); basigin ("the BSG protein"); immunoglobulin superfamily member 2 ("the IGSF2 protein"); immunoglobulin superfamily member 3 ("the IGSF3 protein"); immunoglobulin superfamily member 8 ("the IGSF8 protein"); integrin beta-1 ("the ITGB1 protein); integrin alpha-4 ("the ITGA4 protein"); 4F2 cell-surface antigen heavy chain ("the SLC3A2 protein"); and a class of ATP transporter proteins ("the ATP1A1 protein," "the ATP1A2 protein," "the ATP1A3 protein," "the ATP1A4 protein," "the ATP1B3 protein," "the ATP2B1 protein," "the ATP2B2 protein," "the ATP2B3 protein," "the ATP2B protein"). In some aspects, a Scaffold X protein can be a whole protein or a fragment thereof (*e.g.*, functional fragment, *e.g.*, the smallest fragment that is capable of anchoring another moiety on the exterior surface or on the luminal surface of the EV). In some aspects, a Scaffold X can anchor a moiety (*e.g.*, antigen, adjuvant, and/or immune modulator) to the external surface or the luminal surface of the exosome.

[0131] As used herein, the term "**Scaffold Y**" refers to exosome proteins that were newly identified within the lumen of exosomes. *See, e.g.*, International Appl. No. PCT/US2018/061679, which is incorporated herein by reference in its entirety. Non-limiting examples of Scaffold Y proteins include: myristoylated alanine rich Protein Kinase C substrate ("the MARCKS protein"); myristoylated alanine rich Protein Kinase C substrate like 1 ("the MARCKSL1 protein"); and brain acid soluble protein 1 ("the BASP1 protein"). In some aspects, a Scaffold Y protein can be a whole protein or a fragment thereof (*e.g.*, functional fragment, *e.g.*, the smallest fragment that is capable of anchoring a moiety to the luminal surface of the exosome). In some aspects, a Scaffold Y can

anchor a moiety (*e.g.*, antigen, adjuvant, and/or immune modulator) to the luminal surface of the EV.

[0132] As used herein, the term "**fragment**" of a protein (*e.g.*, therapeutic protein, Scaffold X, or Scaffold Y) refers to an amino acid sequence of a protein that is shorter than the naturally-occurring sequence, N- and/or C-terminally deleted or any part of the protein deleted in comparison to the naturally occurring protein. As used herein, the term "**functional fragment**" refers to a protein fragment that retains protein function. Accordingly, in some aspects, a functional fragment of a Scaffold X protein retains the ability to anchor a moiety on the luminal surface or on the exterior surface of the EV. Similarly, in certain aspects, a functional fragment of a Scaffold Y protein retains the ability to anchor a moiety on the luminal surface of the EV. Whether a fragment is a functional fragment can be assessed by any art known methods to determine the protein content of EVs including Western Blots, FACS analysis and fusions of the fragments with autofluorescent proteins like, *e.g.*, GFP. In certain aspects, a functional fragment of a Scaffold X protein retains at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 100% of the ability, *e.g.*, an ability to anchor a moiety, of the naturally occurring Scaffold X protein. In some aspects, a functional fragment of a Scaffold Y protein retains at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 100% of the ability, *e.g.*, an ability to anchor another molecule, of the naturally occurring Scaffold Y protein.

[0133] As used herein, the term "**variant**" of a molecule (*e.g.*, functional molecule, antigen, Scaffold X and/or Scaffold Y) refers to a molecule that shares certain structural and functional identities with another molecule upon comparison by a method known in the art. For example, a variant of a protein can include a substitution, insertion, deletion, frameshift or rearrangement in another protein.

[0134] A "**conservative amino acid substitution**" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, if an amino acid in a polypeptide is replaced

with another amino acid from the same side chain family, the substitution is considered to be conservative. In another aspect, a string of amino acids can be conservatively replaced with a structurally similar string that differs in order and/or composition of side chain family members.

[0135] The term "**percent sequence identity**" or "**percent identity**" between two polynucleotide or polypeptide sequences refers to the number of identical matched positions shared by the sequences over a comparison window, taking into account additions or deletions (*i.e.*, gaps) that must be introduced for optimal alignment of the two sequences. A matched position is any position where an identical nucleotide or amino acid is presented in both the target and reference sequence. Gaps presented in the target sequence are not counted since gaps are not nucleotides or amino acids. Likewise, gaps presented in the reference sequence are not counted since target sequence nucleotides or amino acids are counted, not nucleotides or amino acids from the reference sequence.

[0136] The percentage of sequence identity is calculated by determining the number of positions at which the identical amino-acid residue or nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. The comparison of sequences and determination of percent sequence identity between two sequences can be accomplished using readily available software both for online use and for download. Suitable software programs are available from various sources, and for alignment of both protein and nucleotide sequences. One suitable program to determine percent sequence identity is bl2seq, part of the BLAST suite of programs available from the U.S. government's National Center for Biotechnology Information BLAST web site (blast.ncbi.nlm.nih.gov). Bl2seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, *e.g.*, Needle, Stretcher, Water, or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk/Tools/psa.

[0137] Different regions within a single polynucleotide or polypeptide target sequence that aligns with a polynucleotide or polypeptide reference sequence can each have their own percent sequence identity. It is noted that the percent sequence identity value is rounded to the nearest tenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to 80.1, while 80.15, 80.16,

80.17, 80.18, and 80.19 are rounded up to 80.2. It also is noted that the length value will always be an integer.

[0138] One skilled in the art will appreciate that the generation of a sequence alignment for the calculation of a percent sequence identity is not limited to binary sequence-sequence comparisons exclusively driven by primary sequence data. Sequence alignments can be derived from multiple sequence alignments. One suitable program to generate multiple sequence alignments is ClustalW2, available from www.clustal.org. Another suitable program is MUSCLE, available from www.drive5.com/muscle/. ClustalW2 and MUSCLE are alternatively available, *e.g.*, from the EBI.

[0139] It will also be appreciated that sequence alignments can be generated by integrating sequence data with data from heterogeneous sources such as structural data (*e.g.*, crystallographic protein structures), functional data (*e.g.*, location of mutations), or phylogenetic data. A suitable program that integrates heterogeneous data to generate a multiple sequence alignment is T-Coffee, available at worldwideweb.tcoffee.org, and alternatively available, *e.g.*, from the EBI. It will also be appreciated that the final alignment used to calculate percent sequence identity can be curated either automatically or manually.

[0140] The polynucleotide variants can contain alterations in the coding regions, non-coding regions, or both. In one aspect, the polynucleotide variants contain alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. In another aspect, nucleotide variants are produced by silent substitutions due to the degeneracy of the genetic code. In other aspects, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination. Polynucleotide variants can be produced for a variety of reasons, *e.g.*, to optimize codon expression for a particular host (change codons in the human mRNA to others, *e.g.*, a bacterial host such as *E. coli*).

[0141] Using known methods of protein engineering and recombinant DNA technology, variants can be generated to improve or alter the characteristics of the polypeptides. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. Ron *et al.*, *J. Biol. Chem.* 268: 2984-2988 (1993), incorporated herein by reference in its entirety, reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues

from the carboxy terminus of this protein. (Dobeli *et al., J. Biotechnology 7*:199-216 (1988), incorporated herein by reference in its entirety.)

[0142] Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem 268*:22105-22111 (1993), incorporated herein by reference in its entirety) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

[0143] As stated above, polypeptide variants include, *e.g.*, modified polypeptides. Modifications include, *e.g.*, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation (Mei *et al., Blood 116:*270-79 (2010), which is incorporated herein by reference in its entirety), proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. In some aspects, Scaffold X and/or Scaffold Y is modified at any convenient location.

[0144] As used herein, when a molecule described herein (*e.g.*, antigen, adjuvant, immune modulator, targeting moiety, affinity ligand, and/or scaffold moiety) is "**expressed**" in an EV, it means that the molecule is present in or on the EV. As described herein, an EV can express a molecule of interest on its exterior surface, on its luminal surface, in the lumen, or combinations thereof. In some aspects, a molecule can be exogenously introduced into a producer cell or directly into an EV, such that the EV expresses the molecule of interest. In some aspects, a molecule of interest can be produced separately from an EV and then conjugated or linked to a moiety present in the EV, such that the EV expresses the molecule. For instance, in some aspects, an antigen (*e.g.*,

derived from a spike S protein of a coronavirus, *e.g.*, receptor-binding domain of a spike S protein) can be fused to an affinity ligand disclosed herein. Then, the antigen-affinity ligand fusion can be linked or conjugated to a scaffold moiety expressed on the surface of an EV via the affinity ligand. Additional disclosure relating to different methods of expressing a molecule of interest in or on an EV is described elsewhere in the present disclosure.

[0145] As used herein, the term "**linked to**," "**fused**," or "**conjugated to**" are used interchangeably and refer to a covalent or non-covalent bond formed between a first moiety and a second moiety, *e.g.*, Scaffold X and an antigen (or adjuvant or immune modulator), respectively, *e.g.*, a scaffold moiety expressed in or on the extracellular vesicle and an antigen, *e.g.*, Scaffold X (*e.g.*, a PTGFRN protein), respectively, in the luminal surface of or on the external surface of the extracellular vesicle. In some aspects, a payload disclosed herein (*e.g.*, antigen, adjuvant, and/or immune modulator) and/or a targeting moiety can be directly linked to the exterior surface and/or the luminal surface of an EV. As used herein, the term "**directly linked**," "**directly fused**," or "**directly conjugated to**" refer to the process of linking (fusing or conjugating) a moiety (*e.g.*, a payload and/or targeting moiety) to the surface of an EV without the use of a scaffold moiety disclosed herein.

[0146] As used herein, the term "**fusion protein**" refers to two or more proteins that are linked or conjugated to each other. For instance, in some aspects, a fusion protein that can be expressed in an EV disclosed herein comprises (i) a payload (*e.g.*, antigen, adjuvant, and/or immune modulator) and (ii) a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y). In some aspects, the payload (*e.g.*, antigen, adjuvant, and/or immune modulator) is linked or conjugated to the scaffold moiety via an affinity ligand (*e.g.*, those described herein). In some aspects, a fusion protein that can be expressed in an EV useful for the present disclosure comprises (i) a targeting moiety and (ii) a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y). In some aspects, the targeting moiety is linked or conjugated to the scaffold moiety via an affinity ligand (*e.g.*, those described herein). As described herein, in some aspects, EVs of the present disclosure can express multiple fusion proteins, wherein a first fusion protein comprises (i) a payload (*e.g.*, antigen, adjuvant, and/or immune modulator) and (ii) a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y), and wherein a second fusion protein comprises (i) a targeting moiety and (ii) a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y).

[0147] The term "**encapsulated**", or grammatically different forms of the term (*e.g.*, encapsulation, or encapsulating) refers to a status or process of having a first moiety (*e.g.*, antigen,

adjuvant, or immune modulator) inside a second moiety (*e.g.*, an EV) without chemically or physically linking the two moieties. In some aspects, the term "**encapsulated**" can be used interchangeably with the terms "**in the lumen of**" and "**loaded**". Non-limiting examples of encapsulating (or loading) a first moiety (*e.g.*, payload, *e.g.*, antigen, adjuvant, or immune modulator) into a second moiety (*e.g.*, EVs) are disclosed elsewhere herein.

[0148] As used herein, the term "**producer cell**" refers to a cell used for generating an EV. A producer cell can be a cell cultured *in vitro,* or a cell *in vivo.* A producer cell includes, but not limited to, a cell known to be effective in generating EVs *e.g.,* HEK293 cells, Chinese hamster ovary (CHO) cells, mesenchymal stem cells (MSCs), BJ human foreskin fibroblast cells, fHDF fibroblast cells, AGE.HN® neuronal precursor cells, CAP® amniocyte cells, adipose mesenchymal stem cells, RPTEC/TERT1 cells. In certain aspects, a producer cell is not an antigen-presenting cell. In some aspects, a producer cell is not a dendritic cell, a B cell, a mast cell, a macrophage, a neutrophil, Kupffer-Browicz cell, cell derived from any of these cells, or any combination thereof. In some aspects, a producer cell is not a naturally-existing antigen-presenting cell (*i.e.*, has been modified). In some aspects, a producer cell is not a naturally-existing dendritic cell, a B cell, a mast cell, a macrophage, a neutrophil, Kupffer-Browicz cell, cell derived from any of these cells, or any combination thereof. Additional disclosures relating to such producer cells are provided elsewhere in the present disclosure. In some aspects, the EVs useful in the present disclosure do not carry an antigen on MHC class I or class II molecule (*i.e.*, antigen is not presented on MHC class I or class II molecule) exposed on the surface of the EV but instead can carry an antigen in the lumen of the EV or on the surface of the EV by attachment to Scaffold X and/or Scaffold Y.

[0149] As used herein, an "**MHC class I molecule**" refers to a protein product of a wild-type or variant HLA class I gene encoding an MHC class I molecule. Accordingly, "**HLA class I molecule**" and "**MHC class I molecule**" are used interchangeably herein.

[0150] MHC class I molecules are one of two primary classes of major histocompatibility complex (MHC) molecules (the other being MHC class II) and are found on the cell surface of all nucleated cells in the bodies of jawed vertebrates. They also occur on platelets, but not on red blood cells. Their function is to display peptide fragments of proteins from within the cell to cytotoxic T cells; this will trigger an immediate response from the immune system against a particular non-self antigen displayed with the help of an MHC class I protein. Because MHC class I molecules present peptides derived from cytosolic proteins, the pathway of MHC class I presentation is often called cytosolic or endogenous pathway.

[0151] In humans, the HLAs corresponding to MHC class I are HLA-A, HLA-B, and HLA-C. The MHC Class I molecule comprises two protein chains: the alpha chain and the β2-microglobulin (β2m) chain. Human β2m is encoded by the B2M gene. Class I MHC molecules bind peptides generated mainly from degradation of cytosolic proteins by the proteasome. The MHC I:peptide complex is then inserted via endoplasmic reticulum into the external plasma membrane of the cell. The epitope peptide is bound on extracellular parts of the class I MHC molecule. Thus, the function of the class I MHC is to display intracellular proteins to cytotoxic T cells (CTLs). However, class I MHC can also present peptides generated from exogenous proteins, in a process known as cross-presentation.

[0152] A normal cell will display peptides from normal cellular protein turnover on its class I MHC, and CTLs will not be activated in response to them due to central and peripheral tolerance mechanisms. When a cell expresses foreign proteins, such as after viral infection, a fraction of the class I MHC will display these peptides on the cell surface. Consequently, CTLs specific for the MHC:peptide complex will recognize and kill presenting cells. Alternatively, class I MHC itself can serve as an inhibitory ligand for natural killer cells (NKs). Reduction in the normal levels of surface class I MHC, a mechanism employed by some viruses to evade CTL responses, activates NK cell killing.

[0153] As used herein, an "**MHC class II molecule**" refers to a protein product of a wild-type or variant HLA class II gene encoding an MHC class II molecule. Accordingly, "**HLA class II molecule**" and "**MHC class II molecule**" are used interchangeably herein.

[0154] MHC class II molecules are a class of major histocompatibility complex (MHC) molecules normally found only on professional antigen-presenting cells such as dendritic cells, mononuclear phagocytes, some endothelial cells, thymic epithelial cells, and B cells. These cells are important in initiating immune responses. The antigens presented by class II peptides are derived from extracellular proteins (not cytosolic as in MHC class I).

[0155] Like MHC class I molecules, class II molecules are also heterodimers, but in this case consist of two homogenous peptides, an α and β chain, both of which are encoded in the MHC. The subdesignation α1, α2, etc. refers to separate domains within the HLA gene; each domain is usually encoded by a different exon within the gene, and some genes have further domains that encode leader sequences, transmembrane sequences, etc. These molecules have both extracellular regions as well as a transmembrane sequence and a cytoplasmic tail. The α1 and β1 regions of the chains come together to make a membrane-distal peptide-binding domain, while the α2 and β2

regions, the remaining extracellular parts of the chains, form a membrane-proximal immunoglobulin-like domain. The antigen binding groove, where the antigen or peptide binds, is made up of two α-helixes walls and β-sheet. Because the antigen-binding groove of MHC class II molecules is open at both ends while the corresponding groove on class I molecules is closed at each end, the antigens presented by MHC class II molecules are longer, generally between 15 and 24 amino acid residues long. Loading of a MHC class II molecule occurs by phagocytosis; extracellular proteins are endocytosed, digested in lysosomes, and the resulting epitopic peptide fragments are loaded onto MHC class II molecules prior to their migration to the cell surface. In humans, the MHC class II protein complex is encoded by the human leukocyte antigen gene complex (HLA). HLAs corresponding to MHC class II are HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR. Mutations in the HLA gene complex can lead to bare lymphocyte syndrome (BLS), which is a type of MHC class II deficiency.

[0156] As used herein, the terms "**isolate**," "**isolated**," and "**isolating**" or "**purify**," "**purified**," and "**purifying**" as well as "**extracted**" and "**extracting**" are used interchangeably and refer to the state of a preparation (*e.g.*, a plurality of known or unknown amount and/or concentration) of desired EVs, that have undergone one or more processes of purification, *e.g.*, a selection or an enrichment of the desired EV preparation. In some aspects, isolating or purifying as used herein is the process of removing, partially removing (*e.g.*, a fraction) of the EVs from a sample containing producer cells. In some aspects, an isolated EV composition has no detectable undesired activity or, alternatively, the level or amount of the undesired activity is at or below an acceptable level or amount. In other aspects, an isolated EV composition has an amount and/or concentration of desired EVs at or above an acceptable amount and/or concentration. In other aspects, the isolated EV composition is enriched as compared to the starting material (*e.g.*, producer cell preparations) from which the composition is obtained. This enrichment can be by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, 99.9999%, or greater than 99.9999% as compared to the starting material. In some aspects, isolated EV preparations are substantially free of residual biological products. In some aspects, the isolated EV preparations are 100% free, 99% free, 98% free, 97% free, 96% free, 95% free, 94% free, 93% free, 92% free, 91% free, or 90% free of any contaminating biological matter. Residual biological products can include abiotic materials (including chemicals) or unwanted nucleic acids, proteins, lipids, or metabolites. Substantially free of residual biological products can also mean that the EV composition contains no detectable producer cells and that only EVs are detectable.

[0157] As used herein, the term "**immune modulator**" refers to an agent (*i.e.*, payload) that acts on a target (*e.g.*, a target cell) that is contacted with the extracellular vesicle, and regulates the immune system. Non-limiting examples of immune modulator that can be introduced into an EV and/or a producer cell include agents such as, modulators of checkpoint inhibitors, ligands of checkpoint inhibitors, cytokines, derivatives thereof, or any combination thereof. The immune modulator can also include an agonist, an antagonist, an antibody, an antigen-binding fragment, a polynucleotide, such as siRNA, antisense oligonucleotide, a phosphorodiamidate morpholino oligomer (PMO), a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO), miRNA, lncRNA, mRNA DNA, or a small molecule.

[0158] As used herein, the term a "**bio-distribution modifying agent**," which refers to an agent (*i.e.*, payload) that can modify the distribution of extracellular vesicles (*e.g.*, exosomes, nanovesicles) *in vivo* or *in vitro* (*e.g.*, in a mixed culture of cells of different varieties). In some aspects, the term "**targeting moiety**" can be used interchangeably with the term bio-distribution modifying agent. In some aspects, the targeting moiety alters the tropism of the EV ("tropism moiety"). As used herein, the term "**tropism moiety**" refers to a targeting moiety that when expressed on an EV alters and/or enhances the natural movement of the EV. For example, in some aspects, a tropism moiety can promote the EV to be taken up by a particular cell, tissue, or organ. Non-limiting examples of tropism moieties that can be used with the present disclosure include those that can bind to a marker expressed specifically on a dendritic cell (*e.g.*, Clec9A or DEC205) or T cells (*e.g.*, CD3). Unless indicated otherwise, the term "targeting moiety," as used herein, encompasses tropism moieties. The bio-distribution agent can be a biological molecule, such as a protein, a peptide, a lipid, or a carbohydrate, or a synthetic molecule. For example, the bio-distribution modifying agent can be an affinity ligand (e.g., antibody, VHH domain, phage display peptide, fibronectin domain, camelid, VNAR), a synthetic polymer (*e.g.*, PEG), a natural ligand/molecule (*e.g.*, CD40L, albumin, CD47, CD24, CD55, CD59), a recombinant protein (*e.g.*, XTEN), but not limited thereto.

[0159] In certain aspects, the bio-distribution modifying agent, and/or targeting moiety, is displayed on the surface of EVs. The bio-distribution modifying agent can be displayed on the EV surface by being fused to a scaffold protein (*e.g.*, Scaffold X) (*e.g.*, as a genetically encoded fusion molecule). In some aspects, the bio-distribution modifying agent can be displayed on the EV surface by chemical reaction attaching the bio-distribution modifying agent to an EV surface molecule. A non-limiting example is PEGylation. In some aspects, EVs disclosed herein can

further comprise a bio-distribution modifying agent, in addition to an antigen, adjuvant, or immune modulator. Non-limiting examples of bio-distribution modifying agent or targeting moiety that can be used with the present disclosure include a C-type lectin domain family 9 member A (Clec9a) protein, a dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), CD207, CD40, Clec6, dendritic cell immunoreceptor (DCIR), DEC-205, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), MARCO, Clec12a, DC-asialoglycoprotein receptor (DC-ASGPR), DC immunoreceptor 2 (DCIR2), Dectin-1, macrophage mannose receptor (MMR), BDCA-1 (CD303, Clec4c), Dectin-2, Bst-2 (CD317), CD3, or any combination thereof. In certain aspects, the targeting moiety is Clec9a protein. In some aspects, the targeting moiety is a CD3 molecule.

[0160] As used herein, the term "**C-type lectin domain family 9 member A**" (**Clec9a**) protein refers to a group V C-type lectin-like receptor (CTLR) that functions as an activation receptor and is expressed on myeloid lineage cells (*e.g.*, DCs). Huysamen *et al., J Biol Chem* 283(24):16693-701 (2008); U.S. Patent No. 9,988,431 B2, each of which is herein incorporated by reference in its entirety. Synonyms of Clec9a are known and include CD370, DNGR-1, 5B5, HEEE9341, and C-type lectin domain containing 9A. In some aspects, Clec9a protein is expressed on human cDC1 cells. In some aspects, Clec9a protein is expressed on mouse cDC1 and pDC cells. Unless indicated otherwise, Clec9a, as used herein, can refer to Clec9a from one or more species (*e.g.*, humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, and bears).

[0161] As used herein, the term "**CD3**" or "**cluster of differentiation 3**" refers to the protein complex associated with the T cell receptor (TCR). The CD3 molecule is made up of four distinct chains (CD3γ, CD3δ, and two CD3ε chains). These chains associate with the T-cell receptor (TCR) and the ζ-chain to generate an activation signal in T lymphocytes. The TCR, ζ-chain, and CD3 molecules together constitute the TCR complex. CD3 molecules are expressed on all T cells, including both CD4+ T cells and CD8+ T cells. Unless indicated otherwise, CD3, as used herein, can refer to CD3 from one or more species (*e.g.*, humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, and bears).

[0162] As used herein, the term "**payload**" refers to an agent that acts on a target (*e.g.*, a target cell) that is contacted with the EV. In some aspects, unless indicated otherwise, the term payload can be used interchangeably with the term "**biologically active molecules**." Non-limiting examples of payload that can be included on the EV are an antigen, an adjuvant, and/or an immune

modulator. Payloads that can be introduced into an EV and/or a producer cell include agents such as, nucleotides (*e.g.*, nucleotides comprising a detectable moiety or a toxin or that disrupt transcription), nucleic acids (*e.g.*, DNA or mRNA molecules that encode a polypeptide such as an enzyme, or RNA molecules that have regulatory function such as miRNA, dsDNA, lncRNA, siRNA, antisense oligonucleotide, a phosphorodiamidate morpholino oligomer (PMO), a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO), or combinations thereof), amino acids (*e.g.*, amino acids comprising a detectable moiety or a toxin or that disrupt translation), polypeptides (*e.g.*, enzymes), lipids, carbohydrates, and small molecules (*e.g.*, small molecule drugs and toxins). In certain aspects, a payload comprises an antigen. As used herein, the term "**antigen**" refers to any agent that when introduced into a subject elicits an immune response (cellular or humoral) to itself.

[0163] As used herein, the term "**affinity ligand**" refers to a molecule that can selectively and preferentially bind to a specific marker, *e.g.*, expressed on a target cell or on EVs, e.g., a scaffold moiety, e.g., PTGFRN on EVs. As described herein, in some aspects, an affinity ligand comprises a peptide (*e.g.*, linear peptide) or protein that can increase the binding of a molecule of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety) to a moiety on the surface of EVs, *e.g.*, a scaffold moiety disclosed herein. Non-limiting examples of affinity ligands that can be used with the present disclosure include an antibody, phage display peptide, fibronectin domain, camelid, VNAR, VHH domain, and combinations thereof. As used herein, the term "**antibody**" encompasses an immunoglobulin whether natural or partly or wholly synthetically produced, and fragments thereof. The term also covers any protein having a binding domain that is homologous to an immunoglobulin binding domain. "Antibody" further includes a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. Use of the term antibody is meant to include whole antibodies, polyclonal, monoclonal and recombinant antibodies, fragments thereof, and further includes single-chain antibodies, humanized antibodies, murine antibodies, chimeric, mouse-human, mouse-primate, primate-human monoclonal antibodies, anti-idiotype antibodies, antibody fragments, such as, *e.g.*, scFv, $(scFv)_2$, Fab, Fab', and $F(ab')_2$, $F(ab1)_2$, Fv, dAb, and Fd fragments, diabodies, and antibody-related polypeptides. Antibody includes bispecific antibodies and multispecific antibodies so long as they exhibit the desired biological activity or function. Further description of affinity ligands that can be used with an EV are provided elsewhere in the present disclosure (*see, e.g.*, section II.I).

[0164] As used herein, the term "**acceptor domain**" refers to a protein sequence that forms a stable interaction (either covalent or non-covalent) with a cognate protein "**donor domain**." As demonstrated herein, in some aspects, acceptor domains can be displayed on the surface of EVs via fusion to a scaffold moiety (*e.g.*, PTGFRN). In some aspects, by mixing the acceptor EVs (*i.e.*, EVs that comprise the acceptor domain) with a soluble donor (comprising the donor domain and a target molecule of interest) , it can be possible to display the target molecule of interest on the surface of EVs.

[0165] The terms "**individual**," "**subject**," "**host**," and "**patient**," are used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans. The compositions and methods described herein are applicable to both human therapy and veterinary applications. In some aspects, the subject is a mammal, and in other aspects, the subject is a human. As used herein, a "mammalian subject" includes all mammals, including without limitation, humans, domestic animals (*e.g.*, dogs, cats and the like), farm animals (*e.g.*, cows, sheep, pigs, horses and the like) and laboratory animals (*e.g.*, monkey, rats, mice, rabbits, guinea pigs and the like).

[0166] As used herein, the term "**substantially free**" means that the sample comprising EVs comprise less than about 10% of macromolecules by mass/volume (m/v) percentage concentration. Some fractions can contain less than about 0.001%, less than about 0.01%, less than about 0.05%, less than about 0.1%, less than about 0.2%, less than about 0.3%, less than about 0.4%, less than about 0.5%, less than about 0.6%, less than about 0.7%, less than about 0.8%, less than about 0.9%, less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, or less than about 10% (m/v) of macromolecules.

[0167] As used herein, the term "**macromolecule**" means nucleic acids, contaminant proteins, lipids, carbohydrates, metabolites, or a combination thereof.

[0168] As used herein, the term "**conventional exosome protein**" means a protein previously known to be enriched in exosomes, including but is not limited to CD9, CD63, CD81, PDGFR, GPI anchor proteins, lactadherin LAMP2, and LAMP2B, a fragment thereof, or a peptide that binds thereto.

[0169] "**Administering**," as used herein, means to give a composition comprising an EV disclosed herein to a subject via a pharmaceutically acceptable route. Routes of administration can be intravenous, *e.g.*, intravenous injection and intravenous infusion. Additional routes of

administration include, *e.g.*, subcutaneous, intramuscular, oral, nasal, and pulmonary administration. EVs can be administered as part of a pharmaceutical composition comprising at least one excipient.

[0170] An "**immune response**," as used herein, refers to a biological response within a vertebrate against foreign agents or abnormal, *e.g.*, corona virus, which response protects the organism against these agents and diseases caused by them. An immune response is mediated by the action of one or more cells of the immune system (for example, a T lymphocyte, B lymphocyte, natural killer (NK) cell, macrophage, eosinophil, mast cell, dendritic cell or neutrophil) and soluble macromolecules produced by any of these cells or the liver (including antibodies, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and/or elimination from the vertebrate's body of invading pathogens, cells or tissues infected with pathogens, other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues. An immune reaction includes, *e.g.*, activation or inhibition of a T cell, *e.g.*, an effector T cell, a Th cell, a CD4+ cell, a CD8+ T cell, or a Treg cell, or activation or inhibition of any other cell of the immune system, *e.g.*, NK cell. Accordingly an immune response can comprise a humoral immune response (*e.g.*, mediated by B-cells), cellular immune response (*e.g.*, mediated by T cells), or both humoral and cellular immune responses. In some aspects, an immune response is an "inhibitory" immune response. An "**inhibitory**" immune response is an immune response that blocks or diminishes the effects of a stimulus (*e.g.*, antigen). In certain aspects, the inhibitory immune response comprises the production of inhibitory antibodies against the stimulus. In some aspects, an immune response is a "stimulatory" immune response. A "**stimulatory**" immune response is an immune response that results in the generation of effectors cells (*e.g.*, cytotoxic T lymphocytes) that can destroy and clear a target antigen of coronaviruses.

[0171] As used herein, the term "**cellular immune response**" can be used interchangeably with the term "**cell-mediated immune response**" and refers to an immune response that does not predominantly involve antibodies. Instead, a cellular immune response involves the activation of different immune cells (*e.g.*, phagocytes and antigen-specific cytotoxic T-lymphocytes) that produce various effector molecules (*e.g.*, cytokines, perforin, granzymes) upon activation (*e.g.*, via antigen stimulation). As used herein, the term "**humoral immune response**" refers to an immune response predominantly mediated by macromolecules found in extracellular fluids, such as secreted antibodies, complement proteins, and certain antimicrobial peptides. The term "**antibody-**

mediated immune response" refers to an aspect of a humoral immune response that is mediated by antibodies.

[0172] As used herein, the term "**immune cells**" refers to any cells of the immune system that are involved in mediating an immune response. Non-limiting examples of immune cells include a T lymphocyte, B lymphocyte, natural killer (NK) cell, macrophage, eosinophil, mast cell, dendritic cell, neutrophil, or combination thereof. In some aspects, an immune cell expresses CD3. In certain aspects, the CD3-expressing immune cells are T cells (*e.g.*, CD4+ T cells or CD8+ T cells). In some aspects, an immune cell that can be targeted with a targeting moiety disclosed herein (*e.g.*, anti-CD3) comprises a naïve CD4+ T cell. In some aspects, an immune cell comprises a memory CD4+ T cell. In some aspects, an immune cell comprises an effector CD4+ T cell. In some aspects, an immune cell comprises a naïve CD8+ T cell. In some aspects, an immune cell comprises a memory CD8+ T cell. In some aspects, an immune cell comprises an effector CD8+ T cell. In some aspects, an immune cell is a dendritic cell. In certain aspects, a dendritic cell comprises a plasmacytoid dendritic cell (pDC), a conventional dendritic cell 1 (cDC1), a conventional dendritic cell 2 (cDC2), inflammatory monocyte derived dendritic cells, Langerhans cells, dermal dendritic cells, lysozyme-expressing dendritic cells (LysoDCs), Kupffer cells, or any combination thereof. Accordingly, in certain aspects, an immune cell that an EV disclosed herein can specifically target includes a conventional dendritic cell 1 (cDC1) and/or plasmacytoid dendritic cells (pDC).

[0173] As used herein, the term "**T cell**" or "**T-cell**" refers to a type of lymphocyte that matures in the thymus. T cells play an important role in cell-mediated immunity and are distinguished from other lymphocytes, such as B cells, by the presence of a T-cell receptor on the cell surface. T-cells include all types of immune cells expressing CD3, including T-helper cells (CD4+ cells), cytotoxic T-cells (CD8+ cells), natural killer T-cells, T-regulatory cells (Treg), and gamma-delta T cells.

[0174] A "**naïve**" T cell refers to a mature T cell that remains immunologically undifferentiated (*i.e.*, not activated). Following positive and negative selection in the thymus, T cells emerge as either CD4+ or CD8+ naïve T cells. In their naïve state, T cells express L-selectin (CD62L+), IL-7 receptor-α (IL-7R-α), and CD132, but they do not express CD25, CD44, CD69, or CD45RO. As used herein, "**immature**" can also refers to a T cell which exhibits a phenotype characteristic of either a naïve T cell or an immature T cell, such as a TSCM cell or a TCM cell. For example, an immature T cell can express one or more of L-selectin (CD62L+), IL-7Rα, CD132,

CCR7, CD45RA, CD45RO, CD27, CD28, CD95, CXCR3, and LFA-1. Naïve or immature T cells can be contrasted with terminal differentiated effector T cells, such as T_{EM} cells and T_{EFF} cells.

[0175] As used herein, the term "**effector**" T cells or "**T_{EFF}**" cells refers to a T cell that can mediate the removal of a pathogen or cell without requiring further differentiation. Thus, effector T cells are distinguished from naive T cells and memory T cells, and these cells often have to differentiate and proliferate before becoming effector cells.

[0176] As used herein, the term "**memory**" T cells refer to a subset of T cells that have previously encountered and responded to their cognate antigen. In some aspects, the term is synonymous with "**antigen-experienced**" T cells. In some aspects, memory T cells can be effector memory T cells or central memory T cells. In some aspects, the memory T cells are tissue-resident memory T cells. As used herein, the term "**tissue-resident memory T cells**" or "**TRM cells**" refers to a lineage of T cells that occupies tissues (*e.g.*, skin, lung, gastrointestinal tract) without recirculating. TRM cells are transcriptionally, phenotypically and functionally distinct from central memory and effector memory T cells which recirculate between blood, the T cell zones of secondary lymphoid organs, lymph and nonlymphoid tissues. One of the roles of TRM cells is to provide immune protection against infection in extralymphoid tissues.

[0177] As used herein, the term "**dendritic cells**" or "**DCs**" refers to a class of bone-marrow-derived immune cells that are capable of processing extracellular and intracellular proteins and to present antigens in the context of MHC molecules to prime naïve T cells. In some aspects, dendritic cells can be divided into further subtypes, such as conventional dendritic cell 1 (cDC1), conventional dendritic cell 2 (cDC2), plasmacytoid dendritic cell (pDC), inflammatory monocyte derived dendritic cells, Langerhans cells, dermal dendritic cells, lysozyme-expressing dendritic cells (LysoDCs), Kupffer cells, and combinations thereof. In certain aspects, the different DC subsets can be distinguished based on their phenotypic expression. For example, in some aspects, human cDC1 cells are $CD1c^-$ and $CD141^+$. In some aspects, human cDC2 cells are $CD1c^+$ and $CD141^-$. In some aspects, human pDC cells are $CD123^+$. In some aspects, mouse cDC1 cells are $XCR1^+$, $Clec9a^+$, and $Sirpa^-$. In some aspects, mouse cDC2 cells are $CD8^+$, $CD11b^+$, $Sirpa^+$, $XCR1^-$, and $CD1c,b^+$. In some aspects, mouse pDC cells are $CD137^+$, $XCR1^-$, and $Sirpa^-$. Other phenotypic markers for distinguishing the different DC subsets are known in the art. *See, e.g.*, Collin *et al.*, *Immunology* 154(1): 3-20 (2018). In some aspects, the different DC subsets can be distinguished based on their functional properties. For example, in certain aspects, pDCs produce large amounts of IFN-α, while cDC1s and cDC2s produce inflammatory cytokines, such as IL-12,

IL-6, and TNF-α. Other methods of distinguishing the different DC subsets are known in the art. *See*, *e.g.*, U.S. Patent Nos. 8,426,565 B2 and 9,988,431, each of which is herein incorporated by reference in its entirety.

[0178] The term "**immunoconjugate**," as used herein, refers to a compound comprising a binding molecule (*e.g.,* an antibody) and one or more moieties, *e.g.,* therapeutic or diagnostic moieties, chemically conjugated to the binding molecule. In general, an immunoconjugate is defined by a generic formula: A-(L-M)n, wherein A is a binding molecule (*e.g.,* an antibody), L is an optional linker, and M is a heterologous moiety which can be for example a therapeutic agent, a detectable label, etc., and n is an integer. In some aspects, multiple heterologous moieties can be chemically conjugated to the different attachment points in the same binding molecule (*e.g.,* an antibody). In other aspects, multiple heterologous moieties can be concatenated and attached to an attachment point in the binding molecule (*e.g.,* an antibody). In some aspects, multiple heterologous moieties (being the same or different) can be conjugated to the binding molecule (*e.g.,* an antibody).

[0179] Immunoconjugates can also be defined by the generic formula in reverse order. In some aspects, the immunoconjugate is an "**antibody-Drug Conjugate**" ("**ADC**"). In the context of the present disclosure, the term "immunoconjugate" is not limited to chemically or enzymatically conjugates molecules. The term "immunoconjugate" as used in the present disclosure also includes genetic fusions. In some aspects of the present disclosure, the biologically active molecule is an immunoconjugate. The terms "**antibody-drug conjugate**" and "**ADC**" are used interchangeably and refer to an antibody linked, *e.g.,* covalently, to a therapeutic agent (sometimes referred to herein as agent, drug, or active pharmaceutical ingredient) or agents. In some aspects of the present disclosure, the biologically active molecule (*i.e.*, a payload) is an antibody-drug conjugate.

[0180] "**Treat**," "**treatment**," or "**treating**," as used herein refers to, *e.g.*, the reduction in severity of a disease or condition; the reduction in the duration of a disease course; the amelioration or elimination of one or more symptoms associated with a disease or condition; the provision of beneficial effects to a subject with a disease or condition, without necessarily curing the disease or condition. The term also include prophylaxis or prevention of a disease or condition or its symptoms thereof. In one aspect, the term "treating" or "treatment" means inducing an immune response in a subject against an antigen.

[0181] "**Prevent**" or "**preventing**," as used herein, refers to decreasing or reducing the occurrence or severity of a particular outcome. In some aspects, preventing an outcome is achieved through prophylactic treatment.

II. Extracellular Vesicles

[0182] Disclosed herein are EVs capable of regulating the immune system of a subject. As described herein, EVs described herein differ from other platforms (*e.g.*, protein immunization) for regulating an immune system of a subject in that the EVs comprise one or more of the following properties: (i) flexibility of moiety (*e.g.*, antigen) display, (ii) diverse adjuvant and immunomodulatory combinations, (iii) enhanced cell-specific tropism, (iv) enhanced clearance inhibition, or (v) any combination thereof.

[0183] In some aspects, EVs of the present disclosure provide flexibility of moiety display. For instance, the moieties of interest (*e.g.*, antigen) (i) can be directly linked to a surface of the EV (*e.g.*, exterior surface and/or luminal surface), (ii) can be linked to a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y) and then expressed on a surface of the EV (*e.g.*, exterior surface and/or luminal surface), (iii) can be expressed in the lumen of the EV, or (iv) combinations thereof. Such ability to rapidly engineer EVs is particularly useful in developing EV-based vaccines for treating the diseases and disorders described herein. For instance, a single EV engineered to express certain payloads and/or targeting moieties can be used in treating a wide range of diseases or disorders by simply "plugging" a moiety (*e.g.*, antigen of interest) into the EVs (or rapidly attaching a moiety (*e.g.*, antigen of interest) as a "clip-on" attachment to the EVs). Methods of producing such modular or "plug and play" EVs are provided elsewhere in the present disclosure.

[0184] In some aspects, EVs of the present disclosure allow for the diverse combinations of different moieties of interest (*e.g.*, antigens, adjuvants, immunomodulators, and/or targeting moieties). In certain aspects, the EVs allow for the combination of a wide range of adjuvants and immunomodulators. Non-limiting examples of adjuvants and immunomodulators that can be combined in a single EV include small molecule agonists (*e.g.*, STING), small molecule antagonists, co-stimulatory proteins, anti-sense and bacterial adjuvant oligonucleotides. Additional disclosure relating to the different moieties that can be combined together are provided elsewhere in the present disclosure.

[0185] In some aspects, EVs described herein can be engineered to exhibit enhanced cell-specific tropism. For instance, the EVs can be engineered to express on their exterior surface a targeting moiety (*e.g.*, antibodies and/or proteins) that can specifically bind to a marker on a

specific cell. In some aspects, EVs described herein can be engineered to induce certain types of immune responses (*e.g.*, T cell, B cell, and/or Treg/tolerogenic immune responses). Additional disclosure relating to such properties are provided elsewhere in the present disclosure.

[0186] The EVs useful in the present disclosure have been engineered to produce multiple (*e.g.*, at least two) exogenous biologically active molecules (*e.g.*, an antigen, an antibody or an antigen-binding fragment thereof, an adjuvant, and/or an immune modulator), and/or other moieties (*e.g.*, a targeting moiety) together in a single EV. In some aspects, an EV comprises three exogenous biologically active molecules. In other aspects, an EV comprises four exogenous biologically active molecules. In further aspects, an EV comprises five or more exogenous biologically active molecules. In some aspects, an EV comprises 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more exogenous biologically active molecules.

[0187] In some aspects, an EV comprises two or more exogenous biologically active molecules, *e.g.,* (i) one or more antigens and (ii) one or more adjuvants. In other aspects, an EV comprises two or more exogenous biologically active molecules, *e.g.,* (i) one or more antigens and (ii) one or more immune modulators. In further aspects, an EV comprises two or more exogenous biologically active molecules, *e.g.,* (i) one or more antigens, (ii) one or more immune modulators, and (iii) one or more adjuvants. In certain aspects, an EV can further comprise one or more additional moieties, *e.g.,* targeting moieties. In some aspects, an antigen is not expressed (or presented) on major histocompatibility complex I and/or II molecules. In other aspects, while an antigen in the EV is not expressed or presented as part of the MHC class I or II complex, the EV can still contain MHC class I/II molecules on the surface of the EV. Accordingly, in certain aspects, EVs disclosed herein do not directly interact with T-cell receptors (TCRs) of T cells to induce an immune response against the antigen. Similarly, in certain aspects, EVs of the present disclosure do not transfer the antigen directly to the surface of the target cell (*e.g.*, dendritic cell) through cross-dressing. Cross-dressing is a mechanism commonly used by EVs derived from dendritic cells (DEX) to induce T cell activation. *See* Pitt, J.M., *et al.*, *J Clin Invest* 126(4): 1224-32 (2016). In other aspects, the EVs of the present disclosure are engulfed by antigen presenting cells and can be expressed on the surface of the antigen presenting cells as MHC class I and/or MHC class II complex.

[0188] In certain aspects, an EV disclosed herein can also comprise additional moieties, such as a targeting moiety. In some aspects, an antigen is expressed or presented on major histocompatibility complex I and/or II molecules. In other aspects, while an antigen in the EV is

expressed or presented as part of the MHC class I or II complex, the EV can contain MHC class I/II molecules on the surface of the EV. Accordingly, in certain aspects, EVs disclosed herein directly interact with T-cell receptors (TCRs) of T cells to induce an immune response against the antigen. Similarly, in certain aspects, EVs of the present disclosure transfer the antigen directly to the surface of the target cell (*e.g.*, dendritic cell) through cross-dressing. "**Cross-dressing**" is a mechanism commonly used by EVs derived from dendritic cells (DEX) to induce T cell activation. *See* Pitt, J.M., *et al.*, *J Clin Invest* 126(4): 1224-32 (2016). In other aspects, the EVs of the present disclosure are engulfed by antigen presenting cells and can be expressed on the surface of the antigen presenting cells as MHC class I and/or MHC class II complex.

[0189] As described *supra*, EVs described herein are extracellular vesicles with a diameter between about 20-300 nm. In certain aspects, an EV of the present disclosure has a diameter between about 20-290 nm, between about 20-280 nm, between about 20-270 nm, between about 20-260 nm, between about 20-250 nm, between about 20-240 nm, between about 20-230 nm, between about 20-220 nm, between about 20-210 nm, between about 20-200 nm, between about 20-190 nm, between about 20-180 nm, between about 20-170 nm, between about 20-160 nm, between about 20-150 nm, between about 20-140 nm, between about 20-130 nm, between about 20-120 nm, between about 20-110 nm, between about 20-100 nm, between about 20-90 nm, between about 20-80 nm, between about 20-70 nm, between about 20-60 nm, between about 20-50 nm, between about 20-40 nm, or between about 20-30 nm. The size of the EV described herein can be measured according to methods described, *infra*.

[0190] In some aspects, an EV of the present disclosure comprises a bi-lipid membrane ("**EV membrane**"), comprising an interior surface and an exterior surface. In certain aspects, the interior surface faces the inner core (*i.e.*, lumen) of the EV. In certain aspects, the exterior surface can be in contact with the endosome, the multivesicular bodies, or the membrane/cytoplasm of a producer cell or a target cell

[0191] In some aspects, the EV membrane comprises lipids and fatty acids. In some aspects, the EV membrane comprises phospholipids, glycolipids, fatty acids, sphingolipids, phosphoglycerides, sterols, cholesterols, and phosphatidylserines.

[0192] In some aspects, the EV membrane comprises an inner leaflet and an outer leaflet. The composition of the inner and outer leaflet can be determined by transbilayer distribution assays known in the art, *see, e.g.*, Kuypers *et al., Biohim Biophys Acta* 1985 819:170. In some aspects, the composition of the outer leaflet is between approximately 70-90% choline phospholipids,

between approximately 0-15% acidic phospholipids, and between approximately 5-30% phosphatidylethanolamine. In some aspects, the composition of the inner leaflet is between approximately 15-40% choline phospholipids, between approximately 10-50% acidic phospholipids, and between approximately 30-60% phosphatidylethanolamine.

[0193] In some aspects, the EV membrane comprises one or more polysaccharide, such as glycan.

[0194] In some aspects, the EV membrane further comprises one or more scaffold moieties, which are capable of anchoring, *e.g.*, an antigen and/or an adjuvant and/or an immune modulator, to the EV (*e.g.*, either on the luminal surface or on the exterior surface). In certain aspects, scaffold moieties are polypeptides ("exosome proteins"). In other aspects, scaffold moieties are non-polypeptide moieties. In some aspects, exosome proteins include various membrane proteins, such as transmembrane proteins, integral proteins and peripheral proteins, enriched on the exosome membranes. They can include various CD proteins, transporters, integrins, lectins, and cadherins. In certain aspects, a scaffold moiety comprises Scaffold X. In other aspects, a scaffold moiety comprises Scaffold Y. In further aspects, a scaffold moiety comprises both a Scaffold X and a Scaffold Y.

[0195] In some aspects, an EV disclosed herein is capable of delivering a payload (*e.g.*, an antigen, an adjuvant, and/or an immune modulator) to a target. The payload is an agent that acts on a target (*e.g.*, a target cell) that is contacted with the EV. Contacting can occur *in vitro* or in a subject. Non-limiting examples of payloads that can be introduced into an EV include agents such as, nucleotides (*e.g.*, nucleotides comprising a detectable moiety or a toxin or that disrupt transcription), nucleic acids (*e.g.*, DNA or mRNA molecules that encode a polypeptide such as an enzyme, or RNA molecules that have regulatory function such as miRNA, dsDNA, lncRNA, siRNA, antisense oligonucleotide, a phosphorodiamidate morpholino oligomer (PMO), or a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)), amino acids (*e.g.*, amino acids comprising a detectable moiety or a toxin that disrupt translation), polypeptides (*e.g.*, enzymes), lipids, carbohydrates, and small molecules (*e.g.*, small molecule drugs and toxins).

[0196] As demonstrated herein, in some aspects, EVs of the present disclosure are capable of inducing effector and memory T cells. In certain aspects, the memory T cells are tissue-resident memory T cells. Such EVs could be particularly useful as vaccines for certain infectious diseases, such as those described herein, *e.g.*, coronavirus, e.g., SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus.

[0197] In some aspects, EVs disclosed herein are inherently capable of inducing the activation of a signaling pathway involved in an immune response. In certain aspects, the signaling pathway involved in an immune response comprises toll-like receptors (TLRs), retinoid acid-inducible gene I (RIG-I)-like receptors (RLRs), stimulator of interferon genes (STING) pathway, or combinations thereof. In some aspects, the activation of such signaling pathway can result in the production of a type I interferon. For example, in certain aspects, the bi-lipid membrane of an EV disclosed herein comprises one or more lipids that share one of the following features: (i) unsaturated lipid tail, (ii) dihydroimidazole linker, (iii) cyclic amine head groups, and (iv) combinations thereof. Lipids with such features have been shown to activate the TLR/RLR-independent STING pathway. *See* Miao *et al.*, *Nature Biotechnology* 37:1174-1185 (Oct. 2019), which is herein incorporated by reference in its entirety.

II.A Antigen

[0198] In some aspects, an antigen that can be added to a base EV to produce the EV-based vaccines disclosed herein comprises any antigen known in the art, which is capable of eliciting a beneficial immune response in a subject. As used herein, a "**beneficial immune response**" is an immune response that is capable of treating (*e.g.*, reducing and/or alleviating one or more symptoms) and/or preventing a disease or disorder, such as those described herein.

[0199] In some aspects, an antigen comprises a peptide. In certain aspects, the peptide comprises a natural peptide (*e.g.*, such as that derived from a naturally-existing organism, *e.g.*, virus). In some aspects, the peptide comprises a synthetic peptide. In some aspects, the peptide comprises both natural and synthetic peptides.

[0200] In some aspects, the peptide is less than about 150 amino acids in length, less than about 140 amino acids in length, less than about 130 amino acids in length, less than about 120 amino acids in length, less than about 110 amino acids in length, less than about 100 amino acids in length, less than about 90 amino acids in length, less than about 80 amino acids in length, less than about 70 amino acids in length, less than about 60 amino acids in length, less than about 50 amino acids in length, less than about 40 amino acids in length, less than about 30 amino acids in length, less than about 20 amino acids in length, or less than about 10 amino acids in length. In certain aspects, the peptide is less than about 100 amino acids in length. In some aspects, the peptide is less than about 80 amino acids in length.

[0201] In some aspects, an antigen useful for the present disclosure is a polynucleotide, *e.g.*, an mRNA. In some aspects, an antigen useful for the disclosure is a synthetic mRNA encoding an epitope.

[0202] As described herein, in some aspects, an antigen can be linked to the exterior surface and/or luminal surface of EVs by various methods, including, but not limited to, anchoring moieties, affinity agents, chemical conjugation, or combinations thereof. To improve the attachment of the antigens to a surface of the EVs using such methods, the antigens described herein can be further modified. In certain aspects, an antigen comprises a peptide, which has been modified to contain a N-terminal lysine.

[0203] In some aspects, such a modification allows for the attachment of the antigen to a surface of the EV with chemical conjugation. For example, to enable click chemistry conjugation, an azide or strained alkyne (*e.g.*, difluorinated cyclooctyne (DIFO)) would have to be attached (or linked) to the EV and/or to the antigen. In certain aspects, DIFO conjugates to the to the primary amine side chain on the N-terminal lysine of the antigen, which in turn can interact with the azide that can be attached to a surface of the EV. In some aspects, the azide can be attached to the antigen (via the primary amine side chain on the N-terminal lysine), and the strained alkyne can be attached to a surface of the EV.

[0204] In some aspects, modifying the antigen to comprise a N-terminal lysine can also be useful in linking the antigens to a surface of the EVs using anchoring moieties. In such aspects, the anchoring moiety (*i.e.*, cholesterol, fatty acid, and/or vitamin E) can attach to the N-terminal lysine via the primary amine side chain. Once attached, the antigens can be readily inserted into the membrane of the EVs via the anchoring moieties.

[0205] As will be apparent to those skilled in the arts, the above described approaches to linking an antigen to the exterior surface and/or luminal surface of the EVs can also be performed by modifying one or more proteins on the EVs to contain unnatural amino acids with side chains to allow for the binding of molecules such as the azide, strained alkyne (*e.g.*, difluorinated cyclooctyne (DIFO), or combinations thereof. Additional disclosure regarding such approaches to linking an antigen to a surface of the EVs are provided elsewhere in the present disclosure. While the above disclosures are provided in the context of antigens, it will be readily apparent to those skilled in the arts that similar approaches can be used to link other moieties of interest (*e.g.*, adjuvant, targeting moiety, and/or scaffold moiety) to a surface of the EVs.

[0206] As is apparent from the present disclosure, an antigen useful for the present disclosure can comprise various structure and/or length. In some aspects, the differences in the structure and/or length can affect the potency of the EV-based vaccines described herein. In some aspects, the antigen comprises a linear epitope of a protein from which it is derived (*e.g.*, T and/or B cell antigen of a coronavirus), a conformational epitope, or both.

[0207] Non-limiting examples of possible antigen structure are provided below. As described herein, any single aspect of the exemplary structures can be modified. For instance, the length of any of the components noted below can be modified (lengthened or shortened). Additionally, any of the components may be removed (*e.g.*, remove a spacer) or additional components can be added (*e.g.*, add more spacers).

[0208] In some aspects, the antigen comprises a single antigen. In some aspects, the antigen comprises a T cell antigen, which comprises a CD8+ T cell epitope, CD4+ T cell epitope, or both. For example, in certain aspects, an antigen has the following structure: (first flanking region)-(T cell antigen)-(second flanking region). In some aspects, the T cell antigen comprises a CD8+ T cell epitope and is 9 amino acids in length (*e.g.*, T cell antigen of a coronavirus), and each of the first and second flanking regions is 5 amino acids in length, such that the entire antigen is 19 amino acids in length. In some aspects, the T cell antigen comprises a CD4+ T cell epitope and is 25 amino acids in length (*e.g.*, T cell antigen of a coronavirus), and each of the first and second flanking regions is 5 amino acids in length, such that the entire antigen is 35 amino acids in length. As described herein, in some aspects, the antigen comprises a N-terminal lysine.

[0209] In some aspects, the antigen comprises a B cell antigen. In certain aspects, such antigen has the following structure: (B cell antigen)-(spacer)-(T helper peptide). In certain aspects, the B cell antigen (*e.g.*, S2 antigen of a coronavirus) is 31 amino acids in length, the spacer is 3 amino acids in length, and the T helper peptide (*e.g.*, PADRE) is 13 amino acids in length, such that the entire antigen is 47 amino acids in length. Non-limiting examples of spacers that can be used comprise one the following amino acid sequences: CPGPG (SEQ ID NO: 579), AAY, GSGSGS (SEQ ID NO: 580), or combinations thereof.As described herein, in some aspects, the antigen comprises a N-terminal lysine.

[0210] In some aspects, the antigen comprises a concatemer of multiple epitopes of an antigen. For instance, in certain aspects, an antigen has the following structure: (first flanking region)-(first T cell antigen)-(first spacer)-(second T cell antigen)-(second spacer)-(third T cell antigen)-(second flanking region). In some aspects, the first and second flanking regions are 5

amino acids in length; the first, second, and third T cell antigens are 9 amino acids in length; and the first and second spacers are 3 amino acids in length, such that the entire antigen is 43 amino acids in length. As described herein, in some aspects, the antigen comprises a N-terminal lysine.

[0211] In some aspects, the potency of the EV-based vaccines of the present disclosure can be regulated by modifying the structure and/or overall length (*e.g.*, the lengths of the flanking region, spacers, and/or T and B cell antigens).

[0212] As described elsewhere in the present disclosure, the EV-based vaccines described herein can be used to treat a wide range of diseases and disorders, *e.g.*, by simply adding an antigen of interest to the base EV. In some aspects, the antigen is derived from and/or comprises a virus, a bacterium, a parasite, a fungus, a protozoa, a tumor, an allergen, a self-antigen, or any combination thereof.

[0213] In some aspects, the antigen is derived from a virus. In some aspects, the antigen is derived from a virus causing a pandemic. As used herein, the term "**pandemic**" refers to the rapid spread of a certain disease, involving a wide area, and a large proportion of the population, which can form a worldwide epidemic across provincial, national, or even continental borders in a short period of time. In certain aspects, an antigen that can be added to an EV to produce an EV-based vaccine described herein is derived from a virus selected from a coronavirus, an influenza virus, an Ebola virus, a Chikungunya virus (CHIKV), a Crimean-Congo hemorrhagic fever (CCGF) virus, a Hendra virus, a Lassa virus, a Marburg virus, a monkeypox virus, a Nipah virus, a Hendra virus, a Rift Valley fever (RVF) virus, a Variola virus, a yellow fever virus, a Zika virus, a measles virus, a human immunodeficiency virus (HIV), a hepatitis C virus (HCV), a dengue fever virus (DENV), a parvovirus (*e.g.*, B19 virus), a norvovirus, a respiratory syncytial virus (RSV), a lentivirus, an adenovirus, a flavivirus, a filovirus, a rhinovirus, a human papillomavirus (HPV), or any combination thereof.

[0214] In some aspects, the antigen is derived from a non-viral pathogen (*e.g.*, a bacterium, parasite, fungus, protozoa, or combinations thereof). Non-limiting examples of such pathogens include: *Vibrio cholera*, *Yersinia pestis* bacteria, *Mycobacterium tuberculosis* (MTB), *streptococcus* (*e.g.*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*), *staphylococcal* bacteria (*e.g.*, *Staphylococcus aureus*), *shigella*, *Escherichia coli*, *salmonella*, *chlamydia* (*e.g.*, *chlamydia trachomatis*), *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Haemophilus influenza*, *Clostridia difficile*, *Plasmodium*, *Leishmania*, *Schistosoma*, *Trypanosoma*, *Brucella*, *Cryptosporidium*, *Entamoeba*, *Neisseria meningitis*, *Bacillus subtilis*,

Haemophilius influenzae, *Neisseria gonorrhoeae*, *Borrelia burgdorferi*, *corynebacterium diphteriae*, *moraxella catarrhalis*, *campylobacter jejuni*, *clostridium tetanus*, *clostridium perfringens*, *treponema pallidum*, or any combination thereof.

[0215] Additional examples of antigens that can be expressed in an EV of the present disclosure (*e.g.*, using the plug-and-play methods described herein) are provided in WO2020191361A2, which is incorporated herein by reference in its entirety.

[0216] In some aspects, the payload is an antigen derived from a coronavirus (also referred to herein as "coronavirus antigen"), which is capable of inducing an immune response in a subject. In some aspects, the coronavirus is an alphacoronavirus, a betacoronavirus, a gammacoronavirus, a deltacoronavirus, or combinations thereof. Exemplary description of such coronaviruses are provided in, *e.g.*, Krichel *et al.*, *Sci Adv* 7(10):eabf1004 (Mar. 2021), which is incorporated herein by reference in its entirety. In some aspects, the coronavirus comprises SARS-CoV-1 and/or SARS-CoV-2 (COVID-19). In some aspects, the coronavirus comprises Middle East respiratory syndrome-related coronavirus (MERS-CoV; also known as EMC/2012). Unless indicated otherwise, an antigen that can be expressed in an EV disclosed herein can be derived from any species of coronavirus. For instance, in certain aspects, an EV described herein comprises an antigen derived from a bat coronavirus (BtCoV), such as that described in Tsuda *et al.*, *Arch Virol* 157(12): 2349-55 (Dec. 2012), which is incorporated herein by reference in its entirety. In some aspects, the coronavirus comprises zoonotic coronaviruses (*i.e.*, jumped from an animal to human). *See, e.g.*, Cohen *et al.*, *Science* 371(6530): 735-741 (Feb. 2021), which is incorporated herein by reference in its entirety. While certain aspects of the present disclosure relates to SARS-CoV-1 and/or SARS-CoV-2 (COVID-19), it will be apparent to those skilled in the arts that, in some aspects, such disclosures can equally apply to other types of coronaviruses (*e.g.*, MERS-CoV). Additionally, it will be apparent to those skilled in the arts that any relevant disclosure relating to a coronavirus described herein can equally apply to any other antigens described herein.

[0217] In some aspects, an EV disclosed herein comprises a single antigen. In some aspects, an EV disclosed herein comprises multiple antigens. In certain aspects, each of the multiple antigens is different. For instance, in some aspects, the multiple antigens can be derived from the same species of coronavirus (*e.g.*, multiple different proteins of COVID-19). In some aspects, the multiple antigens can be derived from different species of coronavirus (*e.g.*, one or more proteins from SARS-CoV-1, SARS-CoV-2, and MERS-CoV). In some aspects, an EV disclosed herein comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different antigens. As disclosed herein, an antigen

can be linked to a surface of an EV using a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y). In certain aspects, an antigen can be directly linked (*i.e.*, without the use of a scaffold moiety) to a surface of an EV. In some aspects, an antigen can be in the lumen of the EV. As is apparent from the present disclosure, in some aspects, an EV comprising an antigen (*e.g.*, coronavirus antigen) can be used in combination with one or more additional antigens which are in a soluble form (*i.e.*, not associated with an EV). For instance, in certain aspects, an EV-based vaccine described herein comprises (i) an EV comprising the RBD protein of a coronavirus ("exoRBD"), and (ii) a soluble peptide antigen comprising a coronavirus T cell epitope. As described herein, in some aspects, the exoRBD can further comprise an adjuvant (*e.g.*, STING agonist).

[0218] In some aspects, an EV comprises the one or more antigens in combination with one or more additional payloads described herein (*e.g.*, adjuvant and/or immune modulator). In some aspects, an EV can comprise one or more additional moieties (*e.g.*, targeting moiety). For instance, in certain aspects, an EV disclosed herein can comprise (i) one or more additional antigens, (ii) one or more additional payloads (*e.g.*, adjuvant and/or immune modulator), and (iii) one or more targeting moieties.

[0219] In some aspects, the antigen useful for the present disclosure is a universal antigen that is capable of inducing an immune response against any SARS coronavirus, e.g., SARS-CoV-1 and SARS-CoV-2 (COVID-19) virus. Therefore, in some aspects, the antigen useful for the present disclosure comprises an amino acid sequence that has at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to at least five consecutive amino acids from a protein of a SARS coronavirus. In certain aspects, the universal antigen is derived from proteins of multiple coronaviruses (*e.g.*, SARS-CoV-1, SARS-CoV-2, and MERS), such that an EV comprising the universal antigen is capable of inducing an immune response against many different types of coronaviruses (*i.e.*, cross-reactive immune response) when the EV is administered to a subject. As described herein, in some aspects, the universal antigen is derived from the RBD protein of different coronaviruses (*e.g.*, RBD from SARS-CoV-1, SARS-CoV-2, and MERS).

[0220] The coronavirus antigen that is useful for the present disclosure can be derived from any coding region of a coronavirus genome. For instance, in some aspects, the coronavirus antigen is derived from one or more of the open reading frames (ORFs), which code for accessory proteins, such as those that are not essential for virus replication but appear to have a role in pathogenesis. Non-limiting examples of such ORFs include ORF1a, ORF1b, ORF3a, ORF3b, ORF7b, ORF9b,

ORF9c, ORF10, or combinations thereof. *See, e.g.*, Michel *et al.*, *Virol J* 17(1):131 (Aug. 2020); and Finkel *et al.*, *Nature* 589: 125-130 (Sep. 2020); each of which is incorporated herein by reference in its entirety. In certain aspects, the coronavirus antigen is derived from one or more of the coronavirus structural proteins: spike protein, membrane protein, envelope protein, and nucleocapsid protein.

[0221] In some aspects, the EVs of the present disclosure comprises at least two antigens, wherein the first antigen is capable of inducing a humoral immune response, e.g., a B cell response and the second antigen is capable of inducing a cellular immune response, e.g., a T cell (e.g., CD8+ cell) response. In some aspects, the humoral immune response inducing antigen is on the exterior surface of the EVs. In some aspects, the cellular immune response inducing antigen is in the lumen (on the luminal surface) of the EVs. In some aspects, the humoral immune response inducing antigen is in the lumen (on the luminal surface) of the EVs. In some aspects, the cellular immune response inducing antigen is on the exterior surface of the EVs.

[0222] In some aspects, the antigen useful for the present disclosure comprises a receptor binding motif (also known as the "**receptor-binding domain**" (RBD)) of a spike protein derived from a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. As used herein, the term "receptor-binding domain" or "RBD" includes all known RBDs of a coronavirus, such as that set forth in SEQ ID NO: 581, and any variants thereof. In some aspects, the antigen comprises at least five amino acids of the extracelluar domain of an S protein from a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. A spike protein of a coronavirus disclosed herein comprises a trimeric class I fusion protein, which can be in the down (closed) or up (open) conformation. As shown in FIG. 3, the receptor-binding domain of a coronavirus spike protein is exposed when the spike protein is in the up (open) conformation. As described herein, in some aspects, an EV comprises the spike protein of a coronavirus (or a fragment thereof) as the antigen. In such aspects, the spike protein can be in the trimeric configuration. In some aspects, the spike protein can be displayed in the EV as a monomeric subunit. Additional disclosures relating to the spike protein of a coronavirus disclosed herein, as well as the different subunits (*e.g.*, RBD), are provided in Du, L., *et al., Nature Reviews Microbiology* 7:226-236 (2009), which is herein incorporated by reference in its entirety. In certain aspects, the RBD is a monomer. In some aspects, the RBD is a dimer, such as that described in Dai *et al.*, *Cell* 182(3): 722-733 (Aug. 2020), which is herein incorporated by reference in its entirety.

[0223] In some aspects, the antigen useful for the present disclosure comprises at least five amino acids from spike protein S1, S2, and/or S2' from a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, the antigen useful for the present disclosure comprises at least five amino acids from spike protein S1 from a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, the antigen useful for the present disclosure comprises at least five amino acids from spike protein S2 from a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, the antigen comprises a highly conserved region of a coronavirus spike S2 protein that lacks glycosylation ("**glycan hole**"). *See, e.g.*, Yuan *et al.*, *Nat Commun* 8:15092 (Apr. 2017), which is incorporated herein by reference in its entirety. In some aspects, the antigen useful for the present disclosure comprises at least five amino acids from spike protein S2' from a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, the antigen useful for the present disclosure comprises at least five amino acids from spike protein S2' from a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In certain aspects, the antigen comprises a linear epitope derived from the S2 protein. In some aspects, the antigen comprises a conformation epitope of the S2 protein, wherein the conformational epitope is capable of eliciting an immune response and/or is capable of folding into a fold naturally found in the S2 protein.

[0224] In some aspects, the antigen comprises an amino acid epitope derived from a coronavirus, e.g., a coronavirus, e.g., SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, the EV comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more antigens, wherein the first antigen is derived from a coronavirus, e.g., SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, the second antigen is also derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, the second antigen is not derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, the first and second antigens are derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, the first and second antigens are the same. In some aspects, the first and second antigens are the same. In other aspects, the first antigen is derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and the second antigen is not derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus.

[0225] In some aspects, the antigen derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is derived from a spike (S) protein, including any variants thereof. In certain aspects, the antigen comprises the entire S protein. In some aspects, the antigen

comprises a fragment of the S protein. In some aspects, the antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the S protein.

[0226] In some aspects, the antigen derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is derived from an envelope (E) protein, including any variants thereof. In certain aspects, the antigen comprises the entire E protein. In some aspects, the antigen comprises a fragment of the E protein. In some aspects, the antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the E protein.

[0227] In some aspects, the antigen derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is derived from a membrane (M) protein, including any variants thereof. In certain aspects, the antigen comprises the entire M protein. In some aspects, the antigen comprises a fragment of the M protein. In some aspects, the antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the M protein.

[0228] In some aspects, a first antigen is derived from an S protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, e.g., a COVID-19 virus, and the second antigen is derived from an antigen from a coronavirus, e.g., an S protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, a first antigen is derived from an S protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, e.g., a COVID-19 virus, and the second antigen is derived from an E protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, a first antigen is derived from an S protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and the second antigen is derived from an M protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus.

[0229] In some aspects, a first antigen is derived from an E protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and the second antigen is derived from an S protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, a first antigen is derived from an E protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and the second antigen is derived from an E protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, a first antigen is derived from an E protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and the second antigen is derived from an M protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus.

[0230] In some aspects, a first antigen is derived from an M protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and the second antigen is derived from an S protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, a first antigen is derived from an M protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and the second antigen is derived from an E protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. In some aspects, a first antigen is derived from an M protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and the second antigen is derived from an M protein of a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus. Exemplary coronavirus sequences are disclosed below:

Table 1.

SARS-CoV-1 Spike Protein (UniProtKB - P59594 (SPIKE_CVHSA))
MFIFLLFLTL TSGSDLDRCT TFDDVQAPNY TQHTSSMRGV YYPDEIFRSD
TLYLTQDLFL PFYSNVTGFH TINHTFGNPV IPFKDGIYFA ATEKSNVVRG
WVFGSTMNNK SQSVIIINNS TNVVIRACNF ELCDNPFFAV SKPMGTQTHT
MIFDNAFNCT FEYISDAFSL DVSEKSGNFK HLREFVFKNK DGFLYVYKGY
QPIDVVRDLP SGFNTLKPIF KLPLGINITN FRAILTAFSP AQDIWGTSAA
AYFVGYLKPT TFMLKYDENG TITDAVDCSQ NPLAELKCSV KSFEIDKGIY
QTSNFRVVPS GDVVRFPNIT NLCPFGEVFN ATKFPSVYAW ERKKISNCVA
DYSVLYNSTF FSTFKCYGVS ATKLNDLCFS NVYADSFVVK GDDVRQIAPG
QTGVIADYNY KLPDDFMGCV LAWNTRNIDA TSTGNYNYKY RYLRHGKLRP
FERDISNVPF SPDGKPCTPP ALNCYWPLND YGFYTTTGIG YQPYRVVVLS
FELLNAPATV CGPKLSTDLI KNQCVNFNFN GLTGTGVLTP SSKRFQPFQQ
FGRDVSDFTD SVRDPKTSEI LDISPCSFGG VSVITPGTNA SSEVAVLYQD
VNCTDVSTAI HADQLTPAWR IYSTGNNVFQ TQAGCLIGAE HVDTSYECDI
PIGAGICASY HTVSLLRSTS QKSIVAYTMS LGADSSIAYS NNTIAIPTNF
SISITTEVMP VSMAKTSVDC NMYICGDSTE CANLLLQYGS FCTQLNRALS
GIAAEQDRNT REVFAQVKQM YKTPTLKYFG GFNFSQILPD PLKPTKRSFI
EDLLFNKVTL ADAGFMKQYG ECLGDINARD LICAQKFNGL TVLPPLLTDD
MIAAYTAALV SGTATAGWTF GAGAALQIPF AMQMAYRFNG IGVTQNVLYE
NQKQIANQFN KAISQIQESL TTTSTALGKL QDVVNQNAQA LNTLVKQLSS
NFGAISSVLN DILSRLDKVE AEVQIDRLIT GRLQSLQTYV TQQLIRAAEI
RASANLAATK MSECVLGQSK RVDFCGKGYH LMSFPQAAPH GVVFLHVTYV
PSQERNFTTA PAICHEGKAY FPREGVFVFN GTSWFITQRN FFSPQIITTD
NTFVSGNCDV VIGIINNTVY DPLQPELDSF KEELDKYFKN HTSPDVDLGD
ISGINASVVN IQKEIDRLNE VAKNLNESLI DLQELGKYEQ YIKWPWYVWL
GFIAGLIAIV MVTILLCCMT SCCSCLKGAC SCGSCCKFDE DDSEPVLKGV

KLHYT (SEQ ID NO: 417)

Extracellular domain: 14 – 1195

Transmembrane domain: 1196 – 1216

Cytoplasmic domain: 1217 – 1255

Signal peptide	1 – 13	
Chain	14 – 1255	Spike glycoprotein
Chain	14 – 667	Spike protein S1
Chain	668 – 1255	Spike protein S2
Chain	798 – 1255	Spike protein S2'

SARS-CoV-1 Envelop Protein (UniProtKB - P59637 (VEMP_CVHSA))

MYSFVSEETG TLIVNSVLLF LAFVVFLLVT LAILTALRLC AYCCNIVNVS

LVKPTVYVYS RVKNLNSSEG VPDLLV (SEQ ID NO: 418)

SARS-CoV-1 Membrane Protein (UniProtKB - P59596 (VME1_CVHSA))

MADNGTITVE ELKQLLEQWN LVIGFLFLAW IMLLQFAYSN RNRFLYIIKL

VFLWLLWPVT LACFVLAAVY RINWVTGGIA IAMACIVGLM WLSYFVASFR

LFARTRSMWS FNPETNILLN VPLRGTIVTR PLMESELVIG AVIIRGHLRM

AGHSLGRCDI KDLPKEITVA TSRTLSYYKL GASQRVGTDS GFAAYNRYRI

GNYKLNTDHA GSNDNIALLV Q (SEQ ID NO: 419)

[0231] In some aspects, an antigen (*e.g.*, for inducing a humoral immune response) that is useful for the present disclosure is derived from a region of a coronavirus other than the receptor binding domain of a spike protein (S1 protein) and/or other conserved regions (*e.g.*, within the M and/or N protein). In certain aspects, an EV comprising such an antigen can reduce the risk of antibody dependent enhancement of viral infection.

[0232] As described herein, in some aspects, an antigen derived from a coronavirus is expressed in an EV linked to a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y). In some aspects, a coronavirus antigen disclosed herein can be linked directly to the surface (*e.g.*, exterior surface) of an EV. As further described elsewhere in the present disclosure, in some aspects, a coronavirus antigen that can be expressed in an EV of the present disclosure comprises a spike protein derived from a coronavirus. In certain aspects, the coronavirus comprises SARS-CoV-1, SARS-CoV-2 (COVID-19), MERS-CoV, or combinations thereof.

[0233] In some aspects, a coronavirus spike protein (*i.e.*, antigen) that can be expressed in an EV comprises the entire (*i.e.*, full-length) trimeric protein (*i.e.*, "**spike trimer**"). Accordingly, in certain aspects, the spike trimer is linked directly to the surface (*e.g.*, exterior surface) of an EV.

[0234] In some aspects, a coronavirus spike protein (*i.e.*, antigen) that can be expressed in an EV comprises a monomeric subunit of the trimeric spike protein (*i.e.*, "**spike monomer**"). In some aspects, the spike monomer is linked directly to the surface (*e.g.*, exterior surface) of an EV. In some aspects, the spike monomer is expressed on the surface (*e.g.*, exterior surface) of an EV linked to a scaffold moiety disclosed herein (*e.g.*, Scaffold X and/or Scaffold Y). In certain aspects, the spike monomer is expressed on the exterior surface of an EV linked to a Scaffold X.

[0235] In some aspects, a coronavirus spike protein (*i.e.*, antigen) that can be expressed in an EV comprises one or more subunits of a full-length spike protein (*i.e.*, "**exo-split-Spike**"). The structure of the coronavirus spike protein, along with its different subunits, is known in the art. *See, e.g.*, Fang Li, *Annu Rev Virol* 3(1): 237-261 (Sep. 2016). In some aspects, any of the subunits of a coronavirus spike protein can be expressed in an EV of the present disclosure. As described herein, in some aspects, the one or more subunits of a spike protein comprises a receptor-binding domain (RBD) of the spike protein. In some aspects, the RBD is linked directly to the surface (*e.g.*, exterior surface) of an EV. In some aspects, the RBD is expressed on the surface (*e.g.*, exterior surface) of an EV linked to a scaffold moiety disclosed herein (*e.g.*, Scaffold X and/or Scaffold Y). In certain aspects, the RBD of a coronavirus spike protein is expressed on the exterior surface of an EV linked to a Scaffold X. As will be apparent to those skilled in the art,

[0236] As described herein, in some aspects, an EV described herein can express multiple (*e.g.*, two or more) coronavirus antigens (*e.g.*, disclosed herein). In certain aspects, an EV disclosed herein can express a spike protein (*e.g.*, full-length protein or subunit thereof) and a coronavirus antigen comprising a T cell epitope ("**T-antigen**") (*see, e.g.*, FIG. 2). In some of these aspects, the spike protein antigen (*e.g.*, receptor-binding domain) can be expressed on exterior surface of the EV while the T-antigen is expressed on the luminal surface of the EV.

[0237] Accordingly, in some aspects, an EV disclosed herein comprises: (i) a spike protein antigen (*e.g.*, receptor-binding domain) and (ii) a T-antigen, wherein the spike protein antigen is linked to a Scaffold X (*e.g.*, at the N-terminus) on the exterior surface of the EV, and the T-antigen is linked to a Scaffold X (*e.g.*, at the C-terminus) on the luminal surface of the EV. In some aspects, an EV comprises: (i) a spike protein antigen (*e.g.*, receptor-binding domain) and (ii) a T-antigen, wherein the spike protein antigen is linked to a Scaffold X (*e.g.*, at the N-terminus) on the exterior

surface of the EV, and the T-antigen is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV comprises: (i) a spike protein antigen (*e.g.*, receptor-binding domain) and (ii) a T-antigen, wherein the spike protein antigen is linked to a Scaffold X (*e.g.*, at the N-terminus) on the exterior surface of the EV, and the T-antigen is linked directly to the luminal surface of the EV. In some aspects, an EV comprises: (i) a spike protein antigen (*e.g.*, receptor-binding domain) and (ii) a T-antigen, wherein the spike protein antigen is linked directly to the exterior surface of the EV, and the T-antigen is linked to a Scaffold X (*e.g.*, at the C-terminus) on the luminal surface of the EV. In some aspects, an EV comprises (i) a spike protein antigen (*e.g.*, receptor-binding domain) and (ii) a T-antigen, wherein the spike protein antigen is linked directly to the exterior surface of the EV, and the T-antigen is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV comprises (i) a spike protein antigen (*e.g.*, receptor-binding domain) and (ii) a T-antigen, wherein the spike protein antigen is linked directly to the exterior surface of the EV, and the T-antigen is linked directly to the luminal surface of the EV.

[0238] In some aspects, an antigen that can be added to an EV to produce the EV-based vaccines described herein a CD8+ T cell epitope of a coronavirus T cell antigen, such as those described in Wang *et al.*, *J Virol* 78(11): 5612-8 (Jun. 2004); Wang *et al.*, *Blood* 104(1): 200-6 (Jul. 2004); Tsao *et al.*, *Biochem Biophys Res Commun* 344(1):63-71 (May 2006); Lv *et al.*, *BMC Immunol* 10:61 (Dec. 2009); and Ahmed *et al.*, *Viruses* 12(3): 254 (Mar. 2020); Grifoni *et al.*, *Cell Host & Microbe* 27: 671-680 (Apr. 2020); each of which is incorporated herein by reference in its entirety. *See also* Table 2 (below).

Table 2. Exemplary Antigens Comprising T Cell Epitope of Coronavirus

Antigen Sequence
LLLNCLWSV (HCoV-229e, 77-85) (SEQ ID NO: 420)
FKDGIYFAA (SARS-CoV, 83-91) (SEQ ID NO: 421)
LITGRLAAL (HCoV-229e, 881-889) (SEQ ID NO: 422)
LITGRLQSL (SARS-CoV, 978-986) (SEQ ID NO: 423)
ISVVLIFVV (HCoV-229e, 1121-1129) (SEQ ID NO: 424)
FIAGLIAIV (SARS-CoV, 1203-1211) (SEQ ID NO: 425)
GILGFVFTL (influenza virus, 58-66) (SEQ ID NO: 426)
VVFLHVTYV (SEQ ID NO: 427)
RLQSLQTYV (SEQ ID NO: 428)
VLNDILSRL (SEQ ID NO: 429)
VLYENQKQI (SEQ ID NO: 430)

NLNESLIDL (SEQ ID NO: 431)
LLLQYGSFC (SEQ ID NO: 432)
KLPDDFMGC (SEQ ID NO: 433)
ILPDPLKPT (SEQ ID NO: 434)
MIFDNAFNC (SEQ ID NO: 435)
FIFLLFLTL (SEQ ID NO: 436)
VLYQDVNCT (SEQ ID NO: 437)
IITTDNTFV (SEQ ID NO: 438)
RLNEVAKNL (SEQ ID NO: 439)
LLTDDMIAA (SEQ ID NO: 440)
LLQYGSFCT (SEQ ID NO: 441)
ILLCCMTSC (SEQ ID NO: 442)
LLFNKVTLA (SEQ ID NO: 443)
TMNNKSQSV (SEQ ID NO: 444)
ALNTLVKQL (SEQ ID NO: 445)
ELCDNPFFA (SEQ ID NO: 446)
RLNQLESKV (SEQ ID NO: 448)
ILLNKHID (SEQ ID NO: 449)
AFFGMSRIGMEVTPSGTW (SEQ ID NO: 450)
MEVTPSGTWL (SEQ ID NO: 451)
GMSRIGMEV (SEQ ID NO: 452)
ILLNKHIDA (SEQ ID NO: 453)
ALNTPKDHI (SEQ ID NO: 454)
IRQGTDYKHWPQIAQFA (SEQ ID NO: 455)
KHWPQIAQFAPSASAFF (SEQ ID NO: 456)
LALLLLDRL (SEQ ID NO: 457)
LLLDRLNQL (SEQ ID NO: 458)
LLNKHIDAYKTFPPTEPK (SEQ ID NO: 459)
LQLPQGTTL (SEQ ID NO: 460)
AQFAPSASAFFGMSR (SEQ ID NO: 461)
AQFAPSASAFFGMSRIGM (SEQ ID NO: 462)
RRPQGLPNNTASWFT (SEQ ID NO: 463)
YKTFPPTEPKKDKKKK (SEQ ID NO: 464)
GAALQIPFAMQMAYRF (SEQ ID NO: 465)
MAYRFNGIGVTQNVLY (SEQ ID NO: 466)
QLIRAAEIRASANLAATK (SEQ ID NO: 467)
QALNTLVKQLSSNFGAI (SEQ ID NO: 470)
VLNDILSRL (SEQ ID NO: 472)

GLIAIVMVTI (SEQ ID NO: 474), LQYGSFCT (SEQ ID NO: 475), RLDKVEAEV (SEQ ID NO: 476), FPRGQGVPI (SEQ ID NO: 447), LLLLDRLNQ (SEQ ID NO: 468), LLLLDRLNQL (SEQ ID NO: 469), AQFAPSASA (SEQ ID NO: 471), TTLPKGFYA (SEQ ID NO: 473), VLQLPQGTTL (SEQ ID NO: 477)
GYQPYRVVVL (SEQ ID NO: 478), PYRVVVLSF (SEQ ID NO: 479), LSPRWYFYY (SEQ ID NO: 480)
DSFKEELDKY (SEQ ID NO: 481), LIDLQELGKY (SEQ ID NO: 482), GTTLPKGFY (SEQ ID NO: 483), VTPSGTWLTY (SEQ ID NO: 484)
GSFCTQLNR (SEQ ID NO: 485), GVVFLHVTY (SEQ ID NO: 486), AQALNTLVK (SEQ ID NO: 487), MTSCCSCLK (SEQ ID NO: 488), ASANLAATK (SEQ ID NO: 489), SLIDLQELGK (SEQ ID NO: 490), SVLNDILSR (SEQ ID NO: 491), TQNVLYENQK (SEQ ID NO: 492), CMTSCCSCLK (SEQ ID NO: 493), VQIDRLITGR (SEQ ID NO: 494), KTFPPTEPK (SEQ ID NO: 495), KTFPPTEPKK (SEQ ID NO: 496), ASAFFGMSR (SEQ ID NO: 497), ATEGALNTPK (SEQ ID NO: 498), QLPQGTTLPK (SEQ ID NO: 499), QQQGQTVTK (SEQ ID NO: 500), QQQQGQTVTK (SEQ ID NO: 501), SASAFFGMSR (SEQ ID NO: 502), SQASSRSSSR (SEQ ID NO: 503), TPSGTWLTY (SEQ ID NO: 504)
FPNITNLCPF (SEQ ID NO: 505), APHGVVFLHV (SEQ ID NO: 506), APSASAFFGM (SEQ ID NO: 507)
GAALQIPFAMQMAYR (SEQ ID NO: 508), GWTFGAGAALQIPFA (SEQ ID NO: 509), IDRLITGRLQSLQTY (SEQ ID NO: 510), ISGINASVVNIQKEI (SEQ ID NO: 511), LDKYFKNHTSPDVDL (SEQ ID NO: 512), LGDISGINASVVNIQ (SEQ ID NO: 513), LGFIAGLIAIVMVTI (SEQ ID NO: 514), LNTLVKQLSSNFGAI (SEQ ID NO: 515), LQDVVNQNAQALNTL (SEQ ID NO: 516), LQSLQTYVTQQLIRA (SEQ ID NO: 517), LQTYVTQQLIRAAEI (SEQ ID NO: 518), AQKFNGLTVLPPLLT (SEQ ID NO: 519), PCSFGGVSVITPGTN (SEQ ID NO: 520), QIPFAMQMAYRFNGI (SEQ ID NO: 521), QQLIRAAEIRASANL (SEQ ID NO: 522), QTYVTQQLIRAAEIR (SEQ ID NO: 523), AYRFNGIGVTQNVLY (SEQ ID NO: 524), SSNFGAISSVLNDIL (SEQ ID NO: 525), TGRLQSLQTYVTQQL (SEQ ID NO: 526), WLGFIAGLIAIVMVT (SEQ ID NO: 527), CVNFNFNGLTGTGVL (SEQ ID NO: 528), DKYFKNHTSPDVDLG (SEQ ID NO: 529), IDAYKTFPPTEPKKD (SEQ ID NO: 530), MSRIGMEVTPSGTWL (SEQ ID NO: 531), NKHIDAYKTFPPTEP (SEQ ID NO: 532), VLQLPQGTTLPKGFY (SEQ ID NO: 533)
LQIPFAMQM (SEQ ID NO: 534), RVDFCGKGY (SEQ ID NO: 535)
YEQYIKWPWY (SEQ ID NO: 536)
GRLQSLQTY (SEQ ID NO: 537),
VRFPNITNL (SEQ ID NO: 538)
DVVNQNAQALNTLVKQL (SEQ ID NO: 539)

EAEVQIDRLITGRLQSL (SEQ ID NO: 540)
EIDRLNEVAKNLNESLIDLQELGKYEQY (SEQ ID NO: 541)
EVAKNLNESLIDLQELG (SEQ ID NO: 542)
GAALQIPFAMQMAYRFN (SEQ ID NO: 543)
GAGICASY (SEQ ID NO: 544)
AISSVLNDILSRLDKVE (SEQ ID NO: 545)
GSFCTQLN (SEQ ID NO: 546)
ILSRLDKVEAEVQIDRL (SEQ ID NO: 547)
KGIYQTSN (SEQ ID NO: 548)
AMQMAYRF (SEQ ID NO: 549)
KNHTSPDVDLGDISGIN (SEQ ID NO: 550)
MAYRFNGIGVTQNVLYE (SEQ ID NO: 551)
AATKMSECVLGQSKRVD (SEQ ID NO: 552)
PFAMQMAYRFNGIGVTQ (SEQ ID NO: 553)
QLIRAAEIRASANLAAT (SEQ ID NO: 554)
QQFGRD (SEQ ID NO: 555)
RASANLAATKMSECVLG (SEQ ID NO: 556)
RLITGRLQSLQTYVTQQ (SEQ ID NO: 557)
SLQTYVTQQLIRAAEIR (SEQ ID NO: 558)
DLGDISGINASVVNIQK (SEQ ID NO: 559)
FFGMSRIGMEVTPSGTW (SEQ ID NO: 560)
GLPNNTASWFTALTQHGK (SEQ ID NO: 561)
GTTLPK (SEQ ID NO: 562)
KHIDAYKTFPPTEPKKDKKK (SEQ ID NO: 563)
YNVTQAFGRRGPEQTQGNF (SEQ ID NO: 564)
KTFPPTEPKKDKKKK (SEQ ID NO: 565)
LLPAAD (SEQ ID NO: 566)
LNKHIDAYKTFPPTEPK (SEQ ID NO: 567)
LPQGTTLPKG (SEQ ID NO: 568)
LPQRQKKQ (SEQ ID NO: 569)
PKGFYAEGSRGGSQASSR (SEQ ID NO: 570)
QFAPSASAFFGMSRIGM (SEQ ID NO: 571)
QGTDYKHW (SEQ ID NO: 572)
QLPQGTTLPKGFYAE (SEQ ID NO: 573)
QLPQGTTLPKGFYAEGSR (SEQ ID NO: 574)
QLPQGTTLPKGFYAEGSRGGSQ (SEQ ID NO: 575)
TFPPTEPK (SEQ ID NO: 576)

SQASSRSS (SEQ ID NO: 577)
SRGGSQASSRSSSRSR (SEQ ID NO: 578)

[0239] As described herein, in some aspects, an EV comprising a spike protein antigen and a T-antigen described above can further express one or more additional moieties disclosed herein (*e.g.*, adjuvant, immune modulator, and/or targeting moiety). Additional disclosure relating to such EVs are provided elsewhere in the present disclosure.

[0240] In some aspects, an antigen, e.g., a first antigen and/or a second antigen, is expressed on the exterior surface or in the lumen (*e.g.*, on the luminal surface) of the EV. In some aspects, a first and/or second antigen is expressed on the exterior surface or in the luminal surface of the EVs directly connected to the lipid bilayer. In such aspects, the first antigen and/or the second can be linked to a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y).

[0241] In some aspects, an EVs described herein comprises a first scaffold moiety. In certain aspects, the first antigen is linked to the first scaffold moiety. In other aspects, the second antigen is linked to the first scaffold moiety. In further aspects, both the first antigen and the second antigen are linked to the first scaffold moiety. In some aspects, an EVs further comprises a second scaffold moiety. In certain aspects, the first antigen is linked to the first scaffold moiety, and the second antigen is linked to the second scaffold moiety. In some aspects, the first scaffold moiety and the second scaffold moiety are the same (*e.g.*, both Scaffold X or both Scaffold Y). In other aspects, the first scaffold moiety and the second scaffold moiety are different (*e.g.*, first scaffold moiety is Scaffold X and the second scaffold moiety is Scaffold Y; or first scaffold moiety is Scaffold Y and the second scaffold moiety is Scaffold X).

[0242] Non-limiting examples of Scaffold X include: prostaglandin F2 receptor negative regulator (PTGFRN); basigin (BSG); immunoglobulin superfamily member 2 (IGSF2); immunoglobulin superfamily member 3 (IGSF3); immunoglobulin superfamily member 8 (IGSF8); integrin beta-1 (ITGB1); integrin alpha-4 (ITGA4); 4F2 cell-surface antigen heavy chain (SLC3A2); and a class of ATP transporter proteins (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B). In certain aspects, Scaffold X is a whole protein. In other aspects, Scaffold X is a protein fragment (*e.g.*, functional fragment).

[0243] In other aspects, the scaffold moiety useful for the present disclose, a first scaffold moiety, a second scaffold moiety, and/or a third scaffold moiety, includes a conventional exosome protein, including, but not limiting, tetraspanin molecules (*e.g.*, CD63, CD81, CD9 and others), lysosome-associated membrane protein 2 (LAMP2 and LAMP2B), platelet-derived growth factor

receptor (PDGFR), GPI anchor proteins, lactadherin and fragments thereof, peptides that have affinity to any of these proteins or fragments thereof, or any combination thereof.

[0244] Non-limiting examples of Scaffold Y include: the myristoylated alanine rich Protein Kinase C substrate (MARCKS) protein; myristoylated alanine rich Protein Kinase C substrate like 1 (MARCKSL1) protein; and brain acid soluble protein 1 (BASP1) protein. In some aspects, Scaffold Y is a whole protein. In certain aspects, Scaffold Y is a protein fragment (*e.g.*, functional fragment).

[0245] In some aspects, the first antigen is linked to a first scaffold moiety on the luminal surface of the EVs and the second antigen is in the lumen of the EV. As used herein, when a molecule (*e.g.*, first antigen or second antigen) is described as "**in the lumen**" of the EV it means that the molecule is not linked to a scaffold moiety described herein. In some aspects, the first antigen is in the lumen of the EV and the second antigen is linked to a first scaffold moiety on the luminal surface of the EV. In such aspects, the first scaffold moiety can be Scaffold X or Scaffold Y.

[0246] In some aspects, the first antigen is linked to a first scaffold moiety on the luminal surface of the EV and the second antigen is linked to a second scaffold moiety on the exterior surface of the EV. In some aspects, the second antigen is linked to a first scaffold moiety on the luminal surface of the EV and the first antigen is linked to a second scaffold moiety on the exterior surface of the EV. In these aspects, the first scaffold moiety can be Scaffold Y, and the second scaffold moiety can be Scaffold X. In other aspects, each of the first scaffold moiety and the second scaffold moiety can be Scaffold X.

[0247] In some aspects, the first antigen is linked to a first scaffold moiety on the exterior surface of the EVs and the second antigen is linked to a second scaffold moiety on the luminal surface of the EV. In other aspects, the second antigen is linked to a first scaffold moiety on the exterior surface of the EVs and the first antigen is linked to a second scaffold moiety on the luminal surface of the EV. In such aspects, the first scaffold moiety is Scaffold X, and the second scaffold moiety is Scaffold Y; or each of the first scaffold moiety and the second scaffold moiety is Scaffold X.

[0248] In some aspects, the first antigen is in the lumen of the EVs and the second antigen is in the lumen of the EV.

[0249] In some aspects, the first antigen is linked to a first scaffold moiety on the exterior surface of the EVs and the second antigen is linked to a second scaffold moiety on the exterior

surface of the EV. In other aspects, the second antigen is linked to a first scaffold moiety on the exterior surface of the EVs and the first antigen is linked to a second scaffold moiety on the exterior surface of the EV. In some aspects, the first scaffold moiety and the second scaffold moiety are Scaffold X.

[0250] In some aspects, the first antigen is linked to a first scaffold moiety on the exterior surface of the EVs and the second antigen is in the lumen of the EV. In some aspects, the first antigen is in the lumen of the EVs and the second antigen is linked to a first scaffold moiety on the exterior surface of the EV. In such aspects, the first scaffold moiety can be Scaffold X.

[0251] In some aspects, the first antigen is linked to a first scaffold moiety on the exterior surface of the EV and the second antigen is linked to the first scaffold moiety on the luminal surface of the EV. In other aspects, the first antigen is linked to a first scaffold moiety on the luminal surface of the EV and the second antigen is linked to the first scaffold moiety on the exterior surface of the EV. In these aspects, the first scaffold moiety can be Scaffold X.

[0252] Non-limiting examples of specific aspects include EVs comprising (i) a first antigen and (ii) a second antigen, wherein:

(a) the first antigen is linked to a first Scaffold Y on the luminal surface of the EV and the second antigen is linked to a second Scaffold Y on the luminal surface of the EV;

(b) the first antigen is linked to a Scaffold Y on the luminal surface of the EV and the second antigen is in the lumen of the EV not linked to any scaffold moiety;

(c) the first antigen is in the lumen of the EV not linked to any scaffold moiety, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV;

(d) the first antigen is linked to a Scaffold Y on the luminal surface of the EV and the second antigen is linked to a Scaffold X on the exterior surface of the EV;

(e) the first antigen is in the lumen of the EV not linked to any scaffold moiety, and the second antigen is linked to a Scaffold X on the exterior surface of the EV;

(f) the first antigen is linked to a Scaffold Y on the luminal surface of the EV and the second antigen is linked to a Scaffold X on the luminal surface of the EV;

(g) the first antigen is in the lumen of the EV not linked to any scaffold moiety, and the second antigen is linked to a Scaffold X on the luminal surface of the EV;

(h) the first antigen is linked to a Scaffold X on the luminal surface of the EV and the second antigen is linked to the Scaffold X on the exterior surface of the EV;

(i) the first antigen is linked to a first Scaffold X on the exterior surface of the EV and the second antigen is linked to a second Scaffold X on the exterior surface of the EV;

(j) the first antigen is linked to a Scaffold X on the exterior surface of the EV and the second antigen is linked to a Scaffold Y on the luminal surface of the EV;

(k) the first antigen is linked to a Scaffold X on the exterior surface of the EV and the second antigen is in the lumen of the EV not linked to any scaffold moiety;

(l) the first antigen is linked to a Scaffold X on the exterior surface of the EV and the second antigen is linked to the Scaffold X on the luminal surface of the EV;

(m) the first antigen is linked to a first Scaffold X on the luminal surface of the EV and the second antigen is linked to a second Scaffold X on the luminal surface of the EV;

(n) the first antigen is linked to a Scaffold X on the luminal surface of the EV and the second antigen is linked to a Scaffold Y on the luminal surface of the EV;

(o) the first antigen is linked to a Scaffold X on the luminal surface of the EV and the second antigen is in the lumen of the EV not linked to any scaffold moiety;

(p) the first antigen is linked to a first Scaffold X on the exterior surface of the EV and the second antigen is linked to a second Scaffold X on the luminal surface of the EV;

(q) the first antigen is linked to a first Scaffold X on the luminal surface of the EV and the second antigen is linked to a second Scaffold X on the exterior surface of the EV;

(r) the first antigen is in the lumen of the EV not linked to any scaffold moiety, and the second antigen is in the lumen of the EV not linked to any scaffold moiety;

(s) the first antigen is linked directly to the luminal surface of the EV and the second antigen is linked directly to the luminal surface of the EV;

(t) the first antigen is linked directly to the luminal surface of the EV and the second antigen is in the lumen of the EV;

(u) the first antigen is linked directly to the luminal surface of the EV and the second antigen is linked to a Scaffold Y on the luminal surface of the EV;

(v) the first antigen is linked directly to the luminal surface of the EV and the second antigen is linked to a Scaffold X on the luminal surface of the EV;

(w) the first antigen is linked directly to the luminal surface of the EV and the second antigen is linked directly to the exterior of the EV;

(x) the first antigen is linked directly to the luminal surface of the EV and the second antigen is linked to a Scaffold X on the exterior of the EV;

(y) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the second antigen is linked directly to the luminal surface of the EV;
(z) the first antigen is linked to a Scaffold Y on the luminal surface of the EV and the second antigen is linked directly to the exterior of the EV;
(aa) the first antigen is linked to a Scaffold X on the luminal surface of the EV and the second antigen is linked directly to the luminal surface of the EV;
(bb) the first antigen is linked to a Scaffold X on the luminal surface of the EV and the second antigen is linked directly to the exterior of the EV;
(cc) the first antigen is in the lumen of the EV and the second antigen is linked directly to the luminal surface of the EV; or
(dd) the first antigen is in the lumen of the EV and the second antigen is linked directly to the exterior of the EV.

[0253] In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a first Scaffold Y on the luminal surface of the EV and the second antigen is linked to a second Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold Y on the luminal surface of the EV and the second antigen is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is in the lumen of the EV not linked to any scaffold moiety, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold Y on the luminal surface of the EV and the second antigen is linked to a Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is in the lumen of the EV not linked to any scaffold moiety, and the second antigen is linked to a Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold Y on the luminal surface of the EV and the second antigen is linked to a Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is in the lumen of the EV not linked to any scaffold moiety, and the second antigen is linked to a Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure

comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold X on the luminal surface of the EV and the second antigen is linked to the Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a first Scaffold X on the exterior surface of the EV and the second antigen is linked to a second Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold X on the exterior surface of the EV and the second antigen is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold X on the exterior surface of the EV and the second antigen is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold X on the exterior surface of the EV and the second antigen is linked to the Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a first Scaffold X on the luminal surface of the EV and the second antigen is linked to a second Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold X on the luminal surface of the EV and the second antigen is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold X on the luminal surface of the EV and the second antigen is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a first Scaffold X on the exterior surface of the EV and the second antigen is linked to a second Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a first Scaffold X on the luminal surface of the EV and the second antigen is linked to a second Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is in the lumen of the EV not linked to any scaffold moiety, and the second antigen is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked directly to the luminal surface of the EV, and

the second antigen is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked directly to the luminal surface of the EV, and the second antigen is in the lumen of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the luminal surface of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked directly to the exterior of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the exterior of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked directly to the exterior of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked directly to the exterior of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is in the lumen of the EV, and the second antigen is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) a first antigen and (ii) a second antigen, wherein the first antigen is in the lumen of the EV, and the second antigen is linked directly to the exterior of the EV.

II.B Adjuvants

[0254] As described *supra*, EVs of the present disclosure can comprise an adjuvant (*e.g.*, in combination with an antigen and/or other payloads disclosed herein). In some aspects, an EV disclosed herein comprises multiple adjuvants. In certain aspects, each of the multiple adjuvants is different. In some aspects, an EV disclosed herein comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different adjuvants. As disclosed herein, an adjuvant can be linked to a surface of an EV

using a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y). In certain aspects, an adjuvant can be directly linked (*i.e.*, without the use of a scaffold moiety) to a surface of an EV. In some aspects, an adjuvant can be in the lumen of the EV.

[0255] In some aspects, an EV comprises the one or more adjuvants in combination with one or more additional payloads (*e.g.*, antigen, and/or immune modulator). For example, in certain aspects, an EV described herein comprises an antigen and an adjuvant, wherein the adjuvant is present in the EV prior to the addition of the antigen. In such aspects, the adjuvant can be introduced into a producer cell when producing the EV (*e.g.*, base EV). In some aspects, the adjuvant can be added to the EVs after being isolated from the producer cells. In such aspects, the adjuvant can be added to the isolated EVs before adding the antigen. In some aspects, the adjuvant is added to the EV after adding the antigen. In some aspects, the adjuvant is added to the EV together with the antigen. In some aspects, an EV can comprise one or more additional moieties (*e.g.*, targeting moieties). For instance, in certain aspects, an EV disclosed herein can comprise (i) one or more additional adjuvants, (ii) one or more additional payloads (*e.g.*, antigen and/or immune modulator), and (iii) one or more targeting moieties. As described herein, in some aspects, any of the adjuvants, additional payloads, and/or targeting moieties can be present in the EV prior to the addition of any of the other moieties of the EV (*e.g.*, the adjuvant, immune modulator, and/or targeting moiety can be present in the EV prior to the addition of the antigen). In certain aspects, the adjuvants, additional payloads, and/or targeting moieties can be added to the EV concurrently.

[0256] As used herein, the term "**adjuvant**" refers to any substance that enhances the therapeutic effect of the payload (*e.g.*, increasing an immune response to the antigen). Accordingly, EVs described herein comprising an adjuvant are capable of increasing an immune response, *e.g.*, to an antigen, by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 250%, at least about 500%, at least about 750%, at least about 1,000% or more or more, compared to a reference (*e.g.*, corresponding EV without the adjuvant or a non-EV delivery vehicle comprising an antigen alone or in combination with the adjuvant). In some aspects, incorporating an adjuvant disclosed herein to an EV can increase an immune response, *e.g.*, to an antigen, by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at

least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, at least about 10,000-fold or more, compared to a reference (*e.g.*, corresponding EV comprising the antigen alone or a non-EV delivery vehicle comprising an antigen alone or in combination with the adjuvant).

[0257] In some aspects, EVs described herein (*e.g.*, those that can be used as vaccines) comprises a single adjuvant. In some aspects, an EV disclosed herein comprises multiple adjuvants. In such aspects, some or all of the multiple adjuvants: (i) can be introduced into the producer cells, such that the base EVs are produced comprising the adjuvants; (ii) can be added to the EVs are they are isolated from the producer cells but prior to the addition of the antigen; (iii) can be added to the EVs after the addition of the antigen; (iv) can be added to the EVs together with the antigen; or (v) any combination thereof.

[0258] In some aspects, each of the multiple adjuvants is different. In some aspects, an EV disclosed herein comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different adjuvants. As disclosed herein, an adjuvant can be linked to a surface of an EV using a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y). In certain aspects, an adjuvant can be directly linked (*i.e.*, without the use of a scaffold moiety) to a surface of an EV. In some aspects, an adjuvant can be in the lumen of the EV.

[0259] Non-limiting examples of adjuvants that can be used with the present disclosure include: Stimulator of Interferon Genes (STING) agonist, a toll-like receptor (TLR) agonist, an inflammatory mediator, RIG-I agonists, alpha-gal-cer (NKT agonist), heat shock proteins (*e.g.*, HSP65 and HSP70), C-type lectin agonists (*e.g.*, beta glucan (Dectin 1), chitin, and curdlan), and combinations thereof. Additional examples of adjuvants that can be used with the EVs described herein are provided throughout the present disclosure.

[0260] In some aspects, the adjuvant is a TLR9 agonist. In some aspects, the TLR9 agonist comprises a CpG oligonucleotide. As used herein, the term "**CpG oligonucleotide**" (CpG ODN) refers to a short synthetic single-stranded nucleic acid molecules that contain unmethylated CpG dinucleotides in particular sequence contexts (CpG motifs). There are three major classes of CpG ODNs: Class A (Type D), Class B (Type K), and Class C. In some aspects, the adjuvant is a CpG-A ODN. "**CpG-A**" ODNs are characterized by a phosphodiester (PO) central CpG-containing

palindromic motif and a phosphorothioated (PS)-modified 3' poly-G string. They induce high IFN-α production from pDCs but are weak stimulators of TLR9-dependent NF-κB signaling and pro-inflammatory cytokine (e.g. IL-6) production. In some aspects, the adjuvant is a CpG-B ODN. "**CpG-B**" ODNs contain a full PS backbone with one or more CpG dinucleotides. They strongly activate B cells and TLR9-dependent NF-κB signaling but weakly stimulate IFN-α secretion. In some aspects, the adjuvant is a CpG-C ODN. "**CpG-C**" ODNs combine features of both classes A and B. They contain a complete PS backbone and a CpG-containing palindromic motif. C-Class CpG ODNs induce strong IFN-α production from pDC as well as B cell stimulation.

[0261] In some aspects, the adjuvant is a TLR4 agonist. In certain aspects, the TLR4 agonist comprises monophosphoryl lipid A (MPLA), *e.g.*, a derivative of lipid A from *Salmonella minnesota* R595 lipopolysaccharide (LPS or endotoxin).

[0262] In some aspects, incorporating an adjuvant (*e.g.*, such as those disclosed herein) to an EV can broaden an immune response induced by the EV. As used herein, to "**broaden an immune response**" refers to enhancing the diversity of an immune response. In some aspects, the diversity of an immune response can be enhanced through epitope spreading (*i.e.*, inducing and/or increasing an immune response (cellular and/or humoral immune response) against a greater number/variety of epitopes on an antigen). In some aspects, the diversity of an immune response can be enhanced through the production of different and/or multiple antibody isotypes (*e.g.*, IgG, IgA, IgD, IgM, and/or IgE).

[0263] In some aspects, an adjuvant (*e.g.*, such as those disclosed herein) can also help regulate the type of immune response induced by the EV. For example, in some aspects, incorporating an adjuvant to an EV can help drive an immune response towards a more Th1 phenotype. As used herein, a "**Th1**" immune response is generally characterized by the production of IFN-γ, which can activate the bactericidal activities of innate cells (*e.g.*, macrophages), help induce B cells to make opsonizing (marking for phagocytosis) and complement-fixing antibodies, and/or lead to cell-mediated immunity (*i.e.*, not mediated by antibodies). In general, Th1 responses are more effective against intracellular pathogens (viruses and bacteria that are inside host cells).

[0264] In some aspects, incorporating an adjuvant to an EV can help drive an immune response towards a more Th2 phenotype. As used herein, a "**Th2**" immune response can be characterized by the release of certain cytokines, such as IL-5 (induces eosinophils in the clearance of parasites) and IL-4 (facilitates B cell isotype switching). In general, Th2 responses are more effective against extracellular bacteria, parasites including helminths and toxins.

[0265] In some aspects, incorporating an adjuvant to an EV can help drive an immune response towards a more Th17 phenotype. As used herein, a "**Th17**" immune response is mediated by Th17 cells. As used herein, "**Th17 cells**" refer to a subset of CD4+ T cells characterized by the production of pro-inflammatory cytokines, such as IL-17A, IL-17F, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF). Th17 cells are generally thought to play an important role in host defense against infection, by recruiting neutrophils and macrophages to infected tissues.

[0266] In some aspects, incorporating an adjuvant to an EV can help drive an immune response towards a more cellular immune response (*e.g.*, T-cell mediated). In some aspects, incorporating an adjuvant to an EV can help drive an immune response towards a more humoral immune response (*e.g.*, antibody-mediated).

[0267] In some aspects, an adjuvant induces the activation of a cytosolic pattern recognition receptor. In some aspects, such adjuvants are viral nucleic acid mimetics. Not to be bound by any one theory, EVs comprising such adjuvants are capable of preferentially inducing Th1 (*e.g.*, IFN) and/or antibody-mediated immune responses. Non-limiting examples of cytosolic pattern recognition receptor includes: stimulator of interferon genes (STING), retinoic acid-inducible gene I (RIG-1), Melanoma Differentiation-Associated protein 5 (MDA5), Nucleotide-binding oligomerization domain, Leucine rich Repeat and Pyrin domain containing (NLRP), inflammasomes, or combinations thereof. In certain aspects, an adjuvant is a STING agonist. Stimulator of Interferon Genes (STING) is a cytosolic sensor of cyclic dinucleotides that is typically produced by bacteria. Upon activation, it leads to the production of type I interferons (*e.g.*, IFN-α (alpha), IFN-β (beta), IFN-κ (kappa), IFN-δ (delta), IFN-ε (epsilon), IFN-τ (tau), IFN-ω (omega), and IFN-ζ (zeta, also known as limitin)) and initiates an immune response. In certain aspects, the STING agonist comprises a cyclic dinucleotide STING agonist or a non-cyclic dinucleotide STING agonist. As described herein, in some aspects, the STING agonist is loaded in the lumen of the EV. In some aspects, such EVs are referred to herein as "**exoSTING**." Non-limiting examples of exoSTING are provided in International Publication No. WO 2019183578A1, which is herein incorporated by reference in its entirety. Further disclosures of useful STING agonists are also provided throughout the present disclosure.

[0268] Cyclic purine dinucleotides such as, but not limited to, cGMP, cyclic di-GMP (c-di-GMP), cAMP, cyclic di-AMP (c-di-AMP), cyclic-GMP-AMP (cGAMP), cyclic di-IMP (c-di-IMP), cyclic AMP-IMP (cAIMP), and any analogue thereof, are known to stimulate or enhance an

immune or inflammation response in a patient. The CDNs can have 2'2', 2'3', 2'5', 3'3', or 3'5' bonds linking the cyclic dinucleotides, or any combination thereof.

[0269] Cyclic purine dinucleotides can be modified via standard organic chemistry techniques to produce analogues of purine dinucleotides. Suitable purine dinucleotides include, but are not limited to, adenine, guanine, inosine, hypoxanthine, xanthine, isoguanine, or any other appropriate purine dinucleotide known in the art. The cyclic dinucleotides can be modified analogues. Any suitable modification known in the art can be used, including, but not limited to, phosphorothioate, biphosphorothioate, fluorinate, and difluorinate modifications.

[0270] Non cyclic dinucleotide agonists can also be used, such as 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), or any other non-cyclic dinucleotide agonist known in the art.

[0271] Non-limiting examples of STING agonists that can be used with the present disclosure include: DMXAA, STING agonist-1, ML RR-S2 CDA, ML RR-S2c-di-GMP, ML-RR-S2 cGAMP, 2'3'-c-di-AM(PS)2, 2'3'-cGAMP, 2'3'-cGAMPdFHS, 3'3'-cGAMP, 3'3'-cGAMPdFSH, cAIMP, cAIM(PS)2, 3'3'-cAIMP, 3'3'-cAIMPdFSH, 2'2'-cGAMP, 2'3'-cGAM(PS)2, 3'3'-cGAMP, and combinations thereof. Non-limiting examples of the STING agonists can be found at US Patent No. 9,695,212, WO 2014/189805 A1, WO 2014/179335 A1, WO 2018/100558 A1, US Patent No. 10,011,630 B2, WO 2017/027646 A1, WO 2017/161349 A1, and WO 2016/096174 A1, each of which is incorporated by reference in its entirety.

[0272] In some aspects, the STING agonist useful for the present disclosure comprises the compound or a pharmaceutically acceptable salt thereof. See WO 2016/096174 A1, which is incorporated herein by reference in its entirety.

[0273] In some aspects, the STING agonist useful for the present disclosure comprises a compound described in WO 2014/093936, WO 2014/189805, WO 2015/077354, Cell reports 11, 1018-1030 (2015), WO 2013/185052, Sci. Transl. Med. 283,283ra52 (2015), WO 2014/189806, WO 2015/185565, WO 2014/179760, WO 2014/179335, WO 2015/017652, WO 2016/096577, WO 2016/120305, WO 2016/145102, WO 2017/027646, WO 2017/075477, WO 2017/027645, WO 2018/100558, WO 2017/175147, WO 2017/175156, each of which is incorporated herein by reference in its entirety.

[0274] In some aspects, the STING agonist useful for the present disclosure is CL606, CL611, CL602, CL655, CL604, CL609, CL614, CL656, CL647, CL626, CL629, CL603, CL632, CL633, CL659, or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL606 or a pharmaceutically acceptable salt thereof. In some

aspects, the STING agonist useful for the present disclosure is CL611 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL602 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL655 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL604 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL609 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL614 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL656 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL647 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL626 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL629 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL603 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL632 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL633 or a pharmaceutically acceptable salt thereof. In some aspects, the STING agonist useful for the present disclosure is CL659 or a pharmaceutically acceptable salt thereof.

[0275] In some aspects, the EV comprises a cyclic dinucleotide STING agonist and/or a non-cyclic dinucleotide STING agonist. In some aspects, when several cyclic dinucleotide STING agonist are present on an EV disclosed herein, such STING agonists can be the same or they can be different. In some aspects, when several non-cyclic dinucleotide STING agonist are present, such STING agonists can be the same or they can be different. In some aspects, an EV composition of the present disclosure can comprise two or more populations of EVs wherein each population of EVs comprises a different STING agonist or combination thereof.

[0276] The STING agonists can also be modified to increase encapsulation (*i.e.*, loading) of the agonist in an extracellular vesicle or EV (*e.g.*, either unbound in the lumen). In some aspects, the STING agonists are linked to a scaffold moiety, *e.g.*, Scaffold Y. In certain aspects, the modification allows better expression of the STING agonist on the exterior surface of the EV (*e.g.*, linked to a scaffold moiety disclosed herein, *e.g.*, Scaffold X). This modification can include the addition of a lipid binding tag by treating the agonist with a chemical or enzyme, or by physically or chemically altering the polarity or charge of the STING agonist. The STING agonist can be

modified by a single treatment, or by a combination of treatments, *e.g.*, adding a lipid binding tag only, or adding a lipid binding tag and altering the polarity. The previous example is meant to be a non-limiting illustrative instance. It is contemplated that any combination of modifications can be practiced. The modification can increase encapsulation (*i.e.*, loading) of the agonist in the EV by between about 2-fold and about 10,000 fold, between about 10-fold and about 1,000 fold, or between about 100-fold and about 500-fold compared to encapsulation (*i.e.*, loading) of an unmodified agonist. The modification can increase encapsulation (*i.e.*, loading) of the agonist in the EV by at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about ,2000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, or at least about 10,000-fold compared to encapsulation (*i.e.*, loading) of an unmodified agonist.

[0277] In some aspects, STING agonists can be modified to allow for better expression of the agonists on the surface of the EV (*e.g.*, exterior and/or luminal surface of the EV (*e.g.*, linked to a scaffold moiety disclosed herein, *e.g.*, Scaffold X and/or Scaffold Y)). Any of the modifications described above can be used. The modification can increase expression of the agonist in the EV, *e.g.*, on the surface and/or luminal surface of the exosome, by about between 2-fold and 10,000-fold, about between 10-fold and 1,000-fold, or about between 100-fold and 500-fold compared to corresponding expression of an unmodified agonist. The modification can increase expression of the agonist on the exterior surface of the EV by at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, or at least about 10,000-fold compared to expression of an unmodified agonist. The modification can increase expression of the

agonist on the luminal surface of the EV by at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, or at least about 10,000-fold compared to expression of an unmodified agonist.

[0278] The concentration of the STING agonist associated with the EV can be about 0.01 μM to about 1000 μM. The concentration of the associated STING agonist can be between about 0.01-0.05 μM, between about 0.05-0.1 μM, between about 0.1-0.5 μM, between about 0.5-1 μM, between about 1-5 μM, between about 5-10 μM, between about 10-15 μM, between about 15-20 μM, between about 20-25 μM, between about 25-30 μM, between about 30-35 μM, between about 35-40 μM, between about 45-50 μM, between about 55-60 μM, between about 65-70 μM, between about 70-75 μM, between about 75-80 μM, between about 80-85 μM, between about 85-90 μM, between about 90-95 μM, between about 95-100 μM, between about 100-150 μM, between about 150-200 μM, between about 200-250 μM, between about 250-300 μM, between about 300-350 μM, between about 250-400 μM, between about 400-450 μM, between about 450-500 μM, between about 500-550 μM, between about 550-600 μM, between about 600-650 μM, between about 650-700 μM, between about 700-750 μM, between about 750-800 μM, between about 800-850 μM, between about 805-900 μM, between about 900-950 μM, or between about 950-1000 μM. The concentration of the associated STING agonist can be equal to or greater than about 0.01 μM, about 0.1 μM, about 0.5 μM, about 1 μM, about 5 μM, about 10 μM, about 15 μM, about 20 μM, about 25 μM, about 30 μM, about 35 μM, about 40 μM, about 45 μM, about 50 μM, about 55 μM, about 60 μM, about 65 μM, about 70 μM, about 75 μM, about 80 μM, about 85 μM, about 90 μM, about 95 μM, about 100 μM, about 150 μM, about 200 μM, about 250 μM, about 300 μM, about 350 μM, about 400 μM, about 450 μM, about 500 μM, about 550 μM, about 600 μM, about 650 μM, about 700 μM, about 750 μM, about 800 μM, about 850 μM, about 900 μM, about 950 μM, or about 1,000 μM.

[0279] In some aspects, an adjuvant is a TLR agonist. Non-limiting examples of TLR agonists include: TLR2 agonist (*e.g.*, lipoteichoic acid, atypical LPS, MALP-2 and MALP-404,

OspA, porin, LcrV, lipomannan, GPI anchor, lysophosphatidylserine, lipophosphoglycan (LPG), glycophosphatidylinositol (GPI), zymosan, hsp60, gH/gL glycoprotein, hemagglutinin), a TLR3 agonist (*e.g.*, double-stranded RNA, *e.g.*, poly(I:C)), a TLR4 agonist (*e.g.*, lipopolysaccharides (LPS), lipoteichoic acid, β-defensin 2, fibronectin EDA, HMGB1, snapin, tenascin C), a TLR5 agonist (*e.g.*, flagellin), a TLR6 agonist, a TLR7/8 agonist (*e.g.*, single-stranded RNA, CpG-A, Poly G10, Poly G3, Resiquimod), a TLR9 agonist (*e.g.*, unmethylated CpG DNA), and combinations thereof. Non-limiting examples of TLR agonists can be found at WO2008115319A2, US20130202707A1, US20120219615A1, US20100029585A1, WO2009030996A1, WO2009088401A2, and WO2011044246A1, each of which are incorporated by reference in its entirety. Not to be bound by any one theory, in some aspects, EVs comprising a TLR agonist as an adjuvant is capable of preferentially inducing a Th1 and/or antibody-mediated immune response.

[0280] In some aspects, an adjuvant is an inflammatory mediator.

[0281] In some aspects, an adjuvant comprises an aluminum-containing adjuvant (also referred to herein as "alum"). In some aspects, an adjuvant comprises an aluminum salt. In certain aspects, the aluminum salt is aluminum hydroxide. Not to be bound by any one theory, in some aspects, an EV comprising an aluminum salt as an adjuvant is capable of mediating damage-associated molecular pattern (DAMP) (*e.g.*, NLRP3) activation of antigen-presenting cells (APCs). In certain aspects, such EVs are capable of preferentially inducing a Th2-cell and/or antibody-mediated immune response. In some aspects, the aluminum-containing adjuvant can be used in combination with one or more additional adjuvants, such as CpG.

[0282] In some aspects, an adjuvant that can be used with the EVs of the present disclosure comprises emulsions (water-in-oil). In certain aspects, the emulsions include MF59 and AS03. Not to be bound by any one theory, in some aspects, an EV comprising an emulsion as an adjuvant is capable of enhancing APC antigen uptake. In certain aspects, such EVs are capable of inducing robust neutralizing antibodies. In some aspects, such EVs are useful for inducing both Th1 and Th2-mediated immune responses. In some aspects, any suitable adjuvants known in the art can be used with the present disclosure (*e.g.*, AS04 and AS01).

[0283] In some aspects, one or more antigens are expressed on the exterior surface or in the lumen (*e.g.*, on the luminal surface) of the EV. In some aspects, an adjuvant is expressed on the exterior surface or in the luminal surface of the EVs directly connected to the lipid bilayer. In such aspects, the antigen, e.g., a first antigen and/or a second antigen, and/or the adjuvant can be linked to a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y).

[0284] In some aspects, an EVs described herein comprises a first scaffold moiety. In certain aspects, the antigen is linked to the first scaffold moiety. In other aspects, the adjuvant is linked to the first scaffold moiety. In further aspects, both the antigen and the adjuvant are linked to the first scaffold moiety. In some aspects, an EVs further comprises a second scaffold moiety. In certain aspects, the antigen is linked to the first scaffold moiety, and the adjuvant is linked to the second scaffold moiety. In some aspects, the first scaffold moiety and the second scaffold moiety are the same (*e.g.*, both Scaffold X or both Scaffold Y). In other aspects, the first scaffold moiety and the second scaffold moiety are different (*e.g.*, first scaffold moiety is Scaffold X and the second scaffold moiety is Scaffold Y; or first scaffold moiety is Scaffold Y and the second scaffold moiety is Scaffold X).

[0285] Non-limiting examples of Scaffold X include: prostaglandin F2 receptor negative regulator (PTGFRN); basigin (BSG); immunoglobulin superfamily member 2 (IGSF2); immunoglobulin superfamily member 3 (IGSF3); immunoglobulin superfamily member 8 (IGSF8); integrin beta-1 (ITGB1); integrin alpha-4 (ITGA4); 4F2 cell-surface antigen heavy chain (SLC3A2); and a class of ATP transporter proteins (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B). In certain aspects, Scaffold X is a whole protein. In other aspects, Scaffold X is a protein fragment (*e.g.*, functional fragment).

[0286] In other aspects, the scaffold moiety useful for the present disclose, a first scaffold moiety, a second scaffold moiety, and/or a third scaffold moiety, includes a conventional exosome protein, including, but not limiting, tetraspanin molecules (*e.g.*, CD63, CD81, CD9 and others), lysosome-associated membrane protein 2 (LAMP2 and LAMP2B), platelet-derived growth factor receptor (PDGFR), GPI anchor proteins, lactadherin and fragments thereof, peptides that have affinity to any of these proteins or fragments thereof, or any combination thereof.

[0287] Non-limiting examples of Scaffold Y include: the myristoylated alanine rich Protein Kinase C substrate (MARCKS) protein; myristoylated alanine rich Protein Kinase C substrate like 1 (MARCKSL1) protein; and brain acid soluble protein 1 (BASP1) protein. In some aspects, Scaffold Y is a whole protein. In certain aspects, Scaffold Y is a protein fragment (*e.g.*, functional fragment).

[0288] In some aspects, the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a first scaffold moiety on the luminal surface of the EVs and the adjuvant is in the lumen of the EV. In some aspects, the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is in the lumen

of the EV and the adjuvant is linked to a first scaffold moiety on the luminal surface of the EV. In such aspects, the first scaffold moiety can be Scaffold X or Scaffold Y.

[0289] In some aspects, the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a first scaffold moiety on the luminal surface of the EV and the adjuvant is linked to a second scaffold moiety on the exterior surface of the EV. In some aspects, the adjuvant is linked to a first scaffold moiety on the luminal surface of the EV and the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a second scaffold moiety on the exterior surface of the EV. In these aspects, the first scaffold moiety can be Scaffold Y, and the second scaffold moiety can be Scaffold X. In other aspects, each of the first scaffold moiety and the second scaffold moiety can be Scaffold X.

[0290] In some aspects, the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a first scaffold moiety on the exterior surface of the EVs and the adjuvant is linked to a second scaffold moiety on the luminal surface of the EV. In other aspects, the adjuvant is linked to a first scaffold moiety on the exterior surface of the EVs and the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a second scaffold moiety on the luminal surface of the EV. In such aspects, the first scaffold moiety is Scaffold X, and the second scaffold moiety is Scaffold Y; or each of the first scaffold moiety and the second scaffold moiety is Scaffold X.

[0291] In some aspects, the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is in the lumen of the EVs and the adjuvant is in the lumen of the EV.

[0292] In some aspects, the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a first scaffold moiety on the exterior surface of the EVs and the adjuvant is linked to a second scaffold moiety on the exterior surface of the EV. In other aspects, the adjuvant is linked to a first scaffold moiety on the exterior surface of the EVs and the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a second scaffold moiety on the exterior surface of the EV. In some aspects, the first scaffold moiety and the second scaffold moiety are Scaffold X.

[0293] In some aspects, the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a first scaffold moiety on the exterior surface of the EVs and the adjuvant is in the lumen of the EV. In some aspects, the antigen, *e.g.*, derived

from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is in the lumen of the EVs and the adjuvant is linked to a first scaffold moiety on the exterior surface of the EV. In such aspects, the first scaffold moiety can be Scaffold X.

[0294] In some aspects, the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a first scaffold moiety on the exterior surface of the EV and the adjuvant is linked to the first scaffold moiety on the luminal surface of the EV. In other aspects, the antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, is linked to a first scaffold moiety on the luminal surface of the EV and the adjuvant is linked to the first scaffold moiety on the exterior surface of the EV. In these aspects, the first scaffold moiety can be Scaffold X.

[0295] Non-limiting examples of specific aspects, include EVs comprising (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein:

(a) the antigen is linked to a first Scaffold Y on the luminal surface of the EV and the adjuvant is linked to a second Scaffold Y on the luminal surface of the EV;

(b) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is in the lumen of the EV not linked to any scaffold moiety;

(c) the antigen is in the lumen of the EV not linked to any scaffold moiety, and the adjuvant is linked to a Scaffold Y on the luminal surface of the EV;

(d) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is linked to a Scaffold X on the exterior surface of the EV;

(e) the antigen is in the lumen of the EV not linked to any scaffold moiety, and the adjuvant is linked to a Scaffold X on the exterior surface of the EV;

(f) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is linked to a Scaffold X on the luminal surface of the EV;

(g) the antigen is in the lumen of the EV not linked to any scaffold moiety, and the adjuvant is linked to a Scaffold X on the luminal surface of the EV;

(h) the antigen is linked to a Scaffold X on the luminal surface of the EV and the adjuvant is linked to the Scaffold X on the exterior surface of the EV;

(i) the antigen is linked to a first Scaffold X on the exterior surface of the EV and the adjuvant is linked to a second Scaffold X on the exterior surface of the EV;

(j) the antigen is linked to a Scaffold X on the exterior surface of the EV and the adjuvant is linked to a Scaffold Y on the luminal surface of the EV;

(k) the antigen is linked to a Scaffold X on the exterior surface of the EV and the adjuvant is in the lumen of the EV not linked to any scaffold moiety;

(l) the antigen is linked to a Scaffold X on the exterior surface of the EV and the adjuvant is linked to the Scaffold X on the luminal surface of the EV;

(m) the antigen is linked to a first Scaffold X on the luminal surface of the EV and the adjuvant is linked to a second Scaffold X on the luminal surface of the EV;

(n) the antigen is linked to a Scaffold X on the luminal surface of the EV and the adjuvant is linked to a Scaffold Y on the luminal surface of the EV;

(o) the antigen is linked to a Scaffold X on the luminal surface of the EV and the adjuvant is in the lumen of the EV not linked to any scaffold moiety;

(p) the antigen is linked to a first Scaffold X on the exterior surface of the EV and the adjuvant is linked to a second Scaffold X on the luminal surface of the EV;

(q) the antigen is linked to a first Scaffold X on the luminal surface of the EV and the adjuvant is linked to a second Scaffold X on the exterior surface of the EV;

(r) the antigen is in the lumen of the EV not linked to any scaffold moiety, and the adjuvant is in the lumen of the EV not linked to any scaffold moiety;

(s) the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked directly to the luminal surface of the EV;

(t) the antigen is linked directly to the luminal surface of the EV and the adjuvant is in the lumen of the EV;

(u) the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked to a Scaffold Y on the luminal surface of the EV;

(v) the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked to a Scaffold X on the luminal surface of the EV;

(w) the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked directly to the exterior of the EV;

(x) the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked to a Scaffold X on the exterior of the EV;

(y) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is linked directly to the luminal surface of the EV;

(z) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is linked directly to the exterior of the EV;

(aa) the antigen is linked to a Scaffold X on the luminal surface of the EV and the adjuvant is linked directly to the luminal surface of the EV;

(bb) the antigen is linked to a Scaffold X on the luminal surface of the EV and the adjuvant is linked directly to the exterior of the EV;

(cc) the antigen is in the lumen of the EV and the adjuvant is linked directly to the luminal surface of the EV; or

(dd) the antigen is in the lumen of the EV and the adjuvant is linked directly to the exterior of the EV.

[0296] In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a first Scaffold Y on the luminal surface of the EV and the adjuvant is linked to a second Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is in the lumen of the EV not linked to any scaffold moiety, and the adjuvant is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is linked to a Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is in the lumen of the EV not linked to any scaffold moiety, and the adjuvant is linked to a Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is linked to a Scaffold X on the luminal surface of the EV. In some aspects, an EV of the

present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is in the lumen of the EV not linked to any scaffold moiety, and the adjuvant is linked to a Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold X on the luminal surface of the EV and the adjuvant is linked to the Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a first Scaffold X on the exterior surface of the EV, and the adjuvant is linked to a second Scaffold X on the exterior surface of the EV. In some aspects, an EV comprises an antigen, *e.g.*, derived from a coronavirus, *e.g.* a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold X on the exterior surface of the EV and the adjuvant is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold X on the exterior surface of the EV and the adjuvant is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold X on the exterior surface of the EV and the adjuvant is linked to the Scaffold X on the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a first Scaffold X on the luminal surface of the EV and the adjuvant is linked to a second Scaffold X on the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold X on the luminal surface of the EV and the adjuvant is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold X on the luminal surface of the EV and the adjuvant is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an

adjuvant, wherein the antigen is linked to a first Scaffold X on the exterior surface of the EV and the adjuvant is linked to a second Scaffold X on the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a first Scaffold X on the luminal surface of the EV and the adjuvant is linked to a second Scaffold X on the exterior surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is in the lumen of the EV not linked to any scaffold moiety and the adjuvant is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked directly to the luminal surface of the EV and the adjuvant is in the lumen of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked to a Scaffold X on the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked directly to the exterior of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked directly to the luminal surface of the EV and the adjuvant is linked to a Scaffold X on the exterior of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and

(ii) an adjuvant, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV and the adjuvant is linked directly to the exterior of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold X on the luminal surface of the EV and the adjuvant is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is linked to a Scaffold X on the luminal surface of the E, and the adjuvant is linked directly to the exterior of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is in the lumen of the EV and the adjuvant is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an adjuvant, wherein the antigen is in the lumen of the EV and the adjuvant is linked directly to the exterior of the EV.

[0297] In some aspects, an adjuvant and/or antigen can be modified to increase encapsulation (*i.e.*, loading) in an EV. This modification can include the addition of a lipid binding tag by treating the agonist (*i.e.*, adjuvant and/or antigen) with a chemical or enzyme, or by physically or chemically altering the polarity or charge of the adjuvant and/or antigen. The adjuvant and/or antigen can be modified by a single treatment, or by a combination of treatments, *e.g.*, adding a lipid binding tag only, or adding a lipid binding tag and altering the polarity. The previous example is meant to be a non-limiting illustrative instance. It is contemplated that any combination of modifications can be practiced. The modification can increase encapsulation (*i.e.*, loading) of the adjuvant and/or antigen in the EV by between about 2-fold and about 10,000-fold, between about 10-fold and 1,000-fold, or between about 100-fold and about 500-fold compared to encapsulation (*i.e.*, loading) of an unmodified agonist (*i.e.*, adjuvant and/or antigen). The modification can increase encapsulation (*i.e.*, loading) of the adjuvant and/or antigen in the EV by at least about 2-fold, about 5-fold, about 10-fold, about 20-fold, about 30-fold, about 40-fold, about 50-fold, about 60-fold, about 70-fold, about 80-fold, about 90-fold, about 100-fold, about 200-fold, about 300-fold, about 400-fold, about 500-fold, about 600-fold, about 700-fold, about 800-fold, about 900-fold, about 1,000-fold, about 2,000-fold, about 3,000-fold, about 4,000-fold, about 5,000-fold, about 6,000-fold, about 7,000-fold, about 8,000-fold, about 9,000-fold, or about 10,000-fold compared to encapsulation (*i.e.*, loading) of an unmodified adjuvant and/or antigen.

[0298] In some aspects, an adjuvant and/or antigen can be modified to allow for better expression on the surface of the EV (*e.g.*, exterior and/or luminal surface of the EV, *e.g.*, linked to a scaffold moiety disclosed herein, *e.g.*, Scaffold X and/or Scaffold Y). Any of the modifications described above can be used. The modification can increase expression of the agonist in the EV, *e.g.*, on the surface and/or luminal surface of the exosome, by about between 2-fold and 10,000-fold, about between 10-fold and 1,000-fold, or about between 100-fold and 500-fold compared to corresponding expression of an unmodified agonist. The modification can increase expression of the agonist on the exterior surface of the EV by at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, or at least about 10,000-fold compared to expression of an unmodified agonist. The modification can increase expression of the agonist on the luminal surface of the EV by at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, or at least about 10,000-fold compared to expression of an unmodified agonist.

II.C Targeting Moiety (e.g., Tropism Moiety)

[0299] In some aspects, the EV is further modified to display an additional protein (or fragment thereof) that can help direct EV uptake (*e.g.*, targeting moiety), activate, or block cellular pathways to enhance the combinatorial effects associated with the EV (*e.g.*, effect of a payload loaded into an exosome, *e.g.*, STING agonist). In certain aspects, the EV disclosed herein further comprises a targeting moiety that can modify the distribution of the EVs *in vivo* or *in vitro*. In some aspects, the targeting moiety can be a biological molecule, such as a protein, a peptide, a lipid, or

a synthetic molecule. Not to be bound by any one theory, as will be apparent from the present disclosure, in some aspects, the addition of such moieties can further enhance the therapeutic effects of the EVs described herein, *e.g.*, when administered to a subject. Moreover, as described herein, in some aspects, the targeting moiety can be present in the EV prior to the addition of other moieties described herein (*e.g.*, an antigen). In such aspects, the targeting moiety can be introduced into a producer cell when producing the EV (*e.g.*, base EV). In some aspects, the targeting moiety can be added to the EVs after being isolated from the producer cells. In such aspects, the targeting moiety can be added to the isolated EVs before adding the other moieties described herein (*e.g.*, an antigen). In some aspects, the targeting moiety is added to the EV after adding the other moieties described herein (*e.g.*, an antigen). In some aspects, the targeting moiety is added to the EV together with the other moieties described herein.

[0300] In some aspects, a targeting moiety of the present disclosure specifically binds to a marker for a particular type of cells. In some aspects, the cell is an immune cell, *e.g.*, dendritic cell. In certain aspects, the marker is expressed only on dendritic cells. In some aspects, dendritic cells comprise a progenitor (Pre) dendritic cells, inflammatory mono dendritic cells, plasmacytoid dendritic cell (pDC), a myeloid/conventional dendritic cell 1 (cDC1), a myeloid/conventional dendritic cell 2 (cDC2), inflammatory monocyte derived dendritic cells, Langerhans cells, dermal dendritic cells, lysozyme-expressing dendritic cells (LysoDCs), Kupffer cells, nonclassical monocytes, or any combination thereof. Markers that are expressed on these dendritic cells are known in the art. *See, e.g.,* Collin *et al.*, *Immunology* 154(1):3-20 (2018). In some aspects, the targeting moiety is a protein, wherein the protein is an antibody or a fragment thereof that can specifically bind to a marker selected from DEC205, CLEC9A, CLEC6, DCIR, DC-SIGN, LOX-1, MARCO, Clec12a, Clec10a, DC-asialoglycoprotein receptor (DC-ASGPR), DC immunoreceptor 2 (DCIR2), Dectin-1, macrophage mannose receptor (MMR), BDCA-2 (CD303, Clec4c), Dectin-2, Bst-2 (CD317), Langerin, CD206, CD11b, CD11c, CD123, CD304, XCR1, AXL, Siglec 6, CD209, SIRPA, CX3CR1, GPR182, CD14, CD16, CD32, CD34, CD38, CD10, or any combination thereof. In some aspects, a marker useful for the present disclosure comprises a C-type lectin like domain. In certain aspects, a marker is Clec9a and the dendritic cell is cDC1.

[0301] In some aspects, a targeting moiety disclosed herein can bind to both human and mouse Clec9a, including any variants thereof. In some aspects, a targeting moiety of the present disclosure can bind to Clec9a from other species, including but not limited to chimpanzee, rhesus

monkey, dog, cow, horse, or rat. Sequences for such Clec9a protein are known in the art. *See*, *e.g.*, U.S. Pat. No. 8,426,565 B2, which is herein incorporated by reference in its entirety.

[0302] In some aspects, a targeting moiety of the present disclosure specifically binds to a marker for a T cell. In certain aspects, the T cell is a CD4+ T cell. In some aspects, the T cell is a CD8+ T cell.

[0303] In some aspects, a targeting moiety disclosed herein binds to human CD3 protein or a fragment thereof. Sequences for human CD3 protein are known in the art.

[0304] In some aspects, a targeting moiety disclosed herein can bind to both human and mouse CD3, including any variants thereof. In some aspects, a targeting moiety of the present disclosure can bind to CD3 from other species, including but not limited to chimpanzee, rhesus monkey, dog, cow, horse, or rat. Sequences for such CD3 protein are also known in the art.

[0305] In some aspects, a targeting moiety that is useful for the present disclosure specifically binds to a marker expressed on a B cell. Non-limiting examples of markers expressed on B cells include CD40, CD22, CD19, B220, IgM, MHCII, or combinations thereof.

[0306] In some aspects, a targeting moiety can increase the uptake of an EV by follicular DCs. As used herein, "**follicular**" DCs (FDCs) are non-migratory population of immune cells found in primary and secondary follicles of the B cell areas of lymphoid tissues (*e.g.*, lymph nodes, spleen, and mucosa-associated lymphoid tissue (MALT)). FDCs differ from DCs in that they are not derived from bone-marrow hematopoietic stem cells but are of mesenchymal origin. FDCs present antigen to B cells within the germinal center and regulate B cell antibody affinity maturation and B cell memory responses. Non-limiting examples of such tropism moieties include IgG, IgG-antigen complex, IgG-Fc, *S aureus* D domain dimer, anti-CR1 antibody, anti-CR2 antibody, or combinations thereof.

[0307] In some aspects, a targeting moiety disclosed herein can allow for greater uptake of an EV by a cell expressing a marker specific for the targeting moiety (*e.g.*, CD3: CD4+ T cell and/or CD8+ T cell; Clec9a: dendritic cells; CD40, CD22, or CD19: B cells). In some aspects, the uptake of an EV is increased by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-

fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, at least about 10,000-fold or more, compared to a reference (*e.g.*, corresponding EV without the targeting moiety or a non-EV delivery vehicle). In some aspects, a reference comprises an EV that does not express a targeting moiety disclosed herein.

[0308] In some aspects, the increased uptake of an EV disclosed herein can allow for greater immune response. Accordingly, in certain aspects, an EV expressing a targeting moiety disclosed herein can increase an immune response (*e.g.*, against a coronavirus antigen loaded onto the exosome) by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, at least about 10,000-fold or more, compared to a reference (*e.g.*, corresponding EV without the targeting moiety or a non-EV delivery vehicle). In some aspects, a reference comprises an EV that does not express a targeting moiety disclosed herein. In certain aspects, an immune response is mediated by T cells (*e.g.*, CD8+ T cells or CD4+ T cells) and/or B cells.

[0309] As described *supra*, a targeting moiety disclosed herein can comprise a peptide, an antibody or an antigen binding fragment thereof, a chemical compound, or any combination thereof.

[0310] In some aspects, the targeting moiety is a peptide that can specifically bind to Clec9a. *See, e.g.,* Yan *et al., Oncotarget* 7(26): 40437-40450 (2016). For example, in certain aspects, the peptide comprises a soluble fragment of Clec9a. A non-limiting example of such a peptide is described in U.S. Pat. No. 9,988,431 B2, which is herein incorporated by reference in its entirety. In certain aspects, the peptide comprises a ligand (natural or synthetic) of Clec9a, such as those described in Ahrens *et al.*, *Immunity* 36(4): 635-45 (2012); and Zhang *et al., Immunity* 36(4): 646-57 (2012). A non-limiting example of a peptide comprising a Clec9a ligand is described in

International Publ. No. WO 2013/053008 A2, which is herein incorporated by reference in its entirety.

[0311] In some aspects, the targeting moiety is a peptide that can specifically bind to CD3. For example, in certain aspects, the peptide comprises a soluble fragment of CD3. In certain aspects, the peptide comprises a ligand (natural or synthetic) of CD3.

[0312] In some aspects, the targeting moiety is an antibody or an antigen binding fragment thereof. In certain aspects, a targeting moiety is a single-chain Fv antibody fragment. In certain aspects, a targeting moiety is a single-chain F(ab) antibody fragment. In certain aspects, a targeting moiety is a nanobody. In certain aspects, a targeting moiety is a monobody.

[0313] In some aspects, an EV disclosed herein comprises one or more (*e.g.*, 2, 3, 4, 5, or more) targeting moieties. In certain aspects, the one or more targeting moieties are expressed in combination with other exogenous biologically active molecules disclosed herein (*e.g.*, therapeutic molecule, adjuvant, or immune modulator). In some aspects, the one or more targeting moieties can be expressed on the exterior surface of the EV. Accordingly, in certain aspects, the one or more targeting moieties are linked to a scaffold moiety (*e.g.*, Scaffold X) on the exterior surface of the EV. When the one or more targeting moieties are expressed in combination with other exogenous biologically active molecules (*e.g.*, therapeutic molecule, adjuvant, or immune modulator), the other exogenous biologically active molecules can be expressed on the surface (*e.g.*, exterior surface or luminal surface) or in the lumen of the EV.

[0314] The producer cell can be modified to comprise an additional exogenous sequence encoding for the additional protein or fragment thereof. Alternatively, the additional protein or fragment thereof can be covalently linked or conjugated to the EV via any appropriate linking chemistry known in the art. Non-limiting examples of appropriate linking chemistry include amine-reactive groups, carboxyl-reactive groups, sulfhydryl-reactive groups, aldehyde-reactive groups, photoreactive groups, ClickIT chemistry, biotin-streptavidin or other avidin conjugation, or any combination thereof.

II.D Immune Modulator

[0315] In some aspects, an EV of the present disclosure can comprise an immune modulator (*e.g.*, along with an antigen and/or other payloads disclosed herein). In some aspects, an EV disclosed herein comprises multiple immune modulators. In certain aspects, each of the multiple immune modulators is different. In some aspects, an EV disclosed herein comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different immune modulators.

[0316] In certain aspects, an EV comprises the one or more immune modulators in combination with one or more additional payloads (*e.g.*, antigen and/or adjuvants). In some aspects, an EV can comprise one or more additional moieties (*e.g.*, targeting moieties). For instance, in certain aspects, an EV disclosed described herein can comprise (i) one or more immune modulators, (ii) one or more additional payloads (*e.g.*, antigen and/or adjuvant), and (iii) one or more targeting moieties. As described herein, in certain aspects, the immune modulator can be present in the EV prior to the addition of other moieties described herein (*e.g.*, an antigen). In such aspects, the immune modulator can be introduced into a producer cell when producing the EV (*e.g.*, base EV). In some aspects, the immune modulator can be added to the EVs after being isolated from the producer cells. In such aspects, the immune modulator can be added to the isolated EVs before adding the other moieties described herein (*e.g.*, an antigen). In some aspects, the immune modulator is added to the EV after adding the other moieties described herein (*e.g.*, an antigen). In some aspects, the immune modulator is added to the EV together with the other moieties described herein.

[0317] In some aspects, an immune modulator can be expressed on the surface (*e.g.*, exterior surface or luminal surface) or in the lumen of the EV. Accordingly, in certain aspects, the immune modulator is linked to a scaffold moiety (*e.g.*, Scaffold X) on the exterior surface of the EV or on the luminal surface of the EV. In other aspects, the immune modulator is linked to a scaffold moiety (*e.g.*, Scaffold Y) on the luminal surface of the EV. In further aspects, the immune modulator is in the lumen of the exosome (*i.e.*, not linked to either Scaffold X or Scaffold Y). In some aspects, an immune modulator can be directly linked (*i.e.*, without the use of a scaffold moiety) to the exterior surface and/or luminal surface of an EV.

[0318] Non-limiting examples of such aspects, include EVs comprising (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein:

(a) the antigen is linked to a first Scaffold Y on the luminal surface of the EV and the immune modulator is linked to a second Scaffold Y on the luminal surface of the EV;

(b) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is in the lumen of the EV not linked to any scaffold moiety;

(c) the antigen is in the lumen of the EV not linked to any scaffold moiety and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV;

(d) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is linked to a Scaffold X on the exterior surface the EV;

(e) the antigen is linked to a Scaffold X on the luminal surface of the EV and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV;

(f) the antigen is linked to a Scaffold X on the luminal surface of the EV and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV; or

(g) the antigen is linked to a Scaffold X on the exterior surface of the EV and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV.

[0319] Non-limiting examples of specific aspects, include EVs comprising (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein:

(a) the antigen is linked to a first Scaffold Y on the luminal surface of the EV and the immune modulator is linked to a second Scaffold Y on the luminal surface of the EV;

(b) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is in the lumen of the EV not linked to any scaffold moiety;

(c) the antigen is in the lumen of the EV not linked to any scaffold moiety, and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV;

(d) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is linked to a Scaffold X on the exterior surface of the EV;

(e) the antigen is in the lumen of the EV not linked to any scaffold moiety, and the immune modulator is linked to a Scaffold X on the exterior surface of the EV;

(f) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is linked to a Scaffold X on the luminal surface of the EV;

(g) the antigen is in the lumen of the EV not linked to any scaffold moiety, and the immune modulator is linked to a Scaffold X on the luminal surface of the EV;

(h) the antigen is linked to a Scaffold X on the luminal surface of the EV and the immune modulator is linked to the Scaffold X on the exterior surface of the EV;

(i) the antigen is linked to a first Scaffold X on the exterior surface of the EV and the immune modulator is linked to a second Scaffold X on the exterior surface of the EV;

(j) the antigen is linked to a Scaffold X on the exterior surface of the EV and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV;

(k) the antigen is linked to a Scaffold X on the exterior surface of the EV and the immune modulator is in the lumen of the EV not linked to any scaffold moiety;
(l) the antigen is linked to a Scaffold X on the exterior surface of the EV and the immune modulator is linked to the Scaffold X on the luminal surface of the EV;
(m) the antigen is linked to a first Scaffold X on the luminal surface of the EV and the immune modulator is linked to a second Scaffold X on the luminal surface of the EV;
(n) the antigen is linked to a Scaffold X on the luminal surface of the EV and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV;
(o) the antigen is linked to a Scaffold X on the luminal surface of the EV and the immune modulator is in the lumen of the EV not linked to any scaffold moiety;
(p) the antigen is linked to a first Scaffold X on the exterior surface of the EV and the immune modulator is linked to a second Scaffold X on the luminal surface of the EV;
(q) the antigen is linked to a first Scaffold X on the luminal surface of the EV and the immune modulator is linked to a second Scaffold X on the exterior surface of the EV;
(r) the antigen is in the lumen of the EV not linked to any scaffold moiety, and the immune modulator is in the lumen of the EV not linked to any scaffold moiety;
(s) the antigen is linked directly to the luminal surface of the EV and the immune modulator is linked directly to the luminal surface of the EV;
(t) the antigen is linked directly to the luminal surface of the EV and the immune modulator is in the lumen of the EV;
(u) the antigen is linked directly to the luminal surface of the EV and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV;
(v) the antigen is linked directly to the luminal surface of the EV and the immune modulator is linked to a Scaffold X on the luminal surface of the EV;
(w) the antigen is linked directly to the luminal surface of the EV and the immune modulator is linked directly to the exterior of the EV;
(x) the antigen is linked directly to the luminal surface of the EV and the immune modulator is linked to a Scaffold X on the exterior of the EV;
(y) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is linked directly to the luminal surface of the EV;
(z) the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is linked directly to the exterior of the EV;

(aa) the antigen is linked to a Scaffold X on the luminal surface of the EV and the immune modulator is linked directly to the luminal surface of the EV;
(bb) the antigen is linked to a Scaffold X on the luminal surface of the EV and the immune modulator is linked directly to the exterior of the EV;
(cc) the antigen is in the lumen of the EV and the immune modulator is linked directly to the luminal surface of the EV; or
(dd) the antigen is in the lumen of the EV and the immune modulator is linked directly to the exterior of the EV.

[0320] In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a first Scaffold Y on the luminal surface of the EV and the immune modulator is linked to a second Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is in the lumen of the EV not linked to any scaffold moiety, and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is linked to a Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is in the lumen of the EV not linked to any scaffold moiety, and the immune modulator is linked to a Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV and the immune modulator is linked to a Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus,

e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is in the lumen of the EV not linked to any scaffold moiety, and the immune modulator is linked to a Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold X on the luminal surface of the EV and the immune modulator is linked to the Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a first Scaffold X on the exterior surface of the EV and the immune modulator is linked to a second Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold X on the exterior surface of the EV and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold X on the exterior surface of the EV and the immune modulator is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold X on the exterior surface of the EV and the immune modulator is linked to the Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a first Scaffold X on the luminal surface of the EV and the immune modulator is linked to a second Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold X on the luminal surface of the EV and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold X

on the luminal surface of the EV and the immune modulator is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a first Scaffold X on the exterior surface of the EV and the immune modulator is linked to a second Scaffold X on the luminal surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a first Scaffold X on the luminal surface of the EV and the immune modulator is linked to a second Scaffold X on the exterior surface of the EV. In some aspects, an EV of the present disclosure comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is in the lumen of the EV not linked to any scaffold moiety, and the immune modulator is in the lumen of the EV not linked to any scaffold moiety. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked directly to the luminal surface of the EV, and the immune modulator is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked directly to the luminal surface of the EV, and the immune modulator is in the lumen of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked directly to the luminal surface of the EV, and the immune modulator is linked to a Scaffold Y on the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked directly to the luminal surface of the EV, and the immune modulator is linked to a Scaffold X on the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked directly to the luminal surface of the EV, and the immune modulator is linked directly to the exterior of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked directly to the luminal surface

of the EV, and the immune modulator is linked to a Scaffold X on the exterior of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV, and the immune modulator is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold Y on the luminal surface of the EV, and the immune modulator is linked directly to the exterior of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold X on the luminal surface of the EV, and the immune modulator is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein the antigen is linked to a Scaffold X on the luminal surface of the EV, and the immune modulator is linked directly to the exterior of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein antigen is in the lumen of the EV, and the immune modulator is linked directly to the luminal surface of the EV. In some aspects, an EV comprises (i) an antigen, *e.g.*, derived from a coronavirus, e.g., a SARS-CoV-1 and/or SARS-CoV-2 (COVID-19) virus, and (ii) an immune modulator, wherein antigen is in the lumen of the EV, and the immune modulator is linked directly to the exterior of the EV.

[0321] In some aspects, an immune modulator can regulate innate immune response. In some aspects, an immune modulator can regulate adaptive immune response. In some aspects, the immune modulator regulates adaptive immune response by targeting cytotoxic T cells. In further aspects, the immune modulator regulates adaptive immune response by targeting B cells (*e.g.*, resulting in the production of antigen-specific antibodies). In certain aspects, an immune modulator disclosed herein can modulate the distribution of an exosome to a cytotoxic T cell or a B cell (*i.e.*, bio-distribution modifying agent).

[0322] In some aspects, an immune modulator useful for the present disclosure can specifically induce the activation of certain lymphocyte subsets. For instance, in some aspects, an immune modulator can specifically induce the activation of CD4+ T helper cells. CD4+ T helper cells are arguably the most important cells in adaptive immunity, as they are required for almost

all adaptive immune responses. They not only help activate B cells to secrete antibodies and macrophages to destroy ingested microbes, but they also help activate cytotoxic T cells to kill infected target cells. Crott S., *Nat Rev Immunol* 15(3): 185-189 (Mar. 2015). In certain aspects, the immune modulator is a peptide that can specifically induce the activation of CD4+ helper T cells. In some aspects, such peptides are referred to herein as "**CD4+ T helper peptide**". In some aspects, the CD4+ T helper peptides are derived from tetanus, measles, diphtheria toxins, or combinations thereof. The CD4+ T help peptides that are useful for the present disclosure can also comprise the PADRE peptide (AKFVAAWTLKAAA; SEQ ID NO: 386). In certain aspects, such peptides are referred to herein as "**universal CD4+ T helper peptide**," as they are capable of inducing the activation of CD4+ helper T cells in an antigen-independent manner (*i.e.*, non-specific activation). In some aspects, the CD4+ T cell epitope comprises the amino acid sequence QYIKANSKFIGITE (SEQ ID NO: 383) (amino acid residues 830-843 of tetanus). In some aspects, the CD4+ T cell epitope comprises the amino acid sequence QSIALSSLMVAQAIP (SEQ ID NO: 384) (amino acid residues 356-370 of diphtheria toxin).

[0323] In some aspects, an immune modulator comprises an inhibitor for a negative checkpoint regulator or an inhibitor for a binding partner of a negative checkpoint regulator. In certain aspects, the negative checkpoint regulator comprises cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), lymphocyte-activated gene 3 (LAG-3), T-cell immunoglobulin mucin-containing protein 3 (TIM-3), B and T lymphocyte attenuator (BTLA), T cell immunoreceptor with Ig and ITIM domains (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), adenosine A2a receptor (A2aR), killer cell immunoglobulin like receptor (KIR), indoleamine 2,3-dioxygenase (IDO), CD20, CD39, CD73, or any combination thereof.

[0324] In some aspects, the immune modulator is an inhibitor of cytotoxic T-lymphocyte-associate protein 4 (CTLA-4). In certain aspects, the CTLA-4 inhibitor is a monoclonal antibody of CTLA-4 ("anti-CTLA-4 antibody"). In certain aspects, the inhibitor is a fragment of a monoclonal antibody of CTLA-4. In certain aspects, the antibody fragment is a scFv, $(scFv)_2$, Fab, Fab', and $F(ab')_2$, $F(ab1)_2$, Fv, dAb, or Fd of a monoclonal antibody of CTLA-4. In certain aspects, the inhibitor is a nanobody, a bispecific antibody, or a multispecific antibody against CTLA-4. In some aspects, the anti-CTLA-4 antibody is ipilimumab. In other aspects, the anti-CTLA-4 antibody is tremelimumab.

[0325] In some aspects, the immune modulator is an inhibitor of programmed cell death protein 1 (PD-1). In some aspects, the immune modulator is an inhibitor of programmed death-ligand 1 (PD-L1). In some aspects, the immune modulator is an inhibitor of programmed death-ligand 2 (PD-L2). In certain aspects, the inhibitor of PD-1, PD-L1, or PD-L2 is a monoclonal antibody of PD-1 ("anti-PD-1 antibody"), PD-L1 ("anti-PD-L1 antibody"), or PD-L2 ("anti-PD-L2 antibody"). In some aspects, the inhibitor is a fragment of an anti-PD-1 antibody, anti-PD-L1 antibody, or anti-PD-L2 antibody. In certain aspects, the antibody fragment is a scFv, $(scFv)_2$, Fab, Fab', and $F(ab')_2$, $F(ab1)_2$, Fv, dAb, or Fd of a monoclonal antibody of PD-1, PD-L1, or PD-L2. In certain aspects, the inhibitor is a nanobody, a bispecific antibody, or a multispecific antibody against PD-1, PD-L1, or PD-L2. In some aspects, the anti-PD-1 antibody is nivolumab. In some aspects, the anti-PD-1 antibody is pembrolizumab. In some aspects, the anti-PD-1 antibody is pidilizumab. In some aspects, the anti-PD-L1 antibody is atezolizumab. In other aspects, the anti-PD-L1 antibody is avelumab.

[0326] In some aspects, the immune modulator is an inhibitor of lymphocyte-activated gene 3 (LAG3). In certain aspects, the inhibitor of LAG3 is a monoclonal antibody of LAG3 ("anti-LAG3 antibody"). In some aspects, the inhibitor is a fragment of an anti-LAG3 antibody, *e.g.*, scFv, $(scFv)_2$, Fab, Fab', and $F(ab')_2$, $F(ab1)_2$, Fv, dAb, or Fd. In certain aspects, the inhibitor is a nanobody, a bispecific antibody, or a multispecific antibody against LAG3.

[0327] In some aspects, the immune modulator is an inhibitor of T-cell immunoglobulin mucin-containing protein 3 (TIM-3). In some aspects, the immune modulator is an inhibitor of B and T lymphocyte attenuator (BTLA). In some aspects, the immune modulator is an inhibitor of T cell immunoreceptor with Ig and ITIM domains (TIGIT). In some aspects, the immune modulator is an inhibitor of V-domain Ig suppressor of T cell activation (VISTA). In some aspects, the immune modulator is an inhibitor of adenosine A2a receptor (A2aR). In some aspects, the immune modulator is an inhibitor of killer cell immunoglobulin like receptor (KIR). In some aspects, the immune modulator is an inhibitor of indoleamine 2,3-dioxygenase (IDO). In some aspects, the immune modulator is an inhibitor of CD20, CD39, or CD73.

[0328] In some aspects, the immune modulator comprises an activator for a positive co-stimulatory molecule or an activator for a binding partner of a positive co-stimulatory molecule. In certain aspects, the positive co-stimulatory molecule comprises a TNF receptor superfamily member (*e.g.*, CD120a, CD120b, CD18, OX40, CD40, Fas receptor, M68, CD27, CD30, 4-1BB, TRAILR1, TRAILR2, TRAILR3, TRAILR4, RANK, OCIF, TWEAK receptor, TACI, BAFF

receptor, ATAR, CD271, CD269, AITR, TROY, CD358, TRAMP, and XEDAR). In some aspects, the activator for a positive co-stimulatory molecule is a TNF superfamily member (*e.g.*, TNFα, TNF-C, OX40L, CD40L, FasL, LIGHT, TL1A, CD27L, Siva, CD153, 4-1BB ligand, TRAIL, RANKL, TWEAK, APRIL, BAFF, CAMLG, NGF, BDNF, NT-3, NT-4, GITR ligand, and EDA-2).

[0329] In some aspects, the immune modulator is an activator of TNF Receptor Superfamily Member 4 (OX40). In certain aspects, the activator of OX40 is an agonistic anti-OX40 antibody. In further aspects, the activator of OX40 is a OX40 ligand (OX40L).

[0330] In some aspects, the immune modulator is an activator of CD27. In certain aspects, the activator of CD27 is an agonistic anti-CD27 antibody. In other aspects, the activator of CD27 is a CD27 ligand (CD27L).

[0331] In some aspects, the immune modulator is an activator of CD40. In certain aspects, the activator of CD40 is an agonistic anti-CD40 antibody. In some aspects, the activator of CD40 is a CD40 ligand (CD40L). In certain aspects, the CD40L is a monomeric CD40L. In other aspects, the CD40L is a trimeric CD40L.

[0332] In some aspects, the immune modulator is an activator of glucocorticoid-induced TNFR-related protein (GITR). In certain aspects, the activator of GITR is an agonistic anti-GITR antibody. In other aspects, the activator of GITR is a natural ligand of GITR.

[0333] In some aspects, the immune modulator is an activator of 4-1BB. In specific aspects, the activator of 4-1BB is an agonistic anti-4-1BB antibody. In certain aspects, the activator of 4-1BB is a natural ligand of 4-1BB.

[0334] In some aspects, the immune modulator is a Fas receptor (Fas). In such aspects, the Fas receptor is displayed on the surface of the EV. In some aspects, the immune modulator is Fas ligand (FasL). In certain aspects, the Fas ligand is displayed on the surface of the EV. In some aspects, the immune modulator is an anti-Fas antibody or an anti-FasL antibody.

[0335] In some aspects, the immune modulator is an activator of a CD28-superfamily co-stimulatory molecule. In certain aspects, the CD28-superfamily co-stimulatory molecule is ICOS or CD28. In certain aspects, the immunomodulating component is ICOSL, CD80, or CD86.

[0336] In some aspects, the immune modulator is an activator of inducible T cell co-stimulator (ICOS). In certain aspects, the activator of ICOS is an agonistic anti-ICOS antibody. In other aspects, the activator of ICOS is a ICOS ligand (ICOSL).

[0337] In some aspects, the immune modulator is an activator of CD28. In some aspects, the activator of CD28 is an agonistic anti-CD28 antibody. In other aspects, the activator of CD28 is a natural ligand of CD28. In certain aspects, the ligand of CD28 is CD80.

[0338] In some aspects, the immune modulator comprises a cytokine or a binding partner of a cytokine. In some aspects, the cytokine is selected from (i) common gamma chain family of cytokines; (ii) IL-1 family of cytokines; (iii) hematopoietic cytokines; (iv) interferons (*e.g.*, type I, type II, or type III); (v) TNF family of cytokines; (vi) IL-17 family of cytokines; (vii) damage-associated molecular patterns (DAMPs); (viii) tolerogenic cytokines; or (ix) combinations thereof. In certain aspects, the cytokine comprises IL-2, IL-4, IL-7, IL-10, IL-12, IL-15, IL-21, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-36ra, IL-37, IL-38, IL-3, IL-5, IL-6, IL-11, IL-13, IL-23, granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), leukemia inhibitory factor (LIF), stem cell factor (SCF), thrombopoietin (TPO), macrophage-colony stimulating factor (M-CSF), erythropoieticn (EPO), Flt-3, IFN-α, IFN-β, IFN-γ, IL-19, IL-20, IL-22, IL-24, TNF-α, TNF-β, BAFF, APRIL, lymphotoxin beta (TNF-γ), IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F, IL-25, TSLP, IL-35, IL-27, TGF-β, or combinations thereof.

[0339] In some aspects, the immune modulator comprises a chemokine. In certain aspects, chemokine comprises a (i) CC chemokine (*e.g.*, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28); (ii) CXC chemokine (*e.g.*, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17); (iii) C chemokine (*e.g.*, XCL1, XCL2); (iv) CX3C chemokine (*e.g.*, CX3CL1); (v) or combinations thereof.

[0340] In some aspects, the immune modulator comprises an inhibitor of lysophosphatidic acid (LPA). LPA is a highly potent endogenous lipid mediator that protects and rescues cells from programmed cell death. LPA, through its high affinity LPA-1 receptor, is an important mediator of fibrogenesis.

[0341] In some aspects, the immune modulator that can be used with the present disclosure comprises a protein that supports intracellular interactions required for germinal center responses. In certain aspects, such a protein comprises a signaling lymphocyte activation molecule (SLAM) family member or a SLAM-associated protein (SAP). In some aspects, a SLAM family members

comprises SLAM, CD48, CD229 (Ly9), Ly108, 2B4, CD84, NTB-A, CRACC, BLAME, CD2F-10, or combinations thereof. Non-limiting examples of other immune modulators that can play a role in germinal center response includes: ICOS-ICOSL, CD40-40L, CD28/B7, PD-1/L1, IL-4/IL4R, IL21/IL21R, TLR4, TLR7, TLR8, TLR9, CD180, CD22, and combinations thereof.

[0342] In some aspects, the immune modulator comprises a T-cell receptor (TCR) or a derivative thereof. In certain aspects, the immune modulator is a TCR α-chain or a derivative thereof. In other aspects, the immune modulator is a TCR β-chain or a derivative thereof. In further aspects, the immune modulator is a co-receptor of the T-cell or a derivative thereof.

[0343] In some aspects, the immune modulator comprises a chimeric antigen receptor (CAR) or a derivative thereof. In certain aspects, the CAR binds to one or more of the antigens disclosed herein (*e.g.*, tumor antigen, *e.g.*, alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), epithelial tumor antigen (ETA), mucin 1 (MUC1), Tn-MUC1, mucin 16 (MUC16), tyrosinase, melanoma-associated antigen (MAGE), tumor protein p53 (p53), CD4, CD8, CD45, CD80, CD86, programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), NY-ESO-1, PSMA, TAG-72, HER2, GD2, cMET, EGFR, Mesothelin, VEGFR, alpha-folate receptor, CE7R, IL-3, Cancer-testis antigen, MART-1 gp100, and TNF-related apoptosis-inducing ligand).

[0344] In some aspects, the immune modulator comprises an activator of a T-cell receptor or co-receptor. In certain aspects, the immunomodulating component is an activator of CD3. In certain aspects, the activator is a fragment of a monoclonal antibody of CD3. In certain aspects, the antibody fragment is a scFv, $(scFv)_2$, Fab, Fab', and $F(ab')_2$, $F(ab1)_2$, Fv, dAb, or Fd of a monoclonal antibody against CD3. In certain aspects, the activator is a nanobody, a bispecific antibody, or a multispecific antibody against CD3. In certain aspects, the immunomodulating component is an activator of CD28. In certain aspects, the activator is a fragment of a monoclonal antibody of CD28. In certain aspects, the antibody fragment is a scFv, $(scFv)_2$, Fab, Fab', and $F(ab')_2$, $F(ab1)_2$, Fv, dAb, or Fd of a monoclonal antibody of CD28. In certain aspects, the activator is a nanobody, a bispecific antibody, or a multispecific antibody against CD28.

[0345] In some aspects, the immune modulator comprises a tolerance inducing agent. In certain aspects, the tolerance inducing agent comprises a NF-κB inhibitor. Non-limiting examples of NF-κB inhibitors that can be used with the present disclosure includes: IKK complex inhibitors (*e.g.*, TPCA-1, NF-κB Activation Inhibitor VI (BOT-64), BMS 345541, Amlexanox, SC-514 (GK 01140), IMD 0354, IKK-16), IκB degradation inhibitor (*e.g.*, BAY 11-7082, MG-115, MG-132, Lactacystin, Epoxomicin, Parthenolide, Carfilzomib, MLN-4924 (Pevonedistat)), NF-κB nuclear

translocation inhibitor (*e.g.*, JSH-23, Rolipram), p65 acetylation inhibitor (*e.g.*, Gallic acid, Anacardic acid), NF-κB-DNA binding inhibitor (*e.g.*, GYY 4137, p-XSC, CV 3988, Prostaglandin E2 (PGE2)), NF-κB transactivation inhibitor (*e.g.*, LY 294002, Wortmannin, Mesalamine), or combinations thereof. *See also* Gupta, S.C., *et al.*, Biochim Biophys Acta 1799:775-787 (2010), which is herein incorporated by reference in its entirety. In some aspects, an immune modulator that can inhibit NF-κB activity and be used with the EVs disclosed herein comprises an antisense-oligonucleotide that specifically targets NF-κB. In further aspects, an immune modulator capable of inducing tolerance comprises a COX-2 inhibitor, mTOR inhibitor (*e.g.*, rapamycin and derivatives, *e.g.*, antisense oligonucleotides targeting mTor), prostaglandins, nonsteroidal anti-inflammatory agents (NSAIDS), antileukotriene, aryl hydrocarbon receptor (AhR) ligand, vitamin D, retinoic acid, steroids, Fas receptor/ligand, CD22 ligand, IL-10, IL-35, IL-27, metabolic regulator (*e.g.*, glutamate), glycans (*e.g.*, ES62, LewisX, LNFPIII), peroxisome proliferator-activated receptor (PPAR) agonists, immunoglobulin-like transcript (ILT) family of receptors (*e.g.*, ILT3, ILT4, HLA-G, ILT-2), minocycline, TLR4 agonists, or combinations thereof.

[0346] In some aspects, the immune modulator is an agonist. In certain aspects, the agonist is an endogenous agonist, such as a hormone, or a neurotransmitter. In other aspects, the agonist is an exogenous agonist, such as a drug. In some aspects, the agonist is a physical agonist, which can create an agonist response without binding to the receptor. In some aspects, the agonist is a superagonist, which can produce a greater maximal response than the endogenous agonist. In certain aspects, the agonist is a full agonist with full efficacy at the receptor. In other aspects, the agonist is a partial agonist having only partial efficacy at the receptor relative to a full agonist. In some aspects, the agonist is an inverse agonist that can inhibit the constitutive activity of the receptor. In some aspects, the agonist is a co-agonist that works with other co-agonists to produce an effect on the receptor. In certain aspects, the agonist is an irreversible agonist that binds permanently to a receptor through formation of covalent bond. In certain aspects, the agonist is selective agonist for a specific type of receptor

[0347] In some aspects, the immune modulator is an antagonist. In specific aspects, the antagonist is a competitive antagonist, which reversibly binds to the receptor at the same binding site as the endogenous ligand or agonist without activating the receptor. Competitive antagonist can affect the amount of agonist necessary to achieve a maximal response. In other aspects, the antagonist is a non-competitive antagonist, which binds to an active site of the receptor or an allosteric site of the receptor. Non-competitive antagonist can reduce the magnitude of the

maximum response that can be attained by any amount of agonist. In further aspects, the antagonist is an uncompetitive antagonist, which requires receptor activation by an agonist before its binding to a separate allosteric binding site.

[0348] In some aspects, the immune modulator comprises an antibody or an antigen-binding fragment. The immunomodulating component can be a full length protein or a fragment thereof. The antibody or antigen-binding fragment can be derived from natural sources, or partly or wholly synthetically produced. In some aspects, the antibody is a monoclonal antibody. In some of these aspects, the monoclonal antibody is an IgG antibody. In certain aspects, the monoclonal antibody is an IgG1, IgG2, IgG3, or IgG4. In some other aspects, the antibody is a polyclonal antibody. In certain aspects, the antigen-binding fragment is selected from Fab, Fab', and $F(ab')_2$, $F(ab1)_2$, Fv, dAb, and Fd fragments. In certain aspects, the antigen-binding fragment is an scFv or $(scFv)_2$ fragment. In certain other aspects, the antibody or antigen-binding fragment is a Nanobody® (single-domain antibody). In some aspects, the antibody or antigen-binding fragment is a bispecific or multispecific antibody.

[0349] In various aspects, the antibody or antigen-binding fragment is fully human. In some aspects, the antibody or antigen-binding fragment is humanized. In some aspects, the antibody or antigen-binding fragment is chimeric. In some of these aspects, the chimeric antibody has non-human V region domains and human C region domains. In some aspects, the antibody or antigen-binding fragment is non-human, such as murine or veterinary.

[0350] In certain aspects, the immunomodulating component is a polynucleotide. In some of these aspects, the polynucleotide includes, but is not limited to, an mRNA, a miRNA, an siRNA, an antisense oligonucleotide (*e.g.*, antisense RNA or antisense DNA), a phosphorodiamidate morpholino oligomer (PMO), a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO), an shRNA, a lncRNA, a dsDNA, and combinations thereof. In some aspects, the polynucleotide is an RNA (*e.g.*, an mRNA, a miRNA, an siRNA, an antisense oligonucleotide (*e.g.*, antisense RNA), an shRNA, or an lncRNA). In some of these aspects, when the polynucleotide is an mRNA, it can be translated into a desired polypeptide. In some aspects, the polynucleotide is a microRNA (miRNA) or pre-miRNA molecule. In some of these aspects, the miRNA is delivered to the cytoplasm of the target cell, such that the miRNA molecule can silence a native mRNA in the target cell. In some aspects, the polynucleotide is a small interfering RNA (siRNA) or a short hairpin RNA (shRNA) capable of interfering with the expression of an oncogene or other dysregulating polypeptides. In some of these aspects, the siRNA is delivered to

the cytoplasm of the target cell, such that the siRNA molecule can silence a native mRNA in the target cell. In some aspects, the polynucleotide is an antisense oligonucleotide (*e.g.*, antisense RNA) that is complementary to an mRNA. In some aspects, the polynucleotide is a long non-coding RNA (lncRNA) capable of regulating gene expression and modulating diseases. In some aspects, the polynucleotide is a DNA that can be transcribed into an RNA. In some of these aspects, the transcribed RNA can be translated into a desired polypeptide.

[0351] In some aspects, the immunomodulating component is a protein, a peptide, a glycolipid, or a glycoprotein.

[0352] In various aspects, the EV composition comprises two or more above mentioned immunomodulating components, including mixtures, fusions, combinations and conjugates, of atoms, molecules, *etc.* In some aspects, the composition comprises one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve different immunomodulating components associated with the membrane or enclosed within the enclosed volume of the extracellular vesicle. In certain aspects, the composition comprises a nucleic acid combined with a polypeptide. In certain aspects, the composition comprises two or more polypeptides conjugated to each other. In certain aspects, the composition comprises a protein conjugated to a biologically active molecule. In some of these aspects, the biologically active molecule is a prodrug.

[0353] In some aspects, any suitable method can be used to link an antigen or any other molecules of interest (*e.g.*, adjuvant, immune modulator, and/or targeting moiety described herein) to an exterior surface and/or luminal surface of the EV. In certain aspects, the antigen or any other molecules of interest is linked to the exterior surface and/or the luminal surface of the EV by any suitable coupling strategies known in the art. In some aspects, the coupling strategy comprises: an anchoring moiety, affinity agent, chemical conjugation, cell penetrating peptide (CPP), split intein, SpyTag/SpyCatcher, ALFA-tag, Streptavidin/Avitag, Sortase, SNAP-tag, ProA/Fc-binding peptide, or any combinations thereof. In some aspects, the anchoring moiety comprises a cholesterol, fatty acid (*e.g.*, palmitate), tocopherol (*e.g.*, vitamin E), alkyl chain, aromatic ring, or any combination thereof. In some aspects, the chemical conjugation comprises a maleimide moiety, copper-free, biorthogonal click chemistry (*e.g.*, azide/strained alkyne (DIFO)), metal-catalyzed click chemistry (*e.g.*, CUAAC, RUAAC), or any combination thereof. Additional description relating to the different approaches of linking an antigen or any other molecules of interest are provided elsewhere in the present disclosure. For instance, in some aspects, any of the

coupling strategies described above can be used in combination with a scaffold moiety described herein (*e.g.*, Scaffold X, *e.g.*, PTGFRN).

II.E Scaffold X-Engineered EVs

[0354] In some aspects, EVs of the present disclosure comprise a membrane modified in its composition. For example, their membrane compositions can be modified by changing the protein, lipid, or glycan content of the membrane.

[0355] In some aspects, the surface-engineered EVs are generated by chemical and/or physical methods, such as PEG-induced fusion and/or ultrasonic fusion. In other aspects, the surface-engineered EVs are generated by genetic engineering. EVs produced from a genetically-modified producer cell or a progeny of the genetically-modified cell can contain modified membrane compositions. In some aspects, surface-engineered EVs have scaffold moiety (*e.g.*, Scaffold X) at a higher or lower density (*e.g.*, higher number) or include a variant or a fragment of the scaffold moiety.

[0356] For example, surface (*e.g.*, Scaffold X)-engineered EVs, can be produced from a cell (*e.g.*, HEK293 cells) transformed with an exogenous sequence encoding a scaffold moiety (*e.g.*, Scaffold X) or a variant or a fragment thereof. EVs including scaffold moiety expressed from the exogenous sequence can include modified membrane compositions.

[0357] Various modifications or fragments of the scaffold moiety can be used for the aspects of the present disclosure. For example, scaffold moiety modified to have enhanced affinity to a binding agent can be used for generating surface-engineered EV that can be purified using the binding agent. Scaffold moieties modified to be more effectively targeted to EVs and/or membranes can be used. Scaffold moieties modified to comprise a minimal fragment required for specific and effective targeting to exosome membranes can be also used.

[0358] Scaffold moieties can be engineered to be expressed as a fusion molecule, *e.g.*, fusion molecule of Scaffold X to an antigen, an adjuvant, and/or an immune modulator. For example, the fusion molecule can comprise a scaffold moiety disclosed herein (*e.g.*, Scaffold X, *e.g.*, PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, ATP transporter, or a fragment or a variant thereof) linked to an antigen, an adjuvant, and/or an immune modulator. In case of the fusion molecule, the antigen, adjuvant, and/or immune modulator can be a natural peptide, a recombinant peptide, a synthetic peptide, or any combination thereof. In some aspects, a fusion molecule disclosed herein further comprises an affinity ligand. For example, in certain aspects, an affinity ligand is fused to a molecule of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or

targeting moiety), and then the molecule of interest is conjugated to a moiety on EVs, e.g., Scaffold X via the affinity ligand. In certain aspects, the affinity ligand increases the binding of the molecule of interest to a moiety on EVs, *e.g.*, Scaffold X.

[0359] In some aspects, the surface (*e.g.*, Scaffold X)-engineered EVs described herein demonstrate superior characteristics compared to EVs known in the art. For example, surface (*e.g.*, Scaffold X)-engineered contain modified proteins more highly enriched on their surface than naturally occurring EVs or the EVs produced using conventional exosome proteins. Moreover, the surface (*e.g.*, Scaffold X)-engineered EVs of the present disclosure can have greater, more specific, or more controlled biological activity compared to naturally occurring EVs or the EVs produced using conventional exosome proteins.

[0360] In some aspects, the Scaffold X comprises Prostaglandin F2 receptor negative regulator (the PTGFRN polypeptide). The PTGFRN protein can be also referred to as CD9 partner 1 (CD9P-1), Glu-Trp-Ile EWI motif-containing protein F (EWI-F), Prostaglandin F2-alpha receptor regulatory protein, Prostaglandin F2-alpha receptor-associated protein, or CD315. The full length amino acid sequence of the human PTGFRN protein (Uniprot Accession No. Q9P2B2) is shown at TABLE 7 as SEQ ID NO: 1. The PTGFRN polypeptide contains a signal peptide (amino acids 1 to 25 of SEQ ID NO: 1), the extracellular domain (amino acids 26 to 832 of SEQ ID NO: 1), a transmembrane domain (amino acids 833 to 853 of SEQ ID NO: 1), and a cytoplasmic domain (amino acids 854 to 879 of SEQ ID NO: 1). The mature PTGFRN polypeptide consists of SEQ ID NO: 1 without the signal peptide, i.e., amino acids 26 to 879 of SEQ ID NO: 1. In some aspects, a PTGFRN polypeptide fragment useful for the present disclosure comprises a transmembrane domain of the PTGFRN polypeptide. In other aspects, a PTGFRN polypeptide fragment useful for the present disclosure comprises the transmembrane domain of the PTGFRN polypeptide and (i) at least five, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150 amino acids at the N terminus of the transmembrane domain, (ii) at least five, at least 10, at least 15, at least 20, or at least 25 amino acids at the C terminus of the transmembrane domain, or both (i) and (ii).

[0361] In some aspects, the fragments of PTGFRN polypeptide lack one or more functional or structural domains, such as IgV.

[0362] In other aspects, the Scaffold X comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about

95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to amino acids 26 to 879 of SEQ ID NO: 1. In other aspects, the Scaffold X comprises an amino acid sequence at least about at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 33. In other aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 33, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. The mutations can be a substitution, an insertion, a deletion, or any combination thereof. In some aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 33 and 1 amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, ten amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or longer at the N terminus and/or C terminus of SEQ ID NO: 33.

[0363] In other aspects, the Scaffold X comprises an amino acid sequence at least about at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 2, 3, 4, 5, 6, or 7. In other aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6, or 7, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. The mutations can be a substitution, an insertion, a deletion, or any combination thereof. In some aspects, the Scaffold X comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6, or 7 and 1 amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, ten amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or longer at the N terminus and/or C terminus of SEQ ID NO: 2, 3, 4, 5, 6, or 7.

TABLE 7. Exemplary Scaffold X Protein Sequences

Protein	Sequence

The PTGFRN Protein (SEQ ID NO: 1)	MGRLASRPLLLALLSLALCRGRVVRVPTATLVRVVGTELVIPCNVSDYDGPSEQNFDWSF SSLGSSFVELASTWEVGFPAQLYQERLQRGEILLRRTANDAVELHIKNVQPSDQGHYKCS TPSTDATVQGNYEDTVQVKVLADSLHVGPSARPPPSLSLREGEPFELRCTAASASPLHTH LALLWEVHRGPARRSVLALTHEGRFHPGLGYEQRYHSGDVRLDTVGSDAYRLSVSRALSA DQGSYRCIVSEWIAEQGNWQEIQEKAVEVATVVIQPSVLRAAVPKNVSVAEGKELDLTCN ITTDRADDVRPEVTWSFSRMPDSTLPGSRVLARLDRDSLVHSSPHVALSHVDARSYHLLV RDVSKENSGYYYCHVSLWAPGHNRSWHKVAEAVSSPAGVGVTWLEPDYQVYLNASKVPGF ADDPTELACRVVDTKSGEANVRFTVSWYYRMNRRSDNVVTSELLAVMDGDWTLKYGERSK QRAQDGDFIFSKEHTDTFNFRIQRTTEEDRGNYYCVVSAWTKQRNNSWVKSKDVFSKPVN IFWALEDSVLVVKARQPKPFFAAGNTFEMTCKVSSKNIKSPRYSVLIMAEKPVGDLSSPN ETKYIISLDQDSVVKLENWTDASRVDGVVLEKVQEDEFRYRMYQTQVSDAGLYRCMVTAW SPVRGSLWREAATSLSNPIEIDFQTSGPIFNASVHSDTPSVIRGDLIKLFCIITVEGAAL DPDDMAFDVSWFAVHSFGLDKAPVLLSSLDRKGIVTTSRRDWKSDLSLERVSVLEFLLQV HGSEDQDFGNYYCSVTPWVKSPTGSWQKEAEIHSKPVFITVKMDVLNAFKYPLLIGVGLS TVIGLLSCLIGYCSSHWCCKKEVQETRRERRRLMSMEMD
The PTGFRN protein Fragment (SEQ ID NO: 33)	GPIFNASVHSDTPSVIRGDLIKLFCIITVEGAALDPDDMAFDVSWFAVHSFGLDKAPVLL SSLDRKGIVTTSRRDWKSDLSLERVSVLEFLLQVHGSEDQDFGNYYCSVTPWVKSPTGSW QKEAEIHSKPVFITVKMDVLNAFKYPLLIGVGLSTVIGLLSCLIGYCSSHWCCKKEVQET RRERRRLMSMEM 687-878 of SEQ ID NO: 1

[0364] Non-limiting examples of other Scaffold X proteins can be found at US Patent No. US10195290B1, issued Feb. 5, 2019, which is incorporated by reference in its entireties.

[0365] In some aspects, the sequence encodes a fragment of the scaffold moiety lacking at least 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, or 800 amino acids from the N-terminus of the native protein. In some aspects, the sequence encodes a fragment of the scaffold moiety lacking at least 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, or 800 amino acids from the C-terminus of the native protein. In some aspects, the sequence encodes a fragment of the scaffold moiety lacking at least 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, or 800 amino acids from both the N-terminus and C-terminus of the native protein. In some aspects, the sequence encodes a fragment of the scaffold moiety lacking one or more functional or structural domains of the native protein.

[0366] In some aspects, the scaffold moieties, *e.g.*, Scaffold X, *e.g.*, a PTGFRN protein, are linked to one or more heterologous proteins. The one or more heterologous proteins can be linked to the N-terminus of the scaffold moieties. The one or more heterologous proteins can be linked to the C-terminus of the scaffold moieties. In some aspects, the one or more heterologous proteins are linked to both the N-terminus and the C-terminus of the scaffold moieties. In some aspects, the

heterologous protein is a mammalian protein. In some aspects, the heterologous protein is a human protein.

[0367] In some aspects, Scaffold X can be used to link any moiety to the luminal surface and on the exterior surface of the EV at the same time. For example, the PTGFRN polypeptide can be used to link one or more payloads disclosed herein (*e.g.*, an antigen, an adjuvant, and/or an immune modulator) inside the lumen (*e.g.*, on the luminal surface) in addition to the exterior surface of the EV. Therefore, in certain aspects, Scaffold X can be used for dual purposes, *e.g.*, an antigen on the luminal surface and an adjuvant or immune modulator on the exterior surface of the EV an antigen on the exterior surface of the EV and the adjuvant or immune modulator on the luminal surface, an adjuvant on the luminal surface and an immune modulator on the exterior surface of the EV or an immune modulator on the luminal surface and an adjuvant on the exterior surface of the EV.

II.F Scaffold Y-Engineered EVs

[0368] In some aspects, EVs of the present disclosure comprise an internal space (*i.e.*, lumen) that is different from that of the naturally occurring EVs. For example, the EV can be changed such that the composition in the luminal surface of the EV has the protein, lipid, or glycan content different from that of the naturally-occurring exosomes.

[0369] In some aspects, engineered EVs can be produced from a cell transformed with an exogenous sequence encoding a scaffold moiety (*e.g.*, Scaffold Y) or a modification or a fragment of the scaffold moiety that changes the composition or content of the luminal surface of the EV. Various modifications or fragments of the exosome protein that can be expressed on the luminal surface of the EV can be used for the aspects of the present disclosure.

[0370] In some aspects, the exosome proteins that can change the luminal surface of the EVs include, but are not limited to, the myristoylated alanine rich Protein Kinase C substrate (MARCKS) protein, the myristoylated alanine rich Protein Kinase C substrate like 1 (MARCKSL1) protein, the brain acid soluble protein 1 (BASP1) protein, or any combination thereof.

TABLE 8. Exemplary Scaffold Y Protein Sequences

Protein	Sequence
The BASP1 protein	MGGKLSKKKK GYNVNDEKAK EKDKKAEGAA TEEEGTPKES EPQAAAEPAE AKEGKEKPDQ DAEGKAEEKE GEKDAAAAKE EAPKAEPEKT EGAAEAKAEP

(SEQ ID NO: 49)	PKAPEQEQAA PGPAAGGEAP KAAEAAAAPA ESAAPAAGEE PSKEEGEPKK TEAPAAPAAQ ETKSDGAPAS DSKPGSSEAA PSSKETPAAT EAPSSTPKAQ GPAASAEEPK PVEAPAANSD QTVTVKE






[0371] The mature BASP1 protein sequence is missing the first Met from SEQ ID NO: 49 and thus contains amino acids 2 to 227 of SEQ ID NO: 49. Similarly, the mature MARCKS and MARCKSL1 proteins also lack the first Met from SEQ ID NOs: 47 and 48, respectively. Accordingly, the mature MARCKS protein contains amino acids 2 to 332 of SEQ ID NO: 47. The mature MARCKSL1 protein contains amino acids 2 to 227 of SEQ ID NO: 48.

[0372] In other aspects, Scaffold Y useful for the present disclosure comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to amino acids 2 to 227 of SEQ ID NO: 49. In other aspects, the Scaffold Y comprises an amino acid sequence at least about at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to any one of SEQ ID NOs: 50-155. In other aspects, a Scaffold Y useful for the present disclosure comprises the amino acid sequence of SEQ ID NO: 49, except one amino acid mutation, two amino acid mutations, three amino acid mutations, four amino acid mutations, five amino acid mutations, six amino acid mutations, or seven amino acid mutations. The mutations can be a substitution, an insertion, a deletion, or any combination thereof. In some aspects, a Scaffold Y useful for the present disclosure comprises the amino acid sequence of any one of SEQ ID NOs: 50-155 and 1 amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, ten amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids or longer at the N terminus and/or C terminus of SEQ ID NOs: 50-155.

[0373] In some aspects, the protein sequence of any of SEQ ID NOs: 47-155 is sufficient to be a Scaffold Y for the present disclosure (*e.g.*, scaffold moiety linked to an antigen and/or an adjuvant and/or an immune modulator).

[0374] Non-limiting examples of scaffold proteins can be found at WO/2019/099942, published May 23, 2019 and WO/2020/101740, published May 22, 2020, which are incorporated by reference in their entireties.

[0375] In other aspects, the lipid anchor can be any lipid anchor known in the art, *e.g.*, palmitic acid or glycosylphosphatidylinositols. Under unusual circumstances, *e.g.*, by using a culture medium where myristic acid is limiting, some other fatty acids including shorter-chain and unsaturated, can be attached to the N-terminal glycine. For example, in BK channels, myristate has been reported to be attached posttranslationally to internal serine/threonine or tyrosine residues via a hydroxyester linkage. Membrane anchors known in the art are presented in the following table:

Modification	*Modifying Group*
S-Palmitoylation	
N-Palmitoylation	
N-Myristoylation	
O-Acylation	
Farnesylation	
Geranylgeranylation	
Cholesterol	

II.G Conjugated EVs

[0376] Unlike antibodies, EVs can accommodate large numbers of molecules attached to their surface, *e.g.*, on the order of thousands to tens of thousands of molecules per EV. EV-drug conjugates thus represent a platform to deliver a high concentration of therapeutic compound to discrete cell types, while at the same time limiting overall systemic exposure to the compound, which in turn reduces off-target toxicity.

[0377] The present disclosure provide EVs that have been engineered by reacting a first molecular entity comprising a free thiol group with a second molecular entity comprising a maleimide group, wherein the maleimide moiety covalently links the first molecular entity with the second molecular entity via a maleimide moiety as presented in FIG. 31.

[0378] Non-limiting examples of biologically active molecules that can attached to an EV via a maleimide moiety include agents such as, nucleotides (e.g., nucleotides comprising a detectable moiety or a toxin or that disrupt transcription), nucleic acids (e.g., DNA or mRNA molecules that encode a polypeptide such as an enzyme, or RNA molecules that have regulatory function such as miRNA, dsDNA, lncRNA, or siRNA), morpholino, amino acids (e.g., amino acids comprising a detectable moiety or a toxin that disrupt translation), polypeptides (e.g., enzymes), lipids, carbohydrates, small molecules (e.g., small molecule drugs and toxins), antigens (e.g., vaccine antigens), adjuvants (e.g., vaccine adjuvants), etc.

[0379] In some aspects, an EV of the present disclosure can comprise more than one type of biologically active molecule. In some aspects, biologically active molecules can be, *e.g.,* small molecules such as cyclic dinucleotides, toxins such as auristatins (e.g., monoethyl auristatin E, MMAE), antibodies (*e.g.,* naked antibodies or antibody-drug conjugates), STING agonists, tolerizing agents, antisense oligonucleotides, PROTACs, morpholinos, lysophosphatidic acid receptor antagonists (e.g., LPA1 antagonists) or any combinations thereof. In some aspects, an EV of the present disclosure can comprise, e.g., a vaccine antigen and optionally a vaccine adjuvant. In some aspects, an EV of the present disclosure can comprise a therapeutic payload (e.g., a STING or one payload disclosed below) and a targeting moiety and/or a tropism moiety.

II.H Linkers

[0380] As described *supra*, extracellular vesicles (EVs) of the present disclosure can comprises one or more linkers that link a molecule of interest (*e.g.*, antigen, adjuvant, or immune modulator) to the EVs (*e.g.*, to the exterior surface or on the luminal surface). In some aspects, the molecule of interest (*i.e.*, payload) (*e.g.*, antigen, adjuvant, or immune modulator) is linked to the EVs directly or via a scaffold moiety (*e.g.*, Scaffold X or Scaffold Y). For example, in certain aspects, a payload (*e.g.*, an antigen, adjuvant, and/or immune modulator) is linked to the exterior surface of an exosome via Scaffold X. In further aspects, a payload (*e.g.*, an antigen, adjuvant, and/or immune modulator) is linked to the luminal surface of an exosome via Scaffold X or Scaffold Y. In some aspects, a payload (*e.g.*, an antigen, adjuvant, and/or immune modulator) is linked to the luminal surface of an exosome via Scaffold X. In some aspects, a payload (*e.g.*, an antigen, adjuvant, and/or immune modulator) is linked to the luminal surface of an exosome via Scaffold Y. In some aspects, a payload (*e.g.*, an antigen, adjuvant, and/or immune modulator) is linked to the luminal surface of an exosome via Scaffold X and Scaffold Y. In some aspects, a payload (*e.g.*, an antigen, adjuvant, and/or immune modulator) is conjugated to Scaffold X via a

linker (*e.g.*, those described herein). In certain aspects, a payload (*e.g.*, an antigen, adjuvant, and/or immune modulator) is conjugated to Scaffold X using more than one linker (*i.e.*, "**linker combination**"). In some aspects, a payload (*e.g.*, an antigen, adjuvant, and/or immune modulator) is conjugated to Scaffold Y via a linker (*e.g.*, those described herein). In certain aspects, a payload (*e.g.*, an antigen, adjuvant, and/or immune modulator) is conjugated to Scaffold Y using a linker combination. In some aspects, a linker combination comprises at least 2, at least 3, at least 4, at least 5, or at least 6 or more different linkers disclosed herein. In some aspects, linkers in a linker combination can be linked by an ester linkage (e.g., phosphodiester or phosphorothioate ester).

[0381] The linker can be any chemical moiety known in the art.

[0382] As used herein, the term "**linker**" refers to a peptide or polypeptide sequence (*e.g.*, a synthetic peptide or polypeptide sequence) or to a non-polypeptide, *e.g.*, an alkyl chain. In some aspects, two or more linkers can be linked in tandem. When multiple linkers are present, each of the linkers can be the same or different. Generally, linkers provide flexibility or prevent/ameliorate steric hindrances. Linkers are not typically cleaved; however in certain aspects, such cleavage can be desirable. Accordingly, in some aspects, a linker can comprise one or more protease-cleavable sites, which can be located within the sequence of the linker or flanking the linker at either end of the linker sequence.

[0383] In some aspects, the linker is a peptide linker. In some aspects, the peptide linker can comprise at least about two, at least about three, at least about four, at least about five, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, or at least about 100 amino acids.

[0384] In some aspects, the peptide linker can comprise at least about 110, at least about 120, at least about 130, at least about 140, at least about 150, at least about 160, at least about 170, at least about 180, at least about 190, or at least about 200 amino acids.

[0385] In other aspects, the peptide linker can comprise at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, or at least about 1,000 amino acids. The peptide linker can comprise between 1 and about 5 amino acids, between 1 and about 10 amino acids, between 1 and about 20 amino acids, between about 10 and about 50 amino acids, between about 50 and about 100 amino acids, between about 100 and about 200 amino acids, between about 200 and about 300 amino acids,

between about 300 and about 400 amino acids, between about 400 and about 500 amino acids, between about 500 and about 600 amino acids, between about 600 and about 700 amino acids, between about 700 and about 800 amino acids, between about 800 and about 900 amino acids, or between about 900 and about 1000 amino acids.

[0386] As described herein, in some aspects, a linker useful for the present disclosure comprises a glycine/serine linker. In some aspects, the peptide linker is glycine/serine linker according to the formula [(Gly)n-Ser]m (SEQ ID NO: 374), where n is any integer from 1 to 100 and m is any integer from 1 to 100. In some aspects, the glycine/serine linker is according to the formula [(Gly)x-Sery]z (SEQ ID NO: 375), wherein x in an integer from 1 to 4, y is 0 or 1, and z is an integers from 1 to 50. In some aspects, the peptide linker comprises the sequence Gn (SEQ ID NO: 376), where n can be an integer from 1 to 100. In some aspects, the peptide linker can comprise the sequence (GlyAla)n (SEQ ID NO: 377), wherein n is an integer between 1 and 100. In some aspects, the peptide linker can comprise the sequence (GlyGlySer)n (SEQ ID NO: 378), wherein n is an integer between 1 and 100. In certain aspects, the peptide linker comprises the sequence GGGG (SEQ ID NO: 197).

[0387] In some aspects, the peptide linker comprises the sequence (GGGS)n (SEQ ID NO: 203). In certain aspects, the peptide linker comprises the sequence (GGS)n(GGGGS)n (SEQ ID NO: 204). In such aspects, n can be an integer from 1 to 100. In some aspects, n can be an integer from one to 20, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some aspects, n is an integer from 1 to 100.

[0388] Examples of linkers that are useful for the present disclosure include, but are not limited to, GGG, SGGSGGS (SEQ ID NO: 198), GGSGGSGGSGGSGGG (SEQ ID NO: 199), GGSGGSGGGGSGGGGS (SEQ ID NO: 200), GGSGGSGGSGGSGGSGGS (SEQ ID NO: 201), or GGGGSGGGGSGGGGS (SEQ ID NO: 202). In some aspects, the linker is a poly-G sequence (GGGG)n (SEQ ID NO: 373), where n can be an integer from 1-100.

[0389] In some aspects, the peptide linker is synthetic, i.e., non-naturally occurring. In one aspect, a peptide linker includes peptides (or polypeptides) (*e.g.*, natural or non-naturally occurring peptides) which comprise an amino acid sequence that links or genetically fuses a first linear sequence of amino acids to a second linear sequence of amino acids to which it is not naturally linked or genetically fused in nature. For example, in one aspect, the peptide linker can comprise non-naturally occurring polypeptides which are modified forms of naturally occurring polypeptides (*e.g.*, comprising a mutation such as an addition, substitution or deletion).

[0390] In some aspects, the peptide linker can comprise non-naturally occurring amino acids. In yet other aspects, the peptide linker can comprise naturally occurring amino acids occurring in a linear sequence that does not occur in nature. In still other aspects, the peptide linker can comprise a naturally occurring polypeptide sequence.

[0391] In some aspects, the linker comprises a non-peptide linker. In other aspects, the linker consists of a non-peptide linker. In some aspects, the non-peptide linker can be, *e.g.*, maleimido caproyl (MC), maleimido propanoyl (MP), methoxyl polyethyleneglycol (MPEG), succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), N-succinimidyl(4-iodoacetyl)aminobenzonate (SIAB), succinimidyl 6-[3-(2-pyridyldithio)-propionamide]hexanoate (LC-SPDP), 4-succinimidyloxycarbonyl-alpha-methyl-alpha-(2-pyridyldithio)toluene (SMPT), etc. (see, *e.g.*, U.S. Pat. No. 7,375,078, which is herein incorporated by reference in its entirety).

[0392] Linkers can be susceptible to cleavage ("**cleavable linker**") thereby facilitating release of the biologically active molecule (*e.g.*, antigen, adjuvant, or immune modulator). Therefore, in some aspects, a linker that can be used with the present disclosure comprises a cleavable linker. Such cleavable linkers can be susceptible, for example, to acid-induced cleavage, photo-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage, at conditions under which the biologically active molecule remains active. In some aspects, a cleavable linker comprises a spacer. In certain aspects, a spacer comprises PEG.

[0393] In some aspects, the linker is a "**reduction-sensitive linker**." In some aspects, the reduction-sensitive linker contains a disulfide bond. In some aspects, the linker is an "**acid labile linker**." In some aspects, the acid labile linker contains hydrazone. Suitable acid labile linkers also include, for example, a cis-aconitic linker, a hydrazide linker, a thiocarbamoyl linker, or any combination thereof.

[0394] In some aspects, the linker comprises a non-cleavable linker (*i.e.*, resistant or substantially resistant to cleavage).

[0395] In some aspects, a linker combination disclosed herein comprises only cleavable linkers. In some aspects, a linker combination disclosed herein comprises only non-cleavable linkers. In some aspects, a linker combination disclosed herein comprises both cleavable and non-cleavable linkers. Additional disclosure relating to cleavable and non-cleavable linkers that can be used with the present disclosure are provided below.

II.I Affinity Ligands

[0396] EVs disclosed herein can comprise one or more affinity ligands that link or conjugate a molecule of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety) to the EVs (*e.g.*, to the exterior surface or on the luminal surface) or to a target cell. In some aspects, an affinity ligand disclosed herein has one or more of the following properties: (i) derived from a synthetic library, (ii) sub-nanomolar affinity for a scaffold moiety (*e.g.*, Scaffold X) with emphasis on slow off rate, (iii) binds epitope on membrane-distal IgV domain of a scaffold moiety (*e.g.*, Scaffold X), (iv) free of disulfide linkages, (v) free of N-linked glycosylation sites, (vi) less than 20 amino acids in length, (vii) monomeric, (viii) electroneutral at physiological pH, (ix) hydrophilic, (x) resistant to protease digestion, (xi) amenable to expression in prokaryotic and eukaryotic hosts, (xii) can accommodate N- or C-terminus fusion, (xiii) nonimmunogenic, (xiv) can contain a tag for purification and/or separation, *e.g.*, of an EV, and (xv) combinations thereof. As described herein, in some aspects, an affinity ligand disclosed herein can specifically bind (*e.g.*, with high affinity) to a moiety expressed on the surface of an EV. In certain aspects, an affinity ligand specifically binds to a scaffold moiety expressed on the surface of an EV. In some aspects, an affinity ligand specifically binds to any moiety expressed on the surface of an EV (*e.g.*, cholesterol). In some aspects, an affinity ligand disclosed herein can specifically bind (*e.g.*, with high affinity) to a moiety expressed on a target cell. Non-limiting examples of such affinity ligands are provided throughout the present disclosure.

[0397] As described above, an affinity ligand useful for the present disclosure can be engineered to express one or more tags. In some aspects, such tags can be useful in the purification and/or separation of an agent that is conjugated to the affinity ligand. For example, in some aspects, an EV comprises a scaffold moiety that is conjugated to an affinity ligand fusion, which comprises a molecule of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety) and a tag. In such aspects, the tag can be used to purify and/or separate the EV from a sample comprising the EV. In some aspects, a tag of an affinity ligand fusion described above is present between the affinity ligand and the molecule of interest. In some aspects, the tag of an affinity ligand fusion described above can be present at an end (*e.g.*, N-terminus) of the molecule of interest, as long as the tag does not interfere with the activity of the molecule of interest. Any tags useful in the art for purifying and/or separating an agent from a sample can be used in the present disclosure. Non-limiting examples of such tags include polyhistidine tags, polyarginine tags, glutathione-S-transferase (GST), maltose binding protein (MBP), S-tag, influenza virus HA tag, thioredoxin,

staphylococcal protein A tag, FLAG™ epitope, AviTag epitope (for subsequent biotinylation), c-myc epitope, and combinations thereof. *See, e.g.*, U.S. Pat. No. 7,655,413, which is herein incorporated by reference in its entirety.

[0398] As described herein, in some aspects, a molecule of interest can be expressed on the surface of an EV via a scaffold moiety. In some of these aspects, the molecule of interest can be linked or conjugated to the scaffold moiety via an affinity ligand. For instance, as described herein, in certain aspects, an affinity ligand can be fused to a molecule of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety), and then the molecule of interest can be conjugated to a moiety expressed on the surface of an EV (*e.g.*, scaffold moiety) via the affinity ligand. In some aspects, the affinity ligand increases the binding of the molecule of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety) to the moiety on the EV (*e.g.*, scaffold moiety). In certain aspects, the binding of the molecule of interest to the moiety on the EV (*e.g.*, scaffold moiety) is increased by at least about one-fold, at least about two-fold, at least about three -fold, at least about four-fold, at least about five-fold, at least about six-fold, at least about seven-fold, at least about eight-fold, at least about nine-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, at least about 10,000-fold or more, compared to a reference (*e.g.*, binding of the molecule of interest to the moiety on the EV (*e.g.*, scaffold moiety) without the use of an affinity ligand).

[0399] In some aspects, an affinity ligand that can be used with the present disclosure comprises a linear peptide. In certain aspects, an affinity ligand comprises at least about two, at least about three, at least about four, at least about five, at least about seven, at least about eight, at least about nine, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70,

at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, or at least about 100 amino acids.

[0400] Not to be bound by any one theory, using an affinity ligand (*e.g.*, disclosed herein) to link or conjugate a molecule of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety) to a moiety expressed on the surface of an EV (*e.g.*, scaffold moiety) can improve one or more properties of the EV disclosed herein. For instance, in some aspects, by increasing the binding of a molecule of interest to a moiety on the EVs (*e.g.*, scaffold moiety), an affinity ligand disclosed herein can allow for increased expression of the molecule of interest on the surface of an EV (*e.g.*, exterior surface). Accordingly, in certain aspects, a fusion protein comprising (i) a molecule of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety), (ii) an affinity ligand, and (iii) a scaffold moiety is present in the EV (*e.g.*, exterior surface) at a higher density compared to a reference (*e.g.*, corresponding fusion protein without the affinity ligand). In some aspects, the density of the fusion protein on the surface of the exosome is increased by at least about one-fold, at least about two-fold, at least about three -fold, at least about four-fold, at least about five-fold, at least about six-fold, at least about seven-fold, at least about eight-fold, at least about nine-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold, at least about 200-fold, at least about 300-fold, at least about 400-fold, at least about 500-fold, at least about 600-fold, at least about 700-fold, at least about 800-fold, at least about 900-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, at least about 6,000-fold, at least about 7,000-fold, at least about 8,000-fold, at least about 9,000-fold, at least about 10,000-fold or more, compared to the reference.

[0401] In some aspects, an improved binding of a molecule of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety) to a moiety expressed on the surface of an EV (*e.g.*, scaffold moiety) can reduce the time required to produce an EV disclosed herein. Accordingly, in some aspects, an affinity ligand disclosed herein can reduce the time required for producing an engineered EV disclosed herein (*e.g.*, comprising a molecule of interest and a scaffold moiety). In certain aspects, the time required to produce an engineered EV is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% or

more, compared to a reference (*e.g.*, time required to produce the corresponding EV without the affinity ligand).

[0402] In some aspects, an affinity ligand useful for the present disclosure comprises a cleavage site, such as a protease (*e.g.*, thrombin) cleavage site.

[0403] A non-limiting example of an EV comprising an affinity ligand is described below. It will be apparent to those skilled in the art that an affinity ligand disclosed herein can be used in combination with other EVs disclosed herein.

[0404] In some aspects, an EV comprises (i) an antigen, (ii) a scaffold moiety, and (iii) an affinity ligand, wherein the affinity ligand is used to link or conjugate the antigen to the scaffold moiety. As shown in FIG. 7, in some aspects, to produce such EVs, the affinity ligand is fused to an antigen (*e.g.*, spike S protein), and then the antigen-affinity ligand fusion is linked or conjugated to the scaffold moiety via the affinity ligand. In certain aspects, the antigen comprises a receptor-binding domain (RBD) of a spike (S) protein of a coronavirus disclosed herein (*e.g.*, COVID-19). In certain aspects, the scaffold moiety comprises a Scaffold X. Accordingly, in some aspects, an EV comprises (i) a RBD of a coronavirus S protein, (ii) a Scaffold X, and (iii) an affinity ligand, wherein the affinity ligand is used to link or conjugate the RBD of a coronavirus S protein to the Scaffold X. In some aspects, the affinity ligand can be used to link or conjugate a fragment of the RBD of a coronavirus S protein. In certain aspects, a fragment of the RBD of a coronavirus S protein that can be linked or conjugated to a Scaffold X using an affinity ligand disclosed herein is less than about 100 amino acids in length (*e.g.*, less than about 90 amino acids, less than about 80 amino acids, less than about 70 amino acids, less than about 60 amino acids, less than about 50 amino acids, less than about 40 amino acids, less than about 30 amino acids, less than about 20 amino acids, less than about 10 amino acids, or more).

III. Pharmaceutical Compositions

[0405] Provided herein are pharmaceutical compositions comprising an EV of the present disclosure having the desired degree of purity, and a pharmaceutically acceptable carrier or excipient, in a form suitable for administration to a subject. Pharmaceutically acceptable excipients or carriers can be determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions comprising a plurality of extracellular vesicles. (*See*, *e.g.*, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 21st ed. (2005)). The pharmaceutical compositions are generally formulated sterile and in full

compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.

[0406] In some aspects, a pharmaceutical composition comprises one or more therapeutic agents and an exosome described herein. In certain aspects, the EVs are co-administered with of one or more additional therapeutic agents, in a pharmaceutically acceptable carrier. In some aspects, the pharmaceutical composition comprising the EV is administered prior to administration of the additional therapeutic agents. In other aspects, the pharmaceutical composition comprising the EV is administered after the administration of the additional therapeutic agents. In further aspects, the pharmaceutical composition comprising the EV is administered concurrently with the additional therapeutic agents.

[0407] Acceptable carriers, excipients, or stabilizers are nontoxic to recipients (*e.g.*, animals or humans) at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (*e.g.*, Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).

[0408] Examples of carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin. The use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the extracellular vesicles described herein, use thereof in the compositions is contemplated. Supplementary therapeutic agents can also be incorporated into the compositions. Typically, a pharmaceutical composition is formulated to be compatible with its intended route of administration. The EVs can be administered by parenteral, topical, intravenous, oral, subcutaneous, intra-arterial, intradermal, transdermal, rectal, intracranial, intraperitoneal, intranasal, intramuscular route or as inhalants. In certain aspects, the pharmaceutical composition

comprising exosomes is administered intravenously, *e.g.* by injection. The EVs can optionally be administered in combination with other therapeutic agents that are at least partly effective in treating the disease, disorder or condition for which the EVs are intended.

[0409] Solutions or suspensions can include the following components: a sterile diluent such as water, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and compounds for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0410] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (if water soluble) or dispersions and sterile powders. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). The composition is generally sterile and fluid to the extent that easy syringeability exists. The carrier can be a solvent or dispersion medium containing, *e.g.*, water, ethanol, polyol (*e.g.*, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, *e.g.*, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal compounds, *e.g.*, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. If desired, isotonic compounds, *e.g.*, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride can be added to the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition a compound which delays absorption, *e.g.*, aluminum monostearate and gelatin.

[0411] Sterile injectable solutions can be prepared by incorporating the EVs in an effective amount and in an appropriate solvent with one or a combination of ingredients enumerated herein, as desired. Generally, dispersions are prepared by incorporating the EVs into a sterile vehicle that contains a basic dispersion medium and any desired other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The EVs can be administered in the form of a

depot injection or implant preparation which can be formulated in such a manner to permit a sustained or pulsatile release of the EVs.

[0412] Systemic administration of compositions comprising exosomes can also be by transmucosal means. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, *e.g.*, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of, *e.g.*, nasal sprays.

[0413] In certain aspects, the pharmaceutical composition comprising exosomes is administered intravenously into a subject that would benefit from the pharmaceutical composition. In certain other aspects, the composition is administered to the lymphatic system, *e.g.*, by intralymphatic injection or by intranodal injection (*see e.g.*, Senti *et al.*, PNAS 105(46): 17908 (2008)), or by intramuscular injection, by subcutaneous administration, by direct injection into the thymus, or into the liver.

[0414] In certain aspects, the pharmaceutical composition comprising exosomes is administered as a liquid suspension. In certain aspects, the pharmaceutical composition is administered as a formulation that is capable of forming a depot following administration. In certain preferred aspects, the depot slowly releases the EVs into circulation, or remains in depot form.

[0415] Typically, pharmaceutically-acceptable compositions are highly purified to be free of contaminants, are biocompatible and not toxic, and are suited to administration to a subject. If water is a constituent of the carrier, the water is highly purified and processed to be free of contaminants, *e.g.*, endotoxins.

[0416] The pharmaceutically-acceptable carrier can be lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginates, gelatin, calcium silicate, micro-crystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and/or mineral oil, but is not limited thereto. The pharmaceutical composition can further include a lubricant, a wetting agent, a sweetener, a flavor enhancer, an emulsifying agent, a suspension agent, and/or a preservative.

[0417] The pharmaceutical compositions described herein comprise the EVs described herein and optionally a pharmaceutically active or therapeutic agent. The therapeutic agent can be a biological agent, a small molecule agent, or a nucleic acid agent.

[0418] Dosage forms are provided that comprise a pharmaceutical composition comprising the EVs described herein. In some aspects, the dosage form is formulated as a liquid suspension for intravenous injection.

[0419] In certain aspects, the preparation of exosomes is subjected to radiation, *e.g.*, X rays, gamma rays, beta particles, alpha particles, neutrons, protons, elemental nuclei, UV rays in order to damage residual replication-competent nucleic acids.

[0420] In certain aspects, the preparation of exosomes is subjected to gamma irradiation using an irradiation dose of more than 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, or more than 100 kGy.

[0421] In certain aspects, the preparation of exosomes is subjected to X-ray irradiation using an irradiation dose of more than 0.1, 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, or greater than 10000 mSv.

IV. Kits

[0422] Also provided herein are kits comprising one or more exosomes described herein. In some aspects, provided herein is a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions described herein, such as one or more exosomes provided herein, optional an instruction for use. In some aspects, the kits contain a pharmaceutical composition described herein and any prophylactic or therapeutic agent, such as those described herein.

V. Methods of Producing EVs

[0423] EVs of the present disclosure differ from traditional vaccines in that the EVs can be rapidly engineered to express a moiety of interest (*e.g.*, antigen, adjuvant, immune modulator, and/or targeting moiety). As described herein, the moieties of interest (i) can be directly linked to a surface of the EV (*e.g.*, exterior surface and/or luminal surface), (ii) can be linked to a scaffold moiety (*e.g.*, Scaffold X and/or Scaffold Y) and then expressed on a surface of the EV (*e.g.*, exterior surface and/or luminal surface), (iii) can be expressed in the lumen of the EV, or (iv) combinations thereof. Such ability to rapidly engineer EVs is particularly useful in developing EV-based vaccines. For instance, a single EV engineered to express certain payloads and/or targeting moieties can be used in treating a wide range of diseases or disorders by simply "plugging" an antigen of interest into the EVs.

[0424] Accordingly, in some aspects, the present disclosure is directed to methods of producing such modular or "plug and play" EV vaccines. In certain aspects, a method of producing an EV-based vaccine comprises mixing an engineered EV with an antigen of interest, such that the antigen of interest is expressed in the engineered EV. As described herein, in some aspects, an antigen of interest that can be expressed in an EV comprises a full-length protein of a coronavirus (*e.g.*, spike protein, envelope protein, and/or membrane protein). In certain aspects, the antigen of interest comprises a subunit of the full-length protein (*e.g.*, receptor-binding domain of the spike protein). In some aspects, an EV can be engineered using methods disclosed herein to express multiple (*e.g.*, two or more) coronavirus antigens, *e.g.*, such as those described in the present disclosure. In some aspects, the engineered EV comprises one or more of the payloads disclosed herein (*e.g.*, antigen, adjuvant, and/or immune modulator). In certain aspects, the engineered EV further comprises one or more scaffold moieties (*e.g.*, Scaffold X and/or Scaffold Y). In some aspects, the engineered EV additionally comprises one or more targeting moieties. In some aspects, the engineered EV can be produced using any of the methods disclosed herein.

[0425] As will be apparent from the present disclosure, one of the features of the EV-based vaccine platform disclosed herein (*e.g.*, modular or "plug and play" EVs) is that EVs can be isolated from a producer cell and stored indefinitely until they are to be used with the methods disclosed herein. As used herein, EVs that have been "**isolated from a producer cell**" refer to EVs that exist independent of the cells from which they are produced. In some aspects, once produced, the EVs that are useful for the present disclosure are purified or extracted from a culture containing the producer cells, and stored in a separate container until they are ready for further use (*e.g.*, to add one or more antigens disclosed herein). Such EVs are also referred to herein as "**base EVs**" or "**base exosomes**." As described herein, a base EV can differ from a naturally existing EV. For example, the base EVs can be genetically modified (*e.g.*, by introducing a moiety of interest into the producer cells during production) or they can be modified after the EVs are produced and isolated from the producer cells.

[0426] For instance, as described herein, in producing the base EVs, they can be initially produced to comprise one or more moieties of interest, such as those that could be beneficial in a wide range of diseases or disorders (*e.g.*, adjuvant and/or targeting moiety). Then, when desired, the base EVs can be rapidly modified by simply plugging or clipping on a specific antigen of interest, such as those useful to treat a neurological disorder, and thereby, produce or manufacture a vaccine that can be used to treat a disease or disorder described herein (*e.g.*, neurological

disorder). Such antigens can be added to the base EVs at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 year or more after isolating the base EV from the producer cell.

[0427] Not to be bound by any one theory, the use of such base EVs can greatly improve one or more aspects of producing vaccines, particularly at a large manufacturing scale. While many traditional vaccines (*e.g.*, peptide-based) have been used to treat and/or prevent certain diseases or disorders, they are generally poorly immunogenic and require repeated administrations and/or high doses. *See, e.g.*, Hos, B.J., *et al.*, *Front Immunol* 9:884 (2018), which is incorporated herein by reference in its entirety. Additionally, because of manufacturing complexities, compounded by the need for different formulations for different countries and age groups, it often takes multiple years to develop and manufacture a safe and efficacious vaccine. *See, e.g.*, Smith, J., *et al.*, *Lancet* 378(9789): 428-438 (Jul. 2011), which is incorporated herein by reference in its entirety. Accordingly, the ability to simply "plug" or "clip on" an antigen of interest to a base EV can be greatly advantageous when seeking to treat a disease or disorder that is more regional and/or more prevalent in certain individual or subsets of individuals (*e.g.*, age group).

[0428] Accordingly, in some aspects, with the methods disclosed herein, the time required for manufacturing or producing a vaccine ("**manufacturing time**") is reduced compared to a reference manufacturing time. In certain aspects, the reference manufacturing time refers to the time required to manufacture or produce a non-EV-based vaccine. In some aspects, the reference manufacturing time refers to the time required to manufacture or produce an EV-based vaccine wherein the antigen is not added to EVs that have been isolated from the producer cell (*e.g.*, by introducing the antigen into the producer cell, such that when the EVs are produced, they comprise the antigen). In certain aspects, the manufacturing time is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% or more, compared to the reference manufacturing time. In some aspects, the manufacturing time is less than about 12 months, less than about 11 months, less than about 10 months, less than about 9 months, less than about 8 months, less than about 7 months, less than about 6 months, less than about 5 months, less than

about 4 months, less than about 3 months, less than about 2 months, or less than about 1 month. In some aspects, the manufacturing time is less than about 6 months.

[0429] In some aspects, EVs that can be produced or manufactured using the methods described herein are regionalized vaccines. As used herein, the term "**regionalized vaccines**" or "**regional vaccines**" refer to vaccines that are tailored to certain regions of the world. For instance, geographic isolation of certain genetic subtypes/serotypes of an infectious pathogen (*e.g.* virus) could require a more customized vaccine as opposed to a vaccine designed to address the extensive diversity of the pathogen worldwide. In some aspects, the methods disclosed herein can be used to produce or manufacture such regionalized vaccines by adding an antigen to an EV that has been isolated from a producer cell, wherein the antigen has been determined to be associated with a particular pathogen (or genetic subtype/serotype of a pathogen) prevalent within a certain region of the world. Non-limiting examples of such pathogens are provided elsewhere in the present disclosure.

[0430] In some aspects, EV-based vaccines that can be produced or manufactured using the methods described herein are individualized vaccines. As used herein, the term "**individualized vaccines**" and "**personalized vaccines**" can be used interchangeably and refer to vaccines that are tailored to a specific individual or subsets of individuals. Such a personalized vaccine could be of particular interest, *e.g.*, for a cancer vaccine using neoantigens, since many neoantigens are specific for the particular cancer cells of an individual or subsets of individuals (*e.g.*, those who share certain genetic background). In some aspects, the methods disclosed herein can be used to produce or manufacture such regionalized vaccines by adding an antigen to an EV that has been isolated from a producer cell, wherein the antigen has been determined to have (or likely to have) a therapeutic effect (*e.g.*, induces an immune response) in the particular individual or subset of individuals.

[0431] As will be apparent to those skilled in the arts, methods of identifying regional- and/or individual-specific antigens are known in the art. *See, e.g.*, US 2009/0169576; US 2014/0178438; Sakkhachornphop, S., *et al.*, *J Virol Methods* 217: 70-8 (Jun. 2015); and Xu, K., *et al.*, *Sci Rep* 8(1): 1067 (Jan. 2018), each of which is incorporated herein by reference in its entirety.

[0432] In some aspects, the present disclosure is also directed to methods of producing EVs described herein. In some aspects, the method comprises: obtaining the EV from a producer cell, wherein the producer cell contains two or more components of the EV (*e.g.*, (i) antigen and adjuvant, (ii) antigen and immune modulator, (iii) antigen and targeting moiety, (iv) antigen,

adjuvant, and targeting moiety, (v) antigen, immune modulator, and targeting moiety, (vi) antigen, adjuvant, and immune modulator, (vii) antigen, adjuvant, immune modulator, and targeting moiety); and optionally isolating the obtained EV. In some aspects, the method comprises: modifying a producer cell by introducing two or more components of an EV disclosed herein (*e.g.*, (i) antigen and adjuvant, (ii) antigen and immune modulator, (iii) antigen and targeting moiety, (iv) antigen, adjuvant, and targeting moiety, (v) antigen, immune modulator, and targeting moiety, (vi) antigen, adjuvant, and immune modulator, (vii) antigen, adjuvant, immune modulator, and targeting moiety); obtaining the EV from the modified producer cell; and optionally isolating the obtained EV. In further aspects, the method comprises: obtaining an EV from a producer cell; isolating the obtained EV; and modifying the isolated EV (*e.g.*, by inserting multiple exogenous biologically active molecules, *e.g.*, antigens, adjuvants, and/or immune modulators, and/or targeting moieties). In certain aspects, the method further comprises formulating the isolated EV into a pharmaceutical composition.

[0433] As described herein, in some aspects, an EV that can be produced using the methods provided herein comprises one or more of the following features: (i) a luminal T cell antigen (*e.g.*, attached to the luminal surface of the EV using a scaffold moiety); (ii) a surface B cell antigen (*e.g.*, attached to the exterior surface of the EV using a scaffold moiety); and (iii) a STING agonist (*e.g.*, loaded into the lumen of the EV). In addition to the scaffold moieties described herein (*e.g.*, Scaffold X and Scaffold Y), any suitable method can be used to link an antigen or any other molecules of interest (*e.g.*, adjuvant and/or targeting moiety) to an exterior surface and/or luminal surface of the EV. In certain aspects, the antigen or any other molecules of interest (*e.g.*, adjuvant and/or targeting moiety) is linked to the exterior surface and/or the luminal surface of the EV by any suitable coupling strategies known in the art. In some aspects, the coupling strategy comprises: an anchoring moiety, affinity agent, chemical conjugation, cell penetrating peptide (CPP), split intein, SpyTag/SpyCatcher, ALFA-tag, Streptavidin/Avitag, Sortase, SNAP-tag, ProA/Fc-binding peptide, or any combinations thereof. In some aspects, the anchoring moiety comprises a cholesterol, fatty acid (*e.g.*, palmitate), tocopherol (*e.g.*, vitamin E), alkyl chain, aromatic ring, or any combination thereof. In some aspects, the chemical conjugation comprises a maleimide moiety, copper-free, biorthogonal click chemistry (*e.g.*, azide/strained alkyne (DIFO)), metal-catalyzed click chemistry (*e.g.*, CUAAC, RUAAC), or any combination thereof. Additional description relating to the different approaches of linking an antigen or any other molecules of interest (*e.g.*, adjuvant and/or targeting moiety) are provided elsewhere in the present disclosure.

[0434] In some aspects, to identify the T cell antigens that are useful for the present disclosure, an *in silico* structure-based network analysis can be used to determine one or more conserved T cell (*e.g.*, CD8+ T cells) epitopes of a pathogen, *e.g.*, coronavirus (*e.g.*, SARS-CoV-1, SARS-CoV-2 (COVID-19), and/or MERS-CoV). Non-limiting examples of T cell epitopes of a coronavirus are provided in Table 2. In some aspects, the network analysis is applied to the spike, nucleocapsid, and/or non-structural proteins of a coronavirus (*e.g.*, SARS-CoV-1, SARS-CoV-2 (COVID-19), and/or MERS-CoV). In some aspects, the T cell epitopes are CD8+ T cell epitopes and are conserved across different types of coronavirus (*e.g.*, SARS-CoV-1, SARS-CoV-2 (COVID-19), and/or MERS-CoV). Additional disclosure relating to such an analysis is provided, *e.g.*, in Gaiha *et al.*, *Science* 364(6439): 480-484 (May 2019), which is herein incorporated by reference in its entirety.

[0435] In some aspects, to identify the B cell antigens that are useful for the present disclosure, the spike protein of a coronavirus (*e.g.*, SARS-CoV-1, SARS-CoV-2 (COVID-19), and/or MERS-CoV) can be assessed to determine B cell epitopes that are conserved across different types of coronavirus (*e.g.*, SARS-CoV-1, SARS-CoV-2 (COVID-19), and/or MERS-CoV). As described herein, in certain aspects, the B cell antigen that can be attached to an EV (*e.g.*, to the exterior surface of the EV using a scaffold moiety) comprises a receptor-binding domain (RBD) of a coronavirus spike protein. Additional disclosure relating to RBD is provided elsewhere herein.

V.A Methods of Modifying a Producer Cell

[0436] As described *supra*, in some aspects, a method of producing an EV comprises modifying a producer cell with multiple (*e.g.*, two or more) molecule of interest (*e.g.*, exogenous biologically active molecules described herein (*e.g.*, antigen, adjuvant, immune modulator), and/or targeting moiety). In some aspects, a producer cell disclosed herein can be further modified with a scaffold moiety disclosed herein (*e.g.*, Scaffold X or Scaffold Y).

[0437] In some aspects, the producer cell can be a mammalian cell line, a plant cell line, an insect cell line, a fungi cell line, or a prokaryotic cell line. In certain aspects, the producer cell is a mammalian cell line. Non-limiting examples of mammalian cell lines include: a human embryonic kidney (HEK) cell line, a Chinese hamster ovary (CHO) cell line, an HT-1080 cell line, a HeLa cell line, a PERC-6 cell line, a CEVEC cell line, a fibroblast cell line, an amniocyte cell line, an epithelial cell line, a mesenchymal stem cell (MSC) cell line, and combinations thereof. In certain aspects, the mammalian cell line comprises HEK-293 cells, BJ human foreskin fibroblast cells, fHDF fibroblast cells, AGE.HN® neuronal precursor cells, CAP® amniocyte cells, adipose

mesenchymal stem cells, RPTEC/TERT1 cells, or combinations thereof. In some aspects, the producer cell is a primary cell. In certain aspects, the primary cell can be a primary mammalian cell, a primary plant cell, a primary insect cell, a primary fungi cell, or a primary prokaryotic cell.

[0438] In some aspects, the producer cell is not an immune cell, such an antigen presenting cell, a T cell, a B cell, a natural killer cell (NK cell), a macrophage, a T helper cell, or a regulatory T cell (Treg cell). In other aspects, the producer cell is not an antigen presenting cell (*e.g.*, dendritic cells, macrophages, B cells, mast cells, neutrophils, Kupffer-Browicz cell, or a cell derived from any such cells). In some aspects, a producer cell is not a naturally-existing antigen-presenting cell (*i.e.*, has been modified). In some aspects, a producer cell is not a naturally-existing dendritic cell, a B cell, a mast cell, a macrophage, a neutrophil, Kupffer-Browicz cell, cell derived from any of these cells, or any combination thereof.

[0439] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) can be a transgene or mRNA, and introduced into the producer cell by transfection, viral transduction, electroporation, extrusion, sonication, cell fusion, or other methods that are known to the skilled in the art.

[0440] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) is introduced to the producer cell by transfection. In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) can be introduced into suitable producer cells using synthetic macromolecules, such as cationic lipids and polymers (Papapetrou *et al.*, *Gene Therapy* 12: S118-S130 (2005)). In some aspects, the cationic lipids form complexes with the one or more moieties (*e.g.*, payload and/or targeting moiety) through charge interactions. In some of these aspects, the positively charged complexes bind to the negatively charged cell surface and are taken up by the cell by endocytosis. In some other aspects, a cationic polymer can be used to transfect producer cells. In some of these aspects, the cationic polymer is polyethylenimine (PEI). In certain aspects, chemicals such as calcium phosphate, cyclodextrin, or polybrene, can be used to introduce the one or more moieties (*e.g.*, payload and/or targeting moiety) to the producer cells. The one or more moieties (*e.g.*, payload and/or targeting moiety) can also be introduced into a producer cell using a physical method such as particle-mediated transfection, "gene gun", biolistics, or particle bombardment technology (Papapetrou *et al.*, *Gene Therapy* 12: S118-S130 (2005)). A reporter gene such as, for example, beta-galactosidase, chloramphenicol acetyltransferase, luciferase, or green fluorescent protein can be used to assess the transfection efficiency of the producer cell.

[0441] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the producer cell by viral transduction. A number of viruses can be used as gene transfer vehicles, including moloney murine leukemia virus (MMLV), adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), lentiviruses, and spumaviruses. The viral mediated gene transfer vehicles comprise vectors based on DNA viruses, such as adenovirus, adeno-associated virus and herpes virus, as well as retroviral based vectors.

[0442] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the producer cell by electroporation. Electroporation creates transient pores in the cell membrane, allowing for the introduction of various molecules into the cell. In some aspects, DNA and RNA as well as polypeptides and non-polypeptide therapeutic agents can be introduced into the producer cell by electroporation.

[0443] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) introduced to the producer cell by microinjection. In some aspects, a glass micropipette can be used to inject the one or more moieties (*e.g.*, payload and/or targeting moiety) into the producer cell at the microscopic level.

[0444] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the producer cell by extrusion.

[0445] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the producer cell by sonication. In some aspects, the producer cell is exposed to high intensity sound waves, causing transient disruption of the cell membrane allowing loading of the one or more moieties (*e.g.*, payload and/or targeting moiety).

[0446] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the producer cell by cell fusion. In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced by electrical cell fusion. In other aspects, polyethylene glycol (PEG) is used to fuse the producer cells. In further aspects, sendai virus is used to fuse the producer cells.

[0447] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the producer cell by hypotonic lysis. In such aspects, the producer cell can be exposed to low ionic strength buffer causing them to burst allowing loading of the one or more moieties (*e.g.*, payload and/or targeting moiety). In other aspects, controlled dialysis against a hypotonic solution can be used to swell the producer cell and to create pores in the producer cell membrane. The producer cell is subsequently exposed to conditions that allow resealing of the membrane.

[0448] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the producer cell by detergent treatment. In certain aspects, producer cell is treated with a mild detergent which transiently compromises the producer cell membrane by creating pores allowing loading of the one or more moieties (*e.g.*, payload and/or targeting moiety). After producer cells are loaded, the detergent is washed away thereby resealing the membrane.

[0449] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) introduced to the producer cell by receptor mediated endocytosis. In certain aspects, producer cells have a surface receptor which upon binding of the one or more moieties (*e.g.*, payload and/or targeting moiety) induces internalization of the receptor and the associated moieties.

[0450] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the producer cell by filtration. In certain aspects, the producer cells and the one or more moieties (*e.g.*, payload and/or targeting moiety) can be forced through a filter of pore size smaller than the producer cell causing transient disruption of the producer cell membrane and allowing the one or more moieties (*e.g.*, payload and/or targeting moiety) to enter the producer cell.

[0451] In some aspects, the producer cell is subjected to several freeze thaw cycles, resulting in cell membrane disruption allowing loading of the one or more moieties (*e.g.*, payload and/or targeting moiety).

V.B Methods of Modifying an EV

[0452] In some aspects, a method of producing an EV comprises modifying the isolated EV by directly introducing one or more moieties (*e.g.*, payload and/or targeting moiety) into the EVs. In certain aspects, the one or more moieties comprise an antigen, adjuvant, immune modulator, targeting moiety, or combinations thereof. In some aspects, the one or more moieties comprise a scaffold moiety disclosed herein (*e.g.*, Scaffold X or Scaffold Y).

[0453] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the EV by transfection. In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) can be introduced into the EV using synthetic macromolecules such as cationic lipids and polymers (Papapetrou *et al.*, Gene Therapy 12: S118-S130 (2005)). In certain aspects, chemicals such as calcium phosphate, cyclodextrin, or polybrene, can be used to introduce the one or more moieties (*e.g.*, payload and/or targeting moiety) to the EV.

[0454] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the EV by electroporation. In some aspects, EVs are exposed to an electrical field

which causes transient holes in the EV membrane, allowing loading of the one or more moieties (*e.g.*, payload and/or targeting moiety).

[0455] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the EV by microinjection. In some aspects, a glass micropipette can be used to inject the one or more moieties (*e.g.*, payload and/or targeting moiety) directly into the EV at the microscopic level.

[0456] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the EV by extrusion.

[0457] In certain aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the EV by sonication. In some aspects, EVs are exposed to high intensity sound waves, causing transient disruption of the EV membrane allowing loading of the one or more moieties (*e.g.*, payload and/or targeting moiety).

[0458] In some aspects, one or more moieties (*e.g.*, payload and/or targeting moiety) can be conjugated to the surface of the EV (*i.e.*, conjugated or linked directly to the exterior surface of the EV or to the luminal surface of the EV). Conjugation can be achieved chemically or enzymatically, by methods known in the art.

[0459] In some aspects, the EV comprises one or more moieties (*e.g.*, payload and/or targeting moiety) that are chemically conjugated. Chemical conjugation can be accomplished by covalent bonding of the one or more moieties (*e.g.*, payload and/or targeting moiety) to another molecule, with or without use of a linker or affinity ligand disclosed herein. The formation of such conjugates is within the skill of artisans and various techniques are known for accomplishing the conjugation, with the choice of the particular technique being guided by the materials to be conjugated. In certain aspects, polypeptides are conjugated to the EV. In some aspects, non-polypeptides, such as lipids, carbohydrates, nucleic acids, and small molecules, are conjugated to the EV.

[0460] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the EV by hypotonic lysis. In such aspects, the EVs can be exposed to low ionic strength buffer causing them to burst allowing loading of the one or more moieties (*e.g.*, payload and/or targeting moiety). In other aspects, controlled dialysis against a hypotonic solution can be used to swell the EV and to create pores in the EV membrane. The EV is subsequently exposed to conditions that allow resealing of the membrane.

[0461] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the EV by detergent treatment. In certain aspects, extracellular vesicles are treated with a mild detergent which transiently compromises the EV membrane by creating pores allowing loading of the one or more moieties (*e.g.*, payload and/or targeting moiety). After EVs are loaded, the detergent is washed away thereby resealing the membrane.

[0462] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the EV by receptor mediated endocytosis. In certain aspects, EVs have a surface receptor which upon binding of the one or more moieties (*e.g.*, payload and/or targeting moiety) induces internalization of the receptor and the associated moieties.

[0463] In some aspects, the one or more moieties (*e.g.*, payload and/or targeting moiety) are introduced to the EV by mechanical firing. In certain aspects, extracellular vesicles can be bombarded with one or more moieties (*e.g.*, payload and/or targeting moiety) attached to a heavy or charged particle such as gold microcarriers. In some of these aspects, the particle can be mechanically or electrically accelerated such that it traverses the EV membrane.

[0464] In some aspects, extracellular vesicles are subjected to several freeze thaw cycles, resulting in EV membrane disruption allowing loading of the one or more moieties (*e.g.*, payload and/or targeting moiety).

V.C Methods of Isolating an EV

[0465] In some aspects, methods of producing EVs disclosed herein comprises isolating the EV from the producer cells. In certain aspects, the EVs released by the producer cell into the cell culture medium. It is contemplated that all known manners of isolation of EVs are deemed suitable for use herein. For example, physical properties of EVs can be employed to separate them from a medium or other source material, including separation on the basis of electrical charge (*e.g.*, electrophoretic separation), size (*e.g.*, filtration, molecular sieving, *etc.*), density (*e.g.*, regular or gradient centrifugation), Svedberg constant (*e.g.*, sedimentation with or without external force, *etc.*). Alternatively, or additionally, isolation can be based on one or more biological properties, and include methods that can employ surface markers (*e.g.*, for precipitation, reversible binding to solid phase, FACS separation, specific ligand binding, non-specific ligand binding, affinity purification *etc.*).

[0466] Isolation and enrichment can be done in a general and non-selective manner, typically including serial centrifugation. Alternatively, isolation and enrichment can be done in a more specific and selective manner, such as using EV or producer cell-specific surface markers. For

example, specific surface markers can be used in immunoprecipitation, FACS sorting, affinity purification, and magnetic separation with bead-bound ligands.

[0467] In some aspects, size exclusion chromatography can be utilized to isolate the EVs. Size exclusion chromatography techniques are known in the art. Exemplary, non-limiting techniques are provided herein. In some aspects, a void volume fraction is isolated and comprises the EVs of interest. Further, in some aspects, the EVs can be further isolated after chromatographic separation by centrifugation techniques (of one or more chromatography fractions), as is generally known in the art. In some aspects, for example, density gradient centrifugation can be utilized to further isolate the extracellular vesicles. In certain aspects, it can be desirable to further separate the producer cell-derived EVs from EVs of other origin. For example, the producer cell-derived EVs can be separated from non-producer cell-derived EVs by immunosorbent capture using an antigen antibody specific for the producer cell.

[0468] In some aspects, the isolation of EVs can involve combinations of methods that include, but are not limited to, differential centrifugation, size-based membrane filtration, immunoprecipitation, FACS sorting, and magnetic separation.

VII. Methods of Treatment

[0469] Present disclosure also provides methods of preventing and/or treating an infectious disease or disorder, e.g., coronavirus infection, in a subject in need thereof, comprising administering an EV disclosed herein to the subject. Not to be bound by any one theory, in some aspects, an EV disclosed herein can treat and/or prevent these infectious diseases or disorders by inducing neutralizing antibodies that can specifically bind to a molecule associated with the infectious disease or disorder (e.g., S protein, M protein, and/or E protein).

[0470] EVs of the present disclosure can be administered to a subject by any useful method and/or route known in the art. In some aspects, the EVs are administered intravenously to the circulatory system of the subject. In some aspects, the EVs are infused in suitable liquid and administered into a vein of the subject.

[0471] In some aspects, the EVs are administered intra-arterially to the circulatory system of the subject. In some aspects, the EVs are infused in suitable liquid and administered into an artery of the subject.

[0472] In some aspects, the EVs are administered to the subject by intranasal administration. In some aspects, the EVs can be insufflated through the nose in a form of either topical

administration or systemic administration. In certain aspects, the EVs are administered as nasal spray. In some aspects, intranasal administration can allow for the effective delivery of an EV disclosed herein to the gastrointestinal tissues. Such EVs delivered to the gastrointestinal tissues could be useful in providing protection against various gut-associated pathogens.

[0473] In some aspects, the EVs are administered to the subject by intraperitoneal administration. In some aspects, the EVs are infused in suitable liquid and injected into the peritoneum of the subject. In some aspects, the intraperitoneal administration results in distribution of the EVs to the lymphatics. In some aspects, the intraperitoneal administration results in distribution of the EVs to the thymus, spleen, and/or bone marrow. In some aspects, the intraperitoneal administration results in distribution of the EVs to one or more lymph nodes. In some aspects, the intraperitoneal administration results in distribution of the EVs to one or more of the cervical lymph node, the inguinal lymph node, the mediastinal lymph node, or the sternal lymph node. In some aspects, the intraperitoneal administration results in distribution of the EVs to the pancreas.

[0474] Non-limiting examples of other routes of administration that can be used to administer the EVs disclosed herein include parenteral, topical, oral, subcutaneous, intradermal, transdermal, rectal, intraperitoneal, intramuscular, sublingual, or combinations thereof.

[0475] As disclosed herein, in some aspects, EVs disclosed herein can be administered to a subject in combination with one or more additional therapeutic agents. In certain aspects, the one or more additional therapeutic agents and the EVs are administered concurrently. In some aspects, the one or more additional therapeutic agents and the EVs are administered sequentially. In some aspects, the EVs are administered to the subject prior to administering the one or more additional therapeutic agents. In certain aspects, the EVs are administered to the subject after administering the one or more additional therapeutic agents. As used herein, the term "**therapeutic agents**" refers to any agents that can be used in treating an infectious disease or disorder disclosed herein). In some aspects, the one or more additional therapeutic agents that can be used in combination with the EVs of the present disclosure include a payload (*e.g.*, antigen, adjuvant, and/or immune modulator) which is not expressed in an EV. For instance, a treatment method disclosed herein can comprise administering to a subject in need thereof (i) an antigen-less EV and (ii) an antigen that is not expressed in an EV (*e.g.*, soluble antigen).

[0476] In some aspects, a subject that can be treated with the present disclosure is a human. In some aspects, a subject is a non-human mammal (*e.g.*, non-human primates, dogs, cats, guinea

pigs, rabbits, rats, mice, horses, cattle, chickens, birds, and bears). Accordingly, in some aspects, the EVs disclosed herein can be used to improve the health of an animal (*i.e.*, non-human mammal).

[0477] In some aspects, the present disclosure is directed to a method of vaccinating a subject in need thereof, comprising (i) administering a priming dose which comprises an extracellular vesicle comprising an adjuvant and an antigen to the subject and (ii) administering a boosting dose which comprises an extracellular vesicle comprising the antigen to the subject.

[0478] In some aspects, the antigen is derived from a coronavirus.

[0479] In some aspects, the priming dose is administered subcutaneously. In some aspects, the boost dose is administered intranasally.

[0480] In some aspects, the adjuvant is a STING agonist. In some aspects, the antigen is linked to a scaffold moiety. In some aspects, the scaffold moiety is Scaffold X.

[0481] In some aspects, the EV in the boosting dose does not contain any adjuvant.

[0482] In any of the administering methods described herein, in some aspects, an EV can be administered to a subject using a "prime-pull" dosing regimen. As used herein, the term "prime-pull" dosing regimen refers to an administration schedule in which a subject is first immunized with a first dosing regimen (also referred to herein as the "priming dose") and then subsequently receives a second dosing regimen (also referred to herein as the "boosting dose"). In certain aspects, the first dosing regimen comprises a first EV and the second dosing regimen comprises a second EV, wherein the first and second EVs differ in their composition. For instance, in certain aspects, the first EV comprises an antigen and one or more of the other moieties described herein (*e.g.*, adjuvant, immunomodulatory, and/or targeting moiety), and the second EV comprises the antigen but not the one or more of the other moieties present in the first EV. In some aspects, the first dosing regimen and the second dosing regimen are administered to the subject by different routes of administration (*e.g.*, any combination of routes of administration that are known in the art and/or disclosed herein).

[0483] Accordingly, in some aspects, an administration (or vaccinating) method described herein comprises (i) administering a priming dose to a subject, wherein the priming dose comprises a first EV, which comprises an antigen and an adjuvant, and (ii) administering a boosting dose to the subject, wherein the boosting dose comprises a second EV, which comprises the antigen but not the adjuvant present in the first EV. In some aspects, the second EV does not comprise any adjuvant. Not to be bound by any one theory, in some aspects, the prime-pull dosing regimens can further improve the safety of the EV-based vaccines described herein, *e.g.*, by not requiring the use

of adjuvants when administering the boosting dose to the subject and thereby, avoid the risk of non-specific inflammation that can occur with certain adjuvants.

[0484] Moreover, in some aspects, the use of prime-pull dosing regimen can enhance the migration of immune cells to a particular tissue of interest (*e.g.*, lung or other site of coronavirus infection). For instance, in certain aspects, a subject receives a first dosing regimen to prime or activate one or more immune cells, and then subsequently receives a second dosing regimen, wherein the second dosing regimen is capable of promoting the migration of the primed immune cells to the particular tissue of interest. In some aspects, this can be achieved by (i) administering the second dosing regimen using a tissue-specific route of administration, (ii) modifying the EVs of the second dosing regimen to comprise one or more tissue-specific targeting moieties, or (iii) both (i) and (ii). Non-limiting examples of such routes of administration and targeting moieties are provided throughout the present disclosure.

[0485] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. *See*, for example, Sambrook *et al.*, ed. (1989) Molecular Cloning A Laboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press); Sambrook *et al.*, ed. (1992) Molecular Cloning: A Laboratory Manual, (Cold Springs Harbor Laboratory, NY); D. N. Glover ed., (1985) DNA Cloning, Volumes I and II; Gait, ed. (1984) Oligonucleotide Synthesis; Mullis *et al.* U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984) Transcription And Translation; Freshney (1987) Culture Of Animal Cells (Alan R. Liss, Inc.); Immobilized Cells And Enzymes (IRL Press) (1986); Perbal (1984) A Practical Guide To Molecular Cloning; the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Miller and Calos eds. (1987) Gene Transfer Vectors For Mammalian Cells, (Cold Spring Harbor Laboratory); Wu *et al.*, eds., Methods In Enzymology, Vols. 154 and 155; Mayer and Walker, eds. (1987) Immunochemical Methods In Cell And Molecular Biology (Academic Press, London); Weir and Blackwell, eds., (1986) Handbook Of Experimental Immunology, Volumes I-IV; Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); Crooke, Antisense drug Technology: Principles, Strategies and Applications, 2nd Ed. CRC Press (2007) and in Ausubel *et al.* (1989) Current Protocols in Molecular Biology (John Wiley and Sons, Baltimore, Md.).

[0486] All of the references cited above, as well as all references cited herein, are incorporated herein by reference in their entireties.

[0487] The following examples are offered by way of illustration and not by way of limitation.

EXAMPLES

Example 1: Generation of Engineered-Exosomes

[0488] To generate exosomes described herein, human embryonic kidney (HEK) cell line (HEK293SF) was used. The cells were then stably transfected with Scaffold X and/or Scaffold Y linked to an agent of interest (*e.g.*, antigen, adjuvant, or immune modulator). See FIGs. 1A, 1B, and 2. For example, CD40L-expressing exosomes were generated by transfecting HEK293SF cells with CD40L-GFP PTGFRN fusion molecules, which were expressed as a monomer (pCB-518 to pCB-526) or as a forced trimer (pCB-607 and pCB-527). An example of a trimeric CD40L-GFP PTGFRN fusion molecule is shown in FIG. 1A. Similarly, to generate chicken ovalbumin (OVA)-expressing exosomes, ovalbumin was stably expressed in HEK293SF cells as a fusion to amino acids 1-10 of BASP1 ("BASP1(1-10)-OVA").

[0489] Upon transfection, HEK293SF cells were grown to high density in chemically defined medium for 7 days. Conditioned cell culture media was collected and centrifuged at 300 – 800 x g for 5 minutes at room temperature to remove cells and large debris. Media supernatant was then supplemented with 1000 U/L BENZONASE® and incubated at 37 °C for 1 hour in a water bath. Supernatant was collected and centrifuged at 16,000 x g for 30 minutes at 4 °C to remove residual cell debris and other large contaminants. Supernatant was then ultracentrifuged at 133,900 x g for 3 hours at 4 °C to pellet the exosomes. Supernatant was discarded and any residual media was aspirated from the bottom of the tube. The pellet was resuspended in 200 – 1000 μL PBS (-Ca -Mg).

[0490] To further enrich exosome populations, the pellet was processed via density gradient purification (sucrose or OPTIPREP™).

[0491] The gradient was spun at 200,000 x g for 16 hours at 4 °C in a 12 mL Ultra-Clear (344059) tube placed in a SW 41 Ti rotor to separate the exosome fraction.

[0492] The exosome layer was gently removed from the top layer and diluted in ~32.5 mL PBS in a 38.5 mL Ultra-Clear (344058) tube and ultracentrifuged again at 133,900 x g for 3 hours

at 4 °C to pellet the purified exosomes. The resulting pellet was resuspended in a minimal volume of PBS (~200 µL) and stored at 4 °C.

[0493] For OPTIPREP™ gradient, a 3-tier sterile gradient is prepared with equal volumes of 10%, 30%, and 45% OPTIPREP™ in a 12 mL Ultra-Clear (344059) tube for a SW 41 Ti rotor. The pellet was added to the OPTIPREP™ gradient and ultracentrifuged at 200,000 x g for 16 hours at 4 °C to separate the exosome fraction. The exosome layer was then gently collected from the top ~3 mL of the tube.

[0494] The exosome fraction was diluted in ~32 mL PBS in a 38.5 mL Ultra-Clear (344058) tube and ultracentrifuged at 133,900 x g for 3 hours at 4 °C to pellet the purified exosomes. The pelleted exosomes were then resuspended in a minimal volume of PBS (~200 µL) and stored at 4°C until ready to be used.

Example 2: Efficacy of Engineered-Exosomes to Induce Antigen-Specific T Cell Responses

[0495] Virus-specific CD8 T cells are required for pathogen clearance following primary SARS-CoV infection. SARS-CoV-specific memory CD8 T cells protect susceptible hosts from lethal SARS-CoV infection. Ability of the exoVACC platform to generate robust antigen specific CD8+ T-cell response and the ability to expand the tissue resident memory T-cell response provides a unique opportunity to develop a CD8 T-cell based vaccine for SARS-Cov2.

[0496] To demonstrate that the EVs described herein are capable of inducing antigen-specific T cell responses, EVs comprising ovalbumin (OVA) were constructed using methods described herein. OVA was fused to the N-terminus of PTGFRN and displayed on the exterior surface of the EV ("PrX-OVA"). Some of the EVs were further loaded with a STING agonist in the lumen of the EV ("PrX-OVA-STING"). Then, the EVs were administered to mice using the prime-and-pull administration strategy described herein. As shown in FIG. 8, animals were vaccinated twice (*i.e.*, at days 0 and 7 post initial administration) via subcutaneous (SQ), intranasal (IN), or intradermal (ID) administration. Animals were sacrificed at day 14 post initial administration, and T cell immune responses were observed in the animals.

[0497] As shown in FIGs. 9A, 9B, 10A, 10B, 10C, 11A, and 11B, animals that received an EV described herein had significantly greater number of total T cells in the lung (*i.e.*, groups 2-8) compared to animals treated with recombinant OVA + soluble STING agonist (*i.e.*, group 9), demonstrating the potency of the EVs described herein. The increase in total T cells correlated with increases in both OVA-specific CD4+ and CD8+ T cells, including OVA-specific effector memory

CD8+ T cells. The different combinations of administration routes appeared to have minimal effect. Additionally, OVA-specific effector memory CD8+ T cells were also observed in the lung where the EV used for the boost did not comprise the STING agonist (*i.e.*, groups 3, 4, and 7), suggesting that an adjuvant is not necessary for the boost using EVs described herein. Moreover, as shown in FIG. 10C, the prime-pull administration strategy described herein did not lead to non-specific T cell inflammatory activation in the lungs (groups 3 and 4) compared to groups 2 and 5, where an adjuvanted boosting dose was administered intranasally. Similar results were observed in the spleen (*see* FIGs. 12A, 12B, 13A, and 13B).

[0498] The above results demonstrate the safety of the EVs described herein and the effectiveness of the prime-and-pull regimen of the present disclosure.

Example 3: Development of a Coronavirus Extracellular Vesicle Vaccine

[0499] To assess the efficacy of EVs described herein in treating a coronavirus, EVs comprising the RBD of a coronavirus spike protein was constructed using the methods described herein ("exoRBD"). The RBD protein was fused to the N-terminus of either the full-length PTGFRN ("exoRBD (l)" or a PTGFRN fragment ("exoRBD (s)"). Some of the EVs were further loaded with a STING agonist in the lumen of the EV ("STING exoRBD"). Then, as shown in FIG. 14A, the different EVs were used to vaccinate mice. Each of the animals received two doses (at day 0 and at day 14) either via subcutaneous (SQ) or intranasal (IN) administration. Then, the sera was collected from the animals at day 28 post initial administration, and the anti-RBD antibody response was assessed using an ELISA assay.

[0500] As shown in FIG. 14B, in all animals that were vaccinated with the exoRBD (with or without the STING agonist) had significant levels of anti-RBD antibodies in the sera. Again, the particular combination of administration routes did not appear to have a significant effect. And, also as observed in Example 2, significant level of anti-RBD antibody was observed even where the STING agonist was not included as part of the 2nd dose (either as soluble STING or loaded in the lumen of the EV). Moreover, the antibodies observed in animals from some of the EV vaccinated groups were also neutralizing (*see, e.g.*, groups 1, 3, 5, and 8 in FIGs. 14C and 14D).

[0501] Next, to assess whether the addition of T helper epitopes or B cell immunomodulators can further enhance the anti-RBD antibody levels, EVs comprising either T helper epitopes Itgb1 or ovalbumin (OVA) fused to PTGFRN on the exterior surface ("PrX-Itgb1") or (“PrX-OVA”) were co-administered with EVs with RBD fused to PTGFRN on the exterior surface or alternately

EVs with RBD fused to PTGFRN on the exterior surface were administered with a B cell co-stimulator (anti-CD40 agonist antibody). Mice were vaccinated (at days 0 and 14) with the different EVs as shown in FIG. 15. Then, at day 35 post initial administration, the animals were sacrificed and the anti-RBD antibody levels and neutralizing antibody activity were observed in the animals.

[0502] As shown in FIGs. 15B-15G, B cell costimulation through CD40 activation enhanced anti-RBD antibody levels and neutralization activity.

Example 4: Further Characterization of EVs Comprising Coronavirus Antigens

[0503] To further demonstrate that the EVs described herein can be engineered to express antigens that would be useful in treating an infectious disease, such as a coronavirus infection, EVs were engineered to comprise both B and T cell antigens of a coronavirus. Specifically, as described in Example 3, the RBD protein of a coronavirus spike protein was fused to the N-terminus of PTGFRN (both full-length and fragment) and displayed on the exterior surface of the EV. Additionally, the EVs were also engineered to comprise T cell epitopes of coronavirus (*e.g.*, spike protein, nucleocapsid, membrane protein, and/or ORF3a), which were expressed on the luminal surface of the EVs (fused to PTGFRN or to BASP1), as a single peptide, as concatemer peptide antigens, or concatemer protein antigens (*see* FIGs. 19A, 19B, and 19C). Expression of the antigens was confirmed by both Western blot and HiBiT assay (*see* FIGs. 20A and 20B, respectively).

[0504] To assess the expression level of the coronavirus antigens, EVs were engineered to comprise either RBD protein or the entire spike protein of coronavirus fused to the N-terminus of PTGFRN and displayed on the exterior surface of the EV (*see* FIG. 21A). As shown in FIG. 21B, each of the EVs constructed expressed multiple copies of the coronavirus antigens on the exterior surface.

[0505] Next, to further assess the expression of the T cell epitopes of coronavirus in the EVs, EVs were modified to comprise the concatemer T cell epitopes of coronavirus either on the exterior surface (fused to PTGFRN) or on the luminal surface (fused to PTGFRN or BASP-1) (*see* FIG. 22A). Expression was confirmed by both Western blot and HiBiT assay (*see* FIGs. 22B and 22C).

[0506] The above results demonstrate the versatility of the EVs described herein, as they can be engineered to comprise multiple antigens (both B and T cell antigens) which can be useful in treating the different diseases or disorders disclosed herein, *e.g.*, coronavirus infection.

Example 5. exoVACC™: a novel exosome-based vaccine platform that induces robust, tunable B and T cell responses.

[0507] Background: exoVACC™ is a novel exosome-based vaccine platform that is designed to selectively deliver exogenous antigens, adjuvants and immunomodulators to antigen presenting cells to induce robust cellular and humoral immune responses. Exosomes are natural extracellular delivery vesicles but are inherently non-immunogenic. We investigated different antigen-adjuvant designs to better understand the properties that influence exoVACC™ immunogenicity. Using exosome scaffold proteins PTGFRN and BASP1, we selectively expressed the model antigen OVA either on the exosome surface, by fusion with PTGFRN, or in the lumen, by fusion with BASP1. We co-loaded different adjuvants and assessed both humoral and cellular immune responses in mice immunized through different routes of administration. The different treatment groups are described in FIG. 16A.

[0508] Results: Immunization with OVA expressed on the exosome surface induced anti-OVA IgG antibody responses as early as 14 days after a single immunization which increased following bi-weekly boost immunizations. *See* FIGs. 16B-16G. Antibody responses were induced without an adjuvant and at higher levels than in mice immunized with traditional soluble OVA and adjuvants. Notably, antibody responses were not enhanced when alum, CpG or both alum and CpG adjuvants were loaded onto exosomes. In contrast, mice immunized with exosomes expressing OVA in the lumen had very poor antibody responses even after several boost immunizations. Anti-OVA IgG antibody levels were significantly lower than in mice immunized with the same amount of soluble OVA. However, loading an adjuvant onto exosomes expressing luminal OVA induced antibody responses comparable to mice immunized with exosomes expressing surface OVA. Similarly, immunization of exosomes expressing luminal OVA without adjuvant also failed to induce antigen-specific T cell responses even after multiple administrations and via multiple routes of administration (RoA).

[0509] As demonstrated earlier (*see, e.g.*, Example 2), loading an adjuvant induced robust T effector memory (TEM) and tissue resident memory T cell (TRM) responses after a single immunization via multiple RoA. Notably, the induction of antigen-specific TRM was markedly superior compared to immunization with soluble OVA and adjuvant. Exosomes expressing OVA on the surface also induced robust T cell responses. OVA-specific lung TRM and TEM were induced via IN immunization of STING adjuvanted exosomes but also through a "prime-pull" regimen where mice were first immunized SC with adjuvanted exosomes followed by an

unadjuvanted IN boost. In contrast mice immunized with soluble OVA and STING adjuvant using the prime-push regimen did not elicit robust T cell responses.

[0510] Finally, we assessed the efficacy of exosomes expressing OVA in the lumen and loaded with a STING agonist adjuvant ("exoVACC") in the E.G7-OVA tumor model. As shown in FIG. 23A, mice received a single administration one of one of the following: (1) PBS alone via subcutaneous administration; (2) exoVACC via intranasal administration; (3) exoVACC via subcutaneous administration; (4) soluble OVA + PolyI:C via intranasal administration; and (5) soluble OVA + PolyI:C via subcutaneous administration. A single prophylactic immunization administered either subcutaneously (SC) or intranasally (IN) significantly reduced tumor growth rate (FIGs. 23B and 23D) and improved survival (FIG. 23C) compared to mice immunized with soluble OVA and polyI:C. 33% of mice immunized SC with the OVA exosomes had complete responses.

[0511] Conclusions: exoVACC™ is a versatile vaccine platform that enables antigen-specific immune responses to be modulated through antigen orientation and adjuvant loading. exoVACC™ induced superior systemic and tissue resident immune responses via multiple routes of administration compared to conventional vaccine formulations in different animal models.

Example 6. Vaccination of Exo-VACC™ with Coronavirus Antigen

[0512] Exo-VACC™ with a coronavirus antigen alone and Exo-VACC™ with a coronavirus antigen and an adjuvant, e.g., STING agonist, were made according to the present disclosure, e.g., Examples 3 and 4. After the exosomes were prepared, the exosomes were administered to a subject using a vaccination regimen, e.g., prime-pull regimen. For example, in certain instances, a subject was subcutaneously administered a priming dose comprising exosomes which comprises a coronavirus antigen and an adjuvant, e.g., STING agonist. The subject was then be intranasally administered a boosting dose comprising exosomes which comprises the coronavirus antigen, but not any adjuvant.

[0513] As further described in Example 3, such a prime-pull administration regimen was effective in inducing coronavirus-specific immune responses *in vivo* (*see, e.g.*, FIGs. 14C, 14D, and 15B-15E). Because an adjuvant is not necessary as part of the boosting dose, the results provided here suggest that the prime-pull administration strategy with the EVs described herein can be safe and effective in treating coronavirus.

Example 7. Construction of EVs Comprising RBD Using the ALFA Plug-and-Play System

[0514] As further demonstration that the EVs described herein can be used to treat a coronavirus, the ALFA plug-and-play system described herein was used to modify the EVs to comprise the RBD protein of a coronavirus spike protein. Briefly, NbALFA nanobody was expressed on the EV surface as a fusion to the surface display scaffold PTGFRN. The RBD was expressed and purified using conventional transient transfection and column chromatography, respectively, and were fused to the ALFAtag. FIG. 17A. RBD-ALFAtag was conjugated to NbALFA EVs by mixing at room temperature for 30 minutes. Unbound ALFAtagged RBD was removed by ultracentrifugation or size exclusion chromatography, resulting in stable association of the ALFAtagged RBD on the surface of NbALFA EVs. FIGs. 17B-17F show the successful purification and loading of the ALFAtagged RBD to the EVs using both SDS-PAGE and Western blot.

[0515] Then, the EVs were administered to mice and the anti-RBD antibody response observed. Specifically, the animals received a single subcutaneous administration of one of the following: (i) "exoRBD" = RBD fused directly to PTGFRN; (ii) "rRBD + STING" = recombinant RBD protein + soluble STING agonist; (iii) "rRBD + Exo" = recombinant RBD protein + EV alone (*i.e.*, RBD not associated with the EV); and (iv) PBS alone. In FIG. 17B, the animals were vaccinated with one of the following: (i) "NbALFA Exo + RBD-ALFAtag" = RBD conjugated to PTGFRN using the ALFA plug-and-play system; (ii) "rRBD" = recombinant RBD protein alone; (iii) "rRBD" = recombinant RBD protein + soluble STING agonist; (iv) "Exo + rRBD" = recombinant RBD protein + EV alone (*i.e.*, RBD not associated with the EV); and (v) PBS alone. Control animals were administered 8 μg recombinant RBD alone (rRBD), 20 μg rRBD adjuvanted with a cyclic dinucleotide STING agonist (rRBD + STING), 8 μg rRBD co-administered with exosomes (rRBD + Exo) or PBS alone. 14 days post-vaccination, non-lethal bleeds were taken from each animal and anti-RBD antibody titer was determined by conventional plate-based ELISA.

[0516] As shown in FIGs. 18A and 18B, superior immunogenicity was observed from exosomes displaying ALFAtagged RBD compared to rRBD, adjuvanted rRBD, or exosomes co-administered with rRBD, suggesting presentation of the antigen on the exosome surface was important for eliciting an immunogenic response. The data also suggest that the ALFA system was functioning as expected in an in vivo context.

[0517] Collectively, the data provided in the above examples demonstrate that EVs described herein (*e.g.*, comprising a coronavirus antigen) can elicit potent coronavirus-specific immune responses, suggesting that they can be useful in treating a coronavirus, such as COVID-19.

Example 8. Construction of EVs Comprising Acceptor Domain Fused to PTGFRN

[0518] To further demonstrate the versatility of the EVs described herein as a vaccine platform, several different "plug-and-play" or "clip-on" strategies were analyzed for their ability to quickly and efficiently attach a molecule to the surface of EVs.

[0519] Briefly, HEK293 cells were transfected with constructs encoding an acceptor domain fused to the N-terminus of PTGFRN. Three different acceptor domains were analyzed: (1) SpyCatcher, (2) CfaC, and (3) ALFANb. As shown in FIGs. 25A and 25B, all of the PTGFRN fusion protein were stably expressed for at least a week post-transfection. Then EVs (*e.g.*, exosomes) comprising the PTGFRN fusion proteins were successfully produced and purified from the producer cells (*see* FIGs. 25C and 25D).

[0520] As described herein and further illustrated in FIG. 26, the EVs (*e.g.*, exosomes) produced here could be useful as "base" EVs to which a moiety of interest (*e.g.*, antigen) could rapidly be attached.

Example 9. Construction of EVs Comprising NanoLuc Luciferase Fused to ALFAtag

[0521] To further address the capability of the EV-based vaccines described herein, EVs overexpressing the ALFANb fused to PTGFRN were functionalized with solubly expressed NanoLuc fused to the ALFAtag peptide. The ALFAtag is capable of interacting with the ALFANb to form a stable, non-covalent interaction. FIG. 27A provides the general methods used. And, as shown FIG. 27B, SDS-PAGE analysis confirmed that the NanoLuc-ALFAtag was able to associate with the ALFANb-PTGFRN protein expressed on the exosome surface, at 1X or 10X molar excess of NanoLuc-ALFAtag. As shown in FIGs. 28A and 28B, compared to the control (*i.e.*, exosomes mixed with NanoLuc fused to poly-histidine tag), loading of the NanoLuc-ALFAtag was significantly higher on the exosomes, indicating that the loading was due to the specific interaction between the ALFAtag and ALFANb-PTGFRN fusion on the exosomes. And, as shown in FIGs. 29A and 29B, the interaction between the ALFAtag and ALFANb-PTGFRN fusion remained stable for an extended period of time under physiologic conditions.

Example 10. Construction of EVs Comprising NanoLuc Luciferase Fused to Cfa Split Intein

[0522] To confirm the results provided above, EVs overexpressing CfaC fused to PTGFRN were functionalized with solubly expressed NanoLuc fused to CfaN. Again, NanoLuc fused to a poly-histidine tag was used as a control. The general methods used are provided in FIG. 30A. Since intein trans-splicing results in covalent attachment of NanoLuc, a clear shift in molecular weight was visible by SDS-PAGE (NL-PTGFRN) (*see* FIG. 30B). The successful attachment of the NanoLuc was further confirmed when the expression of NanoLuc was measured on the exosomes. As shown in FIGs. 31A and 31B, compared to exosomes that were mixed with the NanoLuc-histidine control, exosomes that were mixed with the NanoLuc-CfaN had significantly higher NanoLuc expression.

Example 11. Additional Construction of Modular EVs

[0523] Further to the examples provided above, isolated EVs overexpressing SpyCatcher fused to PTGFRN were functionalized with solubly expressed NanoLuc fused to SpyTag, as described in FIG. 32A. The SDS-PAGE provided in FIG. 32B confirms the loading of NanoLuc-SpyTag onto SpyCatcher-PTGFRN overexpressing exosomes. Since SpyCatcher/SpyTag forms a spontaneous isopeptide bond, covalent attachment of NanoLuc-SpyTag resulted in a clear shift in molecular weight is visible by SDS-PAGE (NL-SpyTag/SpyCatcher-PTGFRN) (*see* FIG. 32B). FIGs. 33A and 33B confirm the results quantitatively.

[0524] As shown in FIG. 34, similar results were observed with the earlier discussed acceptor domains (*i.e.*, ALFANb, CfaC, and SpyCatcher).

[0525] Collectively, the above results confirm that the EVs (*e.g.*, exosomes) described herein could be a useful vaccine platform for rapidly treating a wide range of diseases and disorders.

Example 12. Analysis of the Loading of Multiple Payloads in EVs

[0526] Next, the ability of the EVs described herein to comprise multiple payloads (*e.g.*, antigen, adjuvant, immunomodulatory, and/or targeting moiety) was assessed. Briefly, NANOLUC™ luciferase (Nluc) fused to the ALFAtag peptide (10 μg) (Nluc-ALFAtag) and molar equivalent of mouse IL-12 fused to ALFAtag peptide (mIL12-ALFAtag) were mixed with the following EVs individually or simultaneously: (1) native EVs; or (2) engineered-EVs overexpressing ALFA-specific nanobody (NbALFA) fused to PTGFRN (NbALFA-EVs). The

mixture was incubated for 30 minutes at room temperature. Then, unbound Nluc-ALFAtag and/or mIL12-ALFAtag was removed by ultracentrifugation (20 minutes at 100,000 x g). The EV pellets were resuspended in PBS and analyzed by SDS-PAGE and Western blot.

[0527] As shown in FIG. 44, in native EVs, no meaningful loading was observed for either Nluc-ALFAtag or mIL12-ALFAtag. However, in the NbALFA-EVs, significant loading of Nluc-ALFAtag and mIL12-ALFAtag was observed, as measured by both Western blot and SDS-PAGE. Similar results were observed whether Nluc-ALFAtag and mIL12-ALFAtag were loaded individually or simultaneously.

[0528] The above results further demonstrate that the EVs of the present disclosure can be readily modified to simultaneously comprise multiple payloads. As described herein, such EVs can be useful in treating various diseases and disorders, such as those disclosed herein.

INCORPORATION BY REFERENCE

[0529] All publications, patents, patent applications and other documents cited in this application are hereby incorporated by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent application or other document were individually indicated to be incorporated by reference for all purposes.

EQUIVALENTS

[0530] While various specific aspects have been illustrated and described, the above specification is not restrictive. It will be appreciated that various changes can be made without departing from the spirit and scope of the disclosure(s). Many variations will become apparent to those skilled in the art upon review of this specification.

What is Claimed is:

1. An isolated extracellular vesicle (EV) comprising at least one antigen derived from a coronavirus.
2. The EV of claim 1, wherein the coronavirus is a severe acute respiratory syndrome (SARS) coronavirus.
3. The EV of claim 1 or 2, wherein the antigen is a universal SARS coronavirus antigen.
4. The EV of any one of claims 1 to 3, which comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more antigens, wherein the first antigen is derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus.
5. The EV of claim 4, wherein the second antigen is derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus.
6. The EV of claim 4, wherein the second antigen is not derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus.
7. The EV of claim 4 or 5, wherein the first and second antigens are the same.
8. The EV of claim 4 or 5, wherein the first and second antigens are different.
9. The EV of any one of claims 1 to 8, wherein the antigen derived from COVID-19 virus is derived from a spike (S) protein.
10. The EV of claim 9, wherein the antigen comprises a receptor-binding domain (RBD) of the S protein.
11. The EV of claim 9 or 10, wherein the antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the S protein.
12. The EV of any one of claims 1 to 11, wherein the antigen derived from COVID-19 virus is derived from an envelope (E) protein.
13. The EV of claim 12, wherein the antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the E protein.
14. The EV of any one of claims 1 to 13, wherein the antigen derived from COVID-19 virus is derived from a membrane (M) protein.
15. The EV of claim 14, wherein the antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the M protein.
16. The EV of any one of claims 4 to 15, wherein the second antigen is derived from a spike (S) protein of a COVID-19 virus.

17. The EV of claim 16, wherein the second antigen comprises a receptor-binding domain (RBD) of the S protein.
18. The EV of claim 16 or 17, wherein the second antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the S protein.
19. The EV of any one of claims 4 to 18, wherein the second antigen is derived from an envelope (E) protein of a COVID-19 virus.
20. The EV of claim 19, wherein the second antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the E protein.
21. The EV of any one of claims 4 to 20, wherein the second antigen derived from COVID-19 virus is derived from a membrane (M) protein.
22. The EV of claim 21, wherein the second antigen comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the M protein.
23. The EV of any one of claims 1 to 11, wherein the first antigen comprises a receptor-binding domain (RBD) of the S protein and the second antigen comprises a T-antigen.
24. The EV of any one of claims 1 to 23, further comprising at least one adjuvant.
25. The EV of any one of claims 1 to 24, which induces a cellular immune response, a humoral immune response, or both cellular and humoral immune responses.
26. The EV of claim 25, wherein the induction of the cellular immune response, the humoral immune response, or both cellular and humor immune responses is increased by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more, compared to (i) a corresponding EV that does not comprise the adjuvant or the antigen or (ii) the adjuvant or the antigen without the EV.
27. The EV of any one of claims 1 to 26, which induces a CD4+ T cell response, a CD8+ T cell response, or both CD4+ and CD8+ T cell responses.
28. The EV of any one of claims 1 to 27, which induces a CD8+ T cell response.
29. The EV of any one of claims 1 to 28, wherein the EV expands a tissue resident memory T-cell response.
30. The EV of any one of claims 1 to 29, wherein the EV further comprises a first scaffold moiety.
31. The EV of claim 30, wherein the first antigen is linked to the first scaffold moiety.
32. The EV of claim 30 or 31, wherein the second antigen is linked to the first scaffold moiety.

33. The EV of any one of claims 30 to 32, wherein the EV further comprises a second scaffold moiety.

34. The EV of claim 33, wherein the first antigen is linked to the first scaffold moiety, and the second antigen is linked to the second scaffold moiety.

35. The EV of claim 33 or 34, wherein the first scaffold moiety and the second scaffold moiety are the same.

36. The EV of claim 33 or 34, wherein the first scaffold moiety and the second scaffold moiety are different.

37. The EV of any one of claims 30 to 36, wherein the first scaffold moiety is a Scaffold X.

38. The EV of any one of claims 30 to 36, wherein the first scaffold moiety is a Scaffold Y.

39. The EV of any one of claims 33 to 38, wherein the second scaffold moiety is a Scaffold Y.

40. The EV of any one of claims 33 to 38, wherein the second scaffold moiety is a Scaffold X.

41. The EV of claim 37 or 40, wherein the Scaffold X is capable of: (i) anchoring the first antigen on the luminal surface of the EV; (ii) anchoring the first antigen on the exterior surface of the EV; (iii) anchoring the second antigen on the luminal surface of the EV; (iv) anchoring the second antigen on the exterior surface of the EV; or (v) combinations thereof.

42. The EV of any one of claims 37, 40, and 41, wherein the Scaffold X is selected from the group consisting of prostaglandin F2 receptor negative regulator (the PTGFRN protein); basigin (the BSG protein); immunoglobulin superfamily member 2 (the IGSF2 protein); immunoglobulin superfamily member 3 (the IGSF3 protein); immunoglobulin superfamily member 8 (the IGSF8 protein); integrin beta-1 (the ITGB1 protein); integrin alpha-4 (the ITGA4 protein); 4F2 cell-surface antigen heavy chain (the SLC3A2 protein); a class of ATP transporter proteins (the ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B4 proteins), and any combination thereof.

43. The EV of claim 38 or 39, wherein the Scaffold Y is capable of: (i) anchoring the first antigen on the luminal surface of the EV; (ii) anchoring the second antigen on the luminal surface of the EV; or (iii) both.

44. The EV of any one of claims 38, 39, and 43, wherein the Scaffold Y is selected from the group consisting of myristoylated alanine rich Protein Kinase C substrate (the MARCKS protein); myristoylated alanine rich Protein Kinase C substrate like 1 (the MARCKSL1 protein); brain acid soluble protein 1 (the BASP1 protein), and any combination thereof.

45. The EV of any one of claims 33 to 43, wherein the first antigen is linked to a first scaffold moiety on the luminal surface of the EV, and the second antigen is linked to a second scaffold moiety on the luminal surface of the EV.

46. The EV of claim 43, wherein

a. each of the first scaffold moiety and the second scaffold moiety is Scaffold Y;

b. the first scaffold moiety is Scaffold Y, and the second scaffold moiety is Scaffold X;

c. the first scaffold moiety is Scaffold X, and the second scaffold moiety is Scaffold Y; or

d. each of the first scaffold moiety and the second scaffold moiety is Scaffold X.

47. The EV of any one of claims 4 to 46, wherein the first antigen is linked to a first scaffold moiety on the luminal surface of the EV, and the second antigen is in the lumen of the EV.

48. The EV of any one of claims 4 to 44, wherein the first antigen is in the lumen of the EV, and the second antigen is linked to a first scaffold moiety on the luminal surface of the EV.

49. The EV of any one of claims 4 to 44, wherein the first antigen is linked to a first scaffold moiety on the luminal surface of the EV and the second antigen is linked to a second scaffold moiety on the exterior surface of the EV.

50. The EV of any one of claims 33 to 44, wherein:

a. the first scaffold moiety is Scaffold Y, and the second scaffold moiety is Scaffold X; or

b. each of the first scaffold moiety and the second scaffold moiety is Scaffold X.

51. The EV of any one of claims 4 to 441, wherein the first antigen is linked to a first scaffold moiety on the exterior surface of the EV, and the second antigen is linked to a second scaffold moiety on the luminal surface of the EV.

52. The EV of claim 51, wherein:

a. the first scaffold moiety is Scaffold X, and the second scaffold moiety is Scaffold Y; or

b. each of the first scaffold moiety and the second scaffold moiety is Scaffold X.

53. The EV of any one of claims 4 to 44, wherein the first antigen is in the lumen of the EV and the second antigen is in the lumen of the EV.

54. The EV of any one of claims 4 to 44, wherein the antigen is linked to a first scaffold moiety on the exterior surface of the EV and the adjuvant is linked to a second scaffold moiety on the exterior surface of the EV.

55. The EV of claim 54, wherein the first scaffold and the second scaffold moiety are Scaffold X.

56. The EV of any one of claims 4 to 44, wherein the first antigen is linked to a first scaffold moiety on the exterior surface of the EV and the second antigen is in the lumen of the EV.

57. The EV of claim 56, wherein the first scaffold moiety is Scaffold X.

58. The EV of any one of claims 4 to 44, wherein the first antigen is in the lumen of the EV and the second antigen is linked to a first scaffold moiety on the exterior surface of the EV.

59. The EV of claim 58, wherein the first scaffold moiety is Scaffold X.

60. The EV of any one of claims 4 to 44, wherein the first antigen is linked to a first scaffold moiety on the surface of the EV and the second antigen is linked to the first scaffold moiety on the luminal surface of the EV.

61. The EV of any one of claims 4 to 44, wherein the first antigen is linked to a first scaffold moiety on the luminal surface of the EV and the second antigen is linked to the first scaffold moiety on the exterior surface of the EV.

62. The EV of claim 60 or 61, wherein the first scaffold moiety is Scaffold X.

63. The EV of any one of claims 30 to 44, wherein: (i) the second antigen is linked to the first scaffold moiety by a linker, an affinity ligand, or both, (ii) the second antigen is linked to the second scaffold moiety by a linker, an affinity ligand, or both, (iii) the second antigen is linked to the first scaffold moiety by a linker, an affinity ligand, or both, (iv) the second antigen is linked to the second scaffold moiety by a linker, an affinity ligand, or both, or (v) combinations thereof.

64. The EV of claim 63, wherein the linker and/or the affinity ligand is a polypeptide.

65. The EV of claim 63, wherein the linker is a non-polypeptide moiety.

66. The EV of any one of claims 33 to 65, wherein the first scaffold moiety or the second scaffold moiety is PTGFRN protein.

67. The EV of any one of claims 33 to 65, wherein the first scaffold moiety or the second scaffold moiety comprises an amino acid sequence as set forth in SEQ ID NO: 33.

68. The EV of any one of claims 33 to 65, wherein the first scaffold moiety or the second scaffold moiety comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% identical to SEQ ID NO: 1.

69. The EV of any one of claims 33 to 65, wherein the first scaffold moiety or the second scaffold moiety is BASP1 protein.

70. The EV of any one of claims 33 to 69, wherein the first scaffold moiety or the second scaffold moiety comprises a peptide of (G)(π)(X)(Φ/π)(π)(+)(+), wherein each parenthetical position represents an amino acid, and wherein π is any amino acid selected from the group consisting of Pro, Gly, Ala, and Ser, X is any amino acid, Φ is any amino acid selected from the group consisting of Val, Ile, Leu, Phe, Trp, Tyr, and Met, and (+) is any amino acid selected from the group consisting of Lys, Arg, and His; and wherein position five is not (+) and position six is neither (+) nor (Asp or Glu).

71. The EV of any one of claims 33 to 70, wherein the first scaffold moiety or the second scaffold moiety comprises an amino acid sequence set forth in any one of SEQ ID NOs: 50-155.

72. The EV of any one of claims 33 to 70, wherein the first scaffold moiety or the second scaffold moiety comprises an amino acid sequence at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% identical to SEQ ID NO: 3.

73. An isolated extracellular vesicle comprising (i) a first antigen derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus and (ii) a second antigen derived from a SARS-CoV-1 or SARS-CoV-2 (COVID-19) virus, wherein:

    a. the first antigen is linked to a first Scaffold Y on the luminal surface, and the second antigen is linked to a second Scaffold Y on the luminal surface of the EV;

    b. the first antigen is linked to a Scaffold Y on the luminal surface, and the second antigen is in the lumen of the EV;

    c. the first antigen is in the lumen of the EV, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV;

d. the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the exterior surface of the EV;

e. the first antigen is in the lumen of the EV, and the second antigen is linked to a Scaffold X on the exterior surface of the EV;

f. the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the luminal surface of the EV;

g. the first antigen is in the lumen of the EV, and the second antigen is linked to a Scaffold X on the luminal surface of the EV;

h. the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked to the Scaffold X on the exterior surface of the EV;

i. the first antigen is linked to a first Scaffold X on the exterior surface of the EV, and the second antigen is linked to a second Scaffold X on the exterior surface of the EV;

j. the first antigen is linked to a Scaffold X on the exterior surface of the EV, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV;

k. the first antigen is linked to a Scaffold X on the exterior surface of the EV, and the second antigen is in the lumen of the EV;

l. the first antigen is linked to a Scaffold X on the exterior surface of the EV, and the second antigen is linked to the Scaffold X on the luminal surface of the EV;

m. the first antigen is linked to a first Scaffold X on the luminal surface of the EV, and the second antigen is linked to a second Scaffold X on the luminal surface of the EV;

n. the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV;

o. the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is in the lumen of the EV;

p. the first antigen is linked to a first Scaffold X on the exterior surface of the EV, and the second antigen is linked to a second Scaffold X on the luminal surface of the EV;

q. the first antigen is linked to a first Scaffold X on the luminal surface of the EV, and the second antigen is linked to a second Scaffold X on the exterior surface of the EV;

r. the first antigen is in the lumen of the EV, and the second antigen is in the lumen of the EV;

s. the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked directly to the luminal surface of the EV;

t. the first antigen is linked directly to the luminal surface of the EV, and the second antigen is in the lumen of the EV;

u. the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked to a Scaffold Y on the luminal surface of the EV;

v. the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the luminal surface of the EV;

w. the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked directly to the exterior surface of the EV;

x. the first antigen is linked directly to the luminal surface of the EV, and the second antigen is linked to a Scaffold X on the exterior surface of the EV;

y. the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked directly to the luminal surface of the EV;

z. the first antigen is linked to a Scaffold Y on the luminal surface of the EV, and the second antigen is linked directly to the exterior surface of the EV;

aa. the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked directly to the luminal surface of the EV;

bb. the first antigen is linked to a Scaffold X on the luminal surface of the EV, and the second antigen is linked directly to the exterior surface of the EV;

cc. the first antigen is in the lumen of the EV, and the second antigen is linked directly to the luminal surface of the EV; or

dd. the first antigen is in the lumen of the EV, and the second antigen is linked directly to the exterior of the EV.

74. The EV of any one of claims 1 to 73, wherein the EV further comprises an immune modulator.

75. The EV of claim 741, wherein the immune modulator is linked directly to the luminal surface or exterior surface of the EV.

76. The EV of claim 73 or 74, wherein the immune modulator is linked to a Scaffold X on the exterior surface of the EV or on the luminal surface of the EV.

77. The EV of claim 73 or 74 wherein the immune modulator is linked to a Scaffold Y on the luminal surface of the EV.

78. The EV of any one of claims 24 to 77, wherein the adjuvant is linked directly to the luminal surface or exterior surface of the EV.

79. The EV of claim 78, wherein the adjuvant is linked to a Scaffold X on the exterior surface of the EV or in the lumen of the EV.

80. The EV of claim 78, wherein the adjuvant is linked to a Scaffold Y on the luminal surface of the EV.

81. The EV of claim 78, wherein the adjuvant is in the lumen of the EV.

82. The EV of any one of claims 24 to 81, the adjuvant is a Stimulator of Interferon Genes (STING) agonist, a toll-like receptor (TLR) agonist, an inflammatory mediator, RIG-I agonists, alpha-gal-cer (NKT agonist), heat shock proteins (*e.g.*, HSP65 and HSP70), C-type lectin agonists (*e.g.*, beta glucan (Dectin 1), chitin, and curdlan), or any combination thereof.

83. The EV of claim 82, wherein the adjuvant is a STING agonist.

84. The EV of claim 83, wherein the STING agonist comprises a cyclic dinucleotide STING agonist or a non-cyclic dinucleotide STING agonist.

85. The EV of claim 82, wherein the adjuvant is a TLR agonist.

86. The EV of claim 85, wherein the TLR agonist comprises a TLR2 agonist (*e.g.*, lipoteichoic acid, atypical LPS, MALP-2 and MALP-404, OspA, porin, LcrV, lipomannan, GPI anchor, lysophosphatidylserine, lipophosphoglycan (LPG), glycophosphatidylinositol (GPI), zymosan, hsp60, gH/gL glycoprotein, hemagglutinin), a TLR3 agonist (*e.g.*, double-stranded RNA, *e.g.*, poly(I:C)), a TLR4 agonist (*e.g.*, lipopolysaccharides (LPS), lipoteichoic acid, β-defensin 2, fibronectin EDA, HMGB1, snapin, tenascin C), a TLR5 agonist (*e.g.*, flagellin), a TLR6 agonist, a TLR7/8 agonist (*e.g.*, single-stranded RNA,

CpG-A, Poly G10, Poly G3, Resiquimod), a TLR9 agonist (*e.g.*, unmethylated CpG DNA), or any combination thereof.

87. The EV of any one of claims 1 to 86, wherein the EV is an exosome.

88. The EV of any one of claims 1 to 87, further comprising a targeting moiety.

89. The EV of claim 88, wherein the targeting moiety specifically binds to a marker for a dendritic cell.

90. The EV of claim 89, wherein the marker is present only on the dendritic cell.

91. The EV of claim 89 or 90, wherein the dendritic cell comprises a plasmacytoid dendritic cell (pDC), a myeloid/conventional dendritic cell 1 (cDC1), a myeloid/conventional dendritic cell 2 (cDC2), inflammatory monocyte derived dendritic cells, Langerhans cells, dermal dendritic cells, lysozyme-expressing dendritic cells (LysoDCs), Kupffer cells, or any combination thereof.

92. The EV of claim 91, wherein the dendritic cell is cDC1.

93. The EV of any one of claims 90 to 92, wherein the marker comprises a C-type lectin domain family 9 member A (Clec9a) protein, a dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), CD207, CD40, Clec6, dendritic cell immunoreceptor (DCIR), DEC-205, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), MARCO, Clec12a, Clec10a, DC-asialoglycoprotein receptor (DC-ASGPR), DC immunoreceptor 2 (DCIR2), Dectin-1, macrophage mannose receptor (MMR), BDCA-1 (CD303, Clec4c), Dectin-2, Bst-2 (CD317), Langerin, CD206, CD11b, CD11c, CD123, CD304, XCR1, AXL, Siglec 6, CD209, SIRPA, CX3CR1, GPR182, CD14, CD16, CD32, CD34, CD38, CD10, or any combination thereof.

94. The EV of claim 93, wherein the marker is Clec9a protein.

95. The EV of claim 89, wherein the targeting moiety specifically binds to a marker for a T cell.

96. The EV of claim 95, wherein the marker comprises a CD3 molecule.

97. The EV of any one of claims 88 to 96, wherein the targeting moiety is linked directly to the exterior surface of the EV.

98. The EV of any one of claims 88 to 97, wherein the targeting moiety is linked to a Scaffold X on the exterior surface of the EV.

99. The EV of claim 97, wherein the targeting moiety is linked directly to the exterior surface of the EV by a linker.

100. The EV of claim 98, wherein the targeting moiety is linked to the Scaffold X by a linker, an affinity ligand, or both.
101. The EV of claim 99 or 100, wherein the linker and/or the affinity ligand is a polypeptide.
102. A pharmaceutical composition comprising the EV of any one of claims 1 to 101 and a pharmaceutically acceptable carrier.
103. A cell that produces the EV of any one of claims 1 to 101.
104. A cell comprising one or more vectors, wherein the vectors comprises a nucleic acid sequence encoding: (i) the antigen in any one of claims 1 to 101, (ii) the adjuvant in any one of claims 21 to 99, (iii) the targeting moiety in any one of claims 88 to 101, or (iv) combinations thereof.
105. A kit comprising the EV of any one of claims 1 to 101 and instructions for use.
106. An EV-drug conjugate comprising the EV of any one of claims 1 to 101.
107. A method of making EVs comprising culturing the cell of claim 103 or 104 under a suitable condition and obtaining the EVs.
108. A method of inducing an immune response in a subject in need thereof comprising administering the EV of any one of claims 1 to 101 to the subject.
109. A method of preventing or treating a disease in a subject in need thereof, comprising administering the EV of any one of claims 1 to 101, wherein the disease is associated with the antigen.
110. The method of claim 109, wherein the disease is an infection.
111. The method of any one of claims 109 to 110, wherein the EV is administered parenterally, orally, intravenously, intramuscularly, intranasally, subcutaneously, or intraperitoneally.
112. The method of any one of claims 108 to 111, comprising administering an additional therapeutic agent.
113. A method of vaccinating a subject in need thereof, comprising (i) administering a priming dose which comprises an extracellular vesicle comprising an adjuvant and an antigen to the subject and (ii) administering a boosting dose which comprises an extracellular vesicle comprising the antigen to the subject.
114. The method of claim 113, wherein the antigen is derived from a coronavirus.
115. The method of claim 113 or 114, wherein the priming dose is administered subcutaneously.
116. The method of any one of claims 113 to 115, wherein the boost dose is administered intranasally.

117. The method of any one of claims 113 to 116, wherein the adjuvant is a STING agonist.

118. The method of any one of claims 113 to 117, wherein the antigen is linked to a scaffold moiety.

119. The method of claim 118, wherein the scaffold moiety is Scaffold X.

120. The method of any one of claims 113 to 119, wherein the EV in the boosting dose does not contain any adjuvant.

121. The EV of any one of claims 1 to 101, wherein the antigen, adjuvant, immune modulator, and/or targeting moiety is linked to a surface of the EV by an anchoring moiety, affinity agent, chemical conjugation, cell penetrating peptide (CPP), split intein, SpyTag/SpyCatcher, ALFA-tag, Streptavidin/Avitag, Sortase, SNAP-tag, ProA/Fc-binding peptide, or any combinations thereof.

122. A method of preparing an extracellular vesicle (EV) for a vaccine, comprising loading an antigen to an EV that has been isolated from a producer cell.

123. A method of manufacturing a vaccine for a disease or disorder, comprising loading an antigen to an extracellular vesicle (EV) that has been isolated from a producer cell.

124. The method of claim 122 or 123, wherein the EV further comprises an adjuvant.

125. The method of claim 124, wherein the EV comprises the adjuvant prior to the loading of the antigen to the EV.

126. The method of claim 124, further comprising loading the adjuvant.

127. The method of claim 126, wherein the adjuvant is loaded before or after the loading of the antigen.

128. The method of claim 126, wherein the adjuvant is loaded together with the antigen.

129. The method of any one of claims 122 to 128, wherein the antigen is linked to the exterior surface and/or the luminal surface of the EV by an anchoring moiety, affinity agent, chemical conjugation, cell penetrating peptide (CPP), split intein, SpyTag/SpyCatcher, ALFA-tag, Streptavidin/Avitag, Sortase, SNAP-tag, ProA/Fc-binding peptide, or any combinations thereof.

130. The method of any one of claims 122 to 129, wherein the antigen is derived from and/or comprises a virus, a bacterium, a parasite, a fungus, a protozoa, a tumor, an allergen, a self-antigen, or any combination thereof.

131. The method of claim 130, wherein the antigen is derived from a virus causing a pandemic.

132. The method of any one of claims 122 to 131, wherein the antigen is derived from a coronavirus, an influenza virus, an Ebola virus, a Chikungunya virus (CHIKV), a Crimean-Congo hemorrhagic fever (CCGF) virus, a Hendra virus, a Lassa virus, a Marburg virus, a monkeypox virus, a Nipah virus, a Hendra virus, a Rift Valley fever (RVF) virus, a Variola virus, a yellow fever virus, a Zika virus, a measles virus, a human immunodeficiency virus (HIV), a hepatitis C virus (HCV), a dengue fever virus (DENV), a parvovirus (*e.g.*, B19 virus), a norvovirus, a respiratory syncytial virus (RSV), a lentivirus, an adenovirus, a flavivirus, a filovirus, a rhinovirus, a human papillomavirus (HPV), or any combination thereof.

133. The method of any one of claims 122 to 129, wherein the antigen is derived from *Vibrio cholera*, *Yersinia pestis* bacteria, *Mycobacterium tuberculosis* (MTB), *streptococcus* bacteria (*e.g.*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*), *staphylococcal* bacteria (*e.g.*, *Staphylococcus aureus*), *shigella* bacteria, *Escherichia coli*, *salmonella, chlamydia* bacteria (*e.g.*, *chlamydia trachomatis*), *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Haemophilus influenza*, *Clostridia difficile*, *Plasmodium*, *Leishmania*, *Schistosoma, Trypanosoma*, *Brucella*, *Cryptosporidium*, *Entamoeba*, *Neisseria meningitis*, *Bacillus subtilis*, *Haemophilius influenzae*, *Neisseria gonorrhoeae*, *Borrelia burgdorferi*, *corynebacterium diphteriae*, *moraxella catarrhalis*, *campylobacter jejuni*, *clostridium tetanus*, *clostridium perfringens*, *treponema pallidum* or any combination thereof.

134. The method of any one of claims 122 to 133, wherein the loading of the antigen to the EV occurs at least about 1 day, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, at least 6 years, at least 7 years, at least 8 years, at least 9 years, at least 10 years, at least 15 years, at least 20 years, at least 25 years or more after isolating the EV from the producer cell.

135. The method of any one of claims 123 to 134, wherein the time required for manufacturing the vaccine ("manufacturing time) is reduced compared to a reference manufacturing time (*e.g.*, manufacturing time of a method wherein the loading of the antigen occurs by

introducing the antigen into the producer cell, or manufacturing time of a method for producing a vaccine that does not comprise an EV, such as a traditional peptide vaccine).

136. The method of claim 135, wherein the manufacturing time is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% or more, compared to the reference manufacturing time.

137. The method of claim 135 or 136, wherein the manufacturing time is less than about 12 months, less than about 11 months, less than about 10 months, less than about 9 months, less than about 8 months, less than about 7 months, less than about 6 months, less than about 5 months, less than about 4 months, less than about 3 months, less than about 2 months, or less than about 1 month.

138. The method of claim 137, wherein the manufacturing time is less than about 6 months.

139. The method of any one of claims 122 to 138, wherein the EV further comprises a targeting moiety.

140. The method of claim 139, wherein the EV comprises the targeting moiety prior to the loading of the antigen to the EV.

141. The method of claim 139 or 140, further comprising loading the targeting moiety.

142. The method of claim 141, wherein the targeting moiety are loaded before or after the loading of the antigen.

143. The method of claim 141, wherein the targeting moiety are loaded together with the antigen.

144. The method of any one of claims 122 to 143, wherein after the loading of the antigen, the EV is capable of inducing a T-cell immune response, a B-cell immune response, or both T-cell and B-cell immune responses.

145. An extracellular vesicle (EV) prepared by the methods of any one of claims 122 to 144.

146. A kit comprising the EV of claim 145, and instructions for use.

147. A vaccine comprising the EV of claim 145, wherein the antigen is capable of eliciting an immune response in a subject that receives an administration of the vaccine.

148. The vaccine of claim 147, which is regionalized or individualized.

149. A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject the EV of claim 145 or the vaccine of claim 148 or 148.

150. The method of claim 149, wherein the disease or disorder comprises an infectious disease.

FIG. 1




Adjuvants
Co-stimulators
(e.g. CD40L)
Agonists
(e.g. STING,
TLRs, others)
Antigen
Luminal & Surface (e.g.
Virus, Aβ, tau)
Tropism
Targeting mAb
(e.g. anti-Clec9A)

FIG. 2


SARS-CoV2 Antigens
Spike Proteins
T cell epitopes
STING
Agonist
PTGFRN




FIG. 3

FIG. 4



(I)
(II)
141KD
RBD (23KD)
(III)
(IV)
RBD (23KD)
PrX (98.5KD)
Spike Trimer
Spike monomer
Spike-PrX
RBD-PrX

FIG. 5



Spike Protein Subunit
Scaffold Moiety (e.g., Scaffold X)
Spike Trimer Spike monomer
Split Spike based on structure

FIG. 6



2nd Step
1st Step
2nd Step
Spike Protein Subunit
Scaffold X
Spike-PrX + T antigen loaded by PrY
T-antigen
Scaffold Y
T-antigen
Other payloads
T antigen fused to C-term of Spike-PrX
Saving PrY- for other payloads

FIG. 7





FIG. 8



Group	Rx	Dose	# Doses	Route	N	0	7	14
1	PBS PBS	100ul	2	SQ, IN	5	○	◉	●
2	PrX-OVA-STING PrX-OVA-STING	1e11 1e11	2	SQ, IN	5	○	◉	●
3	PrX-OVA-STING PrX-OVA	1e11 1e11	2	SQ, IN	5	○	◉	●
4	PrX-OVA-STING PrX-OVA	1e11 1e11	2	IN, SQ	5	◉	○	●
5	PrX-OVA-STING PrX-OVA-STING	1e11 1e11	2	IN, IN	5	◉	◉	●
6	PrX-OVA-STING PrX-OVA-STING	1e11 1e11	2	SQ, SQ	5	○	○	●
7	PrX-OVA-STING PrX-OVA	1e11 1e11	2	ID, IN	5	◌	◉	●
8	PrX-OVA-STING PrX-OVA-STING	1e11 1e11	2	ID, ID	5	◌	◌	●
9	rOVA + free STING rOVA + free STING	400ng, 200ng	2	SQ, IN	5	○	◉	●

FIG. 9A



Lung Tem Cells
CD8+ CD62LloCD44hi
% OVA-reactive cells
80
60
40
20
0
1
2
3
4
5
6
7
8
9
Group

FIG. 9B



CD8+ OVA+ Tem cells
Lung
#OVA+ cell count
250000
200000
150000
100000
50000
0
1
2
3
4
5
6
7
8
9
Group

FIG. 10A




FIG. 10B




FIG. 10C



Lung
Unstimulated
IFNγ SFU/100k Cells
150
100
50
0
1
2
3
4
5
6
7
8
9
Group #

FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 14A

Group	Treatment (1st dose/2nd dose)	Route (1st dose/2nd dose)
1	exoRBD (s) /STING exoRBD (s)	SQ/IN
2	exoRBD (s)/STING	IN/IN
3	exoRBD (s)/STING	SQ/SQ
4	exoRBD(s)	IN/IN
5	exoRBD (l) /STING exoRBD (l)	SQ/IN
6	exoRBD (l)/STING	IN/IN
7	exoRBD (l)/STING	SQ/SQ
8	exoRBD (l)	SQ/IN
9	PTGFRN/STING	IN/IN
10	PBS	IN/IN

FIG. 14B




FIG. 14C



G1
exoRBD(S)_STING SQ
exoRBD(S) IN
G2
exoRBD(S)_STING IN
exoRBD(S)_STING IN
G3
exoRBD(S)_STING SQ
exoRBD(S)_STING SQ
G4
exoRBD(S) IN
exoRBD(S) IN
G5
exoRBD(L)_STING SQ
exoRBD(L) IN
Inhibition (%)
100
50
0
10-4
10-3
10-2
10-1
100
1/Dilution

FIG. 14D



G6
exoRBD(L)_STING IN
exoRBD(L)_STING IN
G7
exoRBD(L)_STING SQ
exoRBD(L)_STING SQ
G8
exoRBD(L) SQ
exoRBD(L) IN
G9
exoSTING IN
exoSTING IN
G10
PBS IN
PBS IN
Inhibition (%)
100
50
0
1/Dilution
10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}

FIG. 15 A

Group	Vaccine 1	Co-Administered Vaccine
1	exoRBD + STING	
2	exoRBD + STING	PrX-Itgb1 + STING
3	exoRBD + STING	PrX-OVA + STING
4	exoRBD + STING	Anti-CD40 agonist
5	PrX-Spike + STING	
6	rRBD + STING	
7	rSpike + STING	
8	PrX + STING	
9	PBS	

FIG. 15B




FIG. 15C



G1
exoRBD + STING
G2
exoRBD + STING
PrX-ITGB1 + STING
G3
exoRBD + STING
PrX-OVA + STING
G4
exoRBD + STING
Anti-CD40 agonist
G5
PrX-Spike + STING
Inhibition (%)
100
50
0
1/Dilution
10-4
10-3
10-2
10-1
100

FIG. 15D




G6
rRBD + STING
G7
rSpike + STING
G8
PrX + STING
G9
PBS
aRBD Control
Inhibition (%)
1/Dilution
[Ab.] (ug/mL)

FIG. 16A



Group	Rx	Dose	# Doses	Route	N	0	14	28	42	56
1	OVA+Alum	30 ul	3	IM	3/3	○	○◎	○◎	◎	●
2	OVA+Alum+CpG	30 ul	3	IM	3/3	○	○◎	○◎	◎	●
3	exoOVA PrX	30 ul, 1e11	3	IM	3/3	○	○◎	○◎	◎	●
4	exoOVA PrX+Alum	30 ul, 1e11	3	IM	3/3	○	○◎	○◎	◎	●
5	exoOVA PrX+Alum+CpG	30 ul, 1e11	3	IM	3/3	○	○◎	○◎	◎	●
6	exoOVA PrY+Alum	30 ul, 1e11	3	IM	3/3	○	○◎	○◎	◎	●
7	exoOVA PrY	30 ul, 1e11	3	IM	3/3	○	○◎	○◎	◎	●
8	exoOVA PrY+Alum+CpG	30 ul, 1e11	3	IM	3/3	○	○◎	○◎	◎	●
9	exoOVA PrY+Alum+CpG	30 ul, 2e11	3	IM	3/3	○	○◎	○◎	◎	●

FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E




FIG. 16F




FIG. 16G




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D





FIG. 17E



Anti-RBD Western blot

FIG. 17F

Sample	Exo Conc. (p/mL)	RBD Conc. (ug/mL)	ug RBD/1E11	RBD per Exo
NbALFA + RBD-ALFAtag High	2.32E+13	672	2.90	618
NbALFA + RBD-ALFAtag Mid	2.16E+13	351	1.63	346
NbALFA + RBD-ALFAtag Low	2.41E+13	214	0.89	189
NbALFA	1.00E+13	-	-	-

FIG. 18A




FIG. 18B




FIG. 19A



(I)
(II)
(III)
(IV)
(V)
2284
2391
2392
2393
2394
FLAG-HiBiT
FLAG-HiBiT
FLAG-HiBiT
FLAG-HiBiT
FLAG-HiBiT

FIG. 19B




FIG. 19C





FIG. 20A



Anti-RBD Sino Biological 40592-T62 1:1000

FIG. 20B




FIG. 21A





FIG. 21B






FIG. 22A

FIG. 22B




FIG. 22C




FIG. 23A

Group	Rx	Dose	# Doses	Route	N
1	PBS		1	SQ	9
2	exoVACC	OVA (0.5 ug)	1	IN	9
3	exoVACC	OVA (0.5 ug)	1	SQ	9
4	OVA + Poly:C	OVA (0.5 ug) + Poly:C (5 ug)	1	IN	9
5	OVA + Poly:C	OVA (0.5 ug) + Poly:C (50 ug)	1	SQ	9

FIG. 23B





FIG. 23C



****, $P < 0.001$
exoVACC (SC) compared to both Unreated and OVA + poly I:C (SC)
exoVACC (IN) compared to both Unreated and OVA + poly I:C (IN)

FIG. 23D




FIG. 24



Antigens
Synthetic peptide (Primary)
Recombinant viral protein (Secondary)
Attachment
Membrane insertion
Cholesterol
Fatty acid
Vitamin E
Chemical conjugation
Maleimide via EV reductin
Click via NHS on EV
Affinity association
anti-PTGFRN ligand
Adjuvants
STING agonist (CL456) via passive
CRM-197 Endogenous or surface-loaded
PADRE
exoVACC

FIG. 25A




FIG. 25B




FIG. 25C





FIG. 25D





NanoLuc
Donor
Acceptor
PTGFRN
Mix
UC
Luciferase quantitation
SDS-PAGE mobility
Biophysical characterization

FIG. 26

FIG. 27A




FIG. 27B




FIG. 28A




FIG. 28B




FIG. 29A




FIG. 29B




FIG. 30A




FIG. 30B




FIG. 31A




FIG. 31B




FIG. 32A




FIG. 32B




FIG. 33A




FIG. 33B





FIG. 34


NanoLuc Concentration (10X)
[NanoLuc] (ng/mL)
10^6
10^5
10^4
10^3
ALFA
Intein
Spy



Moiety of Interest
1. Protein (Vaccine Antigen, Therapeutics, Targeting)
2. Peptide (Enhancing membrane transpassing)
3. Small Molecules (Therapeutics, diagnostics)
4. Oligonucleotide (Aptamer, siRNA, shRNA, mRNA, ASO, PMO)
EXTERIOR
EXOSOME MEMBRANE
LUMEN
SCAFFOLD
SCAFFOLD

FIG. 35

FIG. 36

Functional Group on Exo.	Activation	Functional Group on SM	Degradability of Linkage
-COOH	No	Epoxy	Yes
$-NH_2$	No	NHS-Ester	Yes
	No	pAB-pNP*	Yes
-SS-	Yes, to –SH	Maleimide	No
	Yes, to –SH	Methacrylate	Yes
	Yes, to –SH	Pyridyl disulfide	Yes, redox sensitive
Primary amine	Azide via NHS on primary amine	*DBCO or DIFO	No
Primary amine	DBCO/DIFO via NHS on primary amine	Azide	No
Non-selective, (active H)	No	Isocyanate / Isothiocyanate	Yes
Non-selective, (carbonyl)	No	Hydrazide	Yes

FIG. 37



Reactive Group	Functional Group on Moiety
NHS-Ester, p-nitrophenol, isothiocyanate, isocyanate, aldehyde	Amine
Acrylate, maleimide, pyridyl disulfide	Thiol
isothiocyanate, isocyanate	Hydroxy
Epoxide	Carboxylic acid
Alkyne	Azide

FIG. 38A




FIG. 38B




FIG. 38C




FIG. 38D





FIG. 39A







FIG. 39B






FIG. 40

Functional Group on Exo.	Activation	Functional Group on Protein / Peptide	Degradability of Linkage
Multiple, converted to azide analog	Chemically / Enzymatically	DBCO analog #	No
Mutliple, converted to DBCO analog #	Chemically / Enzymatically	Azide analog, Tetrazine,	No
Amine, Hydrazone	Chemically / Enzymatically	Formylbenzoate, aldehyde	Yes



Exosome
Surface Activation
Exosome
Benzyl Alcohol NHS Ester

FIG. 41

FIG. 42



Tetrazine-Tetra Ethylene glycol-NHS Ester
Surface Activation
Exosome
Exosome

FIG. 43A




FIG. 43B





FIG. 44


WT EV
NbALFA EV
220
120
100
80
60
50
40
30
20
PTGFRN-NbALFA
miL12-ALFAtag
NanoLuc-ALFAtag
80
miL12
20
NanoLuc
miL12-ALFAtag - - + + - - + +
NanoLuc-ALFAtag - + - + - + - +

SEQUENCE LISTING

<110> CODIAK BIOSCIENCES, INC.

<120> EXTRACELLULAR VESICLES FOR THERAPY

<130> 4000.097PC06

<150> PCT/US2020/024023
<151> 2020-03-20

<150> US 63/001,088
<151> 2020-03-27

<150> US 63/003,171
<151> 2020-03-31

<150> US 63/006,585
<151> 2020-04-07

<150> US 63/017,514
<151> 2020-04-29

<150> US 63/142,418
<151> 2021-01-27

<160> 581

<170> PatentIn version 3.5

<210> 1
<211> 879
<212> PRT
<213> Homo sapiens

<400> 1

```
Met Gly Arg Leu Ala Ser Arg Pro Leu Leu Leu Ala Leu Leu Ser Leu
1               5                  10                  15


Ala Leu Cys Arg Gly Arg Val Val Arg Val Pro Thr Ala Thr Leu Val
            20                  25                  30


Arg Val Val Gly Thr Glu Leu Val Ile Pro Cys Asn Val Ser Asp Tyr
        35                  40                  45


Asp Gly Pro Ser Glu Gln Asn Phe Asp Trp Ser Phe Ser Ser Leu Gly
    50                  55                  60


Ser Ser Phe Val Glu Leu Ala Ser Thr Trp Glu Val Gly Phe Pro Ala
65                  70                  75                  80


Gln Leu Tyr Gln Glu Arg Leu Gln Arg Gly Glu Ile Leu Leu Arg Arg
                85                  90                  95


Thr Ala Asn Asp Ala Val Glu Leu His Ile Lys Asn Val Gln Pro Ser
            100                 105                 110


Asp Gln Gly His Tyr Lys Cys Ser Thr Pro Ser Thr Asp Ala Thr Val
        115                 120                 125
```

```
Gln Gly Asn Tyr Glu Asp Thr Val Gln Val Lys Val Leu Ala Asp Ser
    130                 135                 140

Leu His Val Gly Pro Ser Ala Arg Pro Pro Pro Ser Leu Ser Leu Arg
145                 150                 155                 160

Glu Gly Glu Pro Phe Glu Leu Arg Cys Thr Ala Ala Ser Ala Ser Pro
                165                 170                 175

Leu His Thr His Leu Ala Leu Leu Trp Glu Val His Arg Gly Pro Ala
            180                 185                 190

Arg Arg Ser Val Leu Ala Leu Thr His Glu Gly Arg Phe His Pro Gly
        195                 200                 205

Leu Gly Tyr Glu Gln Arg Tyr His Ser Gly Asp Val Arg Leu Asp Thr
    210                 215                 220

Val Gly Ser Asp Ala Tyr Arg Leu Ser Val Ser Arg Ala Leu Ser Ala
225                 230                 235                 240

Asp Gln Gly Ser Tyr Arg Cys Ile Val Ser Glu Trp Ile Ala Glu Gln
                245                 250                 255

Gly Asn Trp Gln Glu Ile Gln Glu Lys Ala Val Glu Val Ala Thr Val
            260                 265                 270

Val Ile Gln Pro Ser Val Leu Arg Ala Ala Val Pro Lys Asn Val Ser
        275                 280                 285

Val Ala Glu Gly Lys Glu Leu Asp Leu Thr Cys Asn Ile Thr Thr Asp
    290                 295                 300

Arg Ala Asp Asp Val Arg Pro Glu Val Thr Trp Ser Phe Ser Arg Met
305                 310                 315                 320

Pro Asp Ser Thr Leu Pro Gly Ser Arg Val Leu Ala Arg Leu Asp Arg
                325                 330                 335

Asp Ser Leu Val His Ser Ser Pro His Val Ala Leu Ser His Val Asp
            340                 345                 350

Ala Arg Ser Tyr His Leu Leu Val Arg Asp Val Ser Lys Glu Asn Ser
        355                 360                 365

Gly Tyr Tyr Tyr Cys His Val Ser Leu Trp Ala Pro Gly His Asn Arg
    370                 375                 380

Ser Trp His Lys Val Ala Glu Ala Val Ser Ser Pro Ala Gly Val Gly
385                 390                 395                 400
```

```
Val Thr Trp Leu Glu Pro Asp Tyr Gln Val Tyr Leu Asn Ala Ser Lys
                405                 410                 415

Val Pro Gly Phe Ala Asp Asp Pro Thr Glu Leu Ala Cys Arg Val Val
            420                 425                 430

Asp Thr Lys Ser Gly Glu Ala Asn Val Arg Phe Thr Val Ser Trp Tyr
        435                 440                 445

Tyr Arg Met Asn Arg Arg Ser Asp Asn Val Val Thr Ser Glu Leu Leu
    450                 455                 460

Ala Val Met Asp Gly Asp Trp Thr Leu Lys Tyr Gly Glu Arg Ser Lys
465                 470                 475                 480

Gln Arg Ala Gln Asp Gly Asp Phe Ile Phe Ser Lys Glu His Thr Asp
                485                 490                 495

Thr Phe Asn Phe Arg Ile Gln Arg Thr Thr Glu Glu Asp Arg Gly Asn
            500                 505                 510

Tyr Tyr Cys Val Val Ser Ala Trp Thr Lys Gln Arg Asn Asn Ser Trp
        515                 520                 525

Val Lys Ser Lys Asp Val Phe Ser Lys Pro Val Asn Ile Phe Trp Ala
    530                 535                 540

Leu Glu Asp Ser Val Leu Val Val Lys Ala Arg Gln Pro Lys Pro Phe
545                 550                 555                 560

Phe Ala Ala Gly Asn Thr Phe Glu Met Thr Cys Lys Val Ser Ser Lys
                565                 570                 575

Asn Ile Lys Ser Pro Arg Tyr Ser Val Leu Ile Met Ala Glu Lys Pro
            580                 585                 590

Val Gly Asp Leu Ser Ser Pro Asn Glu Thr Lys Tyr Ile Ile Ser Leu
        595                 600                 605

Asp Gln Asp Ser Val Val Lys Leu Glu Asn Trp Thr Asp Ala Ser Arg
    610                 615                 620

Val Asp Gly Val Val Leu Glu Lys Val Gln Glu Asp Glu Phe Arg Tyr
625                 630                 635                 640

Arg Met Tyr Gln Thr Gln Val Ser Asp Ala Gly Leu Tyr Arg Cys Met
                645                 650                 655

Val Thr Ala Trp Ser Pro Val Arg Gly Ser Leu Trp Arg Glu Ala Ala
            660                 665                 670

Thr Ser Leu Ser Asn Pro Ile Glu Ile Asp Phe Gln Thr Ser Gly Pro
```

675 680 685

Ile Phe Asn Ala Ser Val His Ser Asp Thr Pro Ser Val Ile Arg Gly
690 695 700

Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr Val Glu Gly Ala Ala Leu
705 710 715 720

Asp Pro Asp Asp Met Ala Phe Asp Val Ser Trp Phe Ala Val His Ser
725 730 735

Phe Gly Leu Asp Lys Ala Pro Val Leu Leu Ser Ser Leu Asp Arg Lys
740 745 750

Gly Ile Val Thr Thr Ser Arg Arg Asp Trp Lys Ser Asp Leu Ser Leu
755 760 765

Glu Arg Val Ser Val Leu Glu Phe Leu Leu Gln Val His Gly Ser Glu
770 775 780

Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser Val Thr Pro Trp Val Lys
785 790 795 800

Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala Glu Ile His Ser Lys Pro
805 810 815

Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala Phe Lys Tyr Pro
820 825 830

Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly Leu Leu Ser Cys
835 840 845

Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys Lys Glu Val Gln
850 855 860

Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met Glu Met Asp
865 870 875

<210> 2
<211> 731
<212> PRT
<213> Homo sapiens

<400> 2

Pro Ser Ala Arg Pro Pro Pro Ser Leu Ser Leu Arg Glu Gly Glu Pro
1 5 10 15

Phe Glu Leu Arg Cys Thr Ala Ala Ser Ala Ser Pro Leu His Thr His
20 25 30

Leu Ala Leu Leu Trp Glu Val His Arg Gly Pro Ala Arg Arg Ser Val
35 40 45

```
Leu Ala Leu Thr His Glu Gly Arg Phe His Pro Gly Leu Gly Tyr Glu
    50                  55                  60

Gln Arg Tyr His Ser Gly Asp Val Arg Leu Asp Thr Val Gly Ser Asp
65                  70                  75                  80

Ala Tyr Arg Leu Ser Val Ser Arg Ala Leu Ser Ala Asp Gln Gly Ser
                85                  90                  95

Tyr Arg Cys Ile Val Ser Glu Trp Ile Ala Glu Gln Gly Asn Trp Gln
            100                 105                 110

Glu Ile Gln Glu Lys Ala Val Glu Val Ala Thr Val Val Ile Gln Pro
        115                 120                 125

Ser Val Leu Arg Ala Ala Val Pro Lys Asn Val Ser Val Ala Glu Gly
    130                 135                 140

Lys Glu Leu Asp Leu Thr Cys Asn Ile Thr Thr Asp Arg Ala Asp Asp
145                 150                 155                 160

Val Arg Pro Glu Val Thr Trp Ser Phe Ser Arg Met Pro Asp Ser Thr
                165                 170                 175

Leu Pro Gly Ser Arg Val Leu Ala Arg Leu Asp Arg Asp Ser Leu Val
            180                 185                 190

His Ser Ser Pro His Val Ala Leu Ser His Val Asp Ala Arg Ser Tyr
        195                 200                 205

His Leu Leu Val Arg Asp Val Ser Lys Glu Asn Ser Gly Tyr Tyr Tyr
    210                 215                 220

Cys His Val Ser Leu Trp Ala Pro Gly His Asn Arg Ser Trp His Lys
225                 230                 235                 240

Val Ala Glu Ala Val Ser Ser Pro Ala Gly Val Gly Val Thr Trp Leu
                245                 250                 255

Glu Pro Asp Tyr Gln Val Tyr Leu Asn Ala Ser Lys Val Pro Gly Phe
            260                 265                 270

Ala Asp Asp Pro Thr Glu Leu Ala Cys Arg Val Val Asp Thr Lys Ser
        275                 280                 285

Gly Glu Ala Asn Val Arg Phe Thr Val Ser Trp Tyr Tyr Arg Met Asn
    290                 295                 300

Arg Arg Ser Asp Asn Val Val Thr Ser Glu Leu Leu Ala Val Met Asp
305                 310                 315                 320
```

```
Gly Asp Trp Thr Leu Lys Tyr Gly Glu Arg Ser Lys Gln Arg Ala Gln
                325                 330                 335

Asp Gly Asp Phe Ile Phe Ser Lys Glu His Thr Asp Thr Phe Asn Phe
            340                 345                 350

Arg Ile Gln Arg Thr Thr Glu Glu Asp Arg Gly Asn Tyr Tyr Cys Val
        355                 360                 365

Val Ser Ala Trp Thr Lys Gln Arg Asn Asn Ser Trp Val Lys Ser Lys
    370                 375                 380

Asp Val Phe Ser Lys Pro Val Asn Ile Phe Trp Ala Leu Glu Asp Ser
385                 390                 395                 400

Val Leu Val Val Lys Ala Arg Gln Pro Lys Pro Phe Phe Ala Ala Gly
                405                 410                 415

Asn Thr Phe Glu Met Thr Cys Lys Val Ser Ser Lys Asn Ile Lys Ser
            420                 425                 430

Pro Arg Tyr Ser Val Leu Ile Met Ala Glu Lys Pro Val Gly Asp Leu
        435                 440                 445

Ser Ser Pro Asn Glu Thr Lys Tyr Ile Ile Ser Leu Asp Gln Asp Ser
    450                 455                 460

Val Val Lys Leu Glu Asn Trp Thr Asp Ala Ser Arg Val Asp Gly Val
465                 470                 475                 480

Val Leu Glu Lys Val Gln Glu Asp Glu Phe Arg Tyr Arg Met Tyr Gln
                485                 490                 495

Thr Gln Val Ser Asp Ala Gly Leu Tyr Arg Cys Met Val Thr Ala Trp
            500                 505                 510

Ser Pro Val Arg Gly Ser Leu Trp Arg Glu Ala Ala Thr Ser Leu Ser
        515                 520                 525

Asn Pro Ile Glu Ile Asp Phe Gln Thr Ser Gly Pro Ile Phe Asn Ala
    530                 535                 540

Ser Val His Ser Asp Thr Pro Ser Val Ile Arg Gly Asp Leu Ile Lys
545                 550                 555                 560

Leu Phe Cys Ile Ile Thr Val Glu Gly Ala Ala Leu Asp Pro Asp Asp
                565                 570                 575

Met Ala Phe Asp Val Ser Trp Phe Ala Val His Ser Phe Gly Leu Asp
            580                 585                 590

Lys Ala Pro Val Leu Leu Ser Ser Leu Asp Arg Lys Gly Ile Val Thr
```

595 600 605

Thr Ser Arg Arg Asp Trp Lys Ser Asp Leu Ser Leu Glu Arg Val Ser
610 615 620

Val Leu Glu Phe Leu Leu Gln Val His Gly Ser Glu Asp Gln Asp Phe
625 630 635 640

Gly Asn Tyr Tyr Cys Ser Val Thr Pro Trp Val Lys Ser Pro Thr Gly
645 650 655

Ser Trp Gln Lys Glu Ala Glu Ile His Ser Lys Pro Val Phe Ile Thr
660 665 670

Val Lys Met Asp Val Leu Asn Ala Phe Lys Tyr Pro Leu Leu Ile Gly
675 680 685

Val Gly Leu Ser Thr Val Ile Gly Leu Leu Ser Cys Leu Ile Gly Tyr
690 695 700

Cys Ser Ser His Trp Cys Cys Lys Lys Glu Val Gln Glu Thr Arg Arg
705 710 715 720

Glu Arg Arg Arg Leu Met Ser Met Glu Met Asp
725 730

<210> 3
<211> 611
<212> PRT
<213> Homo sapiens

<400> 3

Val Ala Thr Val Val Ile Gln Pro Ser Val Leu Arg Ala Ala Val Pro
1 5 10 15

Lys Asn Val Ser Val Ala Glu Gly Lys Glu Leu Asp Leu Thr Cys Asn
20 25 30

Ile Thr Thr Asp Arg Ala Asp Asp Val Arg Pro Glu Val Thr Trp Ser
35 40 45

Phe Ser Arg Met Pro Asp Ser Thr Leu Pro Gly Ser Arg Val Leu Ala
50 55 60

Arg Leu Asp Arg Asp Ser Leu Val His Ser Ser Pro His Val Ala Leu
65 70 75 80

Ser His Val Asp Ala Arg Ser Tyr His Leu Leu Val Arg Asp Val Ser
85 90 95

Lys Glu Asn Ser Gly Tyr Tyr Tyr Cys His Val Ser Leu Trp Ala Pro
100 105 110

```
Gly His Asn Arg Ser Trp His Lys Val Ala Glu Ala Val Ser Ser Pro
        115                 120                 125

Ala Gly Val Gly Val Thr Trp Leu Glu Pro Asp Tyr Gln Val Tyr Leu
    130                 135                 140

Asn Ala Ser Lys Val Pro Gly Phe Ala Asp Asp Pro Thr Glu Leu Ala
145                 150                 155                 160

Cys Arg Val Val Asp Thr Lys Ser Gly Glu Ala Asn Val Arg Phe Thr
                165                 170                 175

Val Ser Trp Tyr Tyr Arg Met Asn Arg Arg Ser Asp Asn Val Val Thr
            180                 185                 190

Ser Glu Leu Leu Ala Val Met Asp Gly Asp Trp Thr Leu Lys Tyr Gly
        195                 200                 205

Glu Arg Ser Lys Gln Arg Ala Gln Asp Gly Asp Phe Ile Phe Ser Lys
    210                 215                 220

Glu His Thr Asp Thr Phe Asn Phe Arg Ile Gln Arg Thr Thr Glu Glu
225                 230                 235                 240

Asp Arg Gly Asn Tyr Tyr Cys Val Val Ser Ala Trp Thr Lys Gln Arg
                245                 250                 255

Asn Asn Ser Trp Val Lys Ser Lys Asp Val Phe Ser Lys Pro Val Asn
            260                 265                 270

Ile Phe Trp Ala Leu Glu Asp Ser Val Leu Val Val Lys Ala Arg Gln
        275                 280                 285

Pro Lys Pro Phe Phe Ala Ala Gly Asn Thr Phe Glu Met Thr Cys Lys
    290                 295                 300

Val Ser Ser Lys Asn Ile Lys Ser Pro Arg Tyr Ser Val Leu Ile Met
305                 310                 315                 320

Ala Glu Lys Pro Val Gly Asp Leu Ser Ser Pro Asn Glu Thr Lys Tyr
                325                 330                 335

Ile Ile Ser Leu Asp Gln Asp Ser Val Val Lys Leu Glu Asn Trp Thr
            340                 345                 350

Asp Ala Ser Arg Val Asp Gly Val Val Leu Glu Lys Val Gln Glu Asp
        355                 360                 365

Glu Phe Arg Tyr Arg Met Tyr Gln Thr Gln Val Ser Asp Ala Gly Leu
    370                 375                 380
```

```
Tyr Arg Cys Met Val Thr Ala Trp Ser Pro Val Arg Gly Ser Leu Trp
385                 390                 395                 400


Arg Glu Ala Ala Thr Ser Leu Ser Asn Pro Ile Glu Ile Asp Phe Gln
                405                 410                 415


Thr Ser Gly Pro Ile Phe Asn Ala Ser Val His Ser Asp Thr Pro Ser
            420                 425                 430


Val Ile Arg Gly Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr Val Glu
        435                 440                 445


Gly Ala Ala Leu Asp Pro Asp Asp Met Ala Phe Asp Val Ser Trp Phe
    450                 455                 460


Ala Val His Ser Phe Gly Leu Asp Lys Ala Pro Val Leu Leu Ser Ser
465                 470                 475                 480


Leu Asp Arg Lys Gly Ile Val Thr Thr Ser Arg Arg Asp Trp Lys Ser
                485                 490                 495


Asp Leu Ser Leu Glu Arg Val Ser Val Leu Glu Phe Leu Leu Gln Val
            500                 505                 510


His Gly Ser Glu Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser Val Thr
        515                 520                 525


Pro Trp Val Lys Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala Glu Ile
    530                 535                 540


His Ser Lys Pro Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala
545                 550                 555                 560


Phe Lys Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly
                565                 570                 575


Leu Leu Ser Cys Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys
            580                 585                 590


Lys Glu Val Gln Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met
        595                 600                 605


Glu Met Asp
    610


<210>  4
<211>  485
<212>  PRT
<213>  homo sapien

<400>  4

Ser Pro Ala Gly Val Gly Val Thr Trp Leu Glu Pro Asp Tyr Gln Val
1               5                   10                  15
```

```
Tyr Leu Asn Ala Ser Lys Val Pro Gly Phe Ala Asp Asp Pro Thr Glu
            20                  25                  30

Leu Ala Cys Arg Val Val Asp Thr Lys Ser Gly Glu Ala Asn Val Arg
        35                  40                  45

Phe Thr Val Ser Trp Tyr Tyr Arg Met Asn Arg Arg Ser Asp Asn Val
    50                  55                  60

Val Thr Ser Glu Leu Leu Ala Val Met Asp Gly Asp Trp Thr Leu Lys
65                  70                  75                  80

Tyr Gly Glu Arg Ser Lys Gln Arg Ala Gln Asp Gly Asp Phe Ile Phe
                85                  90                  95

Ser Lys Glu His Thr Asp Thr Phe Asn Phe Arg Ile Gln Arg Thr Thr
            100                 105                 110

Glu Glu Asp Arg Gly Asn Tyr Tyr Cys Val Val Ser Ala Trp Thr Lys
        115                 120                 125

Gln Arg Asn Asn Ser Trp Val Lys Ser Lys Asp Val Phe Ser Lys Pro
    130                 135                 140

Val Asn Ile Phe Trp Ala Leu Glu Asp Ser Val Leu Val Val Lys Ala
145                 150                 155                 160

Arg Gln Pro Lys Pro Phe Phe Ala Ala Gly Asn Thr Phe Glu Met Thr
                165                 170                 175

Cys Lys Val Ser Ser Lys Asn Ile Lys Ser Pro Arg Tyr Ser Val Leu
            180                 185                 190

Ile Met Ala Glu Lys Pro Val Gly Asp Leu Ser Ser Pro Asn Glu Thr
        195                 200                 205

Lys Tyr Ile Ile Ser Leu Asp Gln Asp Ser Val Val Lys Leu Glu Asn
    210                 215                 220

Trp Thr Asp Ala Ser Arg Val Asp Gly Val Val Leu Glu Lys Val Gln
225                 230                 235                 240

Glu Asp Glu Phe Arg Tyr Arg Met Tyr Gln Thr Gln Val Ser Asp Ala
                245                 250                 255

Gly Leu Tyr Arg Cys Met Val Thr Ala Trp Ser Pro Val Arg Gly Ser
            260                 265                 270

Leu Trp Arg Glu Ala Ala Thr Ser Leu Ser Asn Pro Ile Glu Ile Asp
        275                 280                 285
```

```
Phe Gln Thr Ser Gly Pro Ile Phe Asn Ala Ser Val His Ser Asp Thr
    290                 295                 300

Pro Ser Val Ile Arg Gly Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr
305                 310                 315                 320

Val Glu Gly Ala Ala Leu Asp Pro Asp Asp Met Ala Phe Asp Val Ser
                325                 330                 335

Trp Phe Ala Val His Ser Phe Gly Leu Asp Lys Ala Pro Val Leu Leu
            340                 345                 350

Ser Ser Leu Asp Arg Lys Gly Ile Val Thr Thr Ser Arg Arg Asp Trp
        355                 360                 365

Lys Ser Asp Leu Ser Leu Glu Arg Val Ser Val Leu Glu Phe Leu Leu
    370                 375                 380

Gln Val His Gly Ser Glu Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser
385                 390                 395                 400

Val Thr Pro Trp Val Lys Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala
                405                 410                 415

Glu Ile His Ser Lys Pro Val Phe Ile Thr Val Lys Met Asp Val Leu
            420                 425                 430

Asn Ala Phe Lys Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser Thr Val
        435                 440                 445

Ile Gly Leu Leu Ser Cys Leu Ile Gly Tyr Cys Ser Ser His Trp Cys
    450                 455                 460

Cys Lys Lys Glu Val Gln Glu Thr Arg Arg Glu Arg Arg Arg Leu Met
465                 470                 475                 480

Ser Met Glu Met Asp
                485


<210>  5
<211>  343
<212>  PRT
<213>  Homo sapiens

<400>  5

Lys Pro Val Asn Ile Phe Trp Ala Leu Glu Asp Ser Val Leu Val Val
1               5                   10                  15

Lys Ala Arg Gln Pro Lys Pro Phe Phe Ala Ala Gly Asn Thr Phe Glu
            20                  25                  30

Met Thr Cys Lys Val Ser Ser Lys Asn Ile Lys Ser Pro Arg Tyr Ser
```

```
        35                  40                  45

Val Leu Ile Met Ala Glu Lys Pro Val Gly Asp Leu Ser Ser Pro Asn
    50                  55                  60

Glu Thr Lys Tyr Ile Ile Ser Leu Asp Gln Asp Ser Val Val Lys Leu
65                  70                  75                  80

Glu Asn Trp Thr Asp Ala Ser Arg Val Asp Gly Val Val Leu Glu Lys
                85                  90                  95

Val Gln Glu Asp Glu Phe Arg Tyr Arg Met Tyr Gln Thr Gln Val Ser
            100                 105                 110

Asp Ala Gly Leu Tyr Arg Cys Met Val Thr Ala Trp Ser Pro Val Arg
        115                 120                 125

Gly Ser Leu Trp Arg Glu Ala Ala Thr Ser Leu Ser Asn Pro Ile Glu
    130                 135                 140

Ile Asp Phe Gln Thr Ser Gly Pro Ile Phe Asn Ala Ser Val His Ser
145                 150                 155                 160

Asp Thr Pro Ser Val Ile Arg Gly Asp Leu Ile Lys Leu Phe Cys Ile
                165                 170                 175

Ile Thr Val Glu Gly Ala Ala Leu Asp Pro Asp Asp Met Ala Phe Asp
            180                 185                 190

Val Ser Trp Phe Ala Val His Ser Phe Gly Leu Asp Lys Ala Pro Val
        195                 200                 205

Leu Leu Ser Ser Leu Asp Arg Lys Gly Ile Val Thr Thr Ser Arg Arg
    210                 215                 220

Asp Trp Lys Ser Asp Leu Ser Leu Glu Arg Val Ser Val Leu Glu Phe
225                 230                 235                 240

Leu Leu Gln Val His Gly Ser Glu Asp Gln Asp Phe Gly Asn Tyr Tyr
                245                 250                 255

Cys Ser Val Thr Pro Trp Val Lys Ser Pro Thr Gly Ser Trp Gln Lys
            260                 265                 270

Glu Ala Glu Ile His Ser Lys Pro Val Phe Ile Thr Val Lys Met Asp
        275                 280                 285

Val Leu Asn Ala Phe Lys Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser
    290                 295                 300

Thr Val Ile Gly Leu Leu Ser Cys Leu Ile Gly Tyr Cys Ser Ser His
305                 310                 315                 320
```

```
Trp Cys Cys Lys Lys Glu Val Gln Glu Thr Arg Arg Glu Arg Arg Arg
                325                 330                 335


Leu Met Ser Met Glu Met Asp
            340
```

<210> 6
<211> 217
<212> PRT
<213> Homo sapiens

<400> 6

```
Val Arg Gly Ser Leu Trp Arg Glu Ala Ala Thr Ser Leu Ser Asn Pro
1               5                   10                  15


Ile Glu Ile Asp Phe Gln Thr Ser Gly Pro Ile Phe Asn Ala Ser Val
            20                  25                  30


His Ser Asp Thr Pro Ser Val Ile Arg Gly Asp Leu Ile Lys Leu Phe
        35                  40                  45


Cys Ile Ile Thr Val Glu Gly Ala Ala Leu Asp Pro Asp Asp Met Ala
    50                  55                  60


Phe Asp Val Ser Trp Phe Ala Val His Ser Phe Gly Leu Asp Lys Ala
65                  70                  75                  80


Pro Val Leu Leu Ser Ser Leu Asp Arg Lys Gly Ile Val Thr Thr Ser
                85                  90                  95


Arg Arg Asp Trp Lys Ser Asp Leu Ser Leu Glu Arg Val Ser Val Leu
            100                 105                 110


Glu Phe Leu Leu Gln Val His Gly Ser Glu Asp Gln Asp Phe Gly Asn
        115                 120                 125


Tyr Tyr Cys Ser Val Thr Pro Trp Val Lys Ser Pro Thr Gly Ser Trp
    130                 135                 140


Gln Lys Glu Ala Glu Ile His Ser Lys Pro Val Phe Ile Thr Val Lys
145                 150                 155                 160


Met Asp Val Leu Asn Ala Phe Lys Tyr Pro Leu Leu Ile Gly Val Gly
                165                 170                 175


Leu Ser Thr Val Ile Gly Leu Leu Ser Cys Leu Ile Gly Tyr Cys Ser
            180                 185                 190


Ser His Trp Cys Cys Lys Lys Glu Val Gln Glu Thr Arg Arg Glu Arg
        195                 200                 205
```

Arg Arg Leu Met Ser Met Glu Met Asp
    210   215

<210> 7
<211> 66
<212> PRT
<213> homo sapiens

<400> 7

Ser Lys Pro Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala Phe
1   5   10   15

Lys Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly Leu
            20   25   30

Leu Ser Cys Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys Lys
        35   40   45

Glu Val Gln Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met Glu
    50   55   60

Met Asp
65

<210> 8
<211> 21
<212> PRT
<213> Homo sapiens

<400> 8

Met Gly Arg Leu Ala Ser Arg Pro Leu Leu Leu Ala Leu Leu Ser Leu
1   5   10   15

Ala Leu Cys Arg Gly
            20

<210> 9
<211> 385
<212> PRT
<213> Homo sapiens

<400> 9

Met Ala Ala Ala Leu Phe Val Leu Leu Gly Phe Ala Leu Leu Gly Thr
1   5   10   15

His Gly Ala Ser Gly Ala Ala Gly Phe Val Gln Ala Pro Leu Ser Gln
            20   25   30

Gln Arg Trp Val Gly Gly Ser Val Glu Leu His Cys Glu Ala Val Gly
        35   40   45

Ser Pro Val Pro Glu Ile Gln Trp Trp Phe Glu Gly Gln Gly Pro Asn
    50   55   60

```
Asp Thr Cys Ser Gln Leu Trp Asp Gly Ala Arg Leu Asp Arg Val His
65                  70                  75                  80

Ile His Ala Thr Tyr His Gln His Ala Ala Ser Thr Ile Ser Ile Asp
                85                  90                  95

Thr Leu Val Glu Glu Asp Thr Gly Thr Tyr Glu Cys Arg Ala Ser Asn
            100                 105                 110

Asp Pro Asp Arg Asn His Leu Thr Arg Ala Pro Arg Val Lys Trp Val
        115                 120                 125

Arg Ala Gln Ala Val Val Leu Val Leu Glu Pro Gly Thr Val Phe Thr
    130                 135                 140

Thr Val Glu Asp Leu Gly Ser Lys Ile Leu Leu Thr Cys Ser Leu Asn
145                 150                 155                 160

Asp Ser Ala Thr Glu Val Thr Gly His Arg Trp Leu Lys Gly Gly Val
                165                 170                 175

Val Leu Lys Glu Asp Ala Leu Pro Gly Gln Lys Thr Glu Phe Lys Val
            180                 185                 190

Asp Ser Asp Asp Gln Trp Gly Glu Tyr Ser Cys Val Phe Leu Pro Glu
        195                 200                 205

Pro Met Gly Thr Ala Asn Ile Gln Leu His Gly Pro Pro Arg Val Lys
    210                 215                 220

Ala Val Lys Ser Ser Glu His Ile Asn Glu Gly Glu Thr Ala Met Leu
225                 230                 235                 240

Val Cys Lys Ser Glu Ser Val Pro Pro Val Thr Asp Trp Ala Trp Tyr
                245                 250                 255

Lys Ile Thr Asp Ser Glu Asp Lys Ala Leu Met Asn Gly Ser Glu Ser
            260                 265                 270

Arg Phe Phe Val Ser Ser Ser Gln Gly Arg Ser Glu Leu His Ile Glu
        275                 280                 285

Asn Leu Asn Met Glu Ala Asp Pro Gly Gln Tyr Arg Cys Asn Gly Thr
    290                 295                 300

Ser Ser Lys Gly Ser Asp Gln Ala Ile Ile Thr Leu Arg Val Arg Ser
305                 310                 315                 320

His Leu Ala Ala Leu Trp Pro Phe Leu Gly Ile Val Ala Glu Val Leu
                325                 330                 335

Val Leu Val Thr Ile Ile Phe Ile Tyr Glu Lys Arg Arg Lys Pro Glu
```

```
            340                 345                 350

Asp Val Leu Asp Asp Asp Asp Ala Gly Ser Ala Pro Leu Lys Ser Ser
        355                 360                 365

Gly Gln His Gln Asn Asp Lys Gly Lys Asn Val Arg Gln Arg Asn Ser
    370                 375                 380

Ser
385
```

<210> 10
<211> 247
<212> PRT
<213> Homo sapiens

<400> 10

```
Pro Gly Thr Val Phe Thr Thr Val Glu Asp Leu Gly Ser Lys Ile Leu
1               5                   10                  15

Leu Thr Cys Ser Leu Asn Asp Ser Ala Thr Glu Val Thr Gly His Arg
            20                  25                  30

Trp Leu Lys Gly Gly Val Val Leu Lys Glu Asp Ala Leu Pro Gly Gln
        35                  40                  45

Lys Thr Glu Phe Lys Val Asp Ser Asp Asp Gln Trp Gly Glu Tyr Ser
    50                  55                  60

Cys Val Phe Leu Pro Glu Pro Met Gly Thr Ala Asn Ile Gln Leu His
65                  70                  75                  80

Gly Pro Pro Arg Val Lys Ala Val Lys Ser Ser Glu His Ile Asn Glu
                85                  90                  95

Gly Glu Thr Ala Met Leu Val Cys Lys Ser Glu Ser Val Pro Pro Val
            100                 105                 110

Thr Asp Trp Ala Trp Tyr Lys Ile Thr Asp Ser Glu Asp Lys Ala Leu
        115                 120                 125

Met Asn Gly Ser Glu Ser Arg Phe Phe Val Ser Ser Ser Gln Gly Arg
    130                 135                 140

Ser Glu Leu His Ile Glu Asn Leu Asn Met Glu Ala Asp Pro Gly Gln
145                 150                 155                 160

Tyr Arg Cys Asn Gly Thr Ser Ser Lys Gly Ser Asp Gln Ala Ile Ile
                165                 170                 175

Thr Leu Arg Val Arg Ser His Leu Ala Ala Leu Trp Pro Phe Leu Gly
            180                 185                 190
```

```
Ile Val Ala Glu Val Leu Val Leu Val Thr Ile Ile Phe Ile Tyr Glu
        195                 200                 205


Lys Arg Arg Lys Pro Glu Asp Val Leu Asp Asp Asp Asp Ala Gly Ser
    210                 215                 220


Ala Pro Leu Lys Ser Ser Gly Gln His Gln Asn Asp Lys Gly Lys Asn
225                 230                 235                 240


Val Arg Gln Arg Asn Ser Ser
                245


<210>  11
<211>  168
<212>  PRT
<213>  Homo sapiens

<400>  11

His Gly Pro Pro Arg Val Lys Ala Val Lys Ser Ser Glu His Ile Asn
1               5                   10                  15


Glu Gly Glu Thr Ala Met Leu Val Cys Lys Ser Glu Ser Val Pro Pro
            20                  25                  30


Val Thr Asp Trp Ala Trp Tyr Lys Ile Thr Asp Ser Glu Asp Lys Ala
        35                  40                  45


Leu Met Asn Gly Ser Glu Ser Arg Phe Phe Val Ser Ser Ser Gln Gly
    50                  55                  60


Arg Ser Glu Leu His Ile Glu Asn Leu Asn Met Glu Ala Asp Pro Gly
65                  70                  75                  80


Gln Tyr Arg Cys Asn Gly Thr Ser Ser Lys Gly Ser Asp Gln Ala Ile
                85                  90                  95


Ile Thr Leu Arg Val Arg Ser His Leu Ala Ala Leu Trp Pro Phe Leu
            100                 105                 110


Gly Ile Val Ala Glu Val Leu Val Leu Val Thr Ile Ile Phe Ile Tyr
        115                 120                 125


Glu Lys Arg Arg Lys Pro Glu Asp Val Leu Asp Asp Asp Asp Ala Gly
    130                 135                 140


Ser Ala Pro Leu Lys Ser Ser Gly Gln His Gln Asn Asp Lys Gly Lys
145                 150                 155                 160


Asn Val Arg Gln Arg Asn Ser Ser
                165


<210>  12
```

<211> 66
<212> PRT
<213> homo sapiens

<400> 12

Ser His Leu Ala Ala Leu Trp Pro Phe Leu Gly Ile Val Ala Glu Val
1   5   10   15

Leu Val Leu Val Thr Ile Ile Phe Ile Tyr Glu Lys Arg Arg Lys Pro
            20   25   30

Glu Asp Val Leu Asp Asp Asp Asp Ala Gly Ser Ala Pro Leu Lys Ser
        35   40   45

Ser Gly Gln His Gln Asn Asp Lys Gly Lys Asn Val Arg Gln Arg Asn
    50   55   60

Ser Ser
65

<210> 13
<211> 18
<212> PRT
<213> homo sapiens

<400> 13

Met Ala Ala Ala Leu Phe Val Leu Leu Gly Phe Ala Leu Leu Gly Thr
1   5   10   15

His Gly

<210> 14
<211> 613
<212> PRT
<213> homo sapiens

<400> 14

Met Gly Ala Leu Arg Pro Thr Leu Leu Pro Pro Ser Leu Pro Leu Leu
1   5   10   15

Leu Leu Leu Met Leu Gly Met Gly Cys Trp Ala Arg Glu Val Leu Val
            20   25   30

Pro Glu Gly Pro Leu Tyr Arg Val Ala Gly Thr Ala Val Ser Ile Ser
        35   40   45

Cys Asn Val Thr Gly Tyr Glu Gly Pro Ala Gln Gln Asn Phe Glu Trp
    50   55   60

Phe Leu Tyr Arg Pro Glu Ala Pro Asp Thr Ala Leu Gly Ile Val Ser
65   70   75   80

Thr Lys Asp Thr Gln Phe Ser Tyr Ala Val Phe Lys Ser Arg Val Val

```
                85                  90                  95

Ala Gly Glu Val Gln Val Gln Arg Leu Gln Gly Asp Ala Val Val Leu
            100                 105                 110

Lys Ile Ala Arg Leu Gln Ala Gln Asp Ala Gly Ile Tyr Glu Cys His
        115                 120                 125

Thr Pro Ser Thr Asp Thr Arg Tyr Leu Gly Ser Tyr Ser Gly Lys Val
    130                 135                 140

Glu Leu Arg Val Leu Pro Asp Val Leu Gln Val Ser Ala Ala Pro Pro
145                 150                 155                 160

Gly Pro Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg Met Thr Val
                165                 170                 175

His Glu Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg Thr Ser Thr
            180                 185                 190

Gln Lys His Thr His Leu Ala Val Ser Phe Gly Arg Ser Val Pro Glu
        195                 200                 205

Ala Pro Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly Ile Arg Ser
    210                 215                 220

Asp Leu Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg Leu Ala Ala
225                 230                 235                 240

Gly Glu Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr Arg Met Val
                245                 250                 255

Val Gly Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His Cys Thr Ala
            260                 265                 270

Ala Glu Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln Ile Ala Glu
        275                 280                 285

Lys Arg Ala Val Leu Ala His Val Asp Val Gln Thr Leu Ser Ser Gln
    290                 295                 300

Leu Ala Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu
305                 310                 315                 320

Pro Leu Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly
                325                 330                 335

Arg His Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro Ala Gly Ala
            340                 345                 350

Pro Gly Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly
        355                 360                 365
```

```
Ser Leu Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val
    370                 375                 380

Ala Ser Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp
385                 390                 395                 400

Ala Gly Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly
                405                 410                 415

Thr Arg Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val
            420                 425                 430

His Val Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala
        435                 440                 445

Gly Gly Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile
    450                 455                 460

Ser Val Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp
465                 470                 475                 480

Val Glu Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu
                485                 490                 495

Val Gly Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro
            500                 505                 510

Gly Gly Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg
        515                 520                 525

Leu Arg Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys
    530                 535                 540

Ala Pro Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala
545                 550                 555                 560

Gly Ser Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala
                565                 570                 575

Leu Asp Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu
            580                 585                 590

Val Thr Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys
        595                 600                 605

Arg Leu Arg Lys Arg
    610
```

<210> 15
<211> 456
<212> PRT

<213> homo sapiens

<400> 15

```
Ala Pro Pro Gly Pro Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg
1               5                   10                  15


Met Thr Val His Glu Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg
            20                  25                  30


Thr Ser Thr Gln Lys His Thr His Leu Ala Val Ser Phe Gly Arg Ser
        35                  40                  45


Val Pro Glu Ala Pro Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly
    50                  55                  60


Ile Arg Ser Asp Leu Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg
65                  70                  75                  80


Leu Ala Ala Gly Glu Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr
                85                  90                  95


Arg Met Val Val Gly Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His
            100                 105                 110


Cys Thr Ala Ala Glu Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln
        115                 120                 125


Ile Ala Glu Lys Arg Ala Val Leu Ala His Val Asp Val Gln Thr Leu
    130                 135                 140


Ser Ser Gln Leu Ala Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly
145                 150                 155                 160


Pro Gly Glu Pro Leu Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro
                165                 170                 175


Pro Ala Gly Arg His Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro
            180                 185                 190


Ala Gly Ala Pro Gly Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu
        195                 200                 205


Gly Val Gly Ser Leu Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met
    210                 215                 220


Glu Lys Val Ala Ser Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg
225                 230                 235                 240


Pro Gly Asp Ala Gly Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg
                245                 250                 255


Gly Ser Gly Thr Arg Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro
```

```
            260                 265                 270

Leu Pro Val His Val Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala
        275                 280                 285

Trp Leu Ala Gly Gly Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu
    290                 295                 300

Cys Asn Ile Ser Val Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala
305                 310                 315                 320

Ser Trp Trp Val Glu Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro
                325                 330                 335

Ala Gln Leu Val Gly Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly
            340                 345                 350

Val Arg Pro Gly Gly Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg
        355                 360                 365

Ser His Arg Leu Arg Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val
    370                 375                 380

Tyr His Cys Ala Pro Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp
385                 390                 395                 400

Tyr Gln Ala Gly Ser Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr
                405                 410                 415

Met His Ala Leu Asp Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly
            420                 425                 430

Val Ala Leu Val Thr Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys
        435                 440                 445

Phe Met Lys Arg Leu Arg Lys Arg
    450                 455


<210>  16
<211>  320
<212>  PRT
<213>  Homo sapiens

<400>  16

Ala His Val Asp Val Gln Thr Leu Ser Ser Gln Leu Ala Val Thr Val
1               5                   10                  15

Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu Pro Leu Glu Leu Leu
            20                  25                  30

Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly Arg His Ala Ala Tyr
        35                  40                  45
```

```
Ser Val Gly Trp Glu Met Ala Pro Ala Gly Ala Pro Gly Pro Gly Arg
    50                  55                  60

Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly Ser Leu Gly Pro Gly
65                  70                  75                  80

Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val Ala Ser Arg Thr Tyr
                85                  90                  95

Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp Ala Gly Thr Tyr Arg
            100                 105                 110

Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly Thr Arg Leu Arg Glu
        115                 120                 125

Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val His Val Arg Glu Glu
    130                 135                 140

Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala Gly Gly Thr Val Tyr
145                 150                 155                 160

Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile Ser Val Arg Gly Gly
                165                 170                 175

Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp Val Glu Arg Pro Glu
            180                 185                 190

Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu Val Gly Gly Val Gly
        195                 200                 205

Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro Gly Gly Gly Pro Val
    210                 215                 220

Ser Val Glu Leu Val Gly Pro Arg Ser His Arg Leu Arg Leu His Ser
225                 230                 235                 240

Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys Ala Pro Ser Ala Trp
                245                 250                 255

Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala Gly Ser Ala Arg Ser
            260                 265                 270

Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala Leu Asp Thr Leu Phe
        275                 280                 285

Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu Val Thr Gly Ala Thr
    290                 295                 300

Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys Arg Leu Arg Lys Arg
305                 310                 315                 320
```

<210> 17
<211> 179
<212> PRT
<213> homo sapiens

<400> 17

Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala Gly Gly
1   5   10   15

Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile Ser Val
            20   25   30

Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp Val Glu
        35   40   45

Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu Val Gly
    50   55   60

Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro Gly Gly
65   70   75   80

Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg Leu Arg
                85   90   95

Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys Ala Pro
            100   105   110

Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala Gly Ser
        115   120   125

Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala Leu Asp
    130   135   140

Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu Val Thr
145   150   155   160

Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys Arg Leu
                165   170   175

Arg Lys Arg

<210> 18
<211> 24
<212> PRT
<213> Homo sapiens

<400> 18

Val Ala Leu Val Thr Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys
1   5   10   15

Phe Met Lys Arg Leu Arg Lys Arg
            20

<210> 19
<211> 27
<212> PRT
<213> Homo sapiens

<400> 19

Met Gly Ala Leu Arg Pro Thr Leu Leu Pro Pro Ser Leu Pro Leu Leu
1   5   10   15

Leu Leu Leu Met Leu Gly Met Gly Cys Trp Ala
            20   25

<210> 20
<211> 1195
<212> PRT
<213> homo sapiens

<400> 20

Met Lys Cys Phe Phe Pro Val Leu Ser Cys Leu Ala Val Leu Gly Val
1   5   10   15

Val Ser Ala Gln Arg Gln Val Thr Val Gln Glu Gly Pro Leu Tyr Arg
            20   25   30

Thr Glu Gly Ser His Ile Thr Ile Trp Cys Asn Val Ser Gly Tyr Gln
        35   40   45

Gly Pro Ser Glu Gln Asn Phe Gln Trp Ser Ile Tyr Leu Pro Ser Ser
    50   55   60

Pro Glu Arg Glu Val Gln Ile Val Ser Thr Met Asp Ser Ser Phe Pro
65   70   75   80

Tyr Ala Ile Tyr Thr Gln Arg Val Arg Gly Gly Lys Ile Phe Ile Glu
                85   90   95

Arg Val Gln Gly Asn Ser Thr Leu Leu His Ile Thr Asp Leu Gln Ala
            100   105   110

Arg Asp Ala Gly Glu Tyr Glu Cys His Thr Pro Ser Thr Asp Lys Gln
        115   120   125

Tyr Phe Gly Ser Tyr Ser Ala Lys Met Asn Leu Val Val Ile Pro Asp
    130   135   140

Ser Leu Gln Thr Thr Ala Met Pro Gln Thr Leu His Arg Val Glu Gln
145   150   155   160

Asp Pro Leu Glu Leu Thr Cys Glu Val Ala Ser Glu Thr Ile Gln His
                165   170   175

Ser His Leu Ser Val Ala Trp Leu Arg Gln Lys Val Gly Glu Lys Pro
            180   185   190

```
Val Glu Val Ile Ser Leu Ser Arg Asp Phe Met Leu His Ser Ser Ser
        195                 200                 205

Glu Tyr Ala Gln Arg Gln Ser Leu Gly Glu Val Arg Leu Asp Lys Leu
    210                 215                 220

Gly Arg Thr Thr Phe Arg Leu Thr Ile Phe His Leu Gln Pro Ser Asp
225                 230                 235                 240

Gln Gly Glu Phe Tyr Cys Glu Ala Ala Glu Trp Ile Gln Asp Pro Asp
                245                 250                 255

Gly Ser Trp Tyr Ala Met Thr Arg Lys Arg Ser Glu Gly Ala Val Val
            260                 265                 270

Asn Val Gln Pro Thr Asp Lys Glu Phe Thr Val Arg Leu Glu Thr Glu
        275                 280                 285

Lys Arg Leu His Thr Val Gly Glu Pro Val Glu Phe Arg Cys Ile Leu
    290                 295                 300

Glu Ala Gln Asn Val Pro Asp Arg Tyr Phe Ala Val Ser Trp Ala Phe
305                 310                 315                 320

Asn Ser Ser Leu Ile Ala Thr Met Gly Pro Asn Ala Val Pro Val Leu
                325                 330                 335

Asn Ser Glu Phe Ala His Arg Glu Ala Arg Gly Gln Leu Lys Val Ala
            340                 345                 350

Lys Glu Ser Asp Ser Val Phe Val Leu Lys Ile Tyr His Leu Arg Gln
        355                 360                 365

Glu Asp Ser Gly Lys Tyr Asn Cys Arg Val Thr Glu Arg Glu Lys Thr
    370                 375                 380

Val Thr Gly Glu Phe Ile Asp Lys Glu Ser Lys Arg Pro Lys Asn Ile
385                 390                 395                 400

Pro Ile Ile Val Leu Pro Leu Lys Ser Ser Ile Ser Val Glu Val Ala
                405                 410                 415

Ser Asn Ala Ser Val Ile Leu Glu Gly Glu Asp Leu Arg Phe Ser Cys
            420                 425                 430

Ser Val Arg Thr Ala Gly Arg Pro Gln Gly Arg Phe Ser Val Ile Trp
        435                 440                 445

Gln Leu Val Asp Arg Gln Asn Arg Arg Ser Asn Ile Met Trp Leu Asp
    450                 455                 460
```

```
Arg Asp Gly Thr Val Gln Pro Gly Ser Ser Tyr Trp Glu Arg Ser Ser
465                 470                 475                 480

Phe Gly Gly Val Gln Met Glu Gln Val Gln Pro Asn Ser Phe Ser Leu
                485                 490                 495

Gly Ile Phe Asn Ser Arg Lys Glu Asp Glu Gly Gln Tyr Glu Cys His
            500                 505                 510

Val Thr Glu Trp Val Arg Ala Val Asp Gly Glu Trp Gln Ile Val Gly
        515                 520                 525

Glu Arg Arg Ala Ser Thr Pro Ile Ser Ile Thr Ala Leu Glu Met Gly
    530                 535                 540

Phe Ala Val Thr Ala Ile Ser Arg Thr Pro Gly Val Thr Tyr Ser Asp
545                 550                 555                 560

Ser Phe Asp Leu Gln Cys Ile Ile Lys Pro His Tyr Pro Ala Trp Val
                565                 570                 575

Pro Val Ser Val Thr Trp Arg Phe Gln Pro Val Gly Thr Val Glu Phe
            580                 585                 590

His Asp Leu Val Thr Phe Thr Arg Asp Gly Gly Val Gln Trp Gly Asp
        595                 600                 605

Arg Ser Ser Ser Phe Arg Thr Arg Thr Ala Ile Glu Lys Ala Glu Ser
    610                 615                 620

Ser Asn Asn Val Arg Leu Ser Ile Ser Arg Ala Ser Asp Thr Glu Ala
625                 630                 635                 640

Gly Lys Tyr Gln Cys Val Ala Glu Leu Trp Arg Lys Asn Tyr Asn Asn
                645                 650                 655

Thr Trp Thr Arg Leu Ala Glu Arg Thr Ser Asn Leu Leu Glu Ile Arg
            660                 665                 670

Val Leu Gln Pro Val Thr Lys Leu Gln Val Ser Lys Ser Lys Arg Thr
        675                 680                 685

Leu Thr Leu Val Glu Asn Lys Pro Ile Gln Leu Asn Cys Ser Val Lys
    690                 695                 700

Ser Gln Thr Ser Gln Asn Ser His Phe Ala Val Leu Trp Tyr Val His
705                 710                 715                 720

Lys Pro Ser Asp Ala Asp Gly Lys Leu Ile Leu Lys Thr Thr His Asn
                725                 730                 735
```

```
Ser Ala Phe Glu Tyr Gly Thr Tyr Ala Glu Glu Glu Gly Leu Arg Ala
            740                 745                 750

Arg Leu Gln Phe Glu Arg His Val Ser Gly Gly Leu Phe Ser Leu Thr
        755                 760                 765

Val Gln Arg Ala Glu Val Ser Asp Ser Gly Ser Tyr Tyr Cys His Val
    770                 775                 780

Glu Glu Trp Leu Leu Ser Pro Asn Tyr Ala Trp Tyr Lys Leu Ala Glu
785                 790                 795                 800

Glu Val Ser Gly Arg Thr Glu Val Thr Val Lys Gln Pro Asp Ser Arg
                805                 810                 815

Leu Arg Leu Ser Gln Ala Gln Gly Asn Leu Ser Val Leu Glu Thr Arg
            820                 825                 830

Gln Val Gln Leu Glu Cys Val Val Leu Asn Arg Thr Ser Ile Thr Ser
        835                 840                 845

Gln Leu Met Val Glu Trp Phe Val Trp Lys Pro Asn His Pro Glu Arg
    850                 855                 860

Glu Thr Val Ala Arg Leu Ser Arg Asp Ala Thr Phe His Tyr Gly Glu
865                 870                 875                 880

Gln Ala Ala Lys Asn Asn Leu Lys Gly Arg Leu His Leu Glu Ser Pro
                885                 890                 895

Ser Pro Gly Val Tyr Arg Leu Phe Ile Gln Asn Val Ala Val Gln Asp
            900                 905                 910

Ser Gly Thr Tyr Ser Cys His Val Glu Glu Trp Leu Pro Ser Pro Ser
        915                 920                 925

Gly Met Trp Tyr Lys Arg Ala Glu Asp Thr Ala Gly Gln Thr Ala Leu
    930                 935                 940

Thr Val Met Arg Pro Asp Ala Ser Leu Gln Val Asp Thr Val Val Pro
945                 950                 955                 960

Asn Ala Thr Val Ser Glu Lys Ala Ala Phe Gln Leu Asp Cys Ser Ile
                965                 970                 975

Val Ser Arg Ser Ser Gln Asp Ser Arg Phe Ala Val Ala Trp Tyr Ser
            980                 985                 990

Leu Arg Thr Lys Ala Gly Gly Lys  Arg Ser Ser Pro Gly  Leu Glu Glu
        995                 1000                1005

Gln Glu  Glu Glu Arg Glu Glu  Glu Glu Glu Glu Glu  Glu Asp Asp
```

```
    1010                1015                1020

Asp Asp  Asp Asp Pro Thr Glu  Arg Thr Ala Leu Leu  Ser Val Gly
    1025                1030                1035

Pro Asp  Ala Val Phe Gly Pro  Glu Gly Ser Pro Trp  Glu Gly Arg
    1040                1045                1050

Leu Arg  Phe Gln Arg Leu Ser  Pro Val Leu Tyr Arg  Leu Thr Val
    1055                1060                1065

Leu Gln  Ala Ser Pro Gln Asp  Thr Gly Asn Tyr Ser  Cys His Val
    1070                1075                1080

Glu Glu  Trp Leu Pro Ser Pro  Gln Lys Glu Trp Tyr  Arg Leu Thr
    1085                1090                1095

Glu Glu  Glu Ser Ala Pro Ile  Gly Ile Arg Val Leu  Asp Thr Ser
    1100                1105                1110

Pro Thr  Leu Gln Ser Ile Ile  Cys Ser Asn Asp Ala  Leu Phe Tyr
    1115                1120                1125

Phe Val  Phe Phe Tyr Pro Phe  Pro Ile Phe Gly Ile  Leu Ile Ile
    1130                1135                1140

Thr Ile  Leu Leu Val Arg Phe  Lys Ser Arg Asn Ser  Ser Lys Asn
    1145                1150                1155

Ser Asp  Gly Lys Asn Gly Val  Pro Leu Leu Trp Ile  Lys Glu Pro
    1160                1165                1170

His Leu  Asn Tyr Ser Pro Thr  Cys Leu Glu Pro Pro  Val Leu Ser
    1175                1180                1185

Ile His  Pro Gly Ala Ile Asp
    1190                1195


<210>  21
<211>  798
<212>  PRT
<213>  homo sapiens

<400>  21

Met Asn Leu Gln Pro Ile Phe Trp Ile Gly Leu Ile Ser Ser Val Cys
1               5                   10                  15

Cys Val Phe Ala Gln Thr Asp Glu Asn Arg Cys Leu Lys Ala Asn Ala
            20                  25                  30

Lys Ser Cys Gly Glu Cys Ile Gln Ala Gly Pro Asn Cys Gly Trp Cys
        35                  40                  45
```

```
Thr Asn Ser Thr Phe Leu Gln Glu Gly Met Pro Thr Ser Ala Arg Cys
    50                  55                  60

Asp Asp Leu Glu Ala Leu Lys Lys Lys Gly Cys Pro Pro Asp Asp Ile
65                  70                  75                  80

Glu Asn Pro Arg Gly Ser Lys Asp Ile Lys Lys Asn Lys Asn Val Thr
                85                  90                  95

Asn Arg Ser Lys Gly Thr Ala Glu Lys Leu Lys Pro Glu Asp Ile Thr
            100                 105                 110

Gln Ile Gln Pro Gln Gln Leu Val Leu Arg Leu Arg Ser Gly Glu Pro
        115                 120                 125

Gln Thr Phe Thr Leu Lys Phe Lys Arg Ala Glu Asp Tyr Pro Ile Asp
    130                 135                 140

Leu Tyr Tyr Leu Met Asp Leu Ser Tyr Ser Met Lys Asp Asp Leu Glu
145                 150                 155                 160

Asn Val Lys Ser Leu Gly Thr Asp Leu Met Asn Glu Met Arg Arg Ile
                165                 170                 175

Thr Ser Asp Phe Arg Ile Gly Phe Gly Ser Phe Val Glu Lys Thr Val
            180                 185                 190

Met Pro Tyr Ile Ser Thr Thr Pro Ala Lys Leu Arg Asn Pro Cys Thr
        195                 200                 205

Ser Glu Gln Asn Cys Thr Ser Pro Phe Ser Tyr Lys Asn Val Leu Ser
    210                 215                 220

Leu Thr Asn Lys Gly Glu Val Phe Asn Glu Leu Val Gly Lys Gln Arg
225                 230                 235                 240

Ile Ser Gly Asn Leu Asp Ser Pro Glu Gly Gly Phe Asp Ala Ile Met
                245                 250                 255

Gln Val Ala Val Cys Gly Ser Leu Ile Gly Trp Arg Asn Val Thr Arg
            260                 265                 270

Leu Leu Val Phe Ser Thr Asp Ala Gly Phe His Phe Ala Gly Asp Gly
        275                 280                 285

Lys Leu Gly Gly Ile Val Leu Pro Asn Asp Gly Gln Cys His Leu Glu
    290                 295                 300

Asn Asn Met Tyr Thr Met Ser His Tyr Tyr Asp Tyr Pro Ser Ile Ala
305                 310                 315                 320
```

```
His Leu Val Gln Lys Leu Ser Glu Asn Asn Ile Gln Thr Ile Phe Ala
                325                 330                 335

Val Thr Glu Glu Phe Gln Pro Val Tyr Lys Glu Leu Lys Asn Leu Ile
            340                 345                 350

Pro Lys Ser Ala Val Gly Thr Leu Ser Ala Asn Ser Ser Asn Val Ile
        355                 360                 365

Gln Leu Ile Ile Asp Ala Tyr Asn Ser Leu Ser Ser Glu Val Ile Leu
    370                 375                 380

Glu Asn Gly Lys Leu Ser Glu Gly Val Thr Ile Ser Tyr Lys Ser Tyr
385                 390                 395                 400

Cys Lys Asn Gly Val Asn Gly Thr Gly Glu Asn Gly Arg Lys Cys Ser
                405                 410                 415

Asn Ile Ser Ile Gly Asp Glu Val Gln Phe Glu Ile Ser Ile Thr Ser
            420                 425                 430

Asn Lys Cys Pro Lys Lys Asp Ser Asp Ser Phe Lys Ile Arg Pro Leu
        435                 440                 445

Gly Phe Thr Glu Glu Val Glu Val Ile Leu Gln Tyr Ile Cys Glu Cys
    450                 455                 460

Glu Cys Gln Ser Glu Gly Ile Pro Glu Ser Pro Lys Cys His Glu Gly
465                 470                 475                 480

Asn Gly Thr Phe Glu Cys Gly Ala Cys Arg Cys Asn Glu Gly Arg Val
                485                 490                 495

Gly Arg His Cys Glu Cys Ser Thr Asp Glu Val Asn Ser Glu Asp Met
            500                 505                 510

Asp Ala Tyr Cys Arg Lys Glu Asn Ser Ser Glu Ile Cys Ser Asn Asn
        515                 520                 525

Gly Glu Cys Val Cys Gly Gln Cys Val Cys Arg Lys Arg Asp Asn Thr
    530                 535                 540

Asn Glu Ile Tyr Ser Gly Lys Phe Cys Glu Cys Asp Asn Phe Asn Cys
545                 550                 555                 560

Asp Arg Ser Asn Gly Leu Ile Cys Gly Gly Asn Gly Val Cys Lys Cys
                565                 570                 575

Arg Val Cys Glu Cys Asn Pro Asn Tyr Thr Gly Ser Ala Cys Asp Cys
            580                 585                 590

Ser Leu Asp Thr Ser Thr Cys Glu Ala Ser Asn Gly Gln Ile Cys Asn
```

595 600 605

Gly Arg Gly Ile Cys Glu Cys Gly Val Cys Lys Cys Thr Asp Pro Lys
610 615 620

Phe Gln Gly Gln Thr Cys Glu Met Cys Gln Thr Cys Leu Gly Val Cys
625 630 635 640

Ala Glu His Lys Glu Cys Val Gln Cys Arg Ala Phe Asn Lys Gly Glu
645 650 655

Lys Lys Asp Thr Cys Thr Gln Glu Cys Ser Tyr Phe Asn Ile Thr Lys
660 665 670

Val Glu Ser Arg Asp Lys Leu Pro Gln Pro Val Gln Pro Asp Pro Val
675 680 685

Ser His Cys Lys Glu Lys Asp Val Asp Asp Cys Trp Phe Tyr Phe Thr
690 695 700

Tyr Ser Val Asn Gly Asn Asn Glu Val Met Val His Val Val Glu Asn
705 710 715 720

Pro Glu Cys Pro Thr Gly Pro Asp Ile Ile Pro Ile Val Ala Gly Val
725 730 735

Val Ala Gly Ile Val Leu Ile Gly Leu Ala Leu Leu Leu Ile Trp Lys
740 745 750

Leu Leu Met Ile Ile His Asp Arg Arg Glu Phe Ala Lys Phe Glu Lys
755 760 765

Glu Lys Met Asn Ala Lys Trp Asp Thr Gly Glu Asn Pro Ile Tyr Lys
770 775 780

Ser Ala Val Thr Thr Val Val Asn Pro Lys Tyr Glu Gly Lys
785 790 795

<210> 22
<211> 1032
<212> PRT
<213> homo sapiens

<400> 22

Met Ala Trp Glu Ala Arg Arg Glu Pro Gly Pro Arg Arg Ala Ala Val
1 5 10 15

Arg Glu Thr Val Met Leu Leu Leu Cys Leu Gly Val Pro Thr Gly Arg
20 25 30

Pro Tyr Asn Val Asp Thr Glu Ser Ala Leu Leu Tyr Gln Gly Pro His
35 40 45

```
Asn Thr Leu Phe Gly Tyr Ser Val Val Leu His Ser His Gly Ala Asn
    50                  55                  60

Arg Trp Leu Leu Val Gly Ala Pro Thr Ala Asn Trp Leu Ala Asn Ala
65                  70                  75                  80

Ser Val Ile Asn Pro Gly Ala Ile Tyr Arg Cys Arg Ile Gly Lys Asn
                85                  90                  95

Pro Gly Gln Thr Cys Glu Gln Leu Gln Leu Gly Ser Pro Asn Gly Glu
            100                 105                 110

Pro Cys Gly Lys Thr Cys Leu Glu Glu Arg Asp Asn Gln Trp Leu Gly
        115                 120                 125

Val Thr Leu Ser Arg Gln Pro Gly Glu Asn Gly Ser Ile Val Thr Cys
    130                 135                 140

Gly His Arg Trp Lys Asn Ile Phe Tyr Ile Lys Asn Glu Asn Lys Leu
145                 150                 155                 160

Pro Thr Gly Gly Cys Tyr Gly Val Pro Pro Asp Leu Arg Thr Glu Leu
                165                 170                 175

Ser Lys Arg Ile Ala Pro Cys Tyr Gln Asp Tyr Val Lys Lys Phe Gly
            180                 185                 190

Glu Asn Phe Ala Ser Cys Gln Ala Gly Ile Ser Ser Phe Tyr Thr Lys
        195                 200                 205

Asp Leu Ile Val Met Gly Ala Pro Gly Ser Ser Tyr Trp Thr Gly Ser
    210                 215                 220

Leu Phe Val Tyr Asn Ile Thr Thr Asn Lys Tyr Lys Ala Phe Leu Asp
225                 230                 235                 240

Lys Gln Asn Gln Val Lys Phe Gly Ser Tyr Leu Gly Tyr Ser Val Gly
                245                 250                 255

Ala Gly His Phe Arg Ser Gln His Thr Thr Glu Val Val Gly Gly Ala
            260                 265                 270

Pro Gln His Glu Gln Ile Gly Lys Ala Tyr Ile Phe Ser Ile Asp Glu
        275                 280                 285

Lys Glu Leu Asn Ile Leu His Glu Met Lys Gly Lys Lys Leu Gly Ser
    290                 295                 300

Tyr Phe Gly Ala Ser Val Cys Ala Val Asp Leu Asn Ala Asp Gly Phe
305                 310                 315                 320
```

```
Ser Asp Leu Leu Val Gly Ala Pro Met Gln Ser Thr Ile Arg Glu Glu
                325                 330                 335

Gly Arg Val Phe Val Tyr Ile Asn Ser Gly Ser Gly Ala Val Met Asn
            340                 345                 350

Ala Met Glu Thr Asn Leu Val Gly Ser Asp Lys Tyr Ala Ala Arg Phe
        355                 360                 365

Gly Glu Ser Ile Val Asn Leu Gly Asp Ile Asp Asn Asp Gly Phe Glu
    370                 375                 380

Asp Val Ala Ile Gly Ala Pro Gln Glu Asp Asp Leu Gln Gly Ala Ile
385                 390                 395                 400

Tyr Ile Tyr Asn Gly Arg Ala Asp Gly Ile Ser Ser Thr Phe Ser Gln
                405                 410                 415

Arg Ile Glu Gly Leu Gln Ile Ser Lys Ser Leu Ser Met Phe Gly Gln
            420                 425                 430

Ser Ile Ser Gly Gln Ile Asp Ala Asp Asn Asn Gly Tyr Val Asp Val
        435                 440                 445

Ala Val Gly Ala Phe Arg Ser Asp Ser Ala Val Leu Leu Arg Thr Arg
    450                 455                 460

Pro Val Val Ile Val Asp Ala Ser Leu Ser His Pro Glu Ser Val Asn
465                 470                 475                 480

Arg Thr Lys Phe Asp Cys Val Glu Asn Gly Trp Pro Ser Val Cys Ile
                485                 490                 495

Asp Leu Thr Leu Cys Phe Ser Tyr Lys Gly Lys Glu Val Pro Gly Tyr
            500                 505                 510

Ile Val Leu Phe Tyr Asn Met Ser Leu Asp Val Asn Arg Lys Ala Glu
        515                 520                 525

Ser Pro Pro Arg Phe Tyr Phe Ser Ser Asn Gly Thr Ser Asp Val Ile
    530                 535                 540

Thr Gly Ser Ile Gln Val Ser Ser Arg Glu Ala Asn Cys Arg Thr His
545                 550                 555                 560

Gln Ala Phe Met Arg Lys Asp Val Arg Asp Ile Leu Thr Pro Ile Gln
                565                 570                 575

Ile Glu Ala Ala Tyr His Leu Gly Pro His Val Ile Ser Lys Arg Ser
            580                 585                 590

Thr Glu Glu Phe Pro Pro Leu Gln Pro Ile Leu Gln Gln Lys Lys Glu
```

```
        595                 600                 605

Lys Asp Ile Met Lys Lys Thr Ile Asn Phe Ala Arg Phe Cys Ala His
    610                 615                 620

Glu Asn Cys Ser Ala Asp Leu Gln Val Ser Ala Lys Ile Gly Phe Leu
625                 630                 635                 640

Lys Pro His Glu Asn Lys Thr Tyr Leu Ala Val Gly Ser Met Lys Thr
                645                 650                 655

Leu Met Leu Asn Val Ser Leu Phe Asn Ala Gly Asp Asp Ala Tyr Glu
            660                 665                 670

Thr Thr Leu His Val Lys Leu Pro Val Gly Leu Tyr Phe Ile Lys Ile
        675                 680                 685

Leu Glu Leu Glu Glu Lys Gln Ile Asn Cys Glu Val Thr Asp Asn Ser
    690                 695                 700

Gly Val Val Gln Leu Asp Cys Ser Ile Gly Tyr Ile Tyr Val Asp His
705                 710                 715                 720

Leu Ser Arg Ile Asp Ile Ser Phe Leu Leu Asp Val Ser Ser Leu Ser
                725                 730                 735

Arg Ala Glu Glu Asp Leu Ser Ile Thr Val His Ala Thr Cys Glu Asn
            740                 745                 750

Glu Glu Glu Met Asp Asn Leu Lys His Ser Arg Val Thr Val Ala Ile
        755                 760                 765

Pro Leu Lys Tyr Glu Val Lys Leu Thr Val His Gly Phe Val Asn Pro
    770                 775                 780

Thr Ser Phe Val Tyr Gly Ser Asn Asp Glu Asn Glu Pro Glu Thr Cys
785                 790                 795                 800

Met Val Glu Lys Met Asn Leu Thr Phe His Val Ile Asn Thr Gly Asn
                805                 810                 815

Ser Met Ala Pro Asn Val Ser Val Glu Ile Met Val Pro Asn Ser Phe
            820                 825                 830

Ser Pro Gln Thr Asp Lys Leu Phe Asn Ile Leu Asp Val Gln Thr Thr
        835                 840                 845

Thr Gly Glu Cys His Phe Glu Asn Tyr Gln Arg Val Cys Ala Leu Glu
    850                 855                 860

Gln Gln Lys Ser Ala Met Gln Thr Leu Lys Gly Ile Val Arg Phe Leu
865                 870                 875                 880
```

```
Ser Lys Thr Asp Lys Arg Leu Leu Tyr Cys Ile Lys Ala Asp Pro His
                885                 890                 895


Cys Leu Asn Phe Leu Cys Asn Phe Gly Lys Met Glu Ser Gly Lys Glu
            900                 905                 910


Ala Ser Val His Ile Gln Leu Glu Gly Arg Pro Ser Ile Leu Glu Met
        915                 920                 925


Asp Glu Thr Ser Ala Leu Lys Phe Glu Ile Arg Ala Thr Gly Phe Pro
    930                 935                 940


Glu Pro Asn Pro Arg Val Ile Glu Leu Asn Lys Asp Glu Asn Val Ala
945                 950                 955                 960


His Val Leu Leu Glu Gly Leu His His Gln Arg Pro Lys Arg Tyr Phe
                965                 970                 975


Thr Ile Val Ile Ile Ser Ser Ser Leu Leu Leu Gly Leu Ile Val Leu
            980                 985                 990


Leu Leu Ile Ser Tyr Val Met Trp  Lys Ala Gly Phe Phe  Lys Arg Gln
        995                 1000                1005


Tyr Lys  Ser Ile Leu Gln Glu  Glu Asn Arg Arg Asp  Ser Trp Ser
    1010                1015                1020


Tyr Ile  Asn Ser Lys Ser Asn  Asp Asp
    1025                1030


<210>  23
<211>  660
<212>  PRT
<213>  homo sapiens

<400>  23

Met Glu Leu Gln Pro Pro Glu Ala Ser Ile Ala Val Val Ser Ile Pro
1               5                   10                  15


Arg Gln Leu Pro Gly Ser His Ser Glu Ala Gly Val Gln Gly Leu Ser
            20                  25                  30


Ala Gly Asp Asp Ser Glu Leu Gly Ser His Cys Val Ala Gln Thr Gly
        35                  40                  45


Leu Glu Leu Leu Ala Ser Gly Asp Pro Leu Pro Ser Ala Ser Gln Asn
    50                  55                  60


Ala Glu Met Ile Glu Thr Gly Ser Asp Cys Val Thr Gln Ala Gly Leu
65                  70                  75                  80
```

```
Gln Leu Leu Ala Ser Ser Asp Pro Pro Ala Leu Ala Ser Lys Asn Ala
                85                  90                  95

Glu Val Thr Glu Thr Gly Phe His His Val Ser Gln Ala Asp Ile Glu
            100                 105                 110

Phe Leu Thr Ser Ile Asp Pro Thr Ala Ser Ala Ser Gly Ser Ala Gly
        115                 120                 125

Ile Thr Gly Thr Met Ser Gln Asp Thr Glu Val Asp Met Lys Glu Val
    130                 135                 140

Glu Leu Asn Glu Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala Ser
145                 150                 155                 160

Gly Ala Ala Met Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val Lys
                165                 170                 175

Ile Lys Val Ala Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Lys Phe
            180                 185                 190

Thr Gly Leu Ser Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly
        195                 200                 205

Trp Val Arg Thr Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp
    210                 215                 220

Leu Gly Met Leu Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg
225                 230                 235                 240

Cys Arg Glu Leu Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu Tyr
                245                 250                 255

Arg Ile Gly Asp Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn Leu
            260                 265                 270

Ala Gly Leu Lys Gly Arg Leu Asp Tyr Leu Ser Ser Leu Lys Val Lys
        275                 280                 285

Gly Leu Val Leu Gly Pro Ile His Lys Asn Gln Lys Asp Asp Val Ala
    290                 295                 300

Gln Thr Asp Leu Leu Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu Asp
305                 310                 315                 320

Phe Asp Ser Leu Leu Gln Ser Ala Lys Lys Lys Ser Ile Arg Val Ile
                325                 330                 335

Leu Asp Leu Thr Pro Asn Tyr Arg Gly Glu Asn Ser Trp Phe Ser Thr
            340                 345                 350

Gln Val Asp Thr Val Ala Thr Lys Val Lys Asp Ala Leu Glu Phe Trp
```

```
        355                 360                 365

Leu Gln Ala Gly Val Asp Gly Phe Gln Val Arg Asp Ile Glu Asn Leu
    370                 375                 380

Lys Asp Ala Ser Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys Gly
385                 390                 395                 400

Phe Ser Glu Asp Arg Leu Leu Ile Ala Gly Thr Asn Ser Ser Asp Leu
                405                 410                 415

Gln Gln Ile Leu Ser Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu Thr
            420                 425                 430

Ser Ser Tyr Leu Ser Asp Ser Gly Ser Thr Gly Glu His Thr Lys Ser
        435                 440                 445

Leu Val Thr Gln Tyr Leu Asn Ala Thr Gly Asn Arg Trp Cys Ser Trp
    450                 455                 460

Ser Leu Ser Gln Ala Arg Leu Leu Thr Ser Phe Leu Pro Ala Gln Leu
465                 470                 475                 480

Leu Arg Leu Tyr Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro Val
                485                 490                 495

Phe Ser Tyr Gly Asp Glu Ile Gly Leu Asp Ala Ala Ala Leu Pro Gly
            500                 505                 510

Gln Pro Met Glu Ala Pro Val Met Leu Trp Asp Glu Ser Ser Phe Pro
        515                 520                 525

Asp Ile Pro Gly Ala Val Ser Ala Asn Met Thr Val Lys Gly Gln Ser
    530                 535                 540

Glu Asp Pro Gly Ser Leu Leu Ser Leu Phe Arg Arg Leu Ser Asp Gln
545                 550                 555                 560

Arg Ser Lys Glu Arg Ser Leu Leu His Gly Asp Phe His Ala Phe Ser
                565                 570                 575

Ala Gly Pro Gly Leu Phe Ser Tyr Ile Arg His Trp Asp Gln Asn Glu
            580                 585                 590

Arg Phe Leu Val Val Leu Asn Phe Gly Asp Val Gly Leu Ser Ala Gly
        595                 600                 605

Leu Gln Ala Ser Asp Leu Pro Ala Ser Ala Ser Leu Pro Ala Lys Ala
    610                 615                 620

Asp Leu Leu Leu Ser Thr Gln Pro Gly Arg Glu Glu Gly Ser Pro Leu
625                 630                 635                 640
```

Glu Leu Glu Arg Leu Lys Leu Glu Pro His Glu Gly Leu Leu Leu Arg
645 650 655

Phe Pro Tyr Ala
660

<210> 24
<211> 1023
<212> PRT
<213> homo sapiens

<400> 24

Met Gly Lys Gly Val Gly Arg Asp Lys Tyr Glu Pro Ala Ala Val Ser
1 5 10 15

Glu Gln Gly Asp Lys Lys Gly Lys Lys Gly Lys Lys Asp Arg Asp Met
20 25 30

Asp Glu Leu Lys Lys Glu Val Ser Met Asp Asp His Lys Leu Ser Leu
35 40 45

Asp Glu Leu His Arg Lys Tyr Gly Thr Asp Leu Ser Arg Gly Leu Thr
50 55 60

Ser Ala Arg Ala Ala Glu Ile Leu Ala Arg Asp Gly Pro Asn Ala Leu
65 70 75 80

Thr Pro Pro Pro Thr Thr Pro Glu Trp Ile Lys Phe Cys Arg Gln Leu
85 90 95

Phe Gly Gly Phe Ser Met Leu Leu Trp Ile Gly Ala Ile Leu Cys Phe
100 105 110

Leu Ala Tyr Ser Ile Gln Ala Ala Thr Glu Glu Glu Pro Gln Asn Asp
115 120 125

Asn Leu Tyr Leu Gly Val Val Leu Ser Ala Val Val Ile Ile Thr Gly
130 135 140

Cys Phe Ser Tyr Tyr Gln Glu Ala Lys Ser Ser Lys Ile Met Glu Ser
145 150 155 160

Phe Lys Asn Met Val Pro Gln Gln Ala Leu Val Ile Arg Asn Gly Glu
165 170 175

Lys Met Ser Ile Asn Ala Glu Glu Val Val Val Gly Asp Leu Val Glu
180 185 190

Val Lys Gly Gly Asp Arg Ile Pro Ala Asp Leu Arg Ile Ile Ser Ala
195 200 205

```
Asn Gly Cys Lys Val Asp Asn Ser Ser Leu Thr Gly Glu Ser Glu Pro
    210                 215                 220

Gln Thr Arg Ser Pro Asp Phe Thr Asn Glu Asn Pro Leu Glu Thr Arg
225                 230                 235                 240

Asn Ile Ala Phe Phe Ser Thr Asn Cys Val Glu Gly Thr Ala Arg Gly
                245                 250                 255

Ile Val Val Tyr Thr Gly Asp Arg Thr Val Met Gly Arg Ile Ala Thr
            260                 265                 270

Leu Ala Ser Gly Leu Glu Gly Gly Gln Thr Pro Ile Ala Ala Glu Ile
        275                 280                 285

Glu His Phe Ile His Ile Ile Thr Gly Val Ala Val Phe Leu Gly Val
    290                 295                 300

Ser Phe Phe Ile Leu Ser Leu Ile Leu Glu Tyr Thr Trp Leu Glu Ala
305                 310                 315                 320

Val Ile Phe Leu Ile Gly Ile Ile Val Ala Asn Val Pro Glu Gly Leu
                325                 330                 335

Leu Ala Thr Val Thr Val Cys Leu Thr Leu Thr Ala Lys Arg Met Ala
            340                 345                 350

Arg Lys Asn Cys Leu Val Lys Asn Leu Glu Ala Val Glu Thr Leu Gly
        355                 360                 365

Ser Thr Ser Thr Ile Cys Ser Asp Lys Thr Gly Thr Leu Thr Gln Asn
    370                 375                 380

Arg Met Thr Val Ala His Met Trp Phe Asp Asn Gln Ile His Glu Ala
385                 390                 395                 400

Asp Thr Thr Glu Asn Gln Ser Gly Val Ser Phe Asp Lys Thr Ser Ala
                405                 410                 415

Thr Trp Leu Ala Leu Ser Arg Ile Ala Gly Leu Cys Asn Arg Ala Val
            420                 425                 430

Phe Gln Ala Asn Gln Glu Asn Leu Pro Ile Leu Lys Arg Ala Val Ala
        435                 440                 445

Gly Asp Ala Ser Glu Ser Ala Leu Leu Lys Cys Ile Glu Leu Cys Cys
    450                 455                 460

Gly Ser Val Lys Glu Met Arg Glu Arg Tyr Ala Lys Ile Val Glu Ile
465                 470                 475                 480

Pro Phe Asn Ser Thr Asn Lys Tyr Gln Leu Ser Ile His Lys Asn Pro
```

```
                485                 490                 495

Asn Thr Ser Glu Pro Gln His Leu Leu Val Met Lys Gly Ala Pro Glu
            500                 505                 510

Arg Ile Leu Asp Arg Cys Ser Ser Ile Leu Leu His Gly Lys Glu Gln
        515                 520                 525

Pro Leu Asp Glu Glu Leu Lys Asp Ala Phe Gln Asn Ala Tyr Leu Glu
    530                 535                 540

Leu Gly Gly Leu Gly Glu Arg Val Leu Gly Phe Cys His Leu Phe Leu
545                 550                 555                 560

Pro Asp Glu Gln Phe Pro Glu Gly Phe Gln Phe Asp Thr Asp Asp Val
                565                 570                 575

Asn Phe Pro Ile Asp Asn Leu Cys Phe Val Gly Leu Ile Ser Met Ile
            580                 585                 590

Asp Pro Pro Arg Ala Ala Val Pro Asp Ala Val Gly Lys Cys Arg Ser
        595                 600                 605

Ala Gly Ile Lys Val Ile Met Val Thr Gly Asp His Pro Ile Thr Ala
    610                 615                 620

Lys Ala Ile Ala Lys Gly Val Gly Ile Ile Ser Glu Gly Asn Glu Thr
625                 630                 635                 640

Val Glu Asp Ile Ala Ala Arg Leu Asn Ile Pro Val Ser Gln Val Asn
                645                 650                 655

Pro Arg Asp Ala Lys Ala Cys Val Val His Gly Ser Asp Leu Lys Asp
            660                 665                 670

Met Thr Ser Glu Gln Leu Asp Asp Ile Leu Lys Tyr His Thr Glu Ile
        675                 680                 685

Val Phe Ala Arg Thr Ser Pro Gln Gln Lys Leu Ile Ile Val Glu Gly
    690                 695                 700

Cys Gln Arg Gln Gly Ala Ile Val Ala Val Thr Gly Asp Gly Val Asn
705                 710                 715                 720

Asp Ser Pro Ala Leu Lys Lys Ala Asp Ile Gly Val Ala Met Gly Ile
                725                 730                 735

Ala Gly Ser Asp Val Ser Lys Gln Ala Ala Asp Met Ile Leu Leu Asp
            740                 745                 750

Asp Asn Phe Ala Ser Ile Val Thr Gly Val Glu Glu Gly Arg Leu Ile
        755                 760                 765
```

```
Phe Asp Asn Leu Lys Lys Ser Ile Ala Tyr Thr Leu Thr Ser Asn Ile
    770                 775                 780

Pro Glu Ile Thr Pro Phe Leu Ile Phe Ile Ile Ala Asn Ile Pro Leu
785                 790                 795                 800

Pro Leu Gly Thr Val Thr Ile Leu Cys Ile Asp Leu Gly Thr Asp Met
                805                 810                 815

Val Pro Ala Ile Ser Leu Ala Tyr Glu Gln Ala Glu Ser Asp Ile Met
            820                 825                 830

Lys Arg Gln Pro Arg Asn Pro Lys Thr Asp Lys Leu Val Asn Glu Arg
        835                 840                 845

Leu Ile Ser Met Ala Tyr Gly Gln Ile Gly Met Ile Gln Ala Leu Gly
    850                 855                 860

Gly Phe Phe Thr Tyr Phe Val Ile Leu Ala Glu Asn Gly Phe Leu Pro
865                 870                 875                 880

Ile His Leu Leu Gly Leu Arg Val Asp Trp Asp Asp Arg Trp Ile Asn
                885                 890                 895

Asp Val Glu Asp Ser Tyr Gly Gln Gln Trp Thr Tyr Glu Gln Arg Lys
            900                 905                 910

Ile Val Glu Phe Thr Cys His Thr Ala Phe Phe Val Ser Ile Val Val
        915                 920                 925

Val Gln Trp Ala Asp Leu Val Ile Cys Lys Thr Arg Arg Asn Ser Val
    930                 935                 940

Phe Gln Gln Gly Met Lys Asn Lys Ile Leu Ile Phe Gly Leu Phe Glu
945                 950                 955                 960

Glu Thr Ala Leu Ala Ala Phe Leu Ser Tyr Cys Pro Gly Met Gly Val
                965                 970                 975

Ala Leu Arg Met Tyr Pro Leu Lys Pro Thr Trp Trp Phe Cys Ala Phe
            980                 985                 990

Pro Tyr Ser Leu Leu Ile Phe Val  Tyr Asp Glu Val Arg  Lys Leu Ile
        995                 1000                1005

Ile Arg  Arg Arg Pro Gly Gly  Trp Val Glu Lys Glu  Thr Tyr Tyr
    1010                1015                1020
```

<210> 25
<211> 1020
<212> PRT

<213> homo sapiens

<400> 25

```
Met Gly Arg Gly Ala Gly Arg Glu Tyr Ser Pro Ala Ala Thr Thr Ala
1               5                   10                  15


Glu Asn Gly Gly Gly Lys Lys Lys Gln Lys Glu Lys Glu Leu Asp Glu
            20                  25                  30


Leu Lys Lys Glu Val Ala Met Asp Asp His Lys Leu Ser Leu Asp Glu
        35                  40                  45


Leu Gly Arg Lys Tyr Gln Val Asp Leu Ser Lys Gly Leu Thr Asn Gln
    50                  55                  60


Arg Ala Gln Asp Val Leu Ala Arg Asp Gly Pro Asn Ala Leu Thr Pro
65                  70                  75                  80


Pro Pro Thr Thr Pro Glu Trp Val Lys Phe Cys Arg Gln Leu Phe Gly
                85                  90                  95


Gly Phe Ser Ile Leu Leu Trp Ile Gly Ala Ile Leu Cys Phe Leu Ala
            100                 105                 110


Tyr Gly Ile Gln Ala Ala Met Glu Asp Glu Pro Ser Asn Asp Asn Leu
        115                 120                 125


Tyr Leu Gly Val Val Leu Ala Ala Val Val Ile Val Thr Gly Cys Phe
    130                 135                 140


Ser Tyr Tyr Gln Glu Ala Lys Ser Ser Lys Ile Met Asp Ser Phe Lys
145                 150                 155                 160


Asn Met Val Pro Gln Gln Ala Leu Val Ile Arg Glu Gly Glu Lys Met
                165                 170                 175


Gln Ile Asn Ala Glu Glu Val Val Val Gly Asp Leu Val Glu Val Lys
            180                 185                 190


Gly Gly Asp Arg Val Pro Ala Asp Leu Arg Ile Ile Ser Ser His Gly
        195                 200                 205


Cys Lys Val Asp Asn Ser Ser Leu Thr Gly Glu Ser Glu Pro Gln Thr
    210                 215                 220


Arg Ser Pro Glu Phe Thr His Glu Asn Pro Leu Glu Thr Arg Asn Ile
225                 230                 235                 240


Cys Phe Phe Ser Thr Asn Cys Val Glu Gly Thr Ala Arg Gly Ile Val
                245                 250                 255


Ile Ala Thr Gly Asp Arg Thr Val Met Gly Arg Ile Ala Thr Leu Ala
```

```
            260                 265                 270

Ser Gly Leu Glu Val Gly Arg Thr Pro Ile Ala Met Glu Ile Glu His
        275                 280                 285

Phe Ile Gln Leu Ile Thr Gly Val Ala Val Phe Leu Gly Val Ser Phe
    290                 295                 300

Phe Val Leu Ser Leu Ile Leu Gly Tyr Ser Trp Leu Glu Ala Val Ile
305                 310                 315                 320

Phe Leu Ile Gly Ile Ile Val Ala Asn Val Pro Glu Gly Leu Leu Ala
                325                 330                 335

Thr Val Thr Val Cys Leu Thr Leu Thr Ala Lys Arg Met Ala Arg Lys
            340                 345                 350

Asn Cys Leu Val Lys Asn Leu Glu Ala Val Glu Thr Leu Gly Ser Thr
        355                 360                 365

Ser Thr Ile Cys Ser Asp Lys Thr Gly Thr Leu Thr Gln Asn Arg Met
    370                 375                 380

Thr Val Ala His Met Trp Phe Asp Asn Gln Ile His Glu Ala Asp Thr
385                 390                 395                 400

Thr Glu Asp Gln Ser Gly Ala Thr Phe Asp Lys Arg Ser Pro Thr Trp
                405                 410                 415

Thr Ala Leu Ser Arg Ile Ala Gly Leu Cys Asn Arg Ala Val Phe Lys
            420                 425                 430

Ala Gly Gln Glu Asn Ile Ser Val Ser Lys Arg Asp Thr Ala Gly Asp
        435                 440                 445

Ala Ser Glu Ser Ala Leu Leu Lys Cys Ile Glu Leu Ser Cys Gly Ser
    450                 455                 460

Val Arg Lys Met Arg Asp Arg Asn Pro Lys Val Ala Glu Ile Pro Phe
465                 470                 475                 480

Asn Ser Thr Asn Lys Tyr Gln Leu Ser Ile His Glu Arg Glu Asp Ser
                485                 490                 495

Pro Gln Ser His Val Leu Val Met Lys Gly Ala Pro Glu Arg Ile Leu
            500                 505                 510

Asp Arg Cys Ser Thr Ile Leu Val Gln Gly Lys Glu Ile Pro Leu Asp
        515                 520                 525

Lys Glu Met Gln Asp Ala Phe Gln Asn Ala Tyr Met Glu Leu Gly Gly
    530                 535                 540
```

```
Leu Gly Glu Arg Val Leu Gly Phe Cys Gln Leu Asn Leu Pro Ser Gly
545                 550                 555                 560

Lys Phe Pro Arg Gly Phe Lys Phe Asp Thr Asp Glu Leu Asn Phe Pro
                565                 570                 575

Thr Glu Lys Leu Cys Phe Val Gly Leu Met Ser Met Ile Asp Pro Pro
            580                 585                 590

Arg Ala Ala Val Pro Asp Ala Val Gly Lys Cys Arg Ser Ala Gly Ile
        595                 600                 605

Lys Val Ile Met Val Thr Gly Asp His Pro Ile Thr Ala Lys Ala Ile
    610                 615                 620

Ala Lys Gly Val Gly Ile Ile Ser Glu Gly Asn Glu Thr Val Glu Asp
625                 630                 635                 640

Ile Ala Ala Arg Leu Asn Ile Pro Met Ser Gln Val Asn Pro Arg Glu
                645                 650                 655

Ala Lys Ala Cys Val Val His Gly Ser Asp Leu Lys Asp Met Thr Ser
            660                 665                 670

Glu Gln Leu Asp Glu Ile Leu Lys Asn His Thr Glu Ile Val Phe Ala
        675                 680                 685

Arg Thr Ser Pro Gln Gln Lys Leu Ile Ile Val Glu Gly Cys Gln Arg
    690                 695                 700

Gln Gly Ala Ile Val Ala Val Thr Gly Asp Gly Val Asn Asp Ser Pro
705                 710                 715                 720

Ala Leu Lys Lys Ala Asp Ile Gly Ile Ala Met Gly Ile Ser Gly Ser
                725                 730                 735

Asp Val Ser Lys Gln Ala Ala Asp Met Ile Leu Leu Asp Asp Asn Phe
            740                 745                 750

Ala Ser Ile Val Thr Gly Val Glu Glu Gly Arg Leu Ile Phe Asp Asn
        755                 760                 765

Leu Lys Lys Ser Ile Ala Tyr Thr Leu Thr Ser Asn Ile Pro Glu Ile
    770                 775                 780

Thr Pro Phe Leu Leu Phe Ile Ile Ala Asn Ile Pro Leu Pro Leu Gly
785                 790                 795                 800

Thr Val Thr Ile Leu Cys Ile Asp Leu Gly Thr Asp Met Val Pro Ala
                805                 810                 815
```

```
Ile Ser Leu Ala Tyr Glu Ala Ala Glu Ser Asp Ile Met Lys Arg Gln
            820                 825                 830

Pro Arg Asn Ser Gln Thr Asp Lys Leu Val Asn Glu Arg Leu Ile Ser
        835                 840                 845

Met Ala Tyr Gly Gln Ile Gly Met Ile Gln Ala Leu Gly Gly Phe Phe
    850                 855                 860

Thr Tyr Phe Val Ile Leu Ala Glu Asn Gly Phe Leu Pro Ser Arg Leu
865                 870                 875                 880

Leu Gly Ile Arg Leu Asp Trp Asp Asp Arg Thr Met Asn Asp Leu Glu
                885                 890                 895

Asp Ser Tyr Gly Gln Glu Trp Thr Tyr Glu Gln Arg Lys Val Val Glu
            900                 905                 910

Phe Thr Cys His Thr Ala Phe Phe Ala Ser Ile Val Val Val Gln Trp
        915                 920                 925

Ala Asp Leu Ile Ile Cys Lys Thr Arg Arg Asn Ser Val Phe Gln Gln
    930                 935                 940

Gly Met Lys Asn Lys Ile Leu Ile Phe Gly Leu Leu Glu Glu Thr Ala
945                 950                 955                 960

Leu Ala Ala Phe Leu Ser Tyr Cys Pro Gly Met Gly Val Ala Leu Arg
                965                 970                 975

Met Tyr Pro Leu Lys Val Thr Trp Trp Phe Cys Ala Phe Pro Tyr Ser
            980                 985                 990

Leu Leu Ile Phe Ile Tyr Asp Glu  Val Arg Lys Leu Ile  Leu Arg Arg
        995                 1000                1005

Tyr Pro  Gly Gly Trp Val Glu  Lys Glu Thr Tyr Tyr
    1010                1015                1020


<210>  26
<211>  1026
<212>  PRT
<213>  homo sapiens

<400>  26

Met Gly Ser Gly Gly Ser Asp Ser Tyr Arg Ile Ala Thr Ser Gln Asp
1               5                   10                  15

Lys Lys Asp Asp Lys Asp Ser Pro Lys Lys Asn Lys Gly Lys Glu Arg
            20                  25                  30

Arg Asp Leu Asp Asp Leu Lys Lys Glu Val Ala Met Thr Glu His Lys
```

```
        35                  40                  45

Met Ser Val Glu Glu Val Cys Arg Lys Tyr Asn Thr Asp Cys Val Gln
    50                  55                  60

Gly Leu Thr His Ser Lys Ala Gln Glu Ile Leu Ala Arg Asp Gly Pro
65                  70                  75                  80

Asn Ala Leu Thr Pro Pro Pro Thr Thr Pro Glu Trp Val Lys Phe Cys
                85                  90                  95

Arg Gln Leu Phe Gly Gly Phe Ser Ile Leu Leu Trp Ile Gly Ala Ile
            100                 105                 110

Leu Cys Phe Leu Ala Tyr Gly Ile Gln Ala Gly Thr Glu Asp Asp Pro
        115                 120                 125

Ser Gly Asp Asn Leu Tyr Leu Gly Ile Val Leu Ala Ala Val Val Ile
    130                 135                 140

Ile Thr Gly Cys Phe Ser Tyr Tyr Gln Glu Ala Lys Ser Ser Lys Ile
145                 150                 155                 160

Met Glu Ser Phe Lys Asn Met Val Pro Gln Gln Ala Leu Val Ile Arg
                165                 170                 175

Glu Gly Glu Lys Met Gln Val Asn Ala Glu Glu Val Val Val Gly Asp
            180                 185                 190

Leu Val Glu Ile Lys Gly Gly Asp Arg Val Pro Ala Asp Leu Arg Ile
        195                 200                 205

Ile Ser Ala His Gly Cys Lys Val Asp Asn Ser Ser Leu Thr Gly Glu
    210                 215                 220

Ser Glu Pro Gln Thr Arg Ser Pro Asp Cys Thr His Asp Asn Pro Leu
225                 230                 235                 240

Glu Thr Arg Asn Ile Thr Phe Phe Ser Thr Asn Cys Val Glu Gly Thr
                245                 250                 255

Ala Arg Gly Val Val Val Ala Thr Gly Asp Arg Thr Val Met Gly Arg
            260                 265                 270

Ile Ala Thr Leu Ala Ser Gly Leu Glu Val Gly Lys Thr Pro Ile Ala
        275                 280                 285

Ile Glu Ile Glu His Phe Ile Gln Leu Ile Thr Gly Val Ala Val Phe
    290                 295                 300

Leu Gly Val Ser Phe Phe Ile Leu Ser Leu Ile Leu Gly Tyr Thr Trp
305                 310                 315                 320
```

```
Leu Glu Ala Val Ile Phe Leu Ile Gly Ile Ile Val Ala Asn Val Pro
                325                 330                 335

Glu Gly Leu Leu Ala Thr Val Thr Val Cys Leu Thr Leu Thr Ala Lys
            340                 345                 350

Arg Met Ala Arg Lys Asn Cys Leu Val Lys Asn Leu Glu Ala Val Glu
        355                 360                 365

Thr Leu Gly Ser Thr Ser Thr Ile Cys Ser Asp Lys Thr Gly Thr Leu
    370                 375                 380

Thr Gln Asn Arg Met Thr Val Ala His Met Trp Phe Asp Asn Gln Ile
385                 390                 395                 400

His Glu Ala Asp Thr Thr Glu Asp Gln Ser Gly Thr Ser Phe Asp Lys
                405                 410                 415

Ser Ser His Thr Trp Val Ala Leu Ser His Ile Ala Gly Leu Cys Asn
            420                 425                 430

Arg Ala Val Phe Lys Gly Gly Gln Asp Asn Ile Pro Val Leu Lys Arg
        435                 440                 445

Asp Val Ala Gly Asp Ala Ser Glu Ser Ala Leu Leu Lys Cys Ile Glu
    450                 455                 460

Leu Ser Ser Gly Ser Val Lys Leu Met Arg Glu Arg Asn Lys Lys Val
465                 470                 475                 480

Ala Glu Ile Pro Phe Asn Ser Thr Asn Lys Tyr Gln Leu Ser Ile His
                485                 490                 495

Glu Thr Glu Asp Pro Asn Asp Asn Arg Tyr Leu Leu Val Met Lys Gly
            500                 505                 510

Ala Pro Glu Arg Ile Leu Asp Arg Cys Ser Thr Ile Leu Leu Gln Gly
        515                 520                 525

Lys Glu Gln Pro Leu Asp Glu Glu Met Lys Glu Ala Phe Gln Asn Ala
    530                 535                 540

Tyr Leu Glu Leu Gly Gly Leu Gly Glu Arg Val Leu Gly Phe Cys His
545                 550                 555                 560

Tyr Tyr Leu Pro Glu Glu Gln Phe Pro Lys Gly Phe Ala Phe Asp Cys
                565                 570                 575

Asp Asp Val Asn Phe Thr Thr Asp Asn Leu Cys Phe Val Gly Leu Met
            580                 585                 590
```

```
Ser Met Ile Asp Pro Pro Arg Ala Ala Val Pro Asp Ala Val Gly Lys
        595                 600                 605

Cys Arg Ser Ala Gly Ile Lys Val Ile Met Val Thr Gly Asp His Pro
    610                 615                 620

Ile Thr Ala Lys Ala Ile Ala Lys Gly Val Gly Ile Ile Ser Glu Gly
625                 630                 635                 640

Asn Glu Thr Val Glu Asp Ile Ala Ala Arg Leu Asn Ile Pro Val Ser
                645                 650                 655

Gln Val Asn Pro Arg Asp Ala Lys Ala Cys Val Ile His Gly Thr Asp
            660                 665                 670

Leu Lys Asp Phe Thr Ser Glu Gln Ile Asp Glu Ile Leu Gln Asn His
        675                 680                 685

Thr Glu Ile Val Phe Ala Arg Thr Ser Pro Gln Gln Lys Leu Ile Ile
    690                 695                 700

Val Glu Gly Cys Gln Arg Gln Gly Ala Ile Val Ala Val Thr Gly Asp
705                 710                 715                 720

Gly Val Asn Asp Ser Pro Ala Leu Lys Lys Ala Asp Ile Gly Val Ala
                725                 730                 735

Met Gly Ile Ala Gly Ser Asp Val Ser Lys Gln Ala Ala Asp Met Ile
            740                 745                 750

Leu Leu Asp Asp Asn Phe Ala Ser Ile Val Thr Gly Val Glu Glu Gly
        755                 760                 765

Arg Leu Ile Phe Asp Asn Leu Lys Lys Ser Ile Ala Tyr Thr Leu Thr
    770                 775                 780

Ser Asn Ile Pro Glu Ile Thr Pro Phe Leu Leu Phe Ile Met Ala Asn
785                 790                 795                 800

Ile Pro Leu Pro Leu Gly Thr Ile Thr Ile Leu Cys Ile Asp Leu Gly
                805                 810                 815

Thr Asp Met Val Pro Ala Ile Ser Leu Ala Tyr Glu Ala Ala Glu Ser
            820                 825                 830

Asp Ile Met Lys Arg Gln Pro Arg Asn Pro Arg Thr Asp Lys Leu Val
        835                 840                 845

Asn Glu Arg Leu Ile Ser Met Ala Tyr Gly Gln Ile Gly Met Ile Gln
    850                 855                 860
```

```
Ala Leu Gly Gly Phe Phe Ser Tyr Phe Val Ile Leu Ala Glu Asn Gly
865                 870                 875                 880


Phe Leu Pro Gly Asn Leu Val Gly Ile Arg Leu Asn Trp Asp Asp Arg
                885                 890                 895


Thr Val Asn Asp Leu Glu Asp Ser Tyr Gly Gln Gln Trp Thr Tyr Glu
            900                 905                 910


Gln Arg Lys Val Val Glu Phe Thr Cys His Thr Ala Phe Phe Val Ser
        915                 920                 925


Ile Val Val Val Gln Trp Ala Asp Leu Ile Ile Cys Lys Thr Arg Arg
    930                 935                 940


Asn Ser Val Phe Gln Gln Gly Met Lys Asn Lys Ile Leu Ile Phe Gly
945                 950                 955                 960


Leu Phe Glu Glu Thr Ala Leu Ala Ala Phe Leu Ser Tyr Cys Pro Gly
                965                 970                 975


Met Asp Val Ala Leu Arg Met Tyr Pro Leu Lys Pro Ser Trp Trp Phe
            980                 985                 990


Cys Ala Phe Pro Tyr Ser Phe Leu  Ile Phe Val Tyr Asp  Glu Ile Arg
        995                 1000                1005


Lys Leu  Ile Leu Arg Arg Asn  Pro Gly Gly Trp Val  Glu Lys Glu
    1010                1015                1020


Thr Tyr  Tyr
    1025


<210>  27
<211>  1029
<212>  PRT
<213>  Homo sapiens

<400>  27

Met Gly Leu Trp Gly Lys Lys Gly Thr Val Ala Pro His Asp Gln Ser
1               5                   10                  15


Pro Arg Arg Arg Pro Lys Lys Gly Leu Ile Lys Lys Lys Met Val Lys
            20                  25                  30


Arg Glu Lys Gln Lys Arg Asn Met Glu Glu Leu Lys Lys Glu Val Val
        35                  40                  45


Met Asp Asp His Lys Leu Thr Leu Glu Glu Leu Ser Thr Lys Tyr Ser
    50                  55                  60


Val Asp Leu Thr Lys Gly His Ser His Gln Arg Ala Lys Glu Ile Leu
65                  70                  75                  80
```

```
Thr Arg Gly Gly Pro Asn Thr Val Thr Pro Pro Pro Thr Thr Pro Glu
                85                  90                  95

Trp Val Lys Phe Cys Lys Gln Leu Phe Gly Gly Phe Ser Leu Leu Leu
            100                 105                 110

Trp Thr Gly Ala Ile Leu Cys Phe Val Ala Tyr Ser Ile Gln Ile Tyr
        115                 120                 125

Phe Asn Glu Glu Pro Thr Lys Asp Asn Leu Tyr Leu Ser Ile Val Leu
    130                 135                 140

Ser Val Val Val Ile Val Thr Gly Cys Phe Ser Tyr Tyr Gln Glu Ala
145                 150                 155                 160

Lys Ser Ser Lys Ile Met Glu Ser Phe Lys Asn Met Val Pro Gln Gln
                165                 170                 175

Ala Leu Val Ile Arg Gly Gly Glu Lys Met Gln Ile Asn Val Gln Glu
            180                 185                 190

Val Val Leu Gly Asp Leu Val Glu Ile Lys Gly Gly Asp Arg Val Pro
        195                 200                 205

Ala Asp Leu Arg Leu Ile Ser Ala Gln Gly Cys Lys Val Asp Asn Ser
    210                 215                 220

Ser Leu Thr Gly Glu Ser Glu Pro Gln Ser Arg Ser Pro Asp Phe Thr
225                 230                 235                 240

His Glu Asn Pro Leu Glu Thr Arg Asn Ile Cys Phe Phe Ser Thr Asn
                245                 250                 255

Cys Val Glu Gly Thr Ala Arg Gly Ile Val Ile Ala Thr Gly Asp Ser
            260                 265                 270

Thr Val Met Gly Arg Ile Ala Ser Leu Thr Ser Gly Leu Ala Val Gly
        275                 280                 285

Gln Thr Pro Ile Ala Ala Glu Ile Glu His Phe Ile His Leu Ile Thr
    290                 295                 300

Val Val Ala Val Phe Leu Gly Val Thr Phe Phe Ala Leu Ser Leu Leu
305                 310                 315                 320

Leu Gly Tyr Gly Trp Leu Glu Ala Ile Ile Phe Leu Ile Gly Ile Ile
                325                 330                 335

Val Ala Asn Val Pro Glu Gly Leu Leu Ala Thr Val Thr Val Cys Leu
            340                 345                 350
```

```
Thr Leu Thr Ala Lys Arg Met Ala Arg Lys Asn Cys Leu Val Lys Asn
        355                 360                 365

Leu Glu Ala Val Glu Thr Leu Gly Ser Thr Ser Thr Ile Cys Ser Asp
    370                 375                 380

Lys Thr Gly Thr Leu Thr Gln Asn Arg Met Thr Val Ala His Met Trp
385                 390                 395                 400

Phe Asp Met Thr Val Tyr Glu Ala Asp Thr Thr Glu Glu Gln Thr Gly
                405                 410                 415

Lys Thr Phe Thr Lys Ser Ser Asp Thr Trp Phe Met Leu Ala Arg Ile
            420                 425                 430

Ala Gly Leu Cys Asn Arg Ala Asp Phe Lys Ala Asn Gln Glu Ile Leu
        435                 440                 445

Pro Ile Ala Lys Arg Ala Thr Thr Gly Asp Ala Ser Glu Ser Ala Leu
    450                 455                 460

Leu Lys Phe Ile Glu Gln Ser Tyr Ser Ser Val Ala Glu Met Arg Glu
465                 470                 475                 480

Lys Asn Pro Lys Val Ala Glu Ile Pro Phe Asn Ser Thr Asn Lys Tyr
                485                 490                 495

Gln Met Ser Ile His Leu Arg Glu Asp Ser Ser Gln Thr His Val Leu
            500                 505                 510

Met Met Lys Gly Ala Pro Glu Arg Ile Leu Glu Phe Cys Ser Thr Phe
        515                 520                 525

Leu Leu Asn Gly Gln Glu Tyr Ser Met Asn Asp Glu Met Lys Glu Ala
    530                 535                 540

Phe Gln Asn Ala Tyr Leu Glu Leu Gly Gly Leu Gly Glu Arg Val Leu
545                 550                 555                 560

Gly Phe Cys Phe Leu Asn Leu Pro Ser Ser Phe Ser Lys Gly Phe Pro
                565                 570                 575

Phe Asn Thr Asp Glu Ile Asn Phe Pro Met Asp Asn Leu Cys Phe Val
            580                 585                 590

Gly Leu Ile Ser Met Ile Asp Pro Pro Arg Ala Ala Val Pro Asp Ala
        595                 600                 605

Val Ser Lys Cys Arg Ser Ala Gly Ile Lys Val Ile Met Val Thr Gly
    610                 615                 620
```

```
Asp His Pro Ile Thr Ala Lys Ala Ile Ala Lys Gly Val Gly Ile Ile
625                 630                 635                 640

Ser Glu Gly Thr Glu Thr Ala Glu Glu Val Ala Ala Arg Leu Lys Ile
                645                 650                 655

Pro Ile Ser Lys Val Asp Ala Ser Ala Ala Lys Ala Ile Val Val His
            660                 665                 670

Gly Ala Glu Leu Lys Asp Ile Gln Ser Lys Gln Leu Asp Gln Ile Leu
        675                 680                 685

Gln Asn His Pro Glu Ile Val Phe Ala Arg Thr Ser Pro Gln Gln Lys
    690                 695                 700

Leu Ile Ile Val Glu Gly Cys Gln Arg Leu Gly Ala Val Val Ala Val
705                 710                 715                 720

Thr Gly Asp Gly Val Asn Asp Ser Pro Ala Leu Lys Lys Ala Asp Ile
                725                 730                 735

Gly Ile Ala Met Gly Ile Ser Gly Ser Asp Val Ser Lys Gln Ala Ala
            740                 745                 750

Asp Met Ile Leu Leu Asp Asp Asn Phe Ala Ser Ile Val Thr Gly Val
        755                 760                 765

Glu Glu Gly Arg Leu Ile Phe Asp Asn Leu Lys Lys Ser Ile Met Tyr
    770                 775                 780

Thr Leu Thr Ser Asn Ile Pro Glu Ile Thr Pro Phe Leu Met Phe Ile
785                 790                 795                 800

Ile Leu Gly Ile Pro Leu Pro Leu Gly Thr Ile Thr Ile Leu Cys Ile
                805                 810                 815

Asp Leu Gly Thr Asp Met Val Pro Ala Ile Ser Leu Ala Tyr Glu Ser
            820                 825                 830

Ala Glu Ser Asp Ile Met Lys Arg Leu Pro Arg Asn Pro Lys Thr Asp
        835                 840                 845

Asn Leu Val Asn His Arg Leu Ile Gly Met Ala Tyr Gly Gln Ile Gly
    850                 855                 860

Met Ile Gln Ala Leu Ala Gly Phe Phe Thr Tyr Phe Val Ile Leu Ala
865                 870                 875                 880

Glu Asn Gly Phe Arg Pro Val Asp Leu Leu Gly Ile Arg Leu His Trp
                885                 890                 895

Glu Asp Lys Tyr Leu Asn Asp Leu Glu Asp Ser Tyr Gly Gln Gln Trp
```

```
            900                 905                 910

Thr Tyr Glu Gln Arg Lys Val Val Glu Phe Thr Cys Gln Thr Ala Phe
        915                 920                 925

Phe Val Thr Ile Val Val Val Gln Trp Ala Asp Leu Ile Ile Ser Lys
    930                 935                 940

Thr Arg Arg Asn Ser Leu Phe Gln Gln Gly Met Arg Asn Lys Val Leu
945                 950                 955                 960

Ile Phe Gly Ile Leu Glu Glu Thr Leu Leu Ala Ala Phe Leu Ser Tyr
                965                 970                 975

Thr Pro Gly Met Asp Val Ala Leu Arg Met Tyr Pro Leu Lys Ile Thr
            980                 985                 990

Trp Trp Leu Cys Ala Ile Pro Tyr  Ser Ile Leu Ile Phe  Val Tyr Asp
        995                 1000                1005

Glu Ile  Arg Lys Leu Leu Ile  Arg Gln His Pro Asp  Gly Trp Val
    1010                1015                1020

Glu Arg  Glu Thr Tyr Tyr
    1025


<210>  28
<211>  279
<212>  PRT
<213>  homo sapiens

<400>  28

Met Thr Lys Asn Glu Lys Lys Ser Leu Asn Gln Ser Leu Ala Glu Trp
1               5                   10                  15

Lys Leu Phe Ile Tyr Asn Pro Thr Thr Gly Glu Phe Leu Gly Arg Thr
            20                  25                  30

Ala Lys Ser Trp Gly Leu Ile Leu Leu Phe Tyr Leu Val Phe Tyr Gly
        35                  40                  45

Phe Leu Ala Ala Leu Phe Ser Phe Thr Met Trp Val Met Leu Gln Thr
    50                  55                  60

Leu Asn Asp Glu Val Pro Lys Tyr Arg Asp Gln Ile Pro Ser Pro Gly
65                  70                  75                  80

Leu Met Val Phe Pro Lys Pro Val Thr Ala Leu Glu Tyr Thr Phe Ser
                85                  90                  95

Arg Ser Asp Pro Thr Ser Tyr Ala Gly Tyr Ile Glu Asp Leu Lys Lys
            100                 105                 110
```

```
Phe Leu Lys Pro Tyr Thr Leu Glu Glu Gln Lys Asn Leu Thr Val Cys
        115                 120                 125

Pro Asp Gly Ala Leu Phe Glu Gln Lys Gly Pro Val Tyr Val Ala Cys
    130                 135                 140

Gln Phe Pro Ile Ser Leu Leu Gln Ala Cys Ser Gly Met Asn Asp Pro
145                 150                 155                 160

Asp Phe Gly Tyr Ser Gln Gly Asn Pro Cys Ile Leu Val Lys Met Asn
                165                 170                 175

Arg Ile Ile Gly Leu Lys Pro Glu Gly Val Pro Arg Ile Asp Cys Val
            180                 185                 190

Ser Lys Asn Glu Asp Ile Pro Asn Val Ala Val Tyr Pro His Asn Gly
        195                 200                 205

Met Ile Asp Leu Lys Tyr Phe Pro Tyr Tyr Gly Lys Lys Leu His Val
    210                 215                 220

Gly Tyr Leu Gln Pro Leu Val Ala Val Gln Val Ser Phe Ala Pro Asn
225                 230                 235                 240

Asn Thr Gly Lys Glu Val Thr Val Glu Cys Lys Ile Asp Gly Ser Ala
                245                 250                 255

Asn Leu Lys Ser Gln Asp Asp Arg Asp Lys Phe Leu Gly Arg Val Met
            260                 265                 270

Phe Lys Ile Thr Ala Arg Ala
        275


<210>  29
<211>  1258
<212>  PRT
<213>  Homo sapiens

<400>  29

Met Gly Asp Met Ala Asn Asn Ser Val Ala Tyr Ser Gly Val Lys Asn
1               5                   10                  15

Ser Leu Lys Glu Ala Asn His Asp Gly Asp Phe Gly Ile Thr Leu Ala
            20                  25                  30

Glu Leu Arg Ala Leu Met Glu Leu Arg Ser Thr Asp Ala Leu Arg Lys
        35                  40                  45

Ile Gln Glu Ser Tyr Gly Asp Val Tyr Gly Ile Cys Thr Lys Leu Lys
    50                  55                  60

Thr Ser Pro Asn Glu Gly Leu Ser Gly Asn Pro Ala Asp Leu Glu Arg
```

65 70 75 80

Arg Glu Ala Val Phe Gly Lys Asn Phe Ile Pro Pro Lys Lys Pro Lys
85 90 95

Thr Phe Leu Gln Leu Val Trp Glu Ala Leu Gln Asp Val Thr Leu Ile
100 105 110

Ile Leu Glu Ile Ala Ala Ile Val Ser Leu Gly Leu Ser Phe Tyr Gln
115 120 125

Pro Pro Glu Gly Asp Asn Ala Leu Cys Gly Glu Val Ser Val Gly Glu
130 135 140

Glu Glu Gly Glu Gly Glu Thr Gly Trp Ile Glu Gly Ala Ala Ile Leu
145 150 155 160

Leu Ser Val Val Cys Val Val Leu Val Thr Ala Phe Asn Asp Trp Ser
165 170 175

Lys Glu Lys Gln Phe Arg Gly Leu Gln Ser Arg Ile Glu Gln Glu Gln
180 185 190

Lys Phe Thr Val Ile Arg Gly Gly Gln Val Ile Gln Ile Pro Val Ala
195 200 205

Asp Ile Thr Val Gly Asp Ile Ala Gln Val Lys Tyr Gly Asp Leu Leu
210 215 220

Pro Ala Asp Gly Ile Leu Ile Gln Gly Asn Asp Leu Lys Ile Asp Glu
225 230 235 240

Ser Ser Leu Thr Gly Glu Ser Asp His Val Lys Lys Ser Leu Asp Lys
245 250 255

Asp Pro Leu Leu Leu Ser Gly Thr His Val Met Glu Gly Ser Gly Arg
260 265 270

Met Val Val Thr Ala Val Gly Val Asn Ser Gln Thr Gly Ile Ile Phe
275 280 285

Thr Leu Leu Gly Ala Gly Gly Glu Glu Glu Glu Lys Lys Asp Glu Lys
290 295 300

Lys Lys Glu Lys Lys Asn Lys Lys Gln Asp Gly Ala Ile Glu Asn Arg
305 310 315 320

Asn Lys Ala Lys Ala Gln Asp Gly Ala Ala Met Glu Met Gln Pro Leu
325 330 335

Lys Ser Glu Glu Gly Gly Asp Gly Asp Glu Lys Asp Lys Lys Lys Ala
340 345 350

```
Asn Leu Pro Lys Lys Glu Lys Ser Val Leu Gln Gly Lys Leu Thr Lys
        355                 360                 365

Leu Ala Val Gln Ile Gly Lys Ala Gly Leu Leu Met Ser Ala Ile Thr
    370                 375                 380

Val Ile Ile Leu Val Leu Tyr Phe Val Ile Asp Thr Phe Trp Val Gln
385                 390                 395                 400

Lys Arg Pro Trp Leu Ala Glu Cys Thr Pro Ile Tyr Ile Gln Tyr Phe
                405                 410                 415

Val Lys Phe Phe Ile Ile Gly Val Thr Val Leu Val Val Ala Val Pro
            420                 425                 430

Glu Gly Leu Pro Leu Ala Val Thr Ile Ser Leu Ala Tyr Ser Val Lys
        435                 440                 445

Lys Met Met Lys Asp Asn Asn Leu Val Arg His Leu Asp Ala Cys Glu
    450                 455                 460

Thr Met Gly Asn Ala Thr Ala Ile Cys Ser Asp Lys Thr Gly Thr Leu
465                 470                 475                 480

Thr Met Asn Arg Met Thr Val Val Gln Ala Tyr Ile Asn Glu Lys His
                485                 490                 495

Tyr Lys Lys Val Pro Glu Pro Glu Ala Ile Pro Pro Asn Ile Leu Ser
            500                 505                 510

Tyr Leu Val Thr Gly Ile Ser Val Asn Cys Ala Tyr Thr Ser Lys Ile
        515                 520                 525

Leu Pro Pro Glu Lys Glu Gly Gly Leu Pro Arg His Val Gly Asn Lys
    530                 535                 540

Thr Glu Cys Ala Leu Leu Gly Leu Leu Leu Asp Leu Lys Arg Asp Tyr
545                 550                 555                 560

Gln Asp Val Arg Asn Glu Ile Pro Glu Glu Ala Leu Tyr Lys Val Tyr
                565                 570                 575

Thr Phe Asn Ser Val Arg Lys Ser Met Ser Thr Val Leu Lys Asn Ser
            580                 585                 590

Asp Gly Ser Tyr Arg Ile Phe Ser Lys Gly Ala Ser Glu Ile Ile Leu
        595                 600                 605

Lys Lys Cys Phe Lys Ile Leu Ser Ala Asn Gly Glu Ala Lys Val Phe
    610                 615                 620
```

```
Arg Pro Arg Asp Arg Asp Asp Ile Val Lys Thr Val Ile Glu Pro Met
625                 630                 635                 640

Ala Ser Glu Gly Leu Arg Thr Ile Cys Leu Ala Phe Arg Asp Phe Pro
                645                 650                 655

Ala Gly Glu Pro Glu Pro Glu Trp Asp Asn Glu Asn Asp Ile Val Thr
            660                 665                 670

Gly Leu Thr Cys Ile Ala Val Val Gly Ile Glu Asp Pro Val Arg Pro
        675                 680                 685

Glu Val Pro Asp Ala Ile Lys Lys Cys Gln Arg Ala Gly Ile Thr Val
    690                 695                 700

Arg Met Val Thr Gly Asp Asn Ile Asn Thr Ala Arg Ala Ile Ala Thr
705                 710                 715                 720

Lys Cys Gly Ile Leu His Pro Gly Glu Asp Phe Leu Cys Leu Glu Gly
                725                 730                 735

Lys Asp Phe Asn Arg Arg Ile Arg Asn Glu Lys Gly Glu Ile Glu Gln
            740                 745                 750

Glu Arg Ile Asp Lys Ile Trp Pro Lys Leu Arg Val Leu Ala Arg Ser
        755                 760                 765

Ser Pro Thr Asp Lys His Thr Leu Val Lys Gly Ile Ile Asp Ser Thr
    770                 775                 780

Val Ser Asp Gln Arg Gln Val Val Ala Val Thr Gly Asp Gly Thr Asn
785                 790                 795                 800

Asp Gly Pro Ala Leu Lys Lys Ala Asp Val Gly Phe Ala Met Gly Ile
                805                 810                 815

Ala Gly Thr Asp Val Ala Lys Glu Ala Ser Asp Ile Ile Leu Thr Asp
            820                 825                 830

Asp Asn Phe Thr Ser Ile Val Lys Ala Val Met Trp Gly Arg Asn Val
        835                 840                 845

Tyr Asp Ser Ile Ser Lys Phe Leu Gln Phe Gln Leu Thr Val Asn Val
    850                 855                 860

Val Ala Val Ile Val Ala Phe Thr Gly Ala Cys Ile Thr Gln Asp Ser
865                 870                 875                 880

Pro Leu Lys Ala Val Gln Met Leu Trp Val Asn Leu Ile Met Asp Thr
                885                 890                 895
```

```
Leu Ala Ser Leu Ala Leu Ala Thr Glu Pro Pro Thr Glu Ser Leu Leu
            900                 905                 910

Leu Arg Lys Pro Tyr Gly Arg Asn Lys Pro Leu Ile Ser Arg Thr Met
        915                 920                 925

Met Lys Asn Ile Leu Gly His Ala Phe Tyr Gln Leu Val Val Val Phe
    930                 935                 940

Thr Leu Leu Phe Ala Gly Glu Lys Phe Phe Asp Ile Asp Ser Gly Arg
945                 950                 955                 960

Asn Ala Pro Leu His Ala Pro Pro Ser Glu His Tyr Thr Ile Val Phe
                965                 970                 975

Asn Thr Phe Val Leu Met Gln Leu Phe Asn Glu Ile Asn Ala Arg Lys
            980                 985                 990

Ile His Gly Glu Arg Asn Val Phe  Glu Gly Ile Phe Asn  Asn Ala Ile
        995                 1000                1005

Phe Cys  Thr Ile Val Leu Gly  Thr Phe Val Val Gln  Ile Ile Ile
    1010                1015                1020

Val Gln  Phe Gly Gly Lys Pro  Phe Ser Cys Ser Glu  Leu Ser Ile
    1025                1030                1035

Glu Gln  Trp Leu Trp Ser Ile  Phe Leu Gly Met Gly  Thr Leu Leu
    1040                1045                1050

Trp Gly  Gln Leu Ile Ser Thr  Ile Pro Thr Ser Arg  Leu Lys Phe
    1055                1060                1065

Leu Lys  Glu Ala Gly His Gly  Thr Gln Lys Glu Glu  Ile Pro Glu
    1070                1075                1080

Glu Glu  Leu Ala Glu Asp Val  Glu Glu Ile Asp His  Ala Glu Arg
    1085                1090                1095

Glu Leu  Arg Arg Gly Gln Ile  Leu Trp Phe Arg Gly  Leu Asn Arg
    1100                1105                1110

Ile Gln  Thr Gln Met Asp Val  Val Asn Ala Phe Gln  Ser Gly Ser
    1115                1120                1125

Ser Ile  Gln Gly Ala Leu Arg  Arg Gln Pro Ser Ile  Ala Ser Gln
    1130                1135                1140

His His  Asp Val Thr Asn Ile  Ser Thr Pro Thr His  Ile Arg Val
    1145                1150                1155

Val Asn  Ala Phe Arg Ser Ser  Leu Tyr Glu Gly Leu  Glu Lys Pro
```

```
    1160                1165                1170

Glu Ser  Arg Ser Ser Ile His  Asn Phe Met Thr His  Pro Glu Phe
    1175                1180                1185

Arg Ile  Glu Asp Ser Glu Pro  His Ile Pro Leu Ile  Asp Asp Thr
    1190                1195                1200

Asp Ala  Glu Asp Asp Ala Pro  Thr Lys Arg Asn Ser  Ser Pro Pro
    1205                1210                1215

Pro Ser  Pro Asn Lys Asn Asn  Asn Ala Val Asp Ser  Gly Ile His
    1220                1225                1230

Leu Thr  Ile Glu Met Asn Lys  Ser Ala Thr Ser Ser  Ser Pro Gly
    1235                1240                1245

Ser Pro  Leu His Ser Leu Glu  Thr Ser Leu
    1250                1255
```

<210> 30
<211> 1272
<212> PRT
<213> Homo sapiens

<400> 30

```
Met Gly Asp Met Thr Asn Ser Asp Phe Tyr Ser Lys Asn Gln Arg Asn
1               5                   10                  15

Glu Ser Ser His Gly Gly Glu Phe Gly Cys Thr Met Glu Glu Leu Arg
            20                  25                  30

Ser Leu Met Glu Leu Arg Gly Thr Glu Ala Val Val Lys Ile Lys Glu
        35                  40                  45

Thr Tyr Gly Asp Thr Glu Ala Ile Cys Arg Arg Leu Lys Thr Ser Pro
    50                  55                  60

Val Glu Gly Leu Pro Gly Thr Ala Pro Asp Leu Glu Lys Arg Lys Gln
65                  70                  75                  80

Ile Phe Gly Gln Asn Phe Ile Pro Pro Lys Lys Pro Lys Thr Phe Leu
                85                  90                  95

Gln Leu Val Trp Glu Ala Leu Gln Asp Val Thr Leu Ile Ile Leu Glu
            100                 105                 110

Ile Ala Ala Ile Ile Ser Leu Gly Leu Ser Phe Tyr His Pro Pro Gly
        115                 120                 125

Glu Gly Asn Glu Gly Cys Ala Thr Ala Gln Gly Gly Ala Glu Asp Glu
    130                 135                 140
```

```
Gly Glu Ala Glu Ala Gly Trp Ile Glu Gly Ala Ala Ile Leu Leu Ser
145                 150                 155                 160

Val Ile Cys Val Val Leu Val Thr Ala Phe Asn Asp Trp Ser Lys Glu
                165                 170                 175

Lys Gln Phe Arg Gly Leu Gln Ser Arg Ile Glu Gln Glu Gln Lys Phe
            180                 185                 190

Thr Val Val Arg Ala Gly Gln Val Val Gln Ile Pro Val Ala Glu Ile
        195                 200                 205

Val Val Gly Asp Ile Ala Gln Val Lys Tyr Gly Asp Leu Leu Pro Ala
    210                 215                 220

Asp Gly Leu Phe Ile Gln Gly Asn Asp Leu Lys Ile Asp Glu Ser Ser
225                 230                 235                 240

Leu Thr Gly Glu Ser Asp Gln Val Arg Lys Ser Val Asp Lys Asp Pro
                245                 250                 255

Met Leu Leu Ser Gly Thr His Val Met Glu Gly Ser Gly Arg Met Leu
            260                 265                 270

Val Thr Ala Val Gly Val Asn Ser Gln Thr Gly Ile Ile Phe Thr Leu
        275                 280                 285

Leu Gly Ala Gly Gly Glu Glu Glu Lys Lys Asp Lys Lys Gly Val
    290                 295                 300

Lys Lys Gly Asp Gly Leu Gln Leu Pro Ala Ala Asp Gly Ala Ala Ala
305                 310                 315                 320

Ser Asn Ala Ala Asp Ser Ala Asn Ala Ser Leu Val Asn Gly Lys Met
                325                 330                 335

Gln Asp Gly Asn Val Asp Ala Ser Gln Ser Lys Ala Lys Gln Gln Asp
            340                 345                 350

Gly Ala Ala Ala Met Glu Met Gln Pro Leu Lys Ser Ala Glu Gly Gly
        355                 360                 365

Asp Ala Asp Asp Arg Lys Lys Ala Ser Met His Lys Lys Glu Lys Ser
    370                 375                 380

Val Leu Gln Gly Lys Leu Thr Lys Leu Ala Val Gln Ile Gly Lys Ala
385                 390                 395                 400

Gly Leu Val Met Ser Ala Ile Thr Val Ile Ile Leu Val Leu Tyr Phe
                405                 410                 415
```

```
Thr Val Asp Thr Phe Val Val Asn Lys Lys Pro Trp Leu Pro Glu Cys
            420                 425                 430

Thr Pro Val Tyr Val Gln Tyr Phe Val Lys Phe Phe Ile Ile Gly Val
        435                 440                 445

Thr Val Leu Val Val Ala Val Pro Glu Gly Leu Pro Leu Ala Val Thr
    450                 455                 460

Ile Ser Leu Ala Tyr Ser Val Lys Lys Met Met Lys Asp Asn Asn Leu
465                 470                 475                 480

Val Arg His Leu Asp Ala Cys Glu Thr Met Gly Asn Ala Thr Ala Ile
                485                 490                 495

Cys Ser Asp Lys Thr Gly Thr Leu Thr Thr Asn Arg Met Thr Val Val
            500                 505                 510

Gln Ala Tyr Val Gly Asp Val His Tyr Lys Glu Ile Pro Asp Pro Ser
        515                 520                 525

Ser Ile Asn Thr Lys Thr Met Glu Leu Leu Ile Asn Ala Ile Ala Ile
    530                 535                 540

Asn Ser Ala Tyr Thr Thr Lys Ile Leu Pro Pro Glu Lys Glu Gly Ala
545                 550                 555                 560

Leu Pro Arg Gln Val Gly Asn Lys Thr Glu Cys Gly Leu Leu Gly Phe
                565                 570                 575

Val Leu Asp Leu Lys Gln Asp Tyr Glu Pro Val Arg Ser Gln Met Pro
            580                 585                 590

Glu Glu Lys Leu Tyr Lys Val Tyr Thr Phe Asn Ser Val Arg Lys Ser
        595                 600                 605

Met Ser Thr Val Ile Lys Leu Pro Asp Glu Ser Phe Arg Met Tyr Ser
    610                 615                 620

Lys Gly Ala Ser Glu Ile Val Leu Lys Lys Cys Cys Lys Ile Leu Asn
625                 630                 635                 640

Gly Ala Gly Glu Pro Arg Val Phe Arg Pro Arg Asp Arg Asp Glu Met
                645                 650                 655

Val Lys Lys Val Ile Glu Pro Met Ala Cys Asp Gly Leu Arg Thr Ile
            660                 665                 670

Cys Val Ala Tyr Arg Asp Phe Pro Ser Ser Pro Glu Pro Asp Trp Asp
        675                 680                 685

Asn Glu Asn Asp Ile Leu Asn Glu Leu Thr Cys Ile Cys Val Val Gly
```

```
    690                 695                 700

Ile Glu Asp Pro Val Arg Pro Glu Val Pro Glu Ala Ile Arg Lys Cys
705                 710                 715                 720

Gln Arg Ala Gly Ile Thr Val Arg Met Val Thr Gly Asp Asn Ile Asn
                725                 730                 735

Thr Ala Arg Ala Ile Ala Ile Lys Cys Gly Ile Ile His Pro Gly Glu
            740                 745                 750

Asp Phe Leu Cys Leu Glu Gly Lys Glu Phe Asn Arg Arg Ile Arg Asn
        755                 760                 765

Glu Lys Gly Glu Ile Glu Gln Glu Arg Ile Asp Lys Ile Trp Pro Lys
    770                 775                 780

Leu Arg Val Leu Ala Arg Ser Ser Pro Thr Asp Lys His Thr Leu Val
785                 790                 795                 800

Lys Gly Ile Ile Asp Ser Thr His Thr Glu Gln Arg Gln Val Val Ala
                805                 810                 815

Val Thr Gly Asp Gly Thr Asn Asp Gly Pro Ala Leu Lys Lys Ala Asp
            820                 825                 830

Val Gly Phe Ala Met Gly Ile Ala Gly Thr Asp Val Ala Lys Glu Ala
        835                 840                 845

Ser Asp Ile Ile Leu Thr Asp Asp Asn Phe Ser Ser Ile Val Lys Ala
    850                 855                 860

Val Met Trp Gly Arg Asn Val Tyr Asp Ser Ile Ser Lys Phe Leu Gln
865                 870                 875                 880

Phe Gln Leu Thr Val Asn Val Val Ala Val Ile Val Ala Phe Thr Gly
                885                 890                 895

Ala Cys Ile Thr Gln Asp Ser Pro Leu Lys Ala Val Gln Met Leu Trp
            900                 905                 910

Val Asn Leu Ile Met Asp Thr Phe Ala Ser Leu Ala Leu Ala Thr Glu
        915                 920                 925

Pro Pro Thr Glu Thr Leu Leu Leu Arg Lys Pro Tyr Gly Arg Asn Lys
    930                 935                 940

Pro Leu Ile Ser Arg Thr Met Met Lys Asn Ile Leu Gly His Ala Val
945                 950                 955                 960

Tyr Gln Leu Ala Leu Ile Phe Thr Leu Leu Phe Val Gly Glu Lys Met
                965                 970                 975
```

```
Phe Gln Ile Asp Ser Gly Arg Asn Ala Pro Leu His Ser Pro Pro Ser
            980                 985                 990


Glu His Tyr Thr Ile Ile Phe Asn  Thr Phe Val Met Met  Gln Leu Phe
        995                 1000                1005


Asn Glu  Ile Asn Ala Arg Lys  Ile His Gly Glu Arg  Asn Val Phe
    1010                1015                1020


Asp Gly  Ile Phe Arg Asn Pro  Ile Phe Cys Thr Ile  Val Leu Gly
    1025                1030                1035


Thr Phe  Ala Ile Gln Ile Val  Ile Val Gln Phe Gly  Gly Lys Pro
    1040                1045                1050


Phe Ser  Cys Ser Pro Leu Gln  Leu Asp Gln Trp Met  Trp Cys Ile
    1055                1060                1065


Phe Ile  Gly Leu Gly Glu Leu  Val Trp Gly Gln Val  Ile Ala Thr
    1070                1075                1080


Ile Pro  Thr Ser Arg Leu Lys  Phe Leu Lys Glu Ala  Gly Arg Leu
    1085                1090                1095


Thr Gln  Lys Glu Glu Ile Pro  Glu Glu Glu Leu Asn  Glu Asp Val
    1100                1105                1110


Glu Glu  Ile Asp His Ala Glu  Arg Glu Leu Arg Arg  Gly Gln Ile
    1115                1120                1125


Leu Trp  Phe Arg Gly Leu Asn  Arg Ile Gln Thr Gln  Ile Glu Val
    1130                1135                1140


Val Asn  Thr Phe Lys Ser Gly  Ala Ser Phe Gln Gly  Ala Leu Arg
    1145                1150                1155


Arg Gln  Ser Ser Val Thr Ser  Gln Ser Gln Asp Ile  Arg Val Val
    1160                1165                1170


Lys Ala  Phe Arg Ser Ser Leu  Tyr Glu Gly Leu Glu  Lys Pro Glu
    1175                1180                1185


Ser Arg  Thr Ser Ile His Asn  Phe Met Ala His Pro  Glu Phe Arg
    1190                1195                1200


Ile Glu  Asp Ser Gln Pro His  Ile Pro Leu Ile Asp  Asp Thr Asp
    1205                1210                1215


Leu Glu  Glu Asp Ala Ala Leu  Lys Gln Asn Ser Ser  Pro Pro Ser
    1220                1225                1230
```

```
Ser Leu  Asn Lys Asn Asn Ser  Ala Ile Asp Ser Gly  Ile Asn Leu
    1235                1240                1245


Thr Thr  Asp Thr Ser Lys Ser  Ala Thr Ser Ser Ser  Pro Gly Ser
    1250                1255                1260


Pro Ile  His Ser Leu Glu Thr  Ser Leu
    1265                1270
```

<210> 31
<211> 1241
<212> PRT
<213> Homo sapiens

<400> 31

```
Met Thr Asn Pro Ser Asp Arg Val Leu Pro Ala Asn Ser Met Ala Glu
1               5                   10                  15


Ser Arg Glu Gly Asp Phe Gly Cys Thr Val Met Glu Leu Arg Lys Leu
            20                  25                  30


Met Glu Leu Arg Ser Arg Asp Ala Leu Thr Gln Ile Asn Val His Tyr
        35                  40                  45


Gly Gly Val Gln Asn Leu Cys Ser Arg Leu Lys Thr Ser Pro Val Glu
    50                  55                  60


Gly Leu Ser Gly Asn Pro Ala Asp Leu Glu Lys Arg Arg Gln Val Phe
65                  70                  75                  80


Gly His Asn Val Ile Pro Pro Lys Lys Pro Lys Thr Phe Leu Glu Leu
                85                  90                  95


Val Trp Glu Ala Leu Gln Asp Val Thr Leu Ile Ile Leu Glu Ile Ala
            100                 105                 110


Ala Ile Ile Ser Leu Val Leu Ser Phe Tyr Arg Pro Ala Gly Glu Glu
        115                 120                 125


Asn Glu Leu Cys Gly Gln Val Ala Thr Thr Pro Glu Asp Glu Asn Glu
    130                 135                 140


Ala Gln Ala Gly Trp Ile Glu Gly Ala Ala Ile Leu Phe Ser Val Ile
145                 150                 155                 160


Ile Val Val Leu Val Thr Ala Phe Asn Asp Trp Ser Lys Glu Lys Gln
                165                 170                 175


Phe Arg Gly Leu Gln Cys Arg Ile Glu Gln Glu Gln Lys Phe Ser Ile
            180                 185                 190


Ile Arg Asn Gly Gln Leu Ile Gln Leu Pro Val Ala Glu Ile Val Val
```

```
        195                 200                 205

Gly Asp Ile Ala Gln Val Lys Tyr Gly Asp Leu Leu Pro Ala Asp Gly
    210                 215                 220

Ile Leu Ile Gln Gly Asn Asp Leu Lys Ile Asp Glu Ser Ser Leu Thr
225                 230                 235                 240

Gly Glu Ser Asp His Val Lys Lys Ser Leu Asp Lys Asp Pro Met Leu
                245                 250                 255

Leu Ser Gly Thr His Val Met Glu Gly Ser Gly Arg Met Val Val Thr
            260                 265                 270

Ala Val Gly Val Asn Ser Gln Thr Gly Ile Ile Leu Thr Leu Leu Gly
        275                 280                 285

Val Asn Glu Asp Asp Glu Gly Glu Lys Lys Lys Lys Gly Lys Lys Gln
    290                 295                 300

Gly Val Pro Glu Asn Arg Asn Lys Ala Lys Thr Gln Asp Gly Val Ala
305                 310                 315                 320

Leu Glu Ile Gln Pro Leu Asn Ser Gln Glu Gly Ile Asp Asn Glu Glu
                325                 330                 335

Lys Asp Lys Lys Ala Val Lys Val Pro Lys Lys Glu Lys Ser Val Leu
            340                 345                 350

Gln Gly Lys Leu Thr Arg Leu Ala Val Gln Ile Gly Lys Ala Gly Leu
        355                 360                 365

Leu Met Ser Ala Leu Thr Val Phe Ile Leu Ile Leu Tyr Phe Val Ile
    370                 375                 380

Asp Asn Phe Val Ile Asn Arg Arg Pro Trp Leu Pro Glu Cys Thr Pro
385                 390                 395                 400

Ile Tyr Ile Gln Tyr Phe Val Lys Phe Phe Ile Ile Gly Ile Thr Val
                405                 410                 415

Leu Val Val Ala Val Pro Glu Gly Leu Pro Leu Ala Val Thr Ile Ser
            420                 425                 430

Leu Ala Tyr Ser Val Lys Lys Met Met Lys Asp Asn Asn Leu Val Arg
        435                 440                 445

His Leu Asp Ala Cys Glu Thr Met Gly Asn Ala Thr Ala Ile Cys Ser
    450                 455                 460

Asp Lys Thr Gly Thr Leu Thr Met Asn Arg Met Thr Val Val Gln Ala
465                 470                 475                 480
```

```
Tyr Ile Gly Gly Ile His Tyr Arg Gln Ile Pro Ser Pro Asp Val Phe
                485                 490                 495

Leu Pro Lys Val Leu Asp Leu Ile Val Asn Gly Ile Ser Ile Asn Ser
            500                 505                 510

Ala Tyr Thr Ser Lys Ile Leu Pro Pro Glu Lys Glu Gly Gly Leu Pro
        515                 520                 525

Arg Gln Val Gly Asn Lys Thr Glu Cys Ala Leu Leu Gly Phe Val Thr
    530                 535                 540

Asp Leu Lys Gln Asp Tyr Gln Ala Val Arg Asn Glu Val Pro Glu Glu
545                 550                 555                 560

Lys Leu Tyr Lys Val Tyr Thr Phe Asn Ser Val Arg Lys Ser Met Ser
                565                 570                 575

Thr Val Ile Arg Asn Pro Asn Gly Gly Phe Arg Met Tyr Ser Lys Gly
            580                 585                 590

Ala Ser Glu Ile Ile Leu Arg Lys Cys Asn Arg Ile Leu Asp Arg Lys
        595                 600                 605

Gly Glu Ala Val Pro Phe Lys Asn Lys Asp Arg Asp Asp Met Val Arg
    610                 615                 620

Thr Val Ile Glu Pro Met Ala Cys Asp Gly Leu Arg Thr Ile Cys Ile
625                 630                 635                 640

Ala Tyr Arg Asp Phe Asp Asp Thr Glu Pro Ser Trp Asp Asn Glu Asn
                645                 650                 655

Glu Ile Leu Thr Glu Leu Thr Cys Ile Ala Val Val Gly Ile Glu Asp
            660                 665                 670

Pro Val Arg Pro Glu Val Pro Asp Ala Ile Ala Lys Cys Lys Gln Ala
        675                 680                 685

Gly Ile Thr Val Arg Met Val Thr Gly Asp Asn Ile Asn Thr Ala Arg
    690                 695                 700

Ala Ile Ala Thr Lys Cys Gly Ile Leu Thr Pro Gly Asp Asp Phe Leu
705                 710                 715                 720

Cys Leu Glu Gly Lys Glu Phe Asn Arg Leu Ile Arg Asn Glu Lys Gly
                725                 730                 735

Glu Val Glu Gln Glu Lys Leu Asp Lys Ile Trp Pro Lys Leu Arg Val
            740                 745                 750
```

```
Leu Ala Arg Ser Ser Pro Thr Asp Lys His Thr Leu Val Lys Gly Ile
        755                 760                 765

Ile Asp Ser Thr Val Gly Glu His Arg Gln Val Val Ala Val Thr Gly
    770                 775                 780

Asp Gly Thr Asn Asp Gly Pro Ala Leu Lys Lys Ala Asp Val Gly Phe
785                 790                 795                 800

Ala Met Gly Ile Ala Gly Thr Asp Val Ala Lys Glu Ala Ser Asp Ile
                805                 810                 815

Ile Leu Thr Asp Asp Asn Phe Thr Ser Ile Val Lys Ala Val Met Trp
            820                 825                 830

Gly Arg Asn Val Tyr Asp Ser Ile Ser Lys Phe Leu Gln Phe Gln Leu
        835                 840                 845

Thr Val Asn Val Val Ala Val Ile Val Ala Phe Thr Gly Ala Cys Ile
    850                 855                 860

Thr Gln Asp Ser Pro Leu Lys Ala Val Gln Met Leu Trp Val Asn Leu
865                 870                 875                 880

Ile Met Asp Thr Phe Ala Ser Leu Ala Leu Ala Thr Glu Pro Pro Thr
                885                 890                 895

Glu Ser Leu Leu Lys Arg Arg Pro Tyr Gly Arg Asn Lys Pro Leu Ile
            900                 905                 910

Ser Arg Thr Met Met Lys Asn Ile Leu Gly His Ala Phe Tyr Gln Leu
        915                 920                 925

Ile Val Ile Phe Ile Leu Val Phe Ala Gly Glu Lys Phe Phe Asp Ile
    930                 935                 940

Asp Ser Gly Arg Lys Ala Pro Leu His Ser Pro Pro Ser Gln His Tyr
945                 950                 955                 960

Thr Ile Val Phe Asn Thr Phe Val Leu Met Gln Leu Phe Asn Glu Ile
                965                 970                 975

Asn Ser Arg Lys Ile His Gly Glu Lys Asn Val Phe Ser Gly Ile Tyr
            980                 985                 990

Arg Asn Ile Ile Phe Cys Ser Val  Val Leu Gly Thr Phe  Ile Cys Gln
        995                 1000                1005

Ile Phe  Ile Val Glu Phe Gly  Gly Lys Pro Phe Ser  Cys Thr Ser
    1010                1015                1020
```

```
Leu Ser  Leu Ser Gln Trp Leu  Trp Cys Leu Phe Ile  Gly Ile Gly
    1025                1030                1035


Glu Leu  Leu Trp Gly Gln Phe  Ile Ser Ala Ile Pro  Thr Arg Ser
    1040                1045                1050


Leu Lys  Phe Leu Lys Glu Ala  Gly His Gly Thr Thr  Lys Glu Glu
    1055                1060                1065


Ile Thr  Lys Asp Ala Glu Gly  Leu Asp Glu Ile Asp  His Ala Glu
    1070                1075                1080


Met Glu  Leu Arg Arg Gly Gln  Ile Leu Trp Phe Arg  Gly Leu Asn
    1085                1090                1095


Arg Ile  Gln Thr Gln Ile Asp  Val Ile Asn Thr Phe  Gln Thr Gly
    1100                1105                1110


Ala Ser  Phe Lys Gly Val Leu  Arg Arg Gln Asn Met  Gly Gln His
    1115                1120                1125


Leu Asp  Val Lys Leu Val Pro  Ser Ser Ser Tyr Ile  Lys Val Val
    1130                1135                1140


Lys Ala  Phe His Ser Ser Leu  His Glu Ser Ile Gln  Lys Pro Tyr
    1145                1150                1155


Asn Gln  Lys Ser Ile His Ser  Phe Met Thr His Pro  Glu Phe Ala
    1160                1165                1170


Ile Glu  Glu Glu Leu Pro Arg  Thr Pro Leu Leu Asp  Glu Glu Glu
    1175                1180                1185


Glu Glu  Asn Pro Asp Lys Ala  Ser Lys Phe Gly Thr  Arg Val Leu
    1190                1195                1200


Leu Leu  Asp Gly Glu Val Thr  Pro Tyr Ala Asn Thr  Asn Asn Asn
    1205                1210                1215


Ala Val  Asp Cys Asn Gln Val  Gln Leu Pro Gln Ser  Asp Ser Ser
    1220                1225                1230


Leu Gln  Ser Leu Glu Thr Ser  Val
    1235                1240


<210>  32
<211>  1241
<212>  PRT
<213>  homo sapiens

<400>  32

Met Thr Asn Pro Ser Asp Arg Val Leu Pro Ala Asn Ser Met Ala Glu
1               5                   10                  15
```

```
Ser Arg Glu Gly Asp Phe Gly Cys Thr Val Met Glu Leu Arg Lys Leu
            20                  25                  30

Met Glu Leu Arg Ser Arg Asp Ala Leu Thr Gln Ile Asn Val His Tyr
        35                  40                  45

Gly Gly Val Gln Asn Leu Cys Ser Arg Leu Lys Thr Ser Pro Val Glu
    50                  55                  60

Gly Leu Ser Gly Asn Pro Ala Asp Leu Glu Lys Arg Arg Gln Val Phe
65                  70                  75                  80

Gly His Asn Val Ile Pro Pro Lys Lys Pro Lys Thr Phe Leu Glu Leu
                85                  90                  95

Val Trp Glu Ala Leu Gln Asp Val Thr Leu Ile Ile Leu Glu Ile Ala
            100                 105                 110

Ala Ile Ile Ser Leu Val Leu Ser Phe Tyr Arg Pro Ala Gly Glu Glu
        115                 120                 125

Asn Glu Leu Cys Gly Gln Val Ala Thr Thr Pro Glu Asp Glu Asn Glu
    130                 135                 140

Ala Gln Ala Gly Trp Ile Glu Gly Ala Ala Ile Leu Phe Ser Val Ile
145                 150                 155                 160

Ile Val Val Leu Val Thr Ala Phe Asn Asp Trp Ser Lys Glu Lys Gln
                165                 170                 175

Phe Arg Gly Leu Gln Cys Arg Ile Glu Gln Glu Gln Lys Phe Ser Ile
            180                 185                 190

Ile Arg Asn Gly Gln Leu Ile Gln Leu Pro Val Ala Glu Ile Val Val
        195                 200                 205

Gly Asp Ile Ala Gln Val Lys Tyr Gly Asp Leu Leu Pro Ala Asp Gly
    210                 215                 220

Ile Leu Ile Gln Gly Asn Asp Leu Lys Ile Asp Glu Ser Ser Leu Thr
225                 230                 235                 240

Gly Glu Ser Asp His Val Lys Lys Ser Leu Asp Lys Asp Pro Met Leu
                245                 250                 255

Leu Ser Gly Thr His Val Met Glu Gly Ser Gly Arg Met Val Val Thr
            260                 265                 270

Ala Val Gly Val Asn Ser Gln Thr Gly Ile Ile Leu Thr Leu Leu Gly
        275                 280                 285
```

```
Val Asn Glu Asp Asp Glu Gly Glu Lys Lys Lys Lys Gly Lys Lys Gln
    290                 295                 300

Gly Val Pro Glu Asn Arg Asn Lys Ala Lys Thr Gln Asp Gly Val Ala
305                 310                 315                 320

Leu Glu Ile Gln Pro Leu Asn Ser Gln Glu Gly Ile Asp Asn Glu Glu
                325                 330                 335

Lys Asp Lys Lys Ala Val Lys Val Pro Lys Lys Glu Lys Ser Val Leu
            340                 345                 350

Gln Gly Lys Leu Thr Arg Leu Ala Val Gln Ile Gly Lys Ala Gly Leu
        355                 360                 365

Leu Met Ser Ala Leu Thr Val Phe Ile Leu Ile Leu Tyr Phe Val Ile
    370                 375                 380

Asp Asn Phe Val Ile Asn Arg Arg Pro Trp Leu Pro Glu Cys Thr Pro
385                 390                 395                 400

Ile Tyr Ile Gln Tyr Phe Val Lys Phe Phe Ile Ile Gly Ile Thr Val
                405                 410                 415

Leu Val Val Ala Val Pro Glu Gly Leu Pro Leu Ala Val Thr Ile Ser
            420                 425                 430

Leu Ala Tyr Ser Val Lys Lys Met Met Lys Asp Asn Asn Leu Val Arg
        435                 440                 445

His Leu Asp Ala Cys Glu Thr Met Gly Asn Ala Thr Ala Ile Cys Ser
    450                 455                 460

Asp Lys Thr Gly Thr Leu Thr Met Asn Arg Met Thr Val Val Gln Ala
465                 470                 475                 480

Tyr Ile Gly Gly Ile His Tyr Arg Gln Ile Pro Ser Pro Asp Val Phe
                485                 490                 495

Leu Pro Lys Val Leu Asp Leu Ile Val Asn Gly Ile Ser Ile Asn Ser
            500                 505                 510

Ala Tyr Thr Ser Lys Ile Leu Pro Pro Glu Lys Glu Gly Gly Leu Pro
        515                 520                 525

Arg Gln Val Gly Asn Lys Thr Glu Cys Ala Leu Leu Gly Phe Val Thr
    530                 535                 540

Asp Leu Lys Gln Asp Tyr Gln Ala Val Arg Asn Glu Val Pro Glu Glu
545                 550                 555                 560
```

```
Lys Leu Tyr Lys Val Tyr Thr Phe Asn Ser Val Arg Lys Ser Met Ser
                565                 570                 575

Thr Val Ile Arg Asn Pro Asn Gly Gly Phe Arg Met Tyr Ser Lys Gly
            580                 585                 590

Ala Ser Glu Ile Ile Leu Arg Lys Cys Asn Arg Ile Leu Asp Arg Lys
        595                 600                 605

Gly Glu Ala Val Pro Phe Lys Asn Lys Asp Arg Asp Asp Met Val Arg
    610                 615                 620

Thr Val Ile Glu Pro Met Ala Cys Asp Gly Leu Arg Thr Ile Cys Ile
625                 630                 635                 640

Ala Tyr Arg Asp Phe Asp Asp Thr Glu Pro Ser Trp Asp Asn Glu Asn
                645                 650                 655

Glu Ile Leu Thr Glu Leu Thr Cys Ile Ala Val Val Gly Ile Glu Asp
            660                 665                 670

Pro Val Arg Pro Glu Val Pro Asp Ala Ile Ala Lys Cys Lys Gln Ala
        675                 680                 685

Gly Ile Thr Val Arg Met Val Thr Gly Asp Asn Ile Asn Thr Ala Arg
    690                 695                 700

Ala Ile Ala Thr Lys Cys Gly Ile Leu Thr Pro Gly Asp Asp Phe Leu
705                 710                 715                 720

Cys Leu Glu Gly Lys Glu Phe Asn Arg Leu Ile Arg Asn Glu Lys Gly
                725                 730                 735

Glu Val Glu Gln Glu Lys Leu Asp Lys Ile Trp Pro Lys Leu Arg Val
            740                 745                 750

Leu Ala Arg Ser Ser Pro Thr Asp Lys His Thr Leu Val Lys Gly Ile
        755                 760                 765

Ile Asp Ser Thr Val Gly Glu His Arg Gln Val Val Ala Val Thr Gly
    770                 775                 780

Asp Gly Thr Asn Asp Gly Pro Ala Leu Lys Lys Ala Asp Val Gly Phe
785                 790                 795                 800

Ala Met Gly Ile Ala Gly Thr Asp Val Ala Lys Glu Ala Ser Asp Ile
                805                 810                 815

Ile Leu Thr Asp Asp Asn Phe Thr Ser Ile Val Lys Ala Val Met Trp
            820                 825                 830

Gly Arg Asn Val Tyr Asp Ser Ile Ser Lys Phe Leu Gln Phe Gln Leu
```

```
        835                 840                 845

Thr Val Asn Val Val Ala Val Ile Val Ala Phe Thr Gly Ala Cys Ile
    850                 855                 860

Thr Gln Asp Ser Pro Leu Lys Ala Val Gln Met Leu Trp Val Asn Leu
865                 870                 875                 880

Ile Met Asp Thr Phe Ala Ser Leu Ala Leu Ala Thr Glu Pro Pro Thr
                885                 890                 895

Glu Ser Leu Leu Lys Arg Arg Pro Tyr Gly Arg Asn Lys Pro Leu Ile
            900                 905                 910

Ser Arg Thr Met Met Lys Asn Ile Leu Gly His Ala Phe Tyr Gln Leu
        915                 920                 925

Ile Val Ile Phe Ile Leu Val Phe Ala Gly Glu Lys Phe Phe Asp Ile
    930                 935                 940

Asp Ser Gly Arg Lys Ala Pro Leu His Ser Pro Pro Ser Gln His Tyr
945                 950                 955                 960

Thr Ile Val Phe Asn Thr Phe Val Leu Met Gln Leu Phe Asn Glu Ile
                965                 970                 975

Asn Ser Arg Lys Ile His Gly Glu Lys Asn Val Phe Ser Gly Ile Tyr
            980                 985                 990

Arg Asn Ile Ile Phe Cys Ser Val  Val Leu Gly Thr Phe  Ile Cys Gln
        995                 1000                1005

Ile Phe  Ile Val Glu Phe Gly  Gly Lys Pro Phe Ser  Cys Thr Ser
    1010                1015                1020

Leu Ser  Leu Ser Gln Trp Leu  Trp Cys Leu Phe Ile  Gly Ile Gly
    1025                1030                1035

Glu Leu  Leu Trp Gly Gln Phe  Ile Ser Ala Ile Pro  Thr Arg Ser
    1040                1045                1050

Leu Lys  Phe Leu Lys Glu Ala  Gly His Gly Thr Thr  Lys Glu Glu
    1055                1060                1065

Ile Thr  Lys Asp Ala Glu Gly  Leu Asp Glu Ile Asp  His Ala Glu
    1070                1075                1080

Met Glu  Leu Arg Arg Gly Gln  Ile Leu Trp Phe Arg  Gly Leu Asn
    1085                1090                1095

Arg Ile  Gln Thr Gln Ile Asp  Val Ile Asn Thr Phe  Gln Thr Gly
    1100                1105                1110
```

```
Ala Ser  Phe Lys Gly Val Leu  Arg Arg Gln Asn Met  Gly Gln His
    1115                 1120                 1125


Leu Asp  Val Lys Leu Val Pro  Ser Ser Ser Tyr Ile  Lys Val Val
    1130                 1135                 1140


Lys Ala  Phe His Ser Ser Leu  His Glu Ser Ile Gln  Lys Pro Tyr
    1145                 1150                 1155


Asn Gln  Lys Ser Ile His Ser  Phe Met Thr His Pro  Glu Phe Ala
    1160                 1165                 1170


Ile Glu  Glu Glu Leu Pro Arg  Thr Pro Leu Leu Asp  Glu Glu Glu
    1175                 1180                 1185


Glu Glu  Asn Pro Asp Lys Ala  Ser Lys Phe Gly Thr  Arg Val Leu
    1190                 1195                 1200


Leu Leu  Asp Gly Glu Val Thr  Pro Tyr Ala Asn Thr  Asn Asn Asn
    1205                 1210                 1215


Ala Val  Asp Cys Asn Gln Val  Gln Leu Pro Gln Ser  Asp Ser Ser
    1220                 1225                 1230


Leu Gln  Ser Leu Glu Thr Ser  Val
    1235                 1240
```

<210> 33
<211> 193
<212> PRT
<213> homo sapiens

<400> 33

```
Gly Pro Ile Phe Asn Ala Ser Val His Ser Asp Thr Pro Ser Val Ile
1               5                   10                  15


Arg Gly Asp Leu Ile Lys Leu Phe Cys Ile Ile Thr Val Glu Gly Ala
            20                  25                  30


Ala Leu Asp Pro Asp Asp Met Ala Phe Asp Val Ser Trp Phe Ala Val
        35                  40                  45


His Ser Phe Gly Leu Asp Lys Ala Pro Val Leu Leu Ser Ser Leu Asp
    50                  55                  60


Arg Lys Gly Ile Val Thr Thr Ser Arg Arg Asp Trp Lys Ser Asp Leu
65                  70                  75                  80


Ser Leu Glu Arg Val Ser Val Leu Glu Phe Leu Leu Gln Val His Gly
                85                  90                  95
```

```
Ser Glu Asp Gln Asp Phe Gly Asn Tyr Tyr Cys Ser Val Thr Pro Trp
            100                 105                 110

Val Lys Ser Pro Thr Gly Ser Trp Gln Lys Glu Ala Glu Ile His Ser
        115                 120                 125

Lys Pro Val Phe Ile Thr Val Lys Met Asp Val Leu Asn Ala Phe Lys
    130                 135                 140

Tyr Pro Leu Leu Ile Gly Val Gly Leu Ser Thr Val Ile Gly Leu Leu
145                 150                 155                 160

Ser Cys Leu Ile Gly Tyr Cys Ser Ser His Trp Cys Cys Lys Lys Glu
                165                 170                 175

Val Gln Glu Thr Arg Arg Glu Arg Arg Arg Leu Met Ser Met Glu Met
            180                 185                 190

Asp
```

<210> 34
<211> 1021
<212> PRT
<213> homo sapiens

<400> 34

```
Met Ala Gly Ile Ser Tyr Val Ala Ser Phe Phe Leu Leu Leu Thr Lys
1               5                   10                  15

Leu Ser Ile Gly Gln Arg Glu Val Thr Val Gln Lys Gly Pro Leu Phe
            20                  25                  30

Arg Ala Glu Gly Tyr Pro Val Ser Ile Gly Cys Asn Val Thr Gly His
        35                  40                  45

Gln Gly Pro Ser Glu Gln His Phe Gln Trp Ser Val Tyr Leu Pro Thr
    50                  55                  60

Asn Pro Thr Gln Glu Val Gln Ile Ile Ser Thr Lys Asp Ala Ala Phe
65                  70                  75                  80

Ser Tyr Ala Val Tyr Thr Gln Arg Val Arg Ser Gly Asp Val Tyr Val
                85                  90                  95

Glu Arg Val Gln Gly Asn Ser Val Leu Leu His Ile Ser Lys Leu Gln
            100                 105                 110

Met Lys Asp Ala Gly Glu Tyr Glu Cys His Thr Pro Asn Thr Asp Glu
        115                 120                 125

Lys Tyr Tyr Gly Ser Tyr Ser Ala Lys Thr Asn Leu Ile Val Ile Pro
    130                 135                 140
```

```
Asp Thr Leu Ser Ala Thr Met Ser Ser Gln Thr Leu Gly Lys Glu Glu
145                 150                 155                 160

Gly Glu Pro Leu Ala Leu Thr Cys Glu Ala Ser Lys Ala Thr Ala Gln
                165                 170                 175

His Thr His Leu Ser Val Thr Trp Tyr Leu Thr Gln Asp Gly Gly Gly
            180                 185                 190

Ser Gln Ala Thr Glu Ile Ile Ser Leu Ser Lys Asp Phe Ile Leu Val
        195                 200                 205

Pro Gly Pro Leu Tyr Thr Glu Arg Phe Ala Ala Ser Asp Val Gln Leu
    210                 215                 220

Asn Lys Leu Gly Pro Thr Thr Phe Arg Leu Ser Ile Glu Arg Leu Gln
225                 230                 235                 240

Ser Ser Asp Gln Gly Gln Leu Phe Cys Glu Ala Thr Glu Trp Ile Gln
                245                 250                 255

Asp Pro Asp Glu Thr Trp Met Phe Ile Thr Lys Lys Gln Thr Asp Gln
            260                 265                 270

Thr Thr Leu Arg Ile Gln Pro Ala Val Lys Asp Phe Gln Val Asn Ile
        275                 280                 285

Thr Ala Asp Ser Leu Phe Ala Glu Gly Lys Pro Leu Glu Leu Val Cys
    290                 295                 300

Leu Val Val Ser Ser Gly Arg Asp Pro Gln Leu Gln Gly Ile Trp Phe
305                 310                 315                 320

Phe Asn Gly Thr Glu Ile Ala His Ile Asp Ala Gly Gly Val Leu Gly
                325                 330                 335

Leu Lys Asn Asp Tyr Lys Glu Arg Ala Ser Gln Gly Glu Leu Gln Val
            340                 345                 350

Ser Lys Leu Gly Pro Lys Ala Phe Ser Leu Lys Ile Phe Ser Leu Gly
        355                 360                 365

Pro Glu Asp Glu Gly Ala Tyr Arg Cys Val Val Ala Glu Val Met Lys
    370                 375                 380

Thr Arg Thr Gly Ser Trp Gln Val Leu Gln Arg Lys Gln Ser Pro Asp
385                 390                 395                 400

Ser His Val His Leu Arg Lys Pro Ala Ala Arg Ser Val Val Met Ser
                405                 410                 415
```

```
Thr Lys Asn Lys Gln Gln Val Val Trp Glu Gly Glu Thr Leu Ala Phe
            420                 425                 430

Leu Cys Lys Ala Gly Gly Ala Glu Ser Pro Leu Ser Val Ser Trp Trp
        435                 440                 445

His Ile Pro Arg Asp Gln Thr Gln Pro Glu Phe Val Ala Gly Met Gly
    450                 455                 460

Gln Asp Gly Ile Val Gln Leu Gly Ala Ser Tyr Gly Val Pro Ser Tyr
465                 470                 475                 480

His Gly Asn Thr Arg Leu Glu Lys Met Asp Trp Ala Thr Phe Gln Leu
                485                 490                 495

Glu Ile Thr Phe Thr Ala Ile Thr Asp Ser Gly Thr Tyr Glu Cys Arg
            500                 505                 510

Val Ser Glu Lys Ser Arg Asn Gln Ala Arg Asp Leu Ser Trp Thr Gln
        515                 520                 525

Lys Ile Ser Val Thr Val Lys Ser Leu Glu Ser Ser Leu Gln Val Ser
    530                 535                 540

Leu Met Ser Arg Gln Pro Gln Val Met Leu Thr Asn Thr Phe Asp Leu
545                 550                 555                 560

Ser Cys Val Val Arg Ala Gly Tyr Ser Asp Leu Lys Val Pro Leu Thr
                565                 570                 575

Val Thr Trp Gln Phe Gln Pro Ala Ser Ser His Ile Phe His Gln Leu
            580                 585                 590

Ile Arg Ile Thr His Asn Gly Thr Ile Glu Trp Gly Asn Phe Leu Ser
        595                 600                 605

Arg Phe Gln Lys Lys Thr Lys Val Ser Gln Ser Leu Phe Arg Ser Gln
    610                 615                 620

Leu Leu Val His Asp Ala Thr Glu Glu Glu Thr Gly Val Tyr Gln Cys
625                 630                 635                 640

Glu Val Glu Val Tyr Asp Arg Asn Ser Leu Tyr Asn Asn Arg Pro Pro
                645                 650                 655

Arg Ala Ser Ala Ile Ser His Pro Leu Arg Ile Ala Val Thr Leu Pro
            660                 665                 670

Glu Ser Lys Leu Lys Val Asn Ser Arg Ser Gln Val Gln Glu Leu Ser
        675                 680                 685
```

```
Ile Asn Ser Asn Thr Asp Ile Glu Cys Ser Ile Leu Ser Arg Ser Asn
    690                 695                 700

Gly Asn Leu Gln Leu Ala Ile Ile Trp Tyr Phe Ser Pro Val Ser Thr
705                 710                 715                 720

Asn Ala Ser Trp Leu Lys Ile Leu Glu Met Asp Gln Thr Asn Val Ile
                725                 730                 735

Lys Thr Gly Asp Glu Phe His Thr Pro Gln Arg Lys Gln Lys Phe His
            740                 745                 750

Thr Glu Lys Val Ser Gln Asp Leu Phe Gln Leu His Ile Leu Asn Val
        755                 760                 765

Glu Asp Ser Asp Arg Gly Lys Tyr His Cys Ala Val Glu Glu Trp Leu
    770                 775                 780

Leu Ser Thr Asn Gly Thr Trp His Lys Leu Gly Glu Lys Lys Ser Gly
785                 790                 795                 800

Leu Thr Glu Leu Lys Leu Lys Pro Thr Gly Ser Lys Val Arg Val Ser
                805                 810                 815

Lys Val Tyr Trp Thr Glu Asn Val Thr Glu His Arg Glu Val Ala Ile
            820                 825                 830

Arg Cys Ser Leu Glu Ser Val Gly Ser Ser Ala Thr Leu Tyr Ser Val
        835                 840                 845

Met Trp Tyr Trp Asn Arg Glu Asn Ser Gly Ser Lys Leu Leu Val His
    850                 855                 860

Leu Gln His Asp Gly Leu Leu Glu Tyr Gly Glu Glu Gly Leu Arg Arg
865                 870                 875                 880

His Leu His Cys Tyr Arg Ser Ser Ser Thr Asp Phe Val Leu Lys Leu
                885                 890                 895

His Gln Val Glu Met Glu Asp Ala Gly Met Tyr Trp Cys Arg Val Ala
            900                 905                 910

Glu Trp Gln Leu His Gly His Pro Ser Lys Trp Ile Asn Gln Ala Ser
        915                 920                 925

Asp Glu Ser Gln Arg Met Val Leu Thr Val Leu Pro Ser Glu Pro Thr
    930                 935                 940

Leu Pro Ser Arg Ile Cys Ser Ser Ala Pro Leu Leu Tyr Phe Leu Phe
945                 950                 955                 960

Ile Cys Pro Phe Val Leu Leu Leu Leu Leu Leu Ile Ser Leu Leu Cys
```

965 970 975

Leu Tyr Trp Lys Ala Arg Lys Leu Ser Thr Leu Arg Ser Asn Thr Arg
980 985 990

Lys Glu Lys Ala Leu Trp Val Asp Leu Lys Glu Ala Gly Gly Val Thr
995 1000 1005

Thr Asn Arg Arg Glu Asp Glu Glu Glu Asp Glu Gly Asn
1010 1015 1020

<210> 35
<211> 20
<212> PRT
<213> homo sapiens

<400> 35

Met Ala Gly Ile Ser Tyr Val Ala Ser Phe Phe Leu Leu Leu Thr Lys
1 5 10 15

Leu Ser Ile Gly
20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 36
cgttggcagt ccgccttaac 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide

<400> 37
catagtcact gacgttgcag 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide

<400> 38
ttgtggagct tgcaagcacc 20

<210> 39
<211> 20
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide

<400> 39
gttctttatg tggagctcca 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide

<400> 40
tatcccttgc tgatcggcgt 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide

<400> 41
gctgcagtac ccgatgagac 20

<210> 42
<211> 38
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 42

Glu His Ser Ala Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp
1 5 10 15

Lys Gly Gly Gly Gly Ser Leu Ser Asn Pro Ile Glu Ile Asp Phe Gln
            20 25 30

Thr Ser Gly Pro Ile Phe
        35

<210> 43
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 43

Glu His Ser Ala Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp
1 5 10 15

Lys Gly Gly Gly Gly Ser Ile Glu Ile Asp Phe Gln Thr Ser Gly Pro
            20   25   30

Ile Phe

<210> 44
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 44

Glu His Ser Ala Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp
1   5   10   15

Lys Gly Gly Gly Gly Ser Phe Gln Thr Ser Gly Pro Ile Phe
            20   25   30

<210> 45
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 45

Glu His Ser Ala Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp
1   5   10   15

Lys Gly Gly Gly Gly Ser Gly Pro Ile Phe
            20   25

<210> 46
<211> 42
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 46

Phe Ile Thr Val Lys Met Asp Thr Leu Asp Pro Arg Ser Phe Leu Leu
1   5   10   15

Arg Asn Pro Asn Asp Lys Tyr Glu Pro Phe Trp Glu Asp Glu Glu Lys
            20   25   30

Asn Glu Ser Gly Ser Asp Lys Thr His Thr
        35   40

<210> 47
<211> 332
<212> PRT

<213> Homo sapiens

<400> 47

```
Met Gly Ala Gln Phe Ser Lys Thr Ala Ala Lys Gly Glu Ala Ala Ala
1               5                   10                  15


Glu Arg Pro Gly Glu Ala Ala Val Ala Ser Ser Pro Ser Lys Ala Asn
            20                  25                  30


Gly Gln Glu Asn Gly His Val Lys Val Asn Gly Asp Ala Ser Pro Ala
        35                  40                  45


Ala Ala Glu Ser Gly Ala Lys Glu Glu Leu Gln Ala Asn Gly Ser Ala
    50                  55                  60


Pro Ala Ala Asp Lys Glu Glu Pro Ala Ala Ala Gly Ser Gly Ala Ala
65                  70                  75                  80


Ser Pro Ser Ala Ala Glu Lys Gly Glu Pro Ala Ala Ala Ala Ala Pro
                85                  90                  95


Glu Ala Gly Ala Ser Pro Val Glu Lys Glu Ala Pro Ala Glu Gly Glu
            100                 105                 110


Ala Ala Glu Pro Gly Ser Pro Thr Ala Ala Glu Gly Glu Ala Ala Ser
        115                 120                 125


Ala Ala Ser Ser Thr Ser Ser Pro Lys Ala Glu Asp Gly Ala Thr Pro
    130                 135                 140


Ser Pro Ser Asn Glu Thr Pro Lys Lys Lys Lys Lys Arg Phe Ser Phe
145                 150                 155                 160


Lys Lys Ser Phe Lys Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys
                165                 170                 175


Glu Ala Gly Glu Gly Gly Glu Ala Glu Ala Pro Ala Ala Glu Gly Gly
            180                 185                 190


Lys Asp Glu Ala Ala Gly Gly Ala Ala Ala Ala Ala Ala Glu Ala Gly
        195                 200                 205


Ala Ala Ser Gly Glu Gln Ala Ala Ala Pro Gly Glu Glu Ala Ala Ala
    210                 215                 220


Gly Glu Glu Gly Ala Ala Gly Gly Asp Pro Gln Glu Ala Lys Pro Gln
225                 230                 235                 240


Glu Ala Ala Val Ala Pro Glu Lys Pro Pro Ala Ser Asp Glu Thr Lys
                245                 250                 255


Ala Ala Glu Glu Pro Ser Lys Val Glu Glu Lys Lys Ala Glu Glu Ala
```

```
            260                 265                 270

Gly Ala Ser Ala Ala Ala Cys Glu Ala Pro Ser Ala Ala Gly Pro Gly
        275                 280                 285

Ala Pro Pro Glu Gln Glu Ala Ala Pro Ala Glu Glu Pro Ala Ala Ala
    290                 295                 300

Ala Ala Ser Ser Ala Cys Ala Ala Pro Ser Gln Glu Ala Gln Pro Glu
305                 310                 315                 320

Cys Ser Pro Glu Ala Pro Pro Ala Glu Ala Ala Glu
                325                 330
```

<210> 48
<211> 195
<212> PRT
<213> Homo sapiens

<400> 48

```
Met Gly Ser Gln Ser Ser Lys Ala Pro Arg Gly Asp Val Thr Ala Glu
1               5                   10                  15

Glu Ala Ala Gly Ala Ser Pro Ala Lys Ala Asn Gly Gln Glu Asn Gly
            20                  25                  30

His Val Lys Ser Asn Gly Asp Leu Ser Pro Lys Gly Glu Gly Glu Ser
        35                  40                  45

Pro Pro Val Asn Gly Thr Asp Glu Ala Ala Gly Ala Thr Gly Asp Ala
    50                  55                  60

Ile Glu Pro Ala Pro Pro Ser Gln Gly Ala Glu Ala Lys Gly Glu Val
65                  70                  75                  80

Pro Pro Lys Glu Thr Pro Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
                85                  90                  95

Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg Asn Arg Lys Glu Gly
            100                 105                 110

Gly Gly Asp Ser Ser Ala Ser Ser Pro Thr Glu Glu Glu Gln Glu Gln
        115                 120                 125

Gly Glu Ile Gly Ala Cys Ser Asp Glu Gly Thr Ala Gln Glu Gly Lys
    130                 135                 140

Ala Ala Ala Thr Pro Glu Ser Gln Glu Pro Gln Ala Lys Gly Ala Glu
145                 150                 155                 160

Ala Ser Ala Ala Ser Glu Glu Glu Ala Gly Pro Gln Ala Thr Glu Pro
                165                 170                 175
```

```
Ser Thr Pro Ser Gly Pro Glu Ser Gly Pro Thr Pro Ala Ser Ala Glu
            180                 185                 190


Gln Asn Glu
        195


<210>  49
<211>  227
<212>  PRT
<213>  Homo sapiens

<400>  49

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1               5                   10                  15


Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Thr Glu
            20                  25                  30


Glu Glu Gly Thr Pro Lys Glu Ser Glu Pro Gln Ala Ala Ala Glu Pro
        35                  40                  45


Ala Glu Ala Lys Glu Gly Lys Glu Lys Pro Asp Gln Asp Ala Glu Gly
    50                  55                  60


Lys Ala Glu Glu Lys Glu Gly Glu Lys Asp Ala Ala Ala Ala Lys Glu
65                  70                  75                  80


Glu Ala Pro Lys Ala Glu Pro Glu Lys Thr Glu Gly Ala Ala Glu Ala
                85                  90                  95


Lys Ala Glu Pro Pro Lys Ala Pro Glu Gln Glu Gln Ala Ala Pro Gly
            100                 105                 110


Pro Ala Ala Gly Gly Glu Ala Pro Lys Ala Ala Glu Ala Ala Ala Ala
        115                 120                 125


Pro Ala Glu Ser Ala Ala Pro Ala Ala Gly Glu Glu Pro Ser Lys Glu
    130                 135                 140


Glu Gly Glu Pro Lys Lys Thr Glu Ala Pro Ala Ala Pro Ala Ala Gln
145                 150                 155                 160


Glu Thr Lys Ser Asp Gly Ala Pro Ala Ser Asp Ser Lys Pro Gly Ser
                165                 170                 175


Ser Glu Ala Ala Pro Ser Ser Lys Glu Thr Pro Ala Ala Thr Glu Ala
            180                 185                 190


Pro Ser Ser Thr Pro Lys Ala Gln Gly Pro Ala Ala Ser Ala Glu Glu
        195                 200                 205


Pro Lys Pro Val Glu Ala Pro Ala Ala Asn Ser Asp Gln Thr Val Thr
```

210 215 220

Val Lys Glu
225

<210> 50
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 50

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1 5 10 15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala
20 25 30

<210> 51
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 51

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1 5 10 15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu
20 25

<210> 52
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 52

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1 5 10 15

Glu Lys Ala Lys Glu Lys Asp Lys
20

<210> 53
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 53

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ala Lys Glu
            20

<210> 54
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 54

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys

<210> 55
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 55

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn
1   5   10   15

<210> 56
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 56

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr
1   5   10

<210> 57
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 57

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly
1   5   10

<210> 58
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 58

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys
1   5   10

<210> 59
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 59

Met Gly Gly Lys Leu Ser Lys Lys Lys
1   5

<210> 60
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 60

Met Gly Gly Lys Leu Ser Lys Lys
1   5

<210> 61
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 61

Met Gly Gly Lys Leu Ser Lys
1   5

<210> 62
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 62

Met Gly Gly Lys Leu Ala Lys Lys
1   5

<210> 63
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 63

Met Gly Gly Lys Phe Ser Lys Lys
1   5

<210> 64
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 64

Met Gly Gly Lys Phe Ala Lys Lys
1   5

<210> 65
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 65

Met Gly Gly Lys Ser Ser Lys Lys
1   5

<210> 66
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 66

Met Gly Gly Lys Ser Ala Lys Lys
1   5

<210> 67
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 67

Met Gly Gly Lys Gln Ser Lys Lys

1 5

<210> 68
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 68

Met Gly Gly Lys Gln Ala Lys Lys
1 5

<210> 69
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 69

Met Gly Gly Gln Leu Ser Lys Lys
1 5

<210> 70
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 70

Met Gly Gly Gln Leu Ala Lys Lys
1 5

<210> 71
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 71

Met Gly Gly Gln Phe Ser Lys Lys
1 5

<210> 72
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 72

Met Gly Gly Gln Phe Ala Lys Lys
1   5

<210> 73
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 73

Met Gly Gly Gln Ser Ser Lys Lys
1   5

<210> 74
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 74

Met Gly Gly Gln Ser Ala Lys Lys
1   5

<210> 75
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 75

Met Gly Gly Gln Gln Ser Lys Lys
1   5

<210> 76
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 76

Met Gly Gly Gln Gln Ala Lys Lys
1   5

<210> 77
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 77

Met Gly Ala Lys Leu Ser Lys Lys
1   5

<210> 78
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 78

Met Gly Ala Lys Leu Ala Lys Lys
1   5

<210> 79
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 79

Met Gly Ala Lys Phe Ser Lys Lys
1   5

<210> 80
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 80

Met Gly Ala Lys Phe Ala Lys Lys
1   5

<210> 81
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 81

Met Gly Ala Lys Ser Ser Lys Lys
1   5

<210> 82
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 82

Met Gly Ala Lys Ser Ala Lys Lys
1   5

<210> 83
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 83

Met Gly Ala Lys Gln Ser Lys Lys
1   5

<210> 84
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 84

Met Gly Ala Lys Gln Ala Lys Lys
1   5

<210> 85
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 85

Met Gly Ala Gln Leu Ser Lys Lys
1   5

<210> 86
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 86

Met Gly Ala Gln Leu Ala Lys Lys
1   5

<210> 87
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 87

Met Gly Ala Gln Phe Ser Lys Lys
1 5

<210> 88
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 88

Met Gly Ala Gln Phe Ala Lys Lys
1 5

<210> 89
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 89

Met Gly Ala Gln Ser Ser Lys Lys
1 5

<210> 90
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 90

Met Gly Ala Gln Ser Ala Lys Lys
1 5

<210> 91
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 91

Met Gly Ala Gln Gln Ser Lys Lys
1 5

<210> 92
<211> 8
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 92

Met Gly Ala Gln Gln Ala Lys Lys
1   5

<210> 93
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 93

Met Gly Ser Lys Leu Ser Lys Lys
1   5

<210> 94
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 94

Met Gly Ser Lys Leu Ala Lys Lys
1   5

<210> 95
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 95

Met Gly Ser Lys Phe Ser Lys Lys
1   5

<210> 96
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 96

Met Gly Ser Lys Phe Ala Lys Lys
1   5

<210> 97
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 97

Met Gly Ser Lys Ser Ser Lys Lys
1   5

<210> 98
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 98

Met Gly Ser Lys Ser Ala Lys Lys
1   5

<210> 99
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 99

Met Gly Ser Lys Gln Ser Lys Lys
1   5

<210> 100
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 100

Met Gly Ser Lys Gln Ala Lys Lys
1   5

<210> 101
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 101

Met Gly Ser Gln Leu Ser Lys Lys
1   5

<210> 102
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 102

Met Gly Ser Gln Leu Ala Lys Lys
1   5

<210> 103
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 103

Met Gly Ser Gln Phe Ser Lys Lys
1   5

<210> 104
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 104

Met Gly Ser Gln Phe Ala Lys Lys
1   5

<210> 105
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 105

Met Gly Ser Gln Ser Ser Lys Lys
1   5

<210> 106
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 106

Met Gly Ser Gln Ser Ala Lys Lys
1   5

<210> 107
<211> 8
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 107

Met Gly Ser Gln Gln Ser Lys Lys
1   5

<210> 108
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 108

Met Gly Ser Gln Gln Ala Lys Lys
1   5

<210> 109
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 109

Met Gly Gly Lys Leu Ala Lys
1   5

<210> 110
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 110

Met Gly Gly Lys Phe Ser Lys
1   5

<210> 111
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 111

Met Gly Gly Lys Phe Ala Lys
1   5

<210> 112
<211> 7

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 112

Met Gly Gly Lys Ser Ser Lys
1   5

<210> 113
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 113

Met Gly Gly Lys Ser Ala Lys
1   5

<210> 114
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 114

Met Gly Gly Lys Gln Ser Lys
1   5

<210> 115
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 115

Met Gly Gly Lys Gln Ala Lys
1   5

<210> 116
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 116

Met Gly Gly Gln Leu Ser Lys
1   5

<210> 117

<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 117

Met Gly Gly Gln Leu Ala Lys
1   5

<210> 118
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 118

Met Gly Gly Gln Phe Ser Lys
1   5

<210> 119
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 119

Met Gly Gly Gln Phe Ala Lys
1   5

<210> 120
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 120

Met Gly Gly Gln Ser Ser Lys
1   5

<210> 121
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 121

Met Gly Gly Gln Ser Ala Lys
1   5

<210> 122
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 122

Met Gly Gly Gln Gln Ser Lys
1   5

<210> 123
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 123

Met Gly Gly Gln Gln Ala Lys
1   5

<210> 124
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 124

Met Gly Ala Lys Leu Ser Lys
1   5

<210> 125
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 125

Met Gly Ala Lys Leu Ala Lys
1   5

<210> 126
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 126

Met Gly Ala Lys Phe Ser Lys
1   5

<210> 127
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 127

Met Gly Ala Lys Phe Ala Lys
1   5

<210> 128
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 128

Met Gly Ala Lys Ser Ser Lys
1   5

<210> 129
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 129

Met Gly Ala Lys Ser Ala Lys
1   5

<210> 130
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 130

Met Gly Ala Lys Gln Ser Lys
1   5

<210> 131
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 131

Met Gly Ala Lys Gln Ala Lys
1   5

<210> 132
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 132

Met Gly Ala Gln Leu Ser Lys
1   5

<210> 133
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 133

Met Gly Ala Gln Leu Ala Lys
1   5

<210> 134
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 134

Met Gly Ala Gln Phe Ser Lys
1   5

<210> 135
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 135

Met Gly Ala Gln Phe Ala Lys
1   5

<210> 136
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 136

Met Gly Ala Gln Ser Ser Lys

1 5

<210> 137
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 137

Met Gly Ala Gln Ser Ala Lys
1 5

<210> 138
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 138

Met Gly Ala Gln Gln Ser Lys
1 5

<210> 139
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 139

Met Gly Ala Gln Gln Ala Lys
1 5

<210> 140
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 140

Met Gly Ser Lys Leu Ser Lys
1 5

<210> 141
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 141

Met Gly Ser Lys Leu Ala Lys
1   5

<210> 142
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 142

Met Gly Ser Lys Phe Ser Lys
1   5

<210> 143
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 143

Met Gly Ser Lys Phe Ala Lys
1   5

<210> 144
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 144

Met Gly Ser Lys Ser Ser Lys
1   5

<210> 145
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 145

Met Gly Ser Lys Ser Ala Lys
1   5

<210> 146
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 146

Met Gly Ser Lys Gln Ser Lys
1   5

<210> 147
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 147

Met Gly Ser Lys Gln Ala Lys
1   5

<210> 148
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 148

Met Gly Ser Gln Leu Ser Lys
1   5

<210> 149
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 149

Met Gly Ser Gln Leu Ala Lys
1   5

<210> 150
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 150

Met Gly Ser Gln Phe Ser Lys
1   5

<210> 151
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 151

Met Gly Ser Gln Phe Ala Lys
1 5

<210> 152
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 152

Met Gly Ser Gln Ser Ser Lys
1 5

<210> 153
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 153

Met Gly Ser Gln Ser Ala Lys
1 5

<210> 154
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 154

Met Gly Ser Gln Gln Ser Lys
1 5

<210> 155
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 155

Met Gly Ser Gln Gln Ala Lys
1 5

<210> 156
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 156

Met Gly Ala Lys Leu Ser Lys Lys Lys
1 5

<210> 157
<211> 167
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 157

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1 5 10 15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Ser Gly
20 25 30

Gly Ser Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly
35 40 45

Ser Gly Met Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asp Asn Gly
50 55 60

Gly Thr Gly Asp Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly Ile
65 70 75 80

Ala Glu Trp Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr
85 90 95

Cys Ser Val Arg Gln Ser Ser Ala Gln Asn Arg Lys Tyr Thr Ile Lys
100 105 110

Val Glu Val Pro Lys Gly Ala Trp Arg Ser Tyr Leu Asn Met Glu Leu
115 120 125

Thr Ile Pro Ile Phe Ala Thr Asn Ser Asp Cys Glu Leu Ile Val Lys
130 135 140

Ala Met Gln Gly Leu Leu Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile
145 150 155 160

Ala Ala Asn Ser Gly Ile Tyr
165

<210> 158
<211> 167
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 158

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1 5 10 15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Ser Gly
20 25 30

Gly Ser Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly
35 40 45

Ser Gly Met Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asp Asn Gly
50 55 60

Gly Thr Gly Asp Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly Ile
65 70 75 80

Ala Glu Trp Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr
85 90 95

Cys Ser Val Arg Gln Ser Ser Ala Gln Lys Arg Lys Tyr Thr Ile Lys
100 105 110

Val Glu Val Pro Lys Gly Ala Trp Arg Ser Tyr Leu Asn Met Glu Leu
115 120 125

Thr Ile Pro Ile Phe Ala Thr Asn Ser Asp Cys Glu Leu Ile Val Lys
130 135 140

Ala Met Gln Gly Leu Leu Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile
145 150 155 160

Ala Ala Asn Ser Gly Ile Tyr
165

<210> 159
<211> 296
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 159

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1 5 10 15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Ser Gly
20 25 30

Gly Ser Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly
35 40 45

Ser Gly Met Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asp Asn Gly

```
    50                  55                  60

Gly Thr Gly Asp Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly Ile
65                  70                  75                  80

Ala Glu Trp Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr
                85                  90                  95

Cys Ser Val Arg Gln Ser Ser Ala Gln Asn Arg Lys Tyr Thr Ile Lys
            100                 105                 110

Val Glu Val Pro Lys Gly Ala Trp Arg Ser Tyr Leu Asn Met Glu Leu
        115                 120                 125

Thr Ile Pro Ile Phe Ala Thr Asn Ser Asp Cys Glu Leu Ile Val Lys
    130                 135                 140

Ala Met Gln Gly Leu Leu Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile
145                 150                 155                 160

Ala Ala Asn Ser Gly Ile Tyr Gly Ser Gly Gly Ser Gly Gly Ser Gly
                165                 170                 175

Gly Ser Gly Met Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asp Asn
            180                 185                 190

Gly Gly Thr Gly Asp Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly
        195                 200                 205

Ile Ala Glu Trp Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val
    210                 215                 220

Thr Cys Ser Val Arg Gln Ser Ser Ala Gln Asn Arg Lys Tyr Thr Ile
225                 230                 235                 240

Lys Val Glu Val Pro Lys Gly Ala Trp Arg Ser Tyr Leu Asn Met Glu
                245                 250                 255

Leu Thr Ile Pro Ile Phe Ala Thr Asn Ser Asp Cys Glu Leu Ile Val
            260                 265                 270

Lys Ala Met Gln Gly Leu Leu Lys Asp Gly Asn Pro Ile Pro Ser Ala
        275                 280                 285

Ile Ala Ala Asn Ser Gly Ile Tyr
    290                 295


<210>  160
<211>  296
<212>  PRT
<213>  Artificial Sequence

<220>
```

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 160

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1 5 10 15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Ser Gly
20 25 30

Gly Ser Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly
35 40 45

Ser Gly Met Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asp Asn Gly
50 55 60

Gly Thr Gly Asp Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly Ile
65 70 75 80

Ala Glu Trp Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr
85 90 95

Cys Ser Val Arg Gln Ser Ser Ala Gln Lys Arg Lys Tyr Thr Ile Lys
100 105 110

Val Glu Val Pro Lys Gly Ala Trp Arg Ser Tyr Leu Asn Met Glu Leu
115 120 125

Thr Ile Pro Ile Phe Ala Thr Asn Ser Asp Cys Glu Leu Ile Val Lys
130 135 140

Ala Met Gln Gly Leu Leu Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile
145 150 155 160

Ala Ala Asn Ser Gly Ile Tyr Gly Ser Gly Gly Ser Gly Gly Ser Gly
165 170 175

Gly Ser Gly Met Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asp Asn
180 185 190

Gly Gly Thr Gly Asp Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly
195 200 205

Ile Ala Glu Trp Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val
210 215 220

Thr Cys Ser Val Arg Gln Ser Ser Ala Gln Lys Arg Lys Tyr Thr Ile
225 230 235 240

Lys Val Glu Val Pro Lys Gly Ala Trp Arg Ser Tyr Leu Asn Met Glu
245 250 255

Leu Thr Ile Pro Ile Phe Ala Thr Asn Ser Asp Cys Glu Leu Ile Val

260 265 270

Lys Ala Met Gln Gly Leu Leu Lys Asp Gly Asn Pro Ile Pro Ser Ala
275 280 285

Ile Ala Ala Asn Ser Gly Ile Tyr
290 295

<210> 161
<211> 680
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 161
augaagccca ccgagaacaa cgaagacuuc aacaucgugg ccguggccag caacuucgcg 60

accacggauc ucgaugcuga ccgcgggaag uugcccggca agaagcugcc gcuggaggug 120

cucaaagagu uggaagccaa ugcccggaaa gcuggcugca ccaggggcug ucugaucugc 180

cugucccaca ucaagugcac gcccaagaug aagaaguuca ucccaggacg cugccacacc 240

uacgaaggcg acaaagaguc cgcacagggc ggcauaggcg aggcgaucgu cgacauuccu 300

gagauuccug gguucaagga cuuggagccc uuggagcagu ucaucgcaca ggucgaucug 360

uguguggacu gcacaacugg cugccucaaa gggcuugcca acgugcagug uucugaccug 420

cucaagaagu ggcugccgca acgcugugcg accuuugcca gcaagaucca gggccaggug 480

gacaagauca agggggccgg uggugacuaa ggauccaucg auaagcuuca ucgaaacaug 540

aggaucaccc auaucugcag ucgacaucga aacaugagga ucacccaugu cugcagucga 600

caucgaaaca ugaggaucac ccaugucugc agucgacauc gaaacaugag gaucacccau 660

gucugcaguc gacaucgaaa 680

<210> 162
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any Naturally Occuring Amino Acid

<400> 162

Met Gly Xaa Lys Leu Ser Lys Lys Lys
1 5

<210> 163
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (3)..(3)
<223> See specification as filed for detailed description of
       substitutions and preferred embodiments

<400> 163

Met Gly Xaa Lys Leu Ser Lys Lys Lys
1   5

<210> 164
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Gly, Ala, or Ser

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Lys or Gln

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Leu, Phe, Ser, or Gln

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Ser or Ala

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Ser or Ala, See specification as filed for detailed description
       of substitutions and preferred embodiments

<400> 164

Met Gly Xaa Xaa Xaa Xaa Lys Lys
1   5

<210> 165
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 165
tggaggtgct caaagagttg   20

<210> 166
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 166
ttgggcgtgc acttgat   17

<210> 167
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic probe

<400> 167
gggcattggc ttc   13

<210> 168
<211> 60
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 168

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Ser Ala
            20   25   30

Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly
        35   40   45

Gly Ser Val Ser Lys Gly Glu Glu Leu Phe Thr Gly
    50   55   60

<210> 169
<211> 60
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 169

Met Ala Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Ser Ala
            20   25   30

Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly
        35   40   45

Gly Ser Val Ser Lys Gly Glu Glu Leu Phe Thr Gly
    50   55   60

<210> 170
<211> 60
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 170

Met Gly Ala Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Ser Ala
            20   25   30

Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly
        35   40   45

Gly Ser Val Ser Lys Gly Glu Glu Leu Phe Thr Gly
    50   55   60

<210> 171
<211> 60
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 171

Met Ala Ala Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Ser Ala
            20   25   30

Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly
        35   40   45

Gly Ser Val Ser Lys Gly Glu Glu Leu Phe Thr Gly
    50   55   60

<210> 172
<211> 57
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 172

```
Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1               5                   10                  15


Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Ser Ala Gly Gly Gly
            20                  25                  30


Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val
        35                  40                  45


Ser Lys Gly Glu Glu Leu Phe Thr Gly
    50                  55
```

<210> 173
<211> 54
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 173

```
Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1               5                   10                  15


Glu Lys Ala Lys Glu Lys Asp Lys Ser Ala Gly Gly Gly Gly Ser Asp
            20                  25                  30


Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val Ser Lys Gly
        35                  40                  45


Glu Glu Leu Phe Thr Gly
    50
```

<210> 174
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 174

```
Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1               5                   10                  15


Glu Lys Ala Lys Glu Ser Ala Gly Gly Gly Gly Ser Asp Tyr Lys Asp
            20                  25                  30


Asp Asp Asp Lys Gly Gly Gly Gly Ser Val Ser Lys Gly Glu Glu Leu
        35                  40                  45


Phe Thr Gly
    50
```

<210> 175
<211> 48
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 175

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ser Ala Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp
            20   25   30

Lys Gly Gly Gly Gly Ser Val Ser Lys Gly Glu Glu Leu Phe Thr Gly
        35   40   45

<210> 176
<211> 45
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 176

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Ser
1   5   10   15

Ala Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly
            20   25   30

Gly Gly Ser Val Ser Lys Gly Glu Glu Leu Phe Thr Gly
        35   40   45

<210> 177
<211> 42
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 177

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Ser Ala Gly Gly
1   5   10   15

Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser
            20   25   30

Val Ser Lys Gly Glu Glu Leu Phe Thr Gly
        35   40

<210> 178
<211> 39
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 178

Met Gly Gly Lys Leu Ser Lys Lys Lys Ser Ala Gly Gly Gly Gly Ser
1   5   10   15

Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val Ser Lys
            20   25   30

Gly Glu Glu Leu Phe Thr Gly
        35

<210> 179
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 179

Met Gly Gly Lys Leu Ser Ser Ala Gly Gly Gly Gly Ser Asp Tyr Lys
1   5   10   15

Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val Ser Lys Gly Glu Glu
            20   25   30

Leu Phe Thr Gly
        35

<210> 180
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 180

Met Gly Gly Ser Ala Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp
1   5   10   15

Asp Lys Gly Gly Gly Gly Ser Val Ser Lys Gly Glu Glu Leu Phe Thr
            20   25   30

Gly

<210> 181
<211> 54
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 181

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala Ser Ala
            20   25   30

Gly Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly
        35   40   45

Gly Ser Val Ser Lys Gly
    50

<210> 182
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 182

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Ser Ala Gly Gly
1   5   10   15

Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser
            20   25   30

Val Ser Lys Gly
        35

<210> 183
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 183

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Ser Ala Gly Gly Gly
1   5   10   15

Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val
            20   25   30

Ser Lys Gly
        35

<210> 184
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 184

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Ser Ala Gly Gly Gly Gly
1   5   10   15

Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val Ser
            20   25   30

Lys Gly

<210> 185
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 185

Met Gly Gly Lys Leu Ser Lys Lys Lys Ser Ala Gly Gly Gly Gly Ser
1   5   10   15

Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val Ser Lys
            20   25   30

Gly

<210> 186
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 186

Met Gly Gly Lys Leu Ser Lys Lys Ser Ala Gly Gly Gly Gly Ser Asp
1   5   10   15

Tyr Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val Ser Lys Gly
            20   25   30

<210> 187
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 187

Met Gly Gly Lys Leu Ser Lys Ser Ala Gly Gly Gly Gly Ser Asp Tyr
1   5   10   15

Lys Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val Ser Lys Gly
            20   25   30

<210> 188
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 188

Met Gly Gly Lys Leu Ser Ser Ala Gly Gly Gly Gly Ser Asp Tyr Lys
1   5   10   15

Asp Asp Asp Asp Lys Gly Gly Gly Gly Ser Val Ser Lys Gly
            20   25   30

<210> 189
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 189

Met Gly Gly Lys Leu Asp Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala
            20   25   30

<210> 190
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 190

Met Gly Gly Lys Leu Ala Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala
            20   25   30

<210> 191
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 191

Met Gly Gly Lys Gln Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

Glu Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala
            20   25   30

<210> 192
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 192

Met Gly Ala Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe
1   5   10   15

Lys Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu Ala
            20   25   30

<210> 193
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 193

Met Ala Ala Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe
1   5   10   15

Lys Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu Ala
            20   25   30

<210> 194
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 194

Met Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe
1   5   10   15

Lys Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu Ala
            20   25   30

<210> 195
<211> 30
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 195

Met Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Pro Phe
1   5   10   15

Lys Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu Ala
            20   25   30

<210> 196
<211> 153
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 196

Met Gly Gly Lys Leu Ser Lys Lys Lys Lys Ser Ala Gly Gly Ser Gly
1   5   10   15

Gly Ser Thr Ser Gly Ser Gly Asp Tyr Lys Asp Asp Asp Asp Lys Gly
            20   25   30

Ser Gly Phe Glu Met Asp Gln Val Gln Leu Val Glu Ser Gly Gly Ala
        35   40   45

Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
    50   55   60

Phe Pro Val Asn Arg Tyr Ser Met Arg Trp Tyr Arg Gln Ala Pro Gly
65   70   75   80

Lys Glu Arg Glu Trp Val Ala Gly Met Ser Ser Ala Gly Asp Arg Ser
                85   90   95

Ser Tyr Glu Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp
            100   105   110

Ala Arg Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp
        115   120   125

Thr Ala Val Tyr Tyr Cys Asn Val Asn Val Gly Phe Glu Tyr Trp Gly
    130   135   140

Gln Gly Thr Gln Val Thr Val Ser Ser
145   150

<210> 197
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide Linker

<400> 197

Gly Gly Gly Gly
1

<210> 198
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide Linker

<400> 198

Ser Gly Gly Ser Gly Gly Ser
1   5

<210> 199
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide Linker

<400> 199

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Gly
1   5   10   15

<210> 200
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide Linker

<400> 200

Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1   5   10   15

<210> 201
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide Linker

<400> 201

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly
1   5   10   15

Gly Ser

<210> 202
<211> 15

<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide Linker

<400> 202

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1   5   10   15

<210> 203
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide Linker

<220>
<221> MISC_FEATURE
<223> X can be an integer from 1-100

<220>
<221> misc_feature
<222> (5)..(5)
<223> X can be any integer from 1-100

<400> 203

Gly Gly Gly Ser Xaa
1   5

<210> 204
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide Linker

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X can be any integer from 1-100

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X can be any integer from 1-100

<400> 204

Gly Gly Ser Xaa Gly Gly Gly Gly Ser Xaa
1   5   10

<210> 205
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Effector Domain Sequence

<400> 205

Lys Lys Lys Lys
1

<210> 206
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Effector Domain Sequence

<400> 206

Lys Lys Lys Lys Lys
1   5

<210> 207
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Effector Domain Sequence

<400> 207

Arg Arg Arg Arg
1

<210> 208
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Effector Domain Sequence

<400> 208

Arg Arg Arg Arg Arg
1   5

<210> 209
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Effector Domain Sequence

<220>
<221> misc_feature
<222> (1)..(4)
<223> Xaa can be Lys or Arg

<400> 209

Xaa Xaa Xaa Xaa
1

<210> 210

<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Effector Domain Sequence

<220>
<221> misc_feature
<222> (1)..(5)
<223> Xaa can be Lys or Arg

<400> 210

Xaa Xaa Xaa Xaa Xaa
1   5

<210> 211
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 211

Gly Gly Lys Leu Ser Lys Lys
1   5

<210> 212
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 212

Gly Ala Lys Leu Ser Lys Lys
1   5

<210> 213
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 213

Gly Gly Lys Gln Ser Lys Lys
1   5

<210> 214
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 214

Gly Gly Lys Leu Ala Lys Lys
1   5

<210> 215
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 215

Gly Gly Lys Leu Ser Lys
1   5

<210> 216
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 216

Gly Ala Lys Leu Ser Lys
1   5

<210> 217
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 217

Gly Gly Lys Gln Ser Lys
1   5

<210> 218
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 218

Gly Gly Lys Leu Ala Lys
1   5

<210> 219
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 219

Lys Lys Lys Gly
1

<210> 220
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 220

Lys Lys Lys Gly Tyr
1   5

<210> 221
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 221

Lys Lys Lys Gly Tyr Asn
1   5

<210> 222
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 222

Lys Lys Lys Gly Tyr Asn Val
1   5

<210> 223
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 223

Lys Lys Lys Gly Tyr Asn Val Asn
1   5

<210> 224
<211> 6
<212> PRT
<213> Artificial Sequence

<220>

<223> N Terminus Domain Sequence

<400> 224

Lys Lys Lys Gly Tyr Ser
1   5

<210> 225
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 225

Lys Lys Lys Gly Tyr Gly
1   5

<210> 226
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 226

Lys Lys Lys Gly Tyr Gly Gly
1   5

<210> 227
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 227

Lys Lys Lys Gly Ser
1   5

<210> 228
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 228

Lys Lys Lys Gly Ser Gly
1   5

<210> 229
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 229

Lys Lys Lys Gly Ser Gly Ser
1   5

<210> 230
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 230

Lys Lys Lys Ser
1

<210> 231
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 231

Lys Lys Lys Ser Gly
1   5

<210> 232
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 232

Lys Lys Lys Ser Gly Gly
1   5

<210> 233
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 233

Lys Lys Lys Ser Gly Gly Ser
1   5

<210> 234
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 234

Lys Lys Lys Ser Gly Gly Ser Gly
1   5

<210> 235
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 235

Lys Lys Ser Gly Gly Ser Gly Gly
1   5

<210> 236
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 236

Lys Lys Lys Ser Gly Gly Ser Gly Gly Ser
1   5   10

<210> 237
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 237

Lys Arg Phe Ser Phe Lys Lys Ser
1   5

<210> 238
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 238

Gly Gly Lys Leu Ser Lys Lys Lys
1   5

<210> 239
<211> 8
<212> PRT

<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 239

Gly Gly Lys Leu Ser Lys Lys Ser
1   5

<210> 240
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 240

Gly Ala Lys Leu Ser Lys Lys Lys
1   5

<210> 241
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 241

Gly Ala Lys Leu Ser Lys Lys Ser
1   5

<210> 242
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 242

Gly Gly Lys Gln Ser Lys Lys Lys
1   5

<210> 243
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 243

Gly Gly Lys Gln Ser Lys Lys Ser
1   5

<210> 244
<211> 8

<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 244

Gly Gly Lys Leu Ala Lys Lys Lys
1   5

<210> 245
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> N Terminus Domain Sequence

<400> 245

Gly Gly Lys Leu Ala Lys Lys Ser
1   5

<210> 246
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 246

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn
1   5   10

<210> 247
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 247

Gly Ala Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn
1   5   10

<210> 248
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 248

Gly Gly Lys Gln Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn
1   5   10

<210> 249

<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 249

Gly Gly Lys Leu Ala Lys Lys Lys Lys Gly Tyr Asn Val Asn
1   5   10

<210> 250
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 250

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Ser Gly Gly
1   5   10

<210> 251
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 251

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Ser Gly Gly Ser
1   5   10

<210> 252
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 252

Gly Gly Lys Leu Ser Lys Lys Lys Lys Ser Gly Gly Ser Gly
1   5   10

<210> 253
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 253

Gly Gly Lys Leu Ser Lys Lys Lys Ser Gly Gly Ser Gly Gly
1   5   10

<210> 254
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 254

Gly Gly Lys Leu Ser Lys Lys Ser Gly Gly Ser Gly Gly Ser
1   5   10

<210> 255
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 255

Gly Gly Lys Leu Ser Lys Ser Gly Gly Ser Gly Gly Ser Val
1   5   10

<210> 256
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 256

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser
1   5   10

<210> 257
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 257

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala Ala
            20   25

<210> 258
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 258

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly Ala
            20   25

<210> 259
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 259

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu Gly
            20   25

<210> 260
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 260

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu Lys Asp Lys Lys Ala Glu
            20   25

<210> 261
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 261

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu Lys Asp Lys Lys Ala
            20   25

<210> 262
<211> 24
<212> PRT
<213> Artificial Sequence

<220>

<223> Scaffold Y Sequence

<400> 262

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu Lys Asp Lys Lys
            20

<210> 263
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 263

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu Lys Asp Lys
            20

<210> 264
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 264

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu Lys Asp
            20

<210> 265
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 265

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu Lys
            20

<210> 266
<211> 20
<212> PRT

<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 266

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys Glu
            20

<210> 267
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 267

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala Lys

<210> 268
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 268

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys Ala

<210> 269
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 269

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

Lys

<210> 270
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 270

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp Glu
1   5   10   15

<210> 271
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 271

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val Asn Asp
1   5   10   15

<210> 272
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 272

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn Val
1   5   10

<210> 273
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 273

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr Asn
1   5   10

<210> 274
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 274

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly Tyr
1   5   10

<210> 275
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 275

Gly Gly Lys Leu Ser Lys Lys Lys Lys Gly
1   5   10

<210> 276
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 276

Gly Gly Lys Leu Ser Lys Lys Lys Lys
1   5

<210> 277
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 277

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu
            20   25

<210> 278
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 278

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys
            20   25

<210> 279
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 279

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys
            20   25

<210> 280
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 280

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys Asn
            20   25

<210> 281
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 281

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys
            20

<210> 282
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 282

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys
            20

<210> 283

<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 283

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe
            20

<210> 284
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 284

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser
            20

<210> 285
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 285

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe
            20

<210> 286
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 286

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly

<210> 287
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 287

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser

<210> 288
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 288

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu

<210> 289
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 289

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

<210> 290
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 290

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe
1   5   10   15

<210> 291

<400> 291

000

<210> 292
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 292

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys
1   5   10

<210> 293
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 293

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys
1   5   10

<210> 294
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 294

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe
1   5   10

<210> 295
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 295

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser
1   5   10

<210> 296
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 296

Gly Ala Lys Lys Ser Lys Lys Arg Phe

1 5

<210> 297
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 297

Gly Ala Lys Lys Ser Lys Lys Arg
1 5

<210> 298
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 298

Gly Ala Lys Lys Ser Lys Lys
1 5

<210> 299
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 299

Gly Ala Lys Lys Ser Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1 5 10 15

Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu Ala
20 25

<210> 300
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 300

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1 5 10 15

Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu Ala
20 25

<210> 301
<211> 28

<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 301

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe Lys Leu Ser Gly Phe Ser Phe Lys Lys
            20   25

<210> 302
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 302

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe Lys Leu Ser Gly Phe Ser Phe Lys
            20   25

<210> 303
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 303

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe Lys Leu Ser Gly Phe Ser Phe
            20   25

<210> 304
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 304

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe Lys Leu Ser Gly Phe Ser
            20   25

<210> 305
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 305

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe Lys Leu Ser Gly Phe
            20

<210> 306
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 306

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe Lys Leu Ser Gly
            20

<210> 307
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 307

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe Lys Leu Ser
            20

<210> 308
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 308

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe Lys Leu
            20

<210> 309
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 309

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe Lys
            20

<210> 310
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 310

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser Phe

<210> 311
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 311

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1   5   10   15

Lys Ser

<210> 312
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 312

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys

1 5 10 15

Lys

<210> 313
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 313

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys
1 5 10 15

<210> 314
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 314

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser Phe
1 5 10 15

<210> 315
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 315

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe Ser
1 5 10

<210> 316
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 316

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg Phe
1 5 10

<210> 317
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Scaffold Y Sequence

<400> 317

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys Arg
1   5   10

<210> 318
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 318

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys Lys
1   5   10

<210> 319
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 319

Gly Ala Gln Glu Ser Lys Lys Lys Lys Lys
1   5   10

<210> 320
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 320

Gly Ala Gln Glu Ser Lys Lys Lys Lys
1   5

<210> 321
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 321

Gly Ala Gln Glu Ser Lys Lys Lys
1   5

<210> 322
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 322

Gly Ala Gln Glu Ser Lys Lys
1   5

<210> 323
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 323

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg Asn Arg Lys
            20   25   30

<210> 324
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 324

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg Asn Arg
            20   25

<210> 325
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 325

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg Asn
            20   25

<210> 326
<211> 27
<212> PRT
<213> Artificial Sequence

<220>

<223> Scaffold Y Sequence

<400> 326

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys Arg
            20   25

<210> 327
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 327

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser Gly Leu Ser Phe Lys
            20   25

<210> 328
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 328

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser Gly Leu Ser Phe
            20   25

<210> 329
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 329

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser Gly Leu Ser
            20

<210> 330
<211> 23
<212> PRT

<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 330

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser Gly Leu
            20

<210> 331
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 331

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser Gly
            20

<210> 332
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 332

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu Ser
            20

<210> 333
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 333

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys Leu
            20

<210> 334
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 334

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe Lys

<210> 335
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 335

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro Phe

<210> 336
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 336

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

Pro

<210> 337
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 337

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys Lys
1   5   10   15

<210> 338

<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 338

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe Lys
1   5   10   15

<210> 339
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 339

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser Phe
1   5   10

<210> 340
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 340

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe Ser
1   5   10

<210> 341
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 341

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys Phe
1   5   10

<210> 342
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 342

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys Lys
1   5   10

<210> 343
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 343

Gly Ser Gln Ser Ser Lys Lys Lys Lys Lys
1   5   10

<210> 344
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 344

Gly Ser Gln Ser Ser Lys Lys Lys Lys
1   5

<210> 345
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 345

Gly Ser Gln Ser Ser Lys Lys Lys
1   5

<210> 346
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 346

Gly Ser Gln Ser Ser Lys Lys
1   5

<210> 347
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 347

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys Glu
            20   25

<210> 348
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 348

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys Lys
            20   25

<210> 349
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 349

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys Asn Lys
            20   25

<210> 350
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 350

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys Asn
            20   25

<210> 351
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 351

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys Lys
            20

<210> 352
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 352

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe Lys
            20

<210> 353
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 353

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser Phe
            20

<210> 354
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 354

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe Ser
            20

<210> 355
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 355

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly Phe
            20

<210> 356
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 356

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser Gly

<210> 357
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 357

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu Ser

<210> 358
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 358

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

Leu

<210> 359
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 359

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys
1   5   10   15

<210> 360
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 360

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe
1   5   10   15

<210> 361
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 361

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys Ser
1   5   10

<210> 362
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 362

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys Lys
1   5   10

<210> 363
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 363

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe Lys
1   5   10

<210> 364
<211> 11
<212> PRT

<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 364

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser Phe
1   5   10

<210> 365
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 365

Gly Ala Lys Lys Ala Lys Lys Arg Phe Ser
1   5   10

<210> 366
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 366

Gly Ala Lys Lys Ala Lys Lys Arg Phe
1   5

<210> 367
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 367

Gly Ala Lys Lys Ala Lys Lys Arg
1   5

<210> 368
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<400> 368

Gly Ala Lys Lys Ala Lys Lys
1   5

<210> 369
<211> 94

<212> PRT
<213> Artificial Sequence

<220>
<223> ESAT6 Protein Sequence

<400> 369

Met Thr Glu Gln Gln Trp Asn Phe Ala Gly Ile Glu Ala Ala Ala Ser
1   5   10   15

Ala Ile Gln Gly Asn Val Thr Ser Ile His Ser Leu Asp Glu Gly Lys
            20   25   30

Gln Ser Leu Thr Lys Leu Ala Ala Ala Trp Gly Gly Ser Gly Ser Glu
        35   40   45

Ala Tyr Gln Gly Val Gln Gln Lys Trp Asp Ala Thr Ala Thr Glu Leu
    50   55   60

Asn Asn Ala Leu Gln Asn Leu Ala Arg Thr Ile Ser Glu Ala Gly Gln
65   70   75   80

Ala Met Ala Ser Thr Glu Gly Asn Val Thr Gly Met Phe Ala
                85   90

<210> 370
<211> 96
<212> PRT
<213> Artificial Sequence

<220>
<223> TB10.4 Protein Sequence

<400> 370

Met Ser Gln Ile Met Tyr Asn Tyr Pro Ala Met Leu Gly His Ala Gly
1   5   10   15

Asp Met Ala Gly Tyr Ala Gly Thr Leu Gln Ser Leu Gly Ala Glu Ile
            20   25   30

Ala Val Glu Gln Ala Ala Leu Gln Ser Ala Trp Gln Gly Asp Thr Gly
        35   40   45

Ile Thr Tyr Gln Ala Trp Gln Ala Gln Trp Asn Gln Ala Met Glu Asp
    50   55   60

Leu Val Arg Ala Tyr His Ala Met Ser Ser Thr His Glu Ala Asn Thr
65   70   75   80

Met Ala Met Met Ala Arg Asp Thr Ala Glu Ala Ala Lys Trp Gly Gly
                85   90   95

<210> 371
<211> 8
<212> PRT

<213> Artificial Sequence

<220>
<223> Scaffold Y Sequence

<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa can be any naturally occurring amino acid

<400> 371

Gly Xaa Lys Leu Ser Lys Lys Lys
1   5

<210> 372

<400> 372
000

<210> 373
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker

<220>
<221> misc_feature
<222> (5)..(5)
<223> wherein Xaa is any integer between 1-100

<400> 373

Gly Gly Gly Gly Xaa
1   5

<210> 374
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker

<220>
<221> misc_Feature
<222> (2)..(2)
<223> Wherein Xaa is any integer from 1 to 100

<220>
<221> misc_Feature
<222> (4)..(4)
<223> Wherein Xaa is any integer from 1 to 100

<400> 374

Gly Xaa Ser Xaa
1

<210> 375
<211> 5

<212> PRT
<213> Artificial Sequence

<220>
<223> Linker

<220>
<221> misc_feature
<222> (2)..(2)
<223> Wherein Xaa is any integer from 1 to 4

<220>
<221> misc_feature
<222> (4)..(4)
<223> Wherein Xaa is 0 or 1

<220>
<221> misc_feature
<222> (5)..(5)
<223> Wherein Xaa is any integer from 1 to 50

<400> 375

Gly Xaa Ser Xaa Xaa
1   5

<210> 376
<211> 2
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker

<220>
<221> misc_feature
<222> (2)..(2)
<223> wherein Xaa can be any integer between 1-100

<400> 376

Gly Asn
1

<210> 377
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> wherein Xaa is an integer between 1 and 100

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 377

Gly Ala Xaa
1

<210> 378

<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Linker

<220>
<221> misc_feature
<222> (4)..(4)
<223> Wherein Xaa is an integer between 1 and 100

<400> 378

Gly Gly Ser Xaa
1

<210> 379
<211> 42
<212> PRT
<213> Artificial Sequence

<220>
<223> human amyloid-B protein fragment

<400> 379

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1   5   10   15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
            20   25   30

Gly Leu Met Val Gly Gly Val Val Ile Ala
        35   40

<210> 380
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> human amyloid-B protein fragment

<400> 380

Ala Glu Phe Arg His Asp
1   5

<210> 381
<211> 2
<212> PRT
<213> Artificial Sequence

<220>
<223> PolyGA

<220>
<221> misc_feature
<222> (1)..(2)
<223> Wherein the sequence is repeated between integers 10 to 20 times

<400> 381

Gly Ala
1

<210> 382
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> PADRE peptide

<400> 382

Ala Lys Phe Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
1   5   10

<210> 383
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Tetanus fragment

<400> 383

Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu
1   5   10

<210> 384
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Diphtheria toxin fragment

<400> 384

Gln Ser Ile Ala Leu Ser Ser Leu Met Val Ala Gln Ala Ile Pro
1   5   10   15

<210> 385
<211> 119
<212> PRT
<213> artificial sequence

<220>
<223> brain derived neurotrophic factor protein

<400> 385

His Ser Asp Pro Ala Arg Arg Gly Glu Leu Ser Val Cys Asp Ser Ile
1   5   10   15

Ser Glu Trp Val Thr Ala Ala Asp Lys Lys Thr Ala Val Asp Met Ser
            20   25   30

Gly Gly Thr Val Thr Val Leu Glu Lys Val Pro Val Ser Lys Gly Gln
        35   40   45

```
Leu Lys Gln Tyr Phe Tyr Glu Thr Lys Cys Asn Pro Met Gly Tyr Thr
    50                  55                  60

Lys Glu Gly Cys Arg Gly Ile Asp Lys Arg His Trp Asn Ser Gln Cys
65                  70                  75                  80

Arg Thr Thr Gln Ser Tyr Val Arg Ala Leu Thr Met Asp Ser Lys Lys
                85                  90                  95

Arg Ile Gly Trp Arg Phe Ile Arg Ile Asp Thr Ser Cys Val Cys Thr
            100                 105                 110

Leu Thr Ile Lys Arg Gly Arg
        115
```

<210> 386
<211> 120
<212> PRT
<213> artificial sequence

<220>
<223> nerve growth factor protein

<400> 386

```
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp
1               5                   10                  15

Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys
            20                  25                  30

Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val
        35                  40                  45

Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val
    50                  55                  60

Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys
65                  70                  75                  80

Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln
                85                  90                  95

Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu
            100                 105                 110

Ser Arg Lys Ala Val Arg Arg Ala
        115                 120
```

<210> 387
<211> 119
<212> PRT
<213> artificial sequence

<220>

<223> neurotrophin-3 protein

<400> 387

Tyr Ala Glu His Lys Ser His Arg Gly Glu Tyr Ser Val Cys Asp Ser
1   5   10   15

Glu Ser Leu Trp Val Thr Asp Lys Ser Ser Ala Ile Asp Ile Arg Gly
            20   25   30

His Gln Val Thr Val Leu Gly Glu Ile Lys Thr Gly Asn Ser Pro Val
        35   40   45

Lys Gln Tyr Phe Tyr Glu Thr Arg Cys Lys Glu Ala Arg Pro Val Lys
    50   55   60

Asn Gly Cys Arg Gly Ile Asp Asp Lys His Trp Asn Ser Gln Cys Lys
65   70   75   80

Thr Ser Gln Thr Tyr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys Leu
                85   90   95

Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ser Cys Val Cys Ala Leu
            100   105   110

Ser Arg Lys Ile Gly Arg Thr
        115

<210> 388
<211> 130
<212> PRT
<213> artificial sequence

<220>
<223> neurotrophin-4 protein

<400> 388

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala Val
1   5   10   15

Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala Val Asp
            20   25   30

Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro Ala Ala Gly
        35   40   45

Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg Cys Lys Ala Asp
    50   55   60

Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg Gly
65   70   75   80

Val Asp Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr
                85   90   95

Val Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg Trp
            100   105   110

Ile Arg Ile Asp Thr Ala Cys Val Cys Thr Leu Leu Ser Arg Thr Gly
        115   120   125

Arg Ala
    130

<210> 389
<211> 29
<212> PRT
<213> artificial sequence

<220>
<223> RVG peptide

<400> 389

Tyr Thr Ile Trp Met Pro Glu Asn Pro Arg Pro Gly Thr Pro Cys Asp
1   5   10   15

Ile Phe Thr Asn Ser Arg Gly Lys Arg Ala Ser Asn Gly
            20   25

<210> 390
<211> 14
<212> PRT
<213> artificial sequence

<220>
<223> cyclized TAxI peptide

<400> 390

Ser Ala Cys Gln Ser Gln Ser Gln Met Arg Cys Gly Gly Gly
1   5   10

<210> 391
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> TAxI transport peptide #1

<400> 391

Gln Ser Gln Ser Gln Met Arg
1   5

<210> 392
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> TAxI transport peptide #2

<400> 392

Ala Ser Gly Ala Gln Ala Arg
1   5

<210> 393
<211> 14
<212> PRT
<213> artificial sequence

<220>
<223> TAxI transport peptide #3

<400> 393

Thr Ser Thr Ala Pro His Leu Arg Leu Arg Leu Thr Ser Arg
1   5   10

<210> 394
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> nuclear localizing signal #1

<400> 394

Pro Pro Lys Lys Arg Lys Val
1   5

<210> 395
<211> 6
<212> PRT
<213> artificial sequence

<220>
<223> nuclear localizing signal #2

<400> 395

Pro Lys Lys Arg Lys Val
1   5

<210> 396
<211> 19
<212> PRT
<213> artificial sequence

<220>
<223> Angiopep-2

<400> 396

Thr Phe Phe Tyr Gly Gly Ser Arg Gly Lys Arg Asn Asn Phe Lys Thr
1   5   10   15

Glu Glu Tyr

<210> 397
<211> 39
<212> PRT
<213> artificial sequence

<220>
<223> ApoB (3371 3409)

<400> 397

Ser Ser Val Ile Asp Ala Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg
1   5   10   15

Leu Thr Arg Lys Arg Gly Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser
            20   25   30

Asn Lys Phe Val Glu Gly Ser
        35

<210> 398
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> ApoE (159 167)2

<400> 398

Leu Arg Lys Leu Arg Lys Arg Leu Leu Leu Arg Lys Leu Arg Lys Arg
1   5   10   15

Leu Leu

<210> 399
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> Peptide-22

<400> 399

Cys Met Pro Arg Leu Arg Gly Cys
1   5

<210> 400
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> THR

<400> 400

Thr His Arg Pro Pro Met Trp Ser Pro Val Trp Pro
1   5   10

<210> 401
<211> 12
<212> PRT
<213> artificial sequence

<220>

<223> THR retro-enantio

<400> 401

Pro Trp Val Pro Ser Trp Met Pro Pro Arg His Thr
1   5   10

<210> 402
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> CRT

<400> 402

Cys Arg Thr Ile Gly Pro Ser Val Cys
1   5

<210> 403
<211> 30
<212> PRT
<213> artificial sequence

<220>
<223> Leptin30

<400> 403

Tyr Gln Gln Ile Leu Thr Ser Met Pro Ser Arg Asn Val Ile Gln Ile
1   5   10   15

Ser Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val Leu
            20   25   30

<210> 404
<211> 29
<212> PRT
<213> artificial sequence

<220>
<223> RVG29

<400> 404

Tyr Thr Ile Trp Met Pro Glu Asn Pro Arg Pro Gly Thr Pro Cys Asp
1   5   10   15

Ile Phe Thr Asn Ser Arg Gly Lys Arg Ala Ser Asn Gly
            20   25

<210> 405
<211> 16
<212> PRT
<213> artificial sequence

<220>
<223> CDX

<400> 405

Gly Arg Glu Ile Arg Thr Gly Arg Ala Glu Arg Trp Ser Glu Lys Phe

1 5 10 15

<210> 406
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> Apamin

<400> 406

Cys Asn Cys Lys Ala Pro Glu Thr Ala Leu Cys Ala Arg Arg Cys Gln
1 5 10 15

Gln His

<210> 407
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> MiniAp-4

<400> 407

Lys Ala Pro Glu Thr Ala Leu Asp
1 5

<210> 408
<211> 2
<212> PRT
<213> artificial sequence

<220>
<223> GSH

<400> 408

Cys Gly
1

<210> 409
<211> 13
<212> PRT
<213> artificial sequence

<220>
<223> G23

<400> 409

His Leu Asn Ile Leu Ser Thr Leu Trp Lys Tyr Arg Cys
1 5 10

<210> 410
<211> 6
<212> PRT
<213> artificial sequence

<220>

<223> g7

<400> 410

Gly Phe Gly Phe Leu Ser
1   5

<210> 411
<211> 12
<212> PRT
<213> artificial sequence

<220>
<223> TGN

<400> 411

Thr Gly Asn Tyr Lys Ala Leu His Pro His Asn Gly
1   5   10

<210> 412
<211> 11
<212> PRT
<213> artificial sequence

<220>
<223> TAT (47 57)

<400> 412

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1   5   10

<210> 413
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> SynB1

<400> 413

Arg Gly Gly Arg Leu Ser Tyr Ser Arg Arg Arg Phe Ser Thr Ser Thr
1   5   10   15

Gly Arg

<210> 414
<211> 21
<212> PRT
<213> artificial sequence

<220>
<223> Diketopiperazines

<400> 414

Gly Asn Tyr Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr
1   5   10   15

Ile Ile Glu Leu Lys

20

<210> 415
<211> 731
<212> PRT
<213> artificial sequence

<220>
<223> PhPro

<400> 415

Pro Ser Ala Arg Pro Pro Pro Ser Leu Ser Leu Arg Glu Gly Glu Pro
1 5 10 15

Phe Glu Leu Arg Cys Thr Ala Ala Ser Ala Ser Pro Leu His Thr His
20 25 30

Leu Ala Leu Leu Trp Glu Val His Arg Gly Pro Ala Arg Arg Ser Val
35 40 45

Leu Ala Leu Thr His Glu Gly Arg Phe His Pro Gly Leu Gly Tyr Glu
50 55 60

Gln Arg Tyr His Ser Gly Asp Val Arg Leu Asp Thr Val Gly Ser Asp
65 70 75 80

Ala Tyr Arg Leu Ser Val Ser Arg Ala Leu Ser Ala Asp Gln Gly Ser
85 90 95

Tyr Arg Cys Ile Val Ser Glu Trp Ile Ala Glu Gln Gly Asn Trp Gln
100 105 110

Glu Ile Gln Glu Lys Ala Val Glu Val Ala Thr Val Val Ile Gln Pro
115 120 125

Ser Val Leu Arg Ala Ala Val Pro Lys Asn Val Ser Val Ala Glu Gly
130 135 140

Lys Glu Leu Asp Leu Thr Cys Asn Ile Thr Thr Asp Arg Ala Asp Asp
145 150 155 160

Val Arg Pro Glu Val Thr Trp Ser Phe Ser Arg Met Pro Asp Ser Thr
165 170 175

Leu Pro Gly Ser Arg Val Leu Ala Arg Leu Asp Arg Asp Ser Leu Val
180 185 190

His Ser Ser Pro His Val Ala Leu Ser His Val Asp Ala Arg Ser Tyr
195 200 205

His Leu Leu Val Arg Asp Val Ser Lys Glu Asn Ser Gly Tyr Tyr Tyr
210 215 220

```
Cys His Val Ser Leu Trp Ala Pro Gly His Asn Arg Ser Trp His Lys
225                 230                 235                 240

Val Ala Glu Ala Val Ser Ser Pro Ala Gly Val Gly Val Thr Trp Leu
                245                 250                 255

Glu Pro Asp Tyr Gln Val Tyr Leu Asn Ala Ser Lys Val Pro Gly Phe
            260                 265                 270

Ala Asp Asp Pro Thr Glu Leu Ala Cys Arg Val Val Asp Thr Lys Ser
        275                 280                 285

Gly Glu Ala Asn Val Arg Phe Thr Val Ser Trp Tyr Tyr Arg Met Asn
    290                 295                 300

Arg Arg Ser Asp Asn Val Val Thr Ser Glu Leu Leu Ala Val Met Asp
305                 310                 315                 320

Gly Asp Trp Thr Leu Lys Tyr Gly Glu Arg Ser Lys Gln Arg Ala Gln
                325                 330                 335

Asp Gly Asp Phe Ile Phe Ser Lys Glu His Thr Asp Thr Phe Asn Phe
            340                 345                 350

Arg Ile Gln Arg Thr Thr Glu Glu Asp Arg Gly Asn Tyr Tyr Cys Val
        355                 360                 365

Val Ser Ala Trp Thr Lys Gln Arg Asn Asn Ser Trp Val Lys Ser Lys
    370                 375                 380

Asp Val Phe Ser Lys Pro Val Asn Ile Phe Trp Ala Leu Glu Asp Ser
385                 390                 395                 400

Val Leu Val Val Lys Ala Arg Gln Pro Lys Pro Phe Phe Ala Ala Gly
                405                 410                 415

Asn Thr Phe Glu Met Thr Cys Lys Val Ser Ser Lys Asn Ile Lys Ser
            420                 425                 430

Pro Arg Tyr Ser Val Leu Ile Met Ala Glu Lys Pro Val Gly Asp Leu
        435                 440                 445

Ser Ser Pro Asn Glu Thr Lys Tyr Ile Ile Ser Leu Asp Gln Asp Ser
    450                 455                 460

Val Val Lys Leu Glu Asn Trp Thr Asp Ala Ser Arg Val Asp Gly Val
465                 470                 475                 480

Val Leu Glu Lys Val Gln Glu Asp Glu Phe Arg Tyr Arg Met Tyr Gln
                485                 490                 495

Thr Gln Val Ser Asp Ala Gly Leu Tyr Arg Cys Met Val Thr Ala Trp
```

```
            500                 505                 510

Ser Pro Val Arg Gly Ser Leu Trp Arg Glu Ala Ala Thr Ser Leu Ser
        515                 520                 525

Asn Pro Ile Glu Ile Asp Phe Gln Thr Ser Gly Pro Ile Phe Asn Ala
    530                 535                 540

Ser Val His Ser Asp Thr Pro Ser Val Ile Arg Gly Asp Leu Ile Lys
545                 550                 555                 560

Leu Phe Cys Ile Ile Thr Val Glu Gly Ala Ala Leu Asp Pro Asp Asp
                565                 570                 575

Met Ala Phe Asp Val Ser Trp Phe Ala Val His Ser Phe Gly Leu Asp
            580                 585                 590

Lys Ala Pro Val Leu Leu Ser Ser Leu Asp Arg Lys Gly Ile Val Thr
        595                 600                 605

Thr Ser Arg Arg Asp Trp Lys Ser Asp Leu Ser Leu Glu Arg Val Ser
    610                 615                 620

Val Leu Glu Phe Leu Leu Gln Val His Gly Ser Glu Asp Gln Asp Phe
625                 630                 635                 640

Gly Asn Tyr Tyr Cys Ser Val Thr Pro Trp Val Lys Ser Pro Thr Gly
                645                 650                 655

Ser Trp Gln Lys Glu Ala Glu Ile His Ser Lys Pro Val Phe Ile Thr
            660                 665                 670

Val Lys Met Asp Val Leu Asn Ala Phe Lys Tyr Pro Leu Leu Ile Gly
        675                 680                 685

Val Gly Leu Ser Thr Val Ile Gly Leu Leu Ser Cys Leu Ile Gly Tyr
    690                 695                 700

Cys Ser Ser His Trp Cys Cys Lys Lys Glu Val Gln Glu Thr Arg Arg
705                 710                 715                 720

Glu Arg Arg Arg Leu Met Ser Met Glu Met Asp
                725                 730


<210>  416
<211>  29
<212>  PRT
<213>  artificial sequence

<220>
<223>  Linker

<400>  416
```

```
Gly Gly Ser Ser Gly Ser Gly Ser Gly Ser Gly Gly Gly Gly Ser Gly
1               5                   10                  15


Gly Gly Gly Thr Gly Thr Ser Ser Ser Gly Thr Gly Thr
            20                  25


<210>  417
<211>  1255
<212>  PRT
<213>  artificial sequence

<220>
<223>   Spike Protein

<400>  417

Met Phe Ile Phe Leu Leu Phe Leu Thr Leu Thr Ser Gly Ser Asp Leu
1               5                   10                  15


Asp Arg Cys Thr Thr Phe Asp Asp Val Gln Ala Pro Asn Tyr Thr Gln
            20                  25                  30


His Thr Ser Ser Met Arg Gly Val Tyr Tyr Pro Asp Glu Ile Phe Arg
        35                  40                  45


Ser Asp Thr Leu Tyr Leu Thr Gln Asp Leu Phe Leu Pro Phe Tyr Ser
    50                  55                  60


Asn Val Thr Gly Phe His Thr Ile Asn His Thr Phe Gly Asn Pro Val
65                  70                  75                  80


Ile Pro Phe Lys Asp Gly Ile Tyr Phe Ala Ala Thr Glu Lys Ser Asn
                85                  90                  95


Val Val Arg Gly Trp Val Phe Gly Ser Thr Met Asn Asn Lys Ser Gln
            100                 105                 110


Ser Val Ile Ile Ile Asn Asn Ser Thr Asn Val Val Ile Arg Ala Cys
        115                 120                 125


Asn Phe Glu Leu Cys Asp Asn Pro Phe Phe Ala Val Ser Lys Pro Met
    130                 135                 140


Gly Thr Gln Thr His Thr Met Ile Phe Asp Asn Ala Phe Asn Cys Thr
145                 150                 155                 160


Phe Glu Tyr Ile Ser Asp Ala Phe Ser Leu Asp Val Ser Glu Lys Ser
                165                 170                 175


Gly Asn Phe Lys His Leu Arg Glu Phe Val Phe Lys Asn Lys Asp Gly
            180                 185                 190


Phe Leu Tyr Val Tyr Lys Gly Tyr Gln Pro Ile Asp Val Val Arg Asp
        195                 200                 205
```

```
Leu Pro Ser Gly Phe Asn Thr Leu Lys Pro Ile Phe Lys Leu Pro Leu
    210                 215                 220

Gly Ile Asn Ile Thr Asn Phe Arg Ala Ile Leu Thr Ala Phe Ser Pro
225                 230                 235                 240

Ala Gln Asp Ile Trp Gly Thr Ser Ala Ala Ala Tyr Phe Val Gly Tyr
                245                 250                 255

Leu Lys Pro Thr Thr Phe Met Leu Lys Tyr Asp Glu Asn Gly Thr Ile
            260                 265                 270

Thr Asp Ala Val Asp Cys Ser Gln Asn Pro Leu Ala Glu Leu Lys Cys
        275                 280                 285

Ser Val Lys Ser Phe Glu Ile Asp Lys Gly Ile Tyr Gln Thr Ser Asn
    290                 295                 300

Phe Arg Val Val Pro Ser Gly Asp Val Val Arg Phe Pro Asn Ile Thr
305                 310                 315                 320

Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Lys Phe Pro Ser
                325                 330                 335

Val Tyr Ala Trp Glu Arg Lys Lys Ile Ser Asn Cys Val Ala Asp Tyr
            340                 345                 350

Ser Val Leu Tyr Asn Ser Thr Phe Phe Ser Thr Phe Lys Cys Tyr Gly
        355                 360                 365

Val Ser Ala Thr Lys Leu Asn Asp Leu Cys Phe Ser Asn Val Tyr Ala
    370                 375                 380

Asp Ser Phe Val Val Lys Gly Asp Asp Val Arg Gln Ile Ala Pro Gly
385                 390                 395                 400

Gln Thr Gly Val Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe
                405                 410                 415

Met Gly Cys Val Leu Ala Trp Asn Thr Arg Asn Ile Asp Ala Thr Ser
            420                 425                 430

Thr Gly Asn Tyr Asn Tyr Lys Tyr Arg Tyr Leu Arg His Gly Lys Leu
        435                 440                 445

Arg Pro Phe Glu Arg Asp Ile Ser Asn Val Pro Phe Ser Pro Asp Gly
    450                 455                 460

Lys Pro Cys Thr Pro Pro Ala Leu Asn Cys Tyr Trp Pro Leu Asn Asp
465                 470                 475                 480
```

```
Tyr Gly Phe Tyr Thr Thr Thr Gly Ile Gly Tyr Gln Pro Tyr Arg Val
                485                 490                 495

Val Val Leu Ser Phe Glu Leu Leu Asn Ala Pro Ala Thr Val Cys Gly
            500                 505                 510

Pro Lys Leu Ser Thr Asp Leu Ile Lys Asn Gln Cys Val Asn Phe Asn
        515                 520                 525

Phe Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Pro Ser Ser Lys Arg
    530                 535                 540

Phe Gln Pro Phe Gln Gln Phe Gly Arg Asp Val Ser Asp Phe Thr Asp
545                 550                 555                 560

Ser Val Arg Asp Pro Lys Thr Ser Glu Ile Leu Asp Ile Ser Pro Cys
                565                 570                 575

Ser Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Ala Ser Ser
            580                 585                 590

Glu Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Asp Val Ser Thr
        595                 600                 605

Ala Ile His Ala Asp Gln Leu Thr Pro Ala Trp Arg Ile Tyr Ser Thr
    610                 615                 620

Gly Asn Asn Val Phe Gln Thr Gln Ala Gly Cys Leu Ile Gly Ala Glu
625                 630                 635                 640

His Val Asp Thr Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile
                645                 650                 655

Cys Ala Ser Tyr His Thr Val Ser Leu Leu Arg Ser Thr Ser Gln Lys
            660                 665                 670

Ser Ile Val Ala Tyr Thr Met Ser Leu Gly Ala Asp Ser Ser Ile Ala
        675                 680                 685

Tyr Ser Asn Asn Thr Ile Ala Ile Pro Thr Asn Phe Ser Ile Ser Ile
    690                 695                 700

Thr Thr Glu Val Met Pro Val Ser Met Ala Lys Thr Ser Val Asp Cys
705                 710                 715                 720

Asn Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ala Asn Leu Leu Leu
                725                 730                 735

Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Ser Gly Ile
            740                 745                 750

Ala Ala Glu Gln Asp Arg Asn Thr Arg Glu Val Phe Ala Gln Val Lys
```

```
        755                 760                 765

Gln Met Tyr Lys Thr Pro Thr Leu Lys Tyr Phe Gly Gly Phe Asn Phe
    770                 775                 780

Ser Gln Ile Leu Pro Asp Pro Leu Lys Pro Thr Lys Arg Ser Phe Ile
785                 790                 795                 800

Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly Phe Met
                805                 810                 815

Lys Gln Tyr Gly Glu Cys Leu Gly Asp Ile Asn Ala Arg Asp Leu Ile
            820                 825                 830

Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu Leu Thr
        835                 840                 845

Asp Asp Met Ile Ala Ala Tyr Thr Ala Ala Leu Val Ser Gly Thr Ala
    850                 855                 860

Thr Ala Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile Pro Phe
865                 870                 875                 880

Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn
                885                 890                 895

Val Leu Tyr Glu Asn Gln Lys Gln Ile Ala Asn Gln Phe Asn Lys Ala
            900                 905                 910

Ile Ser Gln Ile Gln Glu Ser Leu Thr Thr Thr Ser Thr Ala Leu Gly
        915                 920                 925

Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu
    930                 935                 940

Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn
945                 950                 955                 960

Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln Ile Asp
                965                 970                 975

Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln
            980                 985                 990

Gln Leu Ile Arg Ala Ala Glu Ile  Arg Ala Ser Ala Asn  Leu Ala Ala
        995                 1000                1005

Thr Lys  Met Ser Glu Cys Val  Leu Gly Gln Ser Lys  Arg Val Asp
    1010                1015                1020

Phe Cys  Gly Lys Gly Tyr His  Leu Met Ser Phe Pro  Gln Ala Ala
    1025                1030                1035
```

```
Pro His  Gly Val Val Phe Leu  His Val Thr Tyr Val  Pro Ser Gln
    1040                1045                1050

Glu Arg  Asn Phe Thr Thr Ala  Pro Ala Ile Cys His  Glu Gly Lys
    1055                1060                1065

Ala Tyr  Phe Pro Arg Glu Gly  Val Phe Val Phe Asn  Gly Thr Ser
    1070                1075                1080

Trp Phe  Ile Thr Gln Arg Asn  Phe Phe Ser Pro Gln  Ile Ile Thr
    1085                1090                1095

Thr Asp  Asn Thr Phe Val Ser  Gly Asn Cys Asp Val  Val Ile Gly
    1100                1105                1110

Ile Ile  Asn Asn Thr Val Tyr  Asp Pro Leu Gln Pro  Glu Leu Asp
    1115                1120                1125

Ser Phe  Lys Glu Glu Leu Asp  Lys Tyr Phe Lys Asn  His Thr Ser
    1130                1135                1140

Pro Asp  Val Asp Leu Gly Asp  Ile Ser Gly Ile Asn  Ala Ser Val
    1145                1150                1155

Val Asn  Ile Gln Lys Glu Ile  Asp Arg Leu Asn Glu  Val Ala Lys
    1160                1165                1170

Asn Leu  Asn Glu Ser Leu Ile  Asp Leu Gln Glu Leu  Gly Lys Tyr
    1175                1180                1185

Glu Gln  Tyr Ile Lys Trp Pro  Trp Tyr Val Trp Leu  Gly Phe Ile
    1190                1195                1200

Ala Gly  Leu Ile Ala Ile Val  Met Val Thr Ile Leu  Leu Cys Cys
    1205                1210                1215

Met Thr  Ser Cys Cys Ser Cys  Leu Lys Gly Ala Cys  Ser Cys Gly
    1220                1225                1230

Ser Cys  Cys Lys Phe Asp Glu  Asp Asp Ser Glu Pro  Val Leu Lys
    1235                1240                1245

Gly Val  Lys Leu His Tyr Thr
    1250                1255
```

<210> 418
<211> 76
<212> PRT
<213> artificial sequence

<220>
<223> Envelope Protein

<400> 418

Met Tyr Ser Phe Val Ser Glu Glu Thr Gly Thr Leu Ile Val Asn Ser
1   5   10   15

Val Leu Leu Phe Leu Ala Phe Val Val Phe Leu Leu Val Thr Leu Ala
            20   25   30

Ile Leu Thr Ala Leu Arg Leu Cys Ala Tyr Cys Cys Asn Ile Val Asn
        35   40   45

Val Ser Leu Val Lys Pro Thr Val Tyr Val Tyr Ser Arg Val Lys Asn
    50   55   60

Leu Asn Ser Ser Glu Gly Val Pro Asp Leu Leu Val
65   70   75

<210> 419
<211> 221
<212> PRT
<213> artificial sequence

<220>
<223> Membrane Protein

<400> 419

Met Ala Asp Asn Gly Thr Ile Thr Val Glu Glu Leu Lys Gln Leu Leu
1   5   10   15

Glu Gln Trp Asn Leu Val Ile Gly Phe Leu Phe Leu Ala Trp Ile Met
            20   25   30

Leu Leu Gln Phe Ala Tyr Ser Asn Arg Asn Arg Phe Leu Tyr Ile Ile
        35   40   45

Lys Leu Val Phe Leu Trp Leu Leu Trp Pro Val Thr Leu Ala Cys Phe
    50   55   60

Val Leu Ala Ala Val Tyr Arg Ile Asn Trp Val Thr Gly Gly Ile Ala
65   70   75   80

Ile Ala Met Ala Cys Ile Val Gly Leu Met Trp Leu Ser Tyr Phe Val
                85   90   95

Ala Ser Phe Arg Leu Phe Ala Arg Thr Arg Ser Met Trp Ser Phe Asn
            100   105   110

Pro Glu Thr Asn Ile Leu Leu Asn Val Pro Leu Arg Gly Thr Ile Val
        115   120   125

Thr Arg Pro Leu Met Glu Ser Glu Leu Val Ile Gly Ala Val Ile Ile
    130   135   140

```
Arg Gly His Leu Arg Met Ala Gly His Ser Leu Gly Arg Cys Asp Ile
145                 150                 155                 160


Lys Asp Leu Pro Lys Glu Ile Thr Val Ala Thr Ser Arg Thr Leu Ser
                165                 170                 175


Tyr Tyr Lys Leu Gly Ala Ser Gln Arg Val Gly Thr Asp Ser Gly Phe
            180                 185                 190


Ala Ala Tyr Asn Arg Tyr Arg Ile Gly Asn Tyr Lys Leu Asn Thr Asp
        195                 200                 205


His Ala Gly Ser Asn Asp Asn Ile Ala Leu Leu Val Gln
    210                 215                 220


<210>  420
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  T Cell Epitope

<400>  420

Leu Leu Leu Asn Cys Leu Trp Ser Val
1               5


<210>  421
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  T Cell Epitope

<400>  421

Phe Lys Asp Gly Ile Tyr Phe Ala Ala
1               5


<210>  422
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  T Cell Epitope

<400>  422

Leu Ile Thr Gly Arg Leu Ala Ala Leu
1               5


<210>  423
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  T Cell Epitope
```

<400> 423

Leu Ile Thr Gly Arg Leu Gln Ser Leu
1   5

<210> 424
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 424

Ile Ser Val Val Leu Ile Phe Val Val
1   5

<210> 425
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 425

Phe Ile Ala Gly Leu Ile Ala Ile Val
1   5

<210> 426
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 426

Gly Ile Leu Gly Phe Val Phe Thr Leu
1   5

<210> 427
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 427

Val Val Phe Leu His Val Thr Tyr Val
1   5

<210> 428
<211> 9
<212> PRT
<213> artificial sequence

<220>

<223> T Cell Epitope

<400> 428

Arg Leu Gln Ser Leu Gln Thr Tyr Val
1   5

<210> 429
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 429

Val Leu Asn Asp Ile Leu Ser Arg Leu
1   5

<210> 430
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 430

Val Leu Tyr Glu Asn Gln Lys Gln Ile
1   5

<210> 431
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 431

Asn Leu Asn Glu Ser Leu Ile Asp Leu
1   5

<210> 432
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 432

Leu Leu Leu Gln Tyr Gly Ser Phe Cys
1   5

<210> 433
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 433

Lys Leu Pro Asp Asp Phe Met Gly Cys
1   5

<210> 434
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 434

Ile Leu Pro Asp Pro Leu Lys Pro Thr
1   5

<210> 435
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 435

Met Ile Phe Asp Asn Ala Phe Asn Cys
1   5

<210> 436
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 436

Phe Ile Phe Leu Leu Phe Leu Thr Leu
1   5

<210> 437
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 437

Val Leu Tyr Gln Asp Val Asn Cys Thr
1   5

<210> 438
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 438

Ile Ile Thr Thr Asp Asn Thr Phe Val
1   5

<210> 439
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 439

Arg Leu Asn Glu Val Ala Lys Asn Leu
1   5

<210> 440
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 440

Leu Leu Thr Asp Asp Met Ile Ala Ala
1   5

<210> 441
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 441

Leu Leu Gln Tyr Gly Ser Phe Cys Thr
1   5

<210> 442
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 442

Ile Leu Leu Cys Cys Met Thr Ser Cys
1   5

<210> 443
<211> 9
<212> PRT

<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 443

Leu Leu Phe Asn Lys Val Thr Leu Ala
1   5

<210> 444
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 444

Thr Met Asn Asn Lys Ser Gln Ser Val
1   5

<210> 445
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 445

Ala Leu Asn Thr Leu Val Lys Gln Leu
1   5

<210> 446
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 446

Glu Leu Cys Asp Asn Pro Phe Phe Ala
1   5

<210> 447
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 447

Phe Pro Arg Gly Gln Gly Val Pro Ile
1   5

<210> 448
<211> 9

<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 448

Arg Leu Asn Gln Leu Glu Ser Lys Val
1   5

<210> 449
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 449

Ile Leu Leu Asn Lys His Ile Asp
1   5

<210> 450
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 450

Ala Phe Phe Gly Met Ser Arg Ile Gly Met Glu Val Thr Pro Ser Gly
1   5   10   15

Thr Trp

<210> 451
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 451

Met Glu Val Thr Pro Ser Gly Thr Trp Leu
1   5   10

<210> 452
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 452

Gly Met Ser Arg Ile Gly Met Glu Val

1 5

<210> 453
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 453

Ile Leu Leu Asn Lys His Ile Asp Ala
1 5

<210> 454
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 454

Ala Leu Asn Thr Pro Lys Asp His Ile
1 5

<210> 455
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 455

Ile Arg Gln Gly Thr Asp Tyr Lys His Trp Pro Gln Ile Ala Gln Phe
1 5 10 15

Ala

<210> 456
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 456

Lys His Trp Pro Gln Ile Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe
1 5 10 15

Phe

<210> 457
<211> 9

<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 457

Leu Ala Leu Leu Leu Leu Asp Arg Leu
1   5

<210> 458
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 458

Leu Leu Leu Asp Arg Leu Asn Gln Leu
1   5

<210> 459
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 459

Leu Leu Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu
1   5   10   15

Pro Lys

<210> 460
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 460

Leu Gln Leu Pro Gln Gly Thr Thr Leu
1   5

<210> 461
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 461

Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg

1 5 10 15

<210> 462
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 462

Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg Ile
1 5 10 15

Gly Met

<210> 463
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 463

Arg Arg Pro Gln Gly Leu Pro Asn Asn Thr Ala Ser Trp Phe Thr
1 5 10 15

<210> 464
<211> 16
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 464

Tyr Lys Thr Phe Pro Pro Thr Glu Pro Lys Lys Asp Lys Lys Lys Lys
1 5 10 15

<210> 465
<211> 16
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 465

Gly Ala Ala Leu Gln Ile Pro Phe Ala Met Gln Met Ala Tyr Arg Phe
1 5 10 15

<210> 466
<211> 16
<212> PRT
<213> artificial sequence

<220>

<223> T Cell Epitope

<400> 466

Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn Val Leu Tyr
1   5   10   15

<210> 467
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 467

Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala
1   5   10   15

Thr Lys

<210> 468
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 468

Leu Leu Leu Leu Asp Arg Leu Asn Gln
1   5

<210> 469
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 469

Leu Leu Leu Leu Asp Arg Leu Asn Gln Leu
1   5   10

<210> 470
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 470

Gln Ala Leu Asn Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala
1   5   10   15

Ile

<210> 471
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 471

Ala Gln Phe Ala Pro Ser Ala Ser Ala
1   5

<210> 472
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 472

Val Leu Asn Asp Ile Leu Ser Arg Leu
1   5

<210> 473
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 473

Thr Thr Leu Pro Lys Gly Phe Tyr Ala
1   5

<210> 474
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 474

Gly Leu Ile Ala Ile Val Met Val Thr Ile
1   5   10

<210> 475
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 475

Leu Gln Tyr Gly Ser Phe Cys Thr
1 5

<210> 476
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 476

Arg Leu Asp Lys Val Glu Ala Glu Val
1 5

<210> 477
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 477

Val Leu Gln Leu Pro Gln Gly Thr Thr Leu
1 5 10

<210> 478
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 478

Gly Tyr Gln Pro Tyr Arg Val Val Val Leu
1 5 10

<210> 479
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 479

Pro Tyr Arg Val Val Val Leu Ser Phe
1 5

<210> 480
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 480

Leu Ser Pro Arg Trp Tyr Phe Tyr Tyr
1   5

<210> 481
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 481

Asp Ser Phe Lys Glu Glu Leu Asp Lys Tyr
1   5   10

<210> 482
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 482

Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr
1   5   10

<210> 483
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 483

Gly Thr Thr Leu Pro Lys Gly Phe Tyr
1   5

<210> 484
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 484

Val Thr Pro Ser Gly Thr Trp Leu Thr Tyr
1   5   10

<210> 485
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 485

Gly Ser Phe Cys Thr Gln Leu Asn Arg
1 5

<210> 486
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 486

Gly Val Val Phe Leu His Val Thr Tyr
1 5

<210> 487
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 487

Ala Gln Ala Leu Asn Thr Leu Val Lys
1 5

<210> 488
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 488

Met Thr Ser Cys Cys Ser Cys Leu Lys
1 5

<210> 489
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 489

Ala Ser Ala Asn Leu Ala Ala Thr Lys
1 5

<210> 490
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 490

Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys
1 5 10

<210> 491
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 491

Ser Val Leu Asn Asp Ile Leu Ser Arg
1 5

<210> 492
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 492

Thr Gln Asn Val Leu Tyr Glu Asn Gln Lys
1 5 10

<210> 493
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 493

Cys Met Thr Ser Cys Cys Ser Cys Leu Lys
1 5 10

<210> 494
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 494

Val Gln Ile Asp Arg Leu Ile Thr Gly Arg
1 5 10

<210> 495
<211> 9
<212> PRT
<213> artificial sequence

<220>

<223> T Cell Epitope

<400> 495

Lys Thr Phe Pro Pro Thr Glu Pro Lys
1   5

<210> 496
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 496

Lys Thr Phe Pro Pro Thr Glu Pro Lys Lys
1   5   10

<210> 497
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 497

Ala Ser Ala Phe Phe Gly Met Ser Arg
1   5

<210> 498
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 498

Ala Thr Glu Gly Ala Leu Asn Thr Pro Lys
1   5   10

<210> 499
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 499

Gln Leu Pro Gln Gly Thr Thr Leu Pro Lys
1   5   10

<210> 500
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 500

Gln Gln Gln Gly Gln Thr Val Thr Lys
1   5

<210> 501
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 501

Gln Gln Gln Gln Gly Gln Thr Val Thr Lys
1   5   10

<210> 502
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 502

Ser Ala Ser Ala Phe Phe Gly Met Ser Arg
1   5   10

<210> 503
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 503

Ser Gln Ala Ser Ser Arg Ser Ser Ser Arg
1   5   10

<210> 504
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 504

Thr Pro Ser Gly Thr Trp Leu Thr Tyr
1   5

<210> 505
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 505

Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe
1   5   10

<210> 506
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 506

Ala Pro His Gly Val Val Phe Leu His Val
1   5   10

<210> 507
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 507

Ala Pro Ser Ala Ser Ala Phe Phe Gly Met
1   5   10

<210> 508
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 508

Gly Ala Ala Leu Gln Ile Pro Phe Ala Met Gln Met Ala Tyr Arg
1   5   10   15

<210> 509
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 509

Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile Pro Phe Ala
1   5   10   15

<210> 510
<211> 15
<212> PRT

<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 510

Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr
1   5   10   15

<210> 511
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 511

Ile Ser Gly Ile Asn Ala Ser Val Val Asn Ile Gln Lys Glu Ile
1   5   10   15

<210> 512
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 512

Leu Asp Lys Tyr Phe Lys Asn His Thr Ser Pro Asp Val Asp Leu
1   5   10   15

<210> 513
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 513

Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val Val Asn Ile Gln
1   5   10   15

<210> 514
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 514

Leu Gly Phe Ile Ala Gly Leu Ile Ala Ile Val Met Val Thr Ile
1   5   10   15

<210> 515
<211> 15

<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 515

Leu Asn Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile
1   5   10   15

<210> 516
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 516

Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu
1   5   10   15

<210> 517
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 517

Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln Gln Leu Ile Arg Ala
1   5   10   15

<210> 518
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 518

Leu Gln Thr Tyr Val Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile
1   5   10   15

<210> 519
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 519

Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu Leu Thr
1   5   10   15

<210> 520

<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 520

Pro Cys Ser Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn
1   5   10   15

<210> 521
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 521

Gln Ile Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile
1   5   10   15

<210> 522
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 522

Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu
1   5   10   15

<210> 523
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 523

Gln Thr Tyr Val Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg
1   5   10   15

<210> 524
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 524

Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn Val Leu Tyr
1   5   10   15

<210> 525
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 525

Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn Asp Ile Leu
1   5   10   15

<210> 526
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 526

Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln Gln Leu
1   5   10   15

<210> 527
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 527

Trp Leu Gly Phe Ile Ala Gly Leu Ile Ala Ile Val Met Val Thr
1   5   10   15

<210> 528
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 528

Cys Val Asn Phe Asn Phe Asn Gly Leu Thr Gly Thr Gly Val Leu
1   5   10   15

<210> 529
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 529

Asp Lys Tyr Phe Lys Asn His Thr Ser Pro Asp Val Asp Leu Gly
1   5   10   15

<210> 530
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 530

Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu Pro Lys Lys Asp
1   5   10   15

<210> 531
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 531

Met Ser Arg Ile Gly Met Glu Val Thr Pro Ser Gly Thr Trp Leu
1   5   10   15

<210> 532
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 532

Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu Pro
1   5   10   15

<210> 533
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 533

Val Leu Gln Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr
1   5   10   15

<210> 534
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 534

Leu Gln Ile Pro Phe Ala Met Gln Met
1   5

<210> 535
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 535

Arg Val Asp Phe Cys Gly Lys Gly Tyr
1   5

<210> 536
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 536

Tyr Glu Gln Tyr Ile Lys Trp Pro Trp Tyr
1   5   10

<210> 537
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 537

Gly Arg Leu Gln Ser Leu Gln Thr Tyr
1   5

<210> 538
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 538

Val Arg Phe Pro Asn Ile Thr Asn Leu
1   5

<210> 539
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 539

Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu Val Lys Gln

1 5 10 15

Leu

<210> 540
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 540

Glu Ala Glu Val Gln Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser
1 5 10 15

Leu

<210> 541
<211> 28
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 541

Glu Ile Asp Arg Leu Asn Glu Val Ala Lys Asn Leu Asn Glu Ser Leu
1 5 10 15

Ile Asp Leu Gln Glu Leu Gly Lys Tyr Glu Gln Tyr
20 25

<210> 542
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 542

Glu Val Ala Lys Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu
1 5 10 15

Gly

<210> 543
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 543

Gly Ala Ala Leu Gln Ile Pro Phe Ala Met Gln Met Ala Tyr Arg Phe
1   5   10   15

Asn

<210> 544
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 544

Gly Ala Gly Ile Cys Ala Ser Tyr
1   5

<210> 545
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 545

Ala Ile Ser Ser Val Leu Asn Asp Ile Leu Ser Arg Leu Asp Lys Val
1   5   10   15

Glu

<210> 546
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 546

Gly Ser Phe Cys Thr Gln Leu Asn
1   5

<210> 547
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 547

Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln Ile Asp Arg
1   5   10   15

Leu

<210> 548
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 548

Lys Gly Ile Tyr Gln Thr Ser Asn
1   5

<210> 549
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 549

Ala Met Gln Met Ala Tyr Arg Phe
1   5

<210> 550
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 550

Lys Asn His Thr Ser Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile
1   5   10   15

Asn

<210> 551
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 551

Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn Val Leu Tyr
1   5   10   15

Glu

<210> 552
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 552

Ala Ala Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys Arg Val
1   5   10   15

Asp

<210> 553
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 553

Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr
1   5   10   15

Gln

<210> 554
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 554

Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala
1   5   10   15

Thr

<210> 555
<211> 6
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 555

Gln Gln Phe Gly Arg Asp
1   5

<210> 556

<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 556

Arg Ala Ser Ala Asn Leu Ala Ala Thr Lys Met Ser Glu Cys Val Leu
1   5   10   15

Gly

<210> 557
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 557

Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln
1   5   10   15

Gln

<210> 558
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 558

Ser Leu Gln Thr Tyr Val Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile
1   5   10   15

Arg

<210> 559
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 559

Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val Val Asn Ile Gln
1   5   10   15

Lys

<210> 560
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 560

Phe Phe Gly Met Ser Arg Ile Gly Met Glu Val Thr Pro Ser Gly Thr
1   5   10   15

Trp

<210> 561
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 561

Gly Leu Pro Asn Asn Thr Ala Ser Trp Phe Thr Ala Leu Thr Gln His
1   5   10   15

Gly Lys

<210> 562
<211> 6
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 562

Gly Thr Thr Leu Pro Lys
1   5

<210> 563
<211> 20
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 563

Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu Pro Lys Lys
1   5   10   15

Asp Lys Lys Lys
            20

<210> 564
<211> 19
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 564

Tyr Asn Val Thr Gln Ala Phe Gly Arg Arg Gly Pro Glu Gln Thr Gln
1   5   10   15

Gly Asn Phe

<210> 565
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 565

Lys Thr Phe Pro Pro Thr Glu Pro Lys Lys Asp Lys Lys Lys Lys
1   5   10   15

<210> 566
<211> 6
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 566

Leu Leu Pro Ala Ala Asp
1   5

<210> 567
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 567

Leu Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu Pro
1   5   10   15

Lys

<210> 568
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 568

Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly
1   5   10

<210> 569
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 569

Leu Pro Gln Arg Gln Lys Lys Gln
1   5

<210> 570
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 570

Pro Lys Gly Phe Tyr Ala Glu Gly Ser Arg Gly Gly Ser Gln Ala Ser
1   5   10   15

Ser Arg

<210> 571
<211> 17
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 571

Gln Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg Ile Gly
1   5   10   15

Met

<210> 572
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 572

Gln Gly Thr Asp Tyr Lys His Trp
1   5

<210> 573
<211> 15
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 573

Gln Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr Ala Glu
1   5   10   15

<210> 574
<211> 18
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 574

Gln Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr Ala Glu Gly
1   5   10   15

Ser Arg

<210> 575
<211> 22
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 575

Gln Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr Ala Glu Gly
1   5   10   15

Ser Arg Gly Gly Ser Gln
            20

<210> 576
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 576

Thr Phe Pro Pro Thr Glu Pro Lys
1   5

<210> 577
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 577

Ser Gln Ala Ser Ser Arg Ser Ser
1   5

<210> 578
<211> 16
<212> PRT
<213> artificial sequence

<220>
<223> T Cell Epitope

<400> 578

Ser Arg Gly Gly Ser Gln Ala Ser Ser Arg Ser Ser Ser Arg Ser Arg
1   5   10   15

<210> 579
<211> 5
<212> PRT
<213> artificial sequence

<220>
<223> Spacer

<400> 579

Cys Pro Gly Pro Gly
1   5

<210> 580
<211> 6
<212> PRT
<213> artificial sequence

<220>
<223> Spacer

<400> 580

Gly Ser Gly Ser Gly Ser
1   5

<210> 581
<211> 206
<212> PRT
<213> artificial sequence

<220>
<223> RBD Protein

<400> 581

Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn
1   5   10   15

```
Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser
            20                  25                  30

Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser
        35                  40                  45

Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys
    50                  55                  60

Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val
65                  70                  75                  80

Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr
                85                  90                  95

Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn
            100                 105                 110

Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu
        115                 120                 125

Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu
    130                 135                 140

Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn
145                 150                 155                 160

Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val
                165                 170                 175

Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His
            180                 185                 190

Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu
        195                 200                 205
```